When B-O O
cells B-O O
were B-O O
treated B-O O
with B-O O
IL-4 B-O B-protein
for B-O O
5 B-O O
hours B-O O
before B-O O
LPS B-O O
activation B-O O
, B-O O
both B-O O
the B-O O
c-fos B-O B-DNA
and B-O O
the B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
expression B-O O
was B-O O
decreased B-O O
. B-O O

The B-O O
inhibition B-O O
of B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
expression B-O O
by B-O O
IL-4 B-O B-protein
in B-O O
LPS-treated B-O B-cell_line
cells B-O I-cell_line
was B-O O
shown B-O O
to B-O O
be B-O O
due B-O O
to B-O O
a B-O O
lower B-O O
transcription B-O O
rate B-O O
of B-O O
the B-O O
c-fos B-O B-DNA
and B-O I-DNA
c-jun B-O I-DNA
genes B-O I-DNA
. B-O O

IL-4 B-O B-protein
did B-O O
not B-O O
affect B-O O
the B-O O
stability B-O O
of B-O O
the B-O O
c-fos B-O B-RNA
and B-O I-RNA
c-jun B-O I-RNA
transcripts B-O I-RNA
. B-O O

Finally B-O O
, B-O O
using B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
, B-O O
evidence B-O O
was B-O O
obtained B-O O
that B-O O
IL-4 B-O B-protein
inhibits B-O O
LPS-induced B-O O
expression B-O O
of B-O O
AP-1 B-O B-protein
protein B-O I-protein
. B-O O

These B-O O
data B-O O
indicate B-O O
that B-O O
IL-4 B-O B-protein
suppresses B-O O
the B-O O
induction B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
in B-O O
human B-O B-cell_type
activated B-O I-cell_type
monocytes B-O I-cell_type
. B-O O

Transient B-O O
pseudohypoaldosteronism B-O O
in B-O O
obstructive B-O O
renal B-O O
disease B-O O
with B-O O
transient B-O O
reduction B-O O
of B-O O
lymphocytic B-O B-protein
aldosterone B-O I-protein
receptors B-O I-protein
. B-O O

Results B-O O
in B-O O
two B-O O
affected B-O O
infants B-O O
. B-O O

We B-O O
report B-O O
two B-O O
patients B-O O
with B-O O
transient B-O O
pseudohypoaldosteronism B-O O
due B-O O
to B-O O
obstructive B-O O
renal B-O O
disease B-O O
. B-O O

Both B-O O
patients B-O O
presented B-O O
with B-O O
a B-O O
salt-losing B-O O
episode B-O O
simulating B-O O
adrenal B-O O
insufficiency B-O O
. B-O O

In B-O O
one B-O O
patient B-O O
, B-O O
transient B-O O
reduction B-O O
of B-O O
aldosterone B-O B-protein
receptors B-O I-protein
could B-O O
be B-O O
documented B-O O
, B-O O
while B-O O
in B-O O
the B-O O
second B-O O
patient B-O O
the B-O O
clinical B-O O
and B-O O
biochemical B-O O
parameters B-O O
were B-O O
consistent B-O O
with B-O O
transient B-O O
pseudohypoaldosteronism B-O O
. B-O O

Aldosterone B-O B-protein
receptors B-O I-protein
were B-O O
normal B-O O
in B-O O
both B-O O
patients B-O O

Aldosterone-specific B-O B-protein
membrane B-O I-protein
receptors B-O I-protein
and B-O O
rapid B-O O
non-genomic B-O O
actions B-O O
of B-O O
mineralocorticoids B-O O
. B-O O

Functional B-O O
studies B-O O
in B-O O
extrarenal B-O B-cell_type
, B-O I-cell_type
non-epithelial B-O I-cell_type
cells B-O I-cell_type
such B-O O
as B-O O
smooth B-O B-cell_type
muscle B-O I-cell_type
cells B-O I-cell_type
and B-O O
more B-O O
recently B-O O
circulating B-O B-cell_type
human B-O I-cell_type
lymphocytes B-O I-cell_type
have B-O O
provided B-O O
increasing B-O O
evidence B-O O
that B-O O
aldosterone B-O O
produces B-O O
not B-O O
only B-O O
classical B-O O
genomic B-O O
effects B-O O
, B-O O
but B-O O
also B-O O
rapid B-O O
, B-O O
non-genomic B-O O
effects B-O O
on B-O O
transmembrane B-O O
electrolyte B-O O
movements B-O O
. B-O O

These B-O O
involve B-O O
activation B-O O
of B-O O
the B-O O
sodium/proton B-O B-protein
exchanger B-O I-protein
of B-O O
the B-O O
cell B-O O
membrane B-O O
at B-O O
very B-O O
low B-O O
, B-O O
physiological B-O O
concentrations B-O O
of B-O O
aldosterone B-O O
with B-O O
an B-O O
acute B-O O
onset B-O O
within B-O O
1-2 B-O O
min B-O O
. B-O O

A B-O O
second B-O O
messenger B-O O
cascade B-O O
involved B-O O
is B-O O
the B-O O
inositol B-O O
1 B-O O
, B-O O
4 B-O O
, B-O O
5-trisphosphate B-O O
/calcium B-O O
pathway B-O O
which B-O O
responds B-O O
over B-O O
the B-O O
same B-O O
rapid B-O O
time B-O O
course B-O O
. B-O O

Such B-O O
changes B-O O
clearly B-O O
can B-O O
not B-O O
be B-O O
explained B-O O
by B-O O
genomic B-O O
mechanisms B-O O
, B-O O
which B-O O
are B-O O
responsible B-O O
for B-O O
later B-O O
effects B-O O
than B-O O
the B-O O
membrane B-O O
related B-O O
rapid B-O O
responses B-O O
. B-O O

The B-O O
mechanisms B-O O
underlying B-O O
these B-O O
rapid B-O O
effects B-O O
of B-O O
aldosterone B-O O
on B-O O
electrolytes B-O O
have B-O O
been B-O O
extensively B-O O
studied B-O O
in B-O O
human B-O B-cell_type
lymphocytes B-O I-cell_type
, B-O O
which B-O O
thus B-O O
may B-O O
represent B-O O
valuable B-O O
tools B-O O
in B-O O
the B-O O
delineation B-O O
of B-O O
the B-O O
receptor-effector B-O O
mechanisms B-O O
involved B-O O
. B-O O

The B-O O
unique B-O O
characteristics B-O O
of B-O O
this B-O O
new B-O O
pathway B-O O
for B-O O
steroid B-O O
action B-O O
include B-O O
its B-O O
rapid B-O O
time B-O O
course B-O O
, B-O O
10 B-O O
, B-O O
000-fold B-O O
selectivity B-O O
for B-O O
aldosterone B-O O
over B-O O
cortisol B-O O
and B-O O
the B-O O
ineffectiveness B-O O
of B-O O
spironolactones B-O O
, B-O O
classical B-O O
mineralocorticoid B-O O
antagonists B-O O
, B-O O
as B-O O
antagonists B-O O
of B-O O
the B-O O
response B-O O
. B-O O

Human B-O B-protein
immunodeficiency B-O I-protein
virus B-O I-protein
type B-O I-protein
1 B-O I-protein
Nef B-O I-protein
protein B-O I-protein
inhibits B-O O
NF-kappa B-O B-protein
B B-O I-protein
induction B-O O
in B-O O
human B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
can B-O O
establish B-O O
a B-O O
persistent B-O O
and B-O O
latent B-O O
infection B-O O
in B-O O
CD4+ B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
( B-O O
W.C.Greene B-O O
, B-O O
N.Engl.J. B-O O
Med.324 B-O O
: B-O O
308-317 B-O O
, B-O O
1991 B-O O
; B-O O
S.M.Schnittman B-O O
, B-O O
M.C.Psallidopoulos B-O O
, B-O O
H.C. B-O O
Lane B-O O
, B-O O
L.Thompson B-O O
, B-O O
M.Baseler B-O O
, B-O O
F.Massari B-O O
, B-O O
C.H.Fox B-O O
, B-O O
N.P.Salzman B-O O
, B-O O
and B-O O
A.S.Fauci B-O O
, B-O O
Science B-O O
245 B-O O
: B-O O
305-308 B-O O
, B-O O
1989 B-O O
) B-O O
. B-O O

Production B-O O
of B-O O
HIV-1 B-O O
from B-O O
latently B-O B-cell_type
infected B-O I-cell_type
cells B-O I-cell_type
requires B-O O
host B-O O
cell B-O O
activation B-O O
by B-O O
T-cell B-O B-protein
mitogens B-O I-protein
( B-O O
T.Folks B-O O
, B-O O
D.M.Powell B-O O
, B-O O
M.M.Lightfoote B-O O
, B-O O
S.Benn B-O O
, B-O O
M.A. B-O O
Martin B-O O
, B-O O
and B-O O
A.S.Fauci B-O O
, B-O O
Science B-O O
231 B-O O
: B-O O
600-602 B-O O
, B-O O
1986 B-O O
; B-O O
D.Zagury B-O O
, B-O O
J. B-O O
Bernard B-O O
, B-O O
R.Leonard B-O O
, B-O O
R.Cheynier B-O O
, B-O O
M.Feldman B-O O
, B-O O
P.S.Sarin B-O O
, B-O O
and B-O O
R.C. B-O O
Gallo B-O O
, B-O O
Science B-O O
231 B-O O
: B-O O
850-853 B-O O
, B-O O
1986 B-O O
) B-O O
. B-O O

This B-O O
activation B-O O
is B-O O
mediated B-O O
by B-O O
the B-O O
host B-O B-protein
transcription B-O I-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
[ B-O O
G.Nabel B-O O
and B-O O
D.Baltimore B-O O
, B-O O
Nature B-O O
( B-O O
London B-O O
) B-O O
326 B-O O
: B-O O
711-717 B-O O
, B-O O
1987 B-O O
] B-O O
. B-O O

We B-O O
report B-O O
here B-O O
that B-O O
the B-O O
HIV-1 B-O B-protein
-encoded B-O I-protein
Nef B-O I-protein
protein B-O I-protein
inhibits B-O O
the B-O O
induction B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
DNA-binding B-O O
activity B-O O
by B-O O
mitogens B-O I-protein
. B-O O

However B-O O
, B-O O
Nef B-O B-protein
does B-O O
not B-O O
affect B-O O
the B-O O
DNA-binding B-O O
activity B-O O
of B-O O
other B-O O
transcription B-O B-protein
factors B-O I-protein
implicated B-O O
in B-O O
HIV-1 B-O O
regulation B-O O
, B-O O
including B-O O
SP-1 B-O B-protein
, B-O O
USF B-O B-protein
, B-O O
URS B-O B-protein
, B-O O
and B-O O
NF-AT B-O B-protein
. B-O O

Additionally B-O O
, B-O O
Nef B-O B-protein
inhibits B-O O
the B-O O
induction B-O O
of B-O O
HIV-1- B-O O
and B-O O
interleukin B-O B-protein
2- B-O I-protein
directed B-O O
gene B-O O
expression B-O O
, B-O O
and B-O O
the B-O O
effect B-O O
on B-O O
HIV-1 B-O O
transcription B-O O
depends B-O O
on B-O O
an B-O O
intact B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
-binding B-O I-DNA
site B-O I-DNA
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
defective B-O O
recruitment B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
may B-O O
underlie B-O O
Nef B-O B-protein
's B-O O
negative B-O O
transcriptional B-O O
effects B-O O
on B-O O
the B-O O
HIV-1 B-O B-DNA
and B-O I-DNA
interleukin B-O I-DNA
2 B-O I-DNA
promoters B-O I-DNA
. B-O O

Further B-O O
evidence B-O O
suggests B-O O
that B-O O
Nef B-O B-protein
inhibits B-O O
NF-kappa B-O B-protein
B B-O I-protein
induction B-O O
by B-O O
interfering B-O O
with B-O O
a B-O O
signal B-O O
derived B-O O
from B-O O
the B-O O
T-cell B-O B-protein
receptor B-O I-protein
complex B-O I-protein
. B-O O

Expression B-O O
of B-O O
c-fos B-O B-DNA
, B-O O
c-jun B-O B-DNA
and B-O O
jun B-O B-DNA
B B-O I-DNA
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
lymphocytes B-O I-cell_type
from B-O O
young B-O O
and B-O O
elderly B-O O
adults B-O O
. B-O O

The B-O O
expression B-O O
of B-O O
c-fos B-O B-DNA
, B-O O
c-jun B-O B-DNA
and B-O O
jun B-O B-DNA
B B-O I-DNA
proto-oncogenes B-O I-DNA
was B-O O
studied B-O O
in B-O O
phytohemagglutinin B-O B-cell_line
( B-O I-cell_line
PHA B-O I-cell_line
) B-O I-cell_line
activated B-O I-cell_line
peripheral B-O I-cell_line
blood B-O I-cell_line
lymphocytes B-O I-cell_line
( B-O O
PBL B-O B-cell_type
) B-O O
from B-O O
young B-O O
and B-O O
aged B-O O
humans B-O O
. B-O O

Specific B-O O
mRNAs B-O B-RNA
for B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
were B-O O
detectable B-O O
within B-O O
30 B-O O
min B-O O
after B-O O
cell B-O O
activation B-O O
and B-O O
reached B-O O
maximal B-O O
levels B-O O
within B-O O
2 B-O O
h B-O O
. B-O O

Both B-O O
c-fos B-O B-RNA
and B-O I-RNA
jun B-O I-RNA
B B-O I-RNA
mRNAs B-O I-RNA
decreased B-O O
to B-O O
pre-activation B-O O
levels B-O O
within B-O O
6 B-O O
h B-O O
, B-O O
while B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
remained B-O O
elevated B-O O
. B-O O

In B-O O
PHA B-O B-cell_line
-activated B-O I-cell_line
PBL B-O I-cell_line
, B-O O
no B-O O
age-related B-O O
differences B-O O
were B-O O
observed B-O O
in B-O O
c-fos B-O B-DNA
or B-O O
jun B-O B-RNA
B B-O I-RNA
mRNA B-O I-RNA
expression B-O O
. B-O O

However B-O O
, B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
levels B-O O
decreased B-O O
significantly B-O O
( B-O O
1.73 B-O O
+/- B-O O
0.08 B-O O
vs. B-O O
1.16 B-O O
+/- B-O O
0.09 B-O O
arbitrary B-O O
units B-O O
, B-O O
P B-O B-protein
& B-O I-protein
lt B-O I-protein
; B-O O
0.01 B-O O
, B-O O
young B-O O
vs. B-O O
old B-O O
) B-O O
in B-O O
PBL B-O B-cell_type
from B-O O
elderly B-O O
individuals B-O O
activated B-O O
with B-O O
PHA B-O B-protein
. B-O O

Because B-O O
previous B-O O
work B-O O
has B-O O
demonstrated B-O O
that B-O O
T B-O B-cell_type
cells B-O I-cell_type
from B-O O
elderly B-O O
individuals B-O O
may B-O O
display B-O O
normal B-O O
proliferative B-O O
responses B-O O
when B-O O
activated B-O O
via B-O O
the B-O O
anti-CD2 B-O B-protein
pathway B-O O
, B-O O
c-jun B-O B-DNA
and B-O O
jun B-O O
B B-O O
mRNA B-O O
expression B-O O
was B-O O
also B-O O
studied B-O O
in B-O O
anti-CD2-activated B-O B-cell_line
purified B-O I-cell_line
T B-O I-cell_line
cells B-O I-cell_line
. B-O O

No B-O O
age-related B-O O
differences B-O O
were B-O O
found B-O O
in B-O O
the B-O O
expression B-O O
of B-O O
either B-O O
of B-O O
these B-O O
two B-O O
proto-oncogenes B-O B-DNA
by B-O O
anti-CD2 B-O B-protein
activated B-O I-protein
T B-O I-protein
cells B-O I-protein
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
the B-O O
decreased B-O O
IL-2 B-O B-protein
production B-O O
and B-O O
proliferative B-O O
response B-O O
displayed B-O O
by B-O O
PHA B-O B-protein
-activated B-O O
PBL B-O B-cell_type
from B-O O
elderly B-O O
adults B-O O
may B-O O
be B-O O
related B-O O
to B-O O
age-related B-O O
changes B-O O
in B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
expression B-O O
and B-O O
in B-O O
the B-O O
ratio B-O O
of B-O O
c-fos B-O B-DNA
to B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
. B-O O

Oct2 B-O B-protein
transactivation B-O O
from B-O O
a B-O O
remote B-O B-DNA
enhancer B-O I-DNA
position B-O I-DNA
requires B-O O
a B-O O
B-cell-restricted B-O O
activity B-O O
. B-O O

Previous B-O O
cotransfection B-O O
experiments B-O O
had B-O O
demonstrated B-O O
that B-O O
ectopic B-O O
expression B-O O
of B-O O
the B-O O
lymphocyte-specific B-O B-protein
transcription B-O I-protein
factor B-O I-protein
Oct2 B-O B-protein
could B-O O
efficiently B-O O
activate B-O O
a B-O O
promoter B-O B-DNA
containing B-O O
an B-O O
octamer B-O B-DNA
motif B-O I-DNA
. B-O O

Oct2 B-O B-protein
expression B-O O
was B-O O
unable B-O O
to B-O O
stimulate B-O O
a B-O O
multimerized B-O B-DNA
octamer B-O I-DNA
enhancer B-O I-DNA
element B-O I-DNA
in B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
, B-O O
however B-O O
. B-O O

We B-O O
have B-O O
tested B-O O
a B-O O
variety B-O O
of B-O O
Oct2 B-O B-protein
isoforms B-O I-protein
generated B-O O
by B-O O
alternative B-O O
splicing B-O O
for B-O O
the B-O O
capability B-O O
to B-O O
activate B-O O
an B-O O
octamer B-O B-DNA
enhancer B-O I-DNA
in B-O O
nonlymphoid B-O B-cell_type
cells B-O I-cell_type
and B-O O
a B-O O
B-cell B-O B-cell_line
line B-O I-cell_line
. B-O O

Our B-O O
analyses B-O O
show B-O O
that B-O O
several B-O O
Oct2 B-O B-protein
isoforms B-O I-protein
can B-O O
stimulate B-O O
from B-O O
a B-O O
remote B-O O
position B-O O
but B-O O
that B-O O
this B-O O
stimulation B-O O
is B-O O
restricted B-O O
to B-O O
B B-O B-cell_type
cells B-O I-cell_type
. B-O O

This B-O O
result B-O O
indicates B-O O
the B-O O
involvement B-O O
of B-O O
either B-O O
a B-O O
B-cell-specific B-O B-protein
cofactor B-O I-protein
or B-O O
a B-O O
specific B-O O
modification B-O O
of B-O O
a B-O O
cofactor B-O B-protein
or B-O O
the B-O O
Oct2 B-O B-protein
protein B-O I-protein
in B-O O
Oct2 B-O B-protein
-mediated B-O O
enhancer B-O O
activation B-O O
. B-O O

Mutational B-O O
analyses B-O O
indicate B-O O
that B-O O
the B-O O
carboxy-terminal B-O B-protein
domain B-O I-protein
of B-O O
Oct2 B-O B-protein
is B-O O
critical B-O O
for B-O O
enhancer B-O O
activation B-O O
. B-O O

Moreover B-O O
, B-O O
this B-O O
domain B-O O
conferred B-O O
enhancing B-O O
activity B-O O
when B-O O
fused B-O O
to B-O O
the B-O O
Oct1 B-O B-protein
protein B-O I-protein
, B-O O
which B-O O
by B-O O
itself B-O O
was B-O O
unable B-O O
to B-O O
stimulate B-O O
from B-O O
a B-O O
remote B-O O
position B-O O
. B-O O

The B-O O
glutamine-rich B-O B-protein
activation B-O I-protein
domain B-O I-protein
present B-O O
in B-O O
the B-O O
amino-terminal B-O B-protein
portion B-O I-protein
of B-O O
Oct2 B-O B-protein
and B-O O
the B-O O
POU B-O B-protein
domain B-O I-protein
contribute B-O O
only B-O O
marginally B-O O
to B-O O
the B-O O
transactivation B-O O
function B-O O
from B-O O
a B-O O
distal B-O O
position B-O O
. B-O O

The B-O O
promoter B-O B-DNA
of B-O O
the B-O O
CD19 B-O B-DNA
gene B-O I-DNA
is B-O O
a B-O O
target B-O O
for B-O O
the B-O O
B-cell-specific B-O B-protein
transcription B-O I-protein
factor B-O I-protein
BSAP B-O B-protein
. B-O O

The B-O O
CD19 B-O B-protein
protein B-O I-protein
is B-O O
expressed B-O O
on B-O O
the B-O O
surface B-O O
of B-O O
all B-O O
B-lymphoid B-O B-cell_type
cells B-O I-cell_type
with B-O O
the B-O O
exception B-O O
of B-O O
terminally B-O B-cell_type
differentiated B-O I-cell_type
plasma B-O I-cell_type
cells B-O I-cell_type
and B-O O
has B-O O
been B-O O
implicated B-O O
as B-O O
a B-O O
signal-transducing B-O B-protein
receptor B-O I-protein
in B-O O
the B-O O
control B-O O
of B-O O
proliferation B-O O
and B-O O
differentiation B-O O
. B-O O

Here B-O O
we B-O O
demonstrate B-O O
complete B-O O
correlation B-O O
between B-O O
the B-O O
expression B-O O
pattern B-O O
of B-O O
the B-O O
CD19 B-O B-DNA
gene B-O I-DNA
and B-O O
the B-O O
B-cell-specific B-O B-protein
transcription B-O I-protein
factor B-O I-protein
BSAP B-O B-protein
in B-O O
a B-O O
large B-O O
panel B-O O
of B-O O
B-lymphoid B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

The B-O O
human B-O B-DNA
CD19 B-O I-DNA
gene B-O I-DNA
has B-O O
been B-O O
cloned B-O O
, B-O O
and B-O O
several B-O O
BSAP B-O B-DNA
-binding B-O I-DNA
sites B-O I-DNA
have B-O O
been B-O O
mapped B-O O
by B-O O
in B-O O
vitro B-O O
protein-DNA B-O O
binding B-O O
studies B-O O
. B-O O

In B-O O
particular B-O O
, B-O O
a B-O O
high-affinity B-O B-DNA
BSAP-binding B-O I-DNA
site B-O I-DNA
instead B-O O
of B-O O
a B-O O
TATA B-O B-DNA
sequence B-O I-DNA
is B-O O
located B-O O
in B-O O
the B-O O
-30 B-O B-DNA
promoter B-O I-DNA
region B-O I-DNA
upstream B-O O
of B-O O
a B-O O
cluster B-O O
of B-O O
heterogeneous B-O B-DNA
transcription B-O I-DNA
start B-O I-DNA
sites B-O I-DNA
. B-O O

Moreover B-O O
, B-O O
this B-O O
site B-O O
is B-O O
occupied B-O O
by B-O O
BSAP B-O B-protein
in B-O O
vivo B-O O
in B-O O
a B-O O
CD19-expressing B-O B-cell_line
B-cell B-O I-cell_line
line B-O I-cell_line
but B-O O
not B-O O
in B-O O
plasma B-O B-cell_type
or B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
. B-O O

This B-O O
high-affinity B-O B-DNA
site B-O I-DNA
has B-O O
been B-O O
conserved B-O O
in B-O O
the B-O O
promoters B-O B-DNA
of B-O O
both B-O O
human B-O B-DNA
and B-O I-DNA
mouse B-O I-DNA
CD19 B-O I-DNA
genes B-O I-DNA
and B-O O
was B-O O
furthermore B-O O
shown B-O O
to B-O O
confer B-O O
B-cell B-O O
specificity B-O O
to B-O O
a B-O O
beta-globin B-O B-DNA
reporter B-O I-DNA
gene B-O I-DNA
in B-O O
transient B-O O
transfection B-O O
experiments B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
BSAP B-O B-protein
was B-O O
found B-O O
to B-O O
be B-O O
the B-O O
only B-O O
abundant B-O O
DNA-binding B-O O
activity B-O O
of B-O O
B-cell B-O O
nuclear B-O O
extracts B-O O
that B-O O
interacts B-O O
with B-O O
the B-O O
CD19 B-O B-DNA
promoter B-O I-DNA
. B-O O

Together B-O O
, B-O O
this B-O O
evidence B-O O
strongly B-O O
implicates B-O O
BSAP B-O B-protein
in B-O O
the B-O O
regulation B-O O
of B-O O
the B-O O
CD19 B-O B-DNA
gene B-O I-DNA
. B-O O

Eicosanoids B-O O
in B-O O
breast B-O O
cancer B-O O
patients B-O O
before B-O O
and B-O O
after B-O O
mastectomy B-O O
. B-O O

In B-O O
19 B-O O
patients B-O O
with B-O O
a B-O O
malignant B-O O
breast B-O O
tumor B-O O
, B-O O
tumor B-O O
tissue B-O O
and B-O O
blood B-O O
were B-O O
taken B-O O
to B-O O
determine B-O O
the B-O O
eicosanoid B-O O
profile B-O O
and B-O O
platelet B-O B-cell_type
aggregation B-O O
. B-O O

Values B-O O
were B-O O
compared B-O O
with B-O O
those B-O O
of B-O O
patients B-O O
with B-O O
benign B-O O
tumors B-O O
( B-O O
n B-O O
= B-O O
4 B-O O
) B-O O
, B-O O
or B-O O
undergoing B-O O
a B-O O
mammary B-O O
reduction B-O O
( B-O O
n B-O O
= B-O O
7 B-O O
) B-O O
. B-O O

Postoperatively B-O O
, B-O O
blood B-O O
was B-O O
taken B-O O
as B-O O
well B-O O
in B-O O
order B-O O
to B-O O
compare B-O O
pre- B-O O
and B-O O
postoperative B-O O
values B-O O
. B-O O

Eicosanoids B-O O
were B-O O
measured B-O O
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
and B-O O
mammary B-O O
tissue B-O O
by B-O O
means B-O O
of B-O O
HPLC B-O O
; B-O O
furthermore B-O O
, B-O O
TXA2 B-O B-protein
, B-O O
6-keto-PGF1 B-O B-protein
alpha B-O I-protein
, B-O O
and B-O O
PGE2 B-O B-protein
were B-O O
determined B-O O
by B-O O
RIA B-O O
. B-O O

Differences B-O O
in B-O O
pre- B-O O
and B-O O
postoperative B-O O
values B-O O
of B-O O
cancer B-O O
patients B-O O
were B-O O
seen B-O O
in B-O O
plasma B-O O
RIA B-O O
values B-O O
: B-O O
PGE2 B-O O
and B-O O
6-k-PGF1 B-O O
alpha B-O O
were B-O O
significantly B-O O
higher B-O O
preoperatively B-O O
when B-O O
compared B-O O
with B-O O
postoperatively B-O O
, B-O O
however B-O O
, B-O O
such B-O O
differences B-O O
were B-O O
seen B-O O
in B-O O
the B-O O
control B-O O
groups B-O O
as B-O O
well B-O O
. B-O O

Compared B-O O
to B-O O
benign B-O O
tumor B-O O
or B-O O
mammary B-O O
reduction B-O O
test B-O O
material B-O O
the B-O O
eicosanoid B-O O
profile B-O O
of B-O O
tissue B-O O
obtained B-O O
from B-O O
malignant B-O O
mammary B-O O
tumors B-O O
showed B-O O
important B-O O
differences B-O O
. B-O O

Except B-O O
for B-O O
PGF2 B-O O
alpha B-O O
, B-O O
HHT B-O O
and B-O O
15-HETE B-O O
no B-O O
detectable B-O O
quantities B-O O
of B-O O
eicosanoids B-O O
were B-O O
found B-O O
in B-O O
the B-O O
non-tumor B-O O
material B-O O
, B-O O
whereas B-O O
in B-O O
the B-O O
malignant B-O O
tumor B-O O
material B-O O
substantial B-O O
quantities B-O O
of B-O O
a B-O O
number B-O O
of B-O O
eicosanoid B-O O
metabolites B-O O
were B-O O
present B-O O
. B-O O

Statistically B-O O
significant B-O O
correlations B-O O
could B-O O
be B-O O
established B-O O
between B-O O
patient/histopathology B-O O
data B-O O
and B-O O
the B-O O
results B-O O
of B-O O
the B-O O
platelet B-O B-cell_type
aggregation B-O O
assays B-O O
, B-O O
e.g. B-O O
between B-O O
menopausal B-O O
status B-O O
and B-O O
ADP B-O O
aggregation B-O O
; B-O O
oestrogen B-O B-protein
receptor B-O I-protein
( B-O O
+/- B-O O
) B-O O
and B-O O
collagen B-O B-protein
and B-O O
arachidonic B-O O
acid B-O O
aggregation B-O O
, B-O O
inflammatory B-O O
cell B-O O
infiltration B-O O
score B-O O
and B-O O
arachidonic B-O O
acid B-O O
aggregation B-O O
and B-O O
fibrosis B-O O
score B-O O
and B-O O
ADP B-O O
aggregation B-O O
. B-O O

The B-O O
results B-O O
show B-O O
that B-O O
eicosanoid B-O O
synthesis B-O O
in B-O O
material B-O O
from B-O O
mammary B-O O
cancer B-O O
patients B-O O
is B-O O
different B-O O
from B-O O
that B-O O
in B-O O
benign B-O O
mammary B-O O
tissue B-O O
. B-O O

The B-O O
implications B-O O
, B-O O
in B-O O
particular B-O O
, B-O O
in B-O O
relation B-O O
to B-O O
future B-O O
prognosis B-O O
of B-O O
the B-O O
patient B-O O
, B-O O
remain B-O O
obscure B-O O
. B-O O

Mineralocorticoids B-O O
and B-O O
mineralocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
in B-O O
patients B-O O
with B-O O
pregnancy-induced B-O O
hypertension B-O O
. B-O O

To B-O O
examine B-O O
the B-O O
role B-O O
of B-O O
mineralocorticoids B-O O
in B-O O
the B-O O
pathophysiology B-O O
of B-O O
pregnancy-induced B-O O
hypertension B-O O
( B-O O
PIH B-O O
) B-O O
, B-O O
we B-O O
studied B-O O
plasma B-O O
aldosterone B-O O
and B-O O
18-hydroxycorticosterone B-O O
levels B-O O
in B-O O
25 B-O O
women B-O O
with B-O O
PIH B-O O
and B-O O
25 B-O O
normal B-O O
pregnant B-O O
women B-O O
, B-O O
as B-O O
controls B-O O
. B-O O

Furthermore B-O O
, B-O O
we B-O O
evaluated B-O O
the B-O O
mineralocorticoid B-O B-protein
receptor B-O I-protein
( B-O O
MR B-O B-protein
) B-O O
status B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
in B-O O
the B-O O
2 B-O O
groups B-O O
. B-O O

MR B-O B-protein
count B-O O
was B-O O
significantly B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.0005 B-O O
) B-O O
decreased B-O O
in B-O O
the B-O O
PIH B-O O
group B-O O
( B-O O
148 B-O O
+/- B-O O
9 B-O O
binding B-O O
sites/cell B-O O
) B-O O
compared B-O O
with B-O O
the B-O O
control B-O O
group B-O O
( B-O O
300 B-O O
+/- B-O O
17 B-O O
binding B-O O
sites/cell B-O O
; B-O O
mean B-O O
+/- B-O O
SEM B-O O
) B-O O
. B-O O

Plasma B-O O
aldosterone B-O O
in B-O O
women B-O O
with B-O O
PIH B-O O
was B-O O
281 B-O O
+/- B-O O
61 B-O O
pmol/L B-O O
; B-O O
in B-O O
normal B-O O
pregnant B-O O
women B-O O
it B-O O
was B-O O
697 B-O O
+/- B-O O
172 B-O O
pmol/L B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.025 B-O O
) B-O O
. B-O O

Plasma B-O O
18-hydroxycorticosterone B-O O
was B-O O
also B-O O
significantly B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.025 B-O O
) B-O O
lower B-O O
( B-O O
PIH B-O O
, B-O O
1071 B-O O
+/- B-O O
149 B-O O
pmol/L B-O O
; B-O O
controls B-O O
, B-O O
1907 B-O O
+/- B-O O
318 B-O O
pmol/L B-O O
) B-O O
. B-O O

These B-O O
values B-O O
were B-O O
determined B-O O
at B-O O
the B-O O
onset B-O O
of B-O O
clinical B-O O
symptoms B-O O
of B-O O
PIH B-O O
. B-O O

These B-O O
results B-O O
can B-O O
not B-O O
be B-O O
explained B-O O
by B-O O
receptor B-O O
down-regulation B-O O
due B-O O
to B-O O
higher B-O O
levels B-O O
of B-O O
mineralocorticoids B-O O
in B-O O
PIH B-O O
; B-O O
a B-O O
hitherto B-O O
unknown B-O O
mineralocorticoid B-O O
may B-O O
, B-O O
thus B-O O
, B-O O
be B-O O
responsible B-O O
for B-O O
the B-O O
hypertension B-O O
and B-O O
altered B-O O
MR B-O B-protein
status B-O O
. B-O O

Structure B-O O
function B-O O
analysis B-O O
of B-O O
vitamin B-O O
D B-O O
analogs B-O O
with B-O O
C-ring B-O O
modifications B-O O
. B-O O

Analogs B-O O
of B-O O
1 B-O O
alpha B-O O
, B-O O
25-dihydroxyvitamin B-O O
D3 B-O O
( B-O O
1 B-O O
alpha B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
) B-O O
with B-O O
substitutions B-O O
on B-O O
C-11 B-O O
were B-O O
synthesized B-O O
. B-O O

Small B-O O
apolar B-O O
substitutions B-O O
( B-O O
11 B-O O
alpha-methyl B-O O
, B-O O
11 B-O O
alpha-fluoromethyl B-O O
) B-O O
did B-O O
not B-O O
markedly B-O O
decrease B-O O
the B-O O
affinity B-O O
for B-O O
the B-O O
vitamin B-O B-protein
D B-O I-protein
receptor B-O I-protein
, B-O O
but B-O O
larger B-O O
( B-O O
11 B-O O
alpha-chloromethyl B-O O
or B-O O
11 B-O O
alpha- B-O O
or B-O O
11 B-O O
beta-phenyl B-O O
) B-O O
or B-O O
more B-O O
polar B-O O
substitutions B-O O
( B-O O
11 B-O O
alpha-hydroxymethyl B-O O
, B-O O
11 B-O O
alpha- B-O O
( B-O O
2-hydroxyethyl B-O O
] B-O O
decreased B-O O
the B-O O
affinity B-O O
to B-O O
less B-O O
than B-O O
5 B-O O
% B-O O
of B-O O
that B-O O
of B-O O
1 B-O O
alpha B-O O
, B-O O
25-OH B-O O
) B-O O
2D3 B-O O
. B-O O

Their B-O O
affinity B-O O
for B-O O
the B-O O
vitamin B-O B-protein
D B-O I-protein
-binding B-O I-protein
protein B-O I-protein
, B-O O
however B-O O
, B-O O
increased B-O O
up B-O O
to B-O O
4-fold B-O O
. B-O O

The B-O O
biological B-O O
activity B-O O
of B-O O
11 B-O O
alpha-methyl-1 B-O O
alpha B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
closely B-O O
resembled B-O O
that B-O O
of B-O O
the B-O O
natural B-O O
hormone B-O O
on B-O O
normal B-O O
and B-O O
leukemic B-O B-cell_type
cell B-O I-cell_type
proliferation B-O O
and B-O O
bone B-O O
resorption B-O O
, B-O O
whereas B-O O
its B-O O
in B-O O
vivo B-O O
effect B-O O
on B-O O
calcium B-O O
metabolism B-O O
of B-O O
the B-O O
rachitic B-O O
chick B-O O
was B-O O
about B-O O
50 B-O O
% B-O O
of B-O O
that B-O O
of B-O O
1 B-O O
alpha B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
. B-O O

The B-O O
11 B-O O
beta-methyl B-O O
analog B-O O
had B-O O
a B-O O
greater B-O O
than B-O O
10-fold B-O O
lower B-O O
activity B-O O
. B-O O

The B-O O
differentiating B-O O
effects B-O O
of B-O O
the B-O O
other B-O O
C-11 B-O O
analogs B-O O
on B-O O
human B-O B-cell_line
promyeloid B-O I-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
( B-O O
HL-60 B-O B-cell_line
) B-O O
agreed B-O O
well B-O O
with B-O O
their B-O O
bone-resorbing B-O O
activity B-O O
and B-O O
receptor B-O O
affinity B-O O
, B-O O
but B-O O
they B-O O
demonstrated B-O O
lower B-O O
calcemic B-O O
effects B-O O
in B-O O
vivo B-O O
. B-O O

Large B-O O
or B-O O
polar B-O O
substitutions B-O O
on B-O O
C-11 B-O O
of B-O O
1 B-O O
alpha B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
thus B-O O
impair B-O O
the B-O O
binding B-O O
of B-O O
the B-O O
vitamin B-O B-protein
D B-O I-protein
receptor B-O I-protein
but B-O O
increase B-O O
the B-O O
affinity B-O O
to B-O O
vitamin B-O B-protein
D-binding B-O I-protein
protein B-O I-protein
. B-O O

The B-O O
effects B-O O
of B-O O
many B-O O
C-11-substituted B-O O
1 B-O O
alpha B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
analogs B-O O
on B-O O
HL-60 B-O B-cell_line
cell B-O I-cell_line
differentiation B-O O
exceeded B-O O
their B-O O
activity B-O O
on B-O O
calcium B-O O
metabolism B-O O
. B-O O

Glucocorticoid B-O B-protein
receptor B-O I-protein
binding B-O O
in B-O O
three B-O O
different B-O O
cell B-O O
types B-O O
in B-O O
major B-O O
depressive B-O O
disorder B-O O
: B-O O
lack B-O O
of B-O O
evidence B-O O
of B-O O
receptor B-O O
binding B-O O
defect B-O O
. B-O O

1 B-O O
. B-O O

In B-O O
order B-O O
to B-O O
further B-O O
understand B-O O
the B-O O
apparent B-O O
glucocorticoid B-O O
resistance B-O O
in B-O O
major B-O O
depressive B-O O
disorder B-O O
, B-O O
circadian B-O O
variation B-O O
in B-O O
cortisol B-O O
concentration B-O O
, B-O O
dexamethasone B-O O
suppression B-O O
and B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
binding B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
, B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
and B-O O
cultured B-O B-cell_line
skin B-O I-cell_line
fibroblasts B-O I-cell_line
were B-O O
measured B-O O
in B-O O
rigidly B-O O
defined B-O O
major B-O O
depressive B-O O
disorder B-O O
patients B-O O
and B-O O
non-depressed B-O O
psychiatric B-O O
controls B-O O
. B-O O

2 B-O O
. B-O O

Mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
binding B-O O
to B-O O
glucocorticoid B-O O
correlated B-O O
significantly B-O O
with B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
binding B-O O
to B-O O
glucocorticoid B-O O
, B-O O
but B-O O
both B-O O
determinations B-O O
failed B-O O
to B-O O
differentiate B-O O
major B-O O
depressive B-O O
disorder B-O O
and B-O O
control B-O O
subjects B-O O
. B-O O

3 B-O O
. B-O O

Initial B-O O
and B-O O
post- B-O O
dexamethasone B-O O
in B-O O
vitro B-O O
fibroblast B-O O
binding B-O O
to B-O O
glucocorticoid B-O O
was B-O O
not B-O O
different B-O O
between B-O O
major B-O O
depressive B-O O
disorder B-O O
and B-O O
non-depressed B-O O
control B-O O
subjects B-O O
. B-O O

4 B-O O
. B-O O

The B-O O
phenomenon B-O O
of B-O O
glucocorticoid B-O O
resistance B-O O
in B-O O
major B-O O
depressive B-O O
disorder B-O O
remains B-O O
unexplained B-O O
. B-O O

High B-O O
affinity B-O O
aldosterone B-O O
binding B-O O
to B-O O
plasma B-O O
membrane B-O O
rich B-O O
fractions B-O O
from B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
: B-O O
is B-O O
there B-O O
a B-O O
membrane B-O B-protein
receptor B-O I-protein
for B-O O
mineralocorticoids B-O O
? B-O O

In B-O O
vitro B-O O
effects B-O O
of B-O O
aldosterone B-O O
on B-O O
the B-O O
intracellular B-O O
concentrations B-O O
of B-O O
sodium B-O O
, B-O O
potassium B-O O
and B-O O
calcium B-O O
, B-O O
cell B-O O
volume B-O O
and B-O O
the B-O O
sodium B-O B-protein
-proton-antiport B-O I-protein
have B-O O
been B-O O
described B-O O
in B-O O
intact B-O O
human B-O B-cell_type
mononuclear B-O I-cell_type
leukocytes B-O I-cell_type
( B-O O
HML B-O B-cell_type
) B-O O
. B-O O

In B-O O
the B-O O
present B-O O
paper B-O O
, B-O O
the B-O O
binding B-O O
of B-O O
a B-O O
[ B-O O
125I B-O O
] B-O O
-labeled B-O O
aldosterone B-O O
derivative B-O O
to B-O O
plasma B-O O
membrane B-O O
rich B-O O
fractions B-O O
of B-O O
HML B-O B-cell_type
was B-O O
studied B-O O
. B-O O

High B-O O
affinity B-O O
binding B-O O
of B-O O
the B-O O
radioligand B-O O
with B-O O
an B-O O
apparent B-O O
Kd B-O O
of B-O O
approximately B-O O
0.1 B-O O
nM B-O O
was B-O O
found B-O O
. B-O O

Aldosterone B-O O
displaced B-O O
the B-O O
tracer B-O O
at B-O O
a B-O O
similar B-O O
Kd B-O O
. B-O O

Both B-O O
canrenone B-O O
and B-O O
cortisol B-O O
were B-O O
inactive B-O O
as B-O O
ligands B-O O
up B-O O
to B-O O
concentrations B-O O
of B-O O
0.1 B-O O
microM B-O O
. B-O O

The B-O O
findings B-O O
are B-O O
the B-O O
first B-O O
to B-O O
demonstrate B-O O
membrane B-O B-protein
binding B-O I-protein
sites B-O I-protein
with B-O O
a B-O O
high B-O O
affinity B-O O
for B-O O
aldosterone B-O O
, B-O O
but B-O O
not B-O O
for B-O O
cortisol B-O O
. B-O O

These B-O O
data B-O O
are B-O O
perfectly B-O O
compatible B-O O
with B-O O
major B-O O
properties B-O O
of B-O O
steroidal B-O O
effects B-O O
on B-O O
the B-O O
sodium-proton-antiport B-O B-protein
in B-O O
HML B-O B-cell_type
and B-O O
thus B-O O
very B-O O
likely B-O O
represent B-O O
membrane B-O B-protein
receptors B-O I-protein
for B-O O
aldosterone B-O O
. B-O O

Natural B-O O
variants B-O O
of B-O O
the B-O O
HIV-1 B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
: B-O O
analysis B-O O
of B-O O
promoters B-O B-DNA
with B-O O
duplicated B-O O
DNA B-O B-DNA
regulatory B-O I-DNA
motifs B-O I-DNA
. B-O O

Sequence B-O O
variation B-O O
in B-O O
the B-O O
long B-O B-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
LTR B-O B-DNA
) B-O O
region B-O O
of B-O O
HIV-1 B-O O
was B-O O
analyzed B-O O
in B-O O
viral B-O O
isolates B-O O
of B-O O
17 B-O O
infected B-O O
individuals B-O O
. B-O O

Two B-O O
classes B-O O
of B-O O
LTR B-O B-DNA
size B-O O
variants B-O O
were B-O O
found B-O O
. B-O O

One B-O O
HIV-1 B-O O
variant B-O O
was B-O O
detected B-O O
containing B-O O
an B-O O
additional B-O O
binding B-O B-DNA
site B-O I-DNA
for B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
Sp1 B-O B-protein
. B-O O

Another B-O O
LTR B-O B-DNA
size B-O I-DNA
variation B-O I-DNA
was B-O O
observed B-O O
in B-O O
four B-O O
patients B-O O
in B-O O
a B-O O
region B-O O
just B-O O
upstream B-O O
of B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
enhancer B-O I-DNA
. B-O O

This B-O O
variation B-O O
was B-O O
the B-O O
result B-O O
of B-O O
a B-O O
duplication B-O O
of B-O O
a B-O O
short B-O B-DNA
DNA B-O I-DNA
sequence B-O I-DNA
( B-O O
CTG-motif B-O B-DNA
) B-O O
. B-O O

Cell B-O O
culture B-O O
experiments B-O O
demonstrated B-O O
that B-O O
the B-O O
natural B-O O
variant B-O O
with B-O O
four B-O O
Sp1 B-O B-DNA
sites B-O I-DNA
had B-O O
a B-O O
slightly B-O O
higher B-O O
promoter B-O O
activity B-O O
and B-O O
viral B-O O
replication B-O O
rate B-O O
than B-O O
the B-O O
isogenic B-O B-DNA
control B-O I-DNA
LTR B-O I-DNA
with B-O O
three B-O O
Sp1 B-O B-DNA
sites B-O I-DNA
. B-O O

No B-O O
positive B-O O
effect B-O O
of B-O O
the B-O O
duplicated B-O O
CTG-motif B-O B-DNA
could B-O O
be B-O O
detected B-O O
. B-O O

In B-O O
order B-O O
to B-O O
measure B-O O
small B-O O
differences B-O O
in B-O O
virus B-O O
production B-O O
more B-O O
accurately B-O O
, B-O O
equal B-O O
amounts B-O O
of B-O O
a B-O O
size B-O O
variant B-O O
and B-O O
the B-O O
wild-type B-O B-DNA
plasmid B-O I-DNA
were B-O O
cotransfected B-O O
into B-O O
T-cells B-O B-cell_type
. B-O O

The B-O O
virus B-O O
with B-O O
four B-O O
Sp1 B-O B-DNA
sites B-O I-DNA
did B-O O
outgrow B-O O
the B-O O
three B-O O
Sp1 B-O B-protein
virus B-O O
in B-O O
35 B-O O
days B-O O
of B-O O
culture B-O O
and B-O O
CTG-monomer B-O O
virus B-O O
outcompeted B-O O
the B-O O
CTG-dimer B-O O
virus B-O O
in B-O O
42 B-O O
days B-O O
. B-O O

Based B-O O
on B-O O
these B-O O
results B-O O
we B-O O
estimate B-O O
a B-O O
5-10 B-O O
% B-O O
difference B-O O
in B-O O
virus B-O O
production B-O O
of B-O O
the B-O O
LTR B-O B-DNA
variants B-O I-DNA
when B-O O
compared B-O O
to B-O O
that B-O O
of B-O O
wild-type B-O O
. B-O O

A B-O O
novel B-O O
B B-O B-protein
cell-derived B-O I-protein
coactivator B-O I-protein
potentiates B-O O
the B-O O
activation B-O O
of B-O O
immunoglobulin B-O B-DNA
promoters B-O I-DNA
by B-O O
octamer-binding B-O B-protein
transcription B-O I-protein
factors B-O I-protein
. B-O O

A B-O O
novel B-O O
B B-O O
cell-restricted B-O O
activity B-O O
, B-O O
required B-O O
for B-O O
high B-O O
levels B-O O
of B-O O
octamer B-O B-DNA
/ B-O O
Oct B-O B-DNA
-dependent B-O O
transcription B-O O
from B-O O
an B-O O
immunoglobulin B-O B-DNA
heavy B-O I-DNA
chain B-O I-DNA
( B-O I-DNA
IgH B-O I-DNA
) B-O I-DNA
promoter B-O I-DNA
, B-O O
was B-O O
detected B-O O
in B-O O
an B-O O
in B-O O
vitro B-O O
system B-O O
consisting B-O O
of B-O O
HeLa B-O B-cell_line
cell B-O I-cell_line
-derived B-O O
extracts B-O O
complemented B-O O
with B-O O
fractionated B-O B-protein
B B-O I-protein
cell B-O I-protein
nuclear B-O I-protein
proteins B-O I-protein
. B-O O

The B-O O
factor B-O O
responsible B-O O
for B-O O
this B-O O
activity B-O O
was B-O O
designated B-O O
Oct B-O B-protein
coactivator B-O I-protein
from B-O O
B B-O B-cell_type
cells B-O I-cell_type
( B-O O
OCA-B B-O B-protein
) B-O O
. B-O O

OCA-B B-O B-protein
stimulates B-O O
the B-O O
transcription B-O O
from B-O O
an B-O O
IgH B-O B-DNA
promoter B-O I-DNA
in B-O O
conjunction B-O O
with B-O O
either B-O O
Oct-1 B-O B-protein
or B-O O
Oct-2 B-O B-protein
but B-O O
shows B-O O
no B-O O
significant B-O O
effect B-O O
on B-O O
the B-O O
octamer B-O B-DNA
/ B-O O
Oct B-O B-DNA
-dependent B-O O
transcription B-O O
of B-O O
the B-O O
ubiquitously B-O B-DNA
expressed B-O I-DNA
histone B-O I-DNA
H2B B-O I-DNA
promoter B-O I-DNA
and B-O O
the B-O O
transcription B-O O
of B-O O
USF- B-O B-DNA
and B-O I-DNA
Sp1- B-O I-DNA
regulated B-O I-DNA
promoters B-O I-DNA
. B-O O

Taken B-O O
together B-O O
, B-O O
our B-O O
results B-O O
suggest B-O O
that B-O O
OCA-B B-O B-protein
is B-O O
a B-O O
tissue- B-O B-DNA
, B-O I-DNA
promoter- B-O I-DNA
, B-O O
and B-O O
factor- B-O O
specific B-O O
coactivator B-O B-protein
and B-O O
that B-O O
OCA-B B-O B-protein
may B-O O
be B-O O
a B-O O
major B-O O
determinant B-O O
for B-O O
B B-O O
cell-specific B-O O
activation B-O O
of B-O O
immunoglobulin B-O B-DNA
promoters B-O I-DNA
. B-O O

In B-O O
light B-O O
of B-O O
the B-O O
evidence B-O O
showing B-O O
physical B-O O
and B-O O
functional B-O O
interactions B-O O
between B-O O
Oct B-O B-protein
factors B-O I-protein
and B-O O
OCA-B B-O B-protein
, B-O O
we B-O O
propose B-O O
a B-O O
mechanism B-O O
of B-O O
action B-O O
for B-O O
OCA-B B-O B-protein
and B-O O
discuss B-O O
the B-O O
implications B-O O
of B-O O
OCA-B B-O B-protein
for B-O O
the B-O O
transcriptional B-O O
regulation B-O O
of B-O O
other B-O O
tissue-specific B-O B-DNA
promoters B-O I-DNA
. B-O O

SCL B-O B-protein
and B-O O
related B-O O
hemopoietic B-O B-protein
helix-loop-helix B-O I-protein
transcription B-O I-protein
factors B-O I-protein
. B-O O

The B-O O
helix-loop-helix B-O B-protein
( B-O I-protein
HLH B-O I-protein
) B-O I-protein
proteins B-O I-protein
are B-O O
a B-O O
family B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
that B-O O
include B-O O
proteins B-O O
critical B-O O
to B-O O
differentiation B-O O
and B-O O
development B-O O
in B-O O
species B-O O
ranging B-O O
from B-O O
plants B-O O
to B-O O
mammals B-O O
. B-O O

Five B-O O
members B-O O
of B-O O
this B-O O
family B-O O
( B-O O
MYC B-O B-protein
, B-O O
SCL B-O B-protein
, B-O O
TAL-2 B-O B-protein
, B-O O
LYL-1 B-O B-protein
and B-O O
E2A B-O B-protein
) B-O O
are B-O O
implicated B-O O
in B-O O
oncogenic B-O O
events B-O O
in B-O O
human B-O O
lymphoid B-O O
tumors B-O O
because B-O O
of B-O O
their B-O O
consistent B-O O
involvement B-O O
in B-O O
chromosomal B-O O
translocations B-O O
. B-O O

Although B-O O
activated B-O O
in B-O O
T B-O O
cell B-O O
leukemias B-O O
, B-O O
expression B-O O
of B-O O
SCL B-O B-protein
and B-O O
LYL-1 B-O B-protein
is B-O O
low B-O O
or B-O O
undetectable B-O O
in B-O O
normal B-O B-cell_type
T B-O I-cell_type
cell B-O I-cell_type
populations B-O I-cell_type
. B-O O

SCL B-O B-protein
is B-O O
expressed B-O O
in B-O O
erythroid B-O B-cell_type
, B-O I-cell_type
megakaryocyte B-O I-cell_type
and B-O I-cell_type
mast B-O I-cell_type
cell B-O I-cell_type
populations B-O I-cell_type
( B-O O
the B-O O
same B-O O
cell B-O O
lineages B-O O
as B-O O
GATA-1 B-O B-protein
, B-O O
a B-O O
zinc-finger B-O B-protein
transcription B-O I-protein
factor B-O I-protein
) B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
both B-O O
SCL B-O B-protein
and B-O O
GATA-1 B-O B-protein
undergo B-O O
coordinate B-O O
modulation B-O O
during B-O O
chemically B-O O
induced B-O O
erythroid B-O O
differentiation B-O O
of B-O O
mouse B-O B-cell_type
erythroleukemia B-O I-cell_type
cells B-O I-cell_type
and B-O O
are B-O O
down-modulated B-O O
during B-O O
myeloid B-O O
differentiation B-O O
of B-O O
human B-O B-cell_line
K562 B-O I-cell_line
cells B-O I-cell_line
, B-O O
thus B-O O
implying B-O O
a B-O O
role B-O O
for B-O O
SCL B-O B-protein
in B-O O
erythroid B-O O
differentiation B-O O
events B-O O
. B-O O

However B-O O
, B-O O
in B-O O
contrast B-O O
to B-O O
GATA-1 B-O B-protein
, B-O O
SCL B-O B-protein
is B-O O
expressed B-O O
in B-O O
the B-O O
developing B-O O
brain B-O O
. B-O O

Studies B-O O
of B-O O
the B-O O
function B-O O
of B-O O
SCL B-O B-protein
suggest B-O O
it B-O O
is B-O O
also B-O O
important B-O O
in B-O O
proliferation B-O O
and B-O O
self-renewal B-O O
events B-O O
in B-O O
erythroid B-O B-cell_type
cells B-O I-cell_type
. B-O O

Induction B-O O
of B-O O
the B-O O
POU B-O B-protein
domain B-O I-protein
transcription B-O I-protein
factor B-O I-protein
Oct-2 B-O B-protein
during B-O O
T-cell B-O B-cell_type
activation B-O O
by B-O O
cognate B-O B-protein
antigen B-O I-protein
. B-O O

Oct-2 B-O B-protein
is B-O O
a B-O O
transcription B-O B-protein
factor B-O I-protein
that B-O O
binds B-O O
specifically B-O O
to B-O O
octamer B-O B-DNA
DNA B-O I-DNA
motifs B-O I-DNA
in B-O O
the B-O O
promoters B-O B-DNA
of B-O O
immunoglobulin B-O B-DNA
and B-O I-DNA
interleukin-2 B-O I-DNA
genes B-O I-DNA
. B-O O

All B-O O
tumor B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
from B-O O
the B-O O
B-cell B-O B-cell_type
lineage B-O I-cell_type
and B-O O
a B-O O
few B-O O
from B-O O
the B-O O
T-cell B-O B-cell_type
lineage B-O I-cell_type
express B-O O
Oct-2 B-O B-protein
. B-O O

To B-O O
address B-O O
the B-O O
role B-O O
of B-O O
Oct-2 B-O B-protein
in B-O O
the B-O O
T-cell B-O B-cell_type
lineage B-O I-cell_type
, B-O O
we B-O O
studied B-O O
the B-O O
expression B-O O
of B-O O
Oct-2 B-O B-RNA
mRNA B-O I-RNA
and B-O O
protein B-O O
in B-O O
nontransformed B-O B-cell_line
human B-O I-cell_line
and B-O I-cell_line
mouse B-O I-cell_line
T B-O I-cell_line
cells B-O I-cell_line
. B-O O

Oct-2 B-O B-protein
was B-O O
found B-O O
in B-O O
CD4+ B-O B-cell_type
and B-O I-cell_type
CD8+ B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
prepared B-O O
from B-O O
human B-O O
peripheral B-O O
blood B-O O
and B-O O
in B-O O
mouse B-O B-cell_type
lymph B-O I-cell_type
node B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

In B-O O
a B-O O
T-cell B-O B-cell_line
clone B-O I-cell_line
specific B-O O
for B-O O
pigeon B-O B-protein
cytochrome B-O I-protein
c B-O I-protein
in B-O O
the B-O O
context B-O O
of B-O O
I-Ek B-O B-protein
, B-O O
Oct-2 B-O B-protein
was B-O O
induced B-O O
by B-O O
antigen B-O O
stimulation B-O O
, B-O O
with B-O O
the B-O O
increase B-O O
in B-O O
Oct-2 B-O B-protein
protein B-O I-protein
seen B-O O
first B-O O
at B-O O
3 B-O O
h B-O O
after B-O O
activation B-O O
and B-O O
continuing B-O O
for B-O O
at B-O O
least B-O O
24 B-O O
h B-O O
. B-O O

Oct-2 B-O B-RNA
mRNA B-O I-RNA
induction B-O O
during B-O O
antigen-driven B-O O
T-cell B-O O
activation B-O O
was B-O O
blocked B-O O
by B-O O
cyclosporin B-O O
A B-O O
, B-O O
as B-O O
well B-O O
as B-O O
by B-O O
protein B-O O
synthesis B-O O
inhibitors B-O O
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
Oct-2 B-O B-protein
participates B-O O
in B-O O
transcriptional B-O O
regulation B-O O
during B-O O
T-cell B-O B-cell_type
activation B-O O
. B-O O
The B-O O
relatively B-O O
delayed B-O O
kinetics B-O O
of B-O O
Oct-2 B-O B-protein
induction B-O O
suggests B-O O
that B-O O
Oct-2 B-O B-protein
mediates B-O O
the B-O O
changes B-O O
in B-O O
gene B-O O
expression B-O O
which B-O O
occur B-O O
many B-O O
hours B-O O
or B-O O
days B-O O
following B-O O
antigen B-O O
stimulation B-O O
of B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

Glucocorticoid B-O B-protein
receptor B-O I-protein
in B-O O
patients B-O O
with B-O O
lupus B-O O
nephritis B-O O
: B-O O
relationship B-O O
between B-O O
receptor B-O O
levels B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
and B-O O
effect B-O O
of B-O O
glucocorticoid B-O O
therapy B-O O
. B-O O

We B-O O
investigated B-O O
the B-O O
clinical B-O O
significance B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
determination B-O O
in B-O O
20 B-O O
patients B-O O
with B-O O
systemic B-O O
lupus B-O O
erythematosus B-O O
( B-O O
SLE B-O O
) B-O O
who B-O O
afterwards B-O O
developed B-O O
nephrotic B-O O
syndrome B-O O
. B-O O

Glucocorticoid B-O B-protein
receptor B-O I-protein
concentrations B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
( B-O O
MNL B-O B-cell_type
) B-O O
in B-O O
these B-O O
patients B-O O
were B-O O
comparable B-O O
with B-O O
those B-O O
in B-O O
both B-O O
other B-O O
patients B-O O
with B-O O
SLE B-O O
and B-O O
healthy B-O O
persons B-O O
. B-O O

Improvement B-O O
in B-O O
urinary B-O O
protein B-O O
excretion B-O O
and B-O O
in B-O O
disease B-O O
activity B-O O
, B-O O
which B-O O
was B-O O
scored B-O O
according B-O O
to B-O O
the B-O O
SLE B-O O
Disease B-O O
Activity B-O O
Index B-O O
system B-O O
of B-O O
the B-O O
University B-O O
of B-O O
Toronto B-O O
, B-O O
closely B-O O
related B-O O
to B-O O
the B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
concentrations B-O O
in B-O O
MNL B-O B-cell_type
isolated B-O O
from B-O O
the B-O O
corresponding B-O O
patients B-O O
. B-O O

In B-O O
summary B-O O
, B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
determination B-O O
in B-O O
patients B-O O
with B-O O
lupus B-O O
nephritis B-O O
may B-O O
be B-O O
a B-O O
predictive B-O O
clue B-O O
for B-O O
assessing B-O O
responsiveness B-O O
to B-O O
glucocorticoid B-O O
therapy B-O O
. B-O O

[ B-O O
Changes B-O O
in B-O O
plasma B-O B-protein
interleukin-1 B-O I-protein
and B-O O
their B-O O
possible B-O O
relationship B-O O
with B-O O
the B-O O
changes B-O O
in B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
in B-O O
aged B-O O
long-distance B-O O
runner B-O O
] B-O O

For B-O O
the B-O O
study B-O O
of B-O O
the B-O O
changes B-O O
in B-O O
plasma B-O B-protein
interleukin-1 B-O I-protein
( B-O O
IL-1 B-O B-protein
) B-O O
and B-O O
their B-O O
possible B-O O
relationship B-O O
with B-O O
the B-O O
changes B-O O
in B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
( B-O O
GR B-O B-protein
) B-O O
, B-O O
plasma B-O O
IL-1 B-O B-protein
and B-O O
GR B-O B-protein
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
leukocytes B-O I-cell_type
in B-O O
aged B-O O
long-distance B-O O
runner B-O O
were B-O O
measured B-O O
simultaneously B-O O
. B-O O

The B-O O
activity B-O O
of B-O O
IL-1 B-O B-protein
was B-O O
expressed B-O O
as B-O O
its B-O O
ability B-O O
to B-O O
stimulate B-O O
3H-TdR B-O B-protein
incorporation B-O O
in B-O O
the B-O O
thymocytes B-O B-cell_type
of B-O O
C57 B-O O
mice B-O O
. B-O O

GR B-O B-protein
was B-O O
determined B-O O
by B-O O
whole B-O O
cell B-O O
assay B-O O
with B-O O
3H-Dex B-O O
. B-O O

The B-O O
results B-O O
showed B-O O
that B-O O
the B-O O
activity B-O O
of B-O O
plasma B-O O
IL-1 B-O B-protein
in B-O O
aged B-O O
long-distance B-O O
runner B-O O
was B-O O
209 B-O O
% B-O O
, B-O O
223 B-O O
% B-O O
and B-O O
145 B-O O
% B-O O
of B-O O
the B-O O
control B-O O
at B-O O
14.7-18.7 B-O O
, B-O O
3.8-7.0 B-O O
and B-O O
1.5-2.6 B-O O
KD B-O O
fractions B-O O
. B-O O

The B-O O
GR B-O B-protein
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
leukocytes B-O I-cell_type
in B-O O
aged B-O O
runner B-O O
was B-O O
65 B-O O
% B-O O
of B-O O
the B-O O
control B-O O
. B-O O

Possible B-O O
relationship B-O O
between B-O O
the B-O O
changes B-O O
in B-O O
IL-1 B-O B-protein
and B-O O
GR B-O B-protein
in B-O O
aged B-O O
long-distance B-O O
runner B-O O
and B-O O
its B-O O
physiological B-O O
significance B-O O
are B-O O
discussed B-O O
. B-O O

Mineralocorticoid B-O O
effector B-O O
mechanism B-O O
in B-O O
preeclampsia B-O O
. B-O O

Mineralocorticoid B-O O
effector B-O O
mechanisms B-O O
were B-O O
evaluated B-O O
in B-O O
29 B-O O
patients B-O O
with B-O O
preeclampsia B-O O
and B-O O
in B-O O
25 B-O O
uncomplicated B-O O
pregnancies B-O O
by B-O O
measurement B-O O
of B-O O
plasma B-O O
aldosterone B-O O
, B-O O
levels B-O O
of B-O O
mineralocorticoid B-O B-protein
receptor B-O I-protein
( B-O O
MR B-O B-protein
) B-O O
in B-O O
mononuclear B-O B-cell_type
leucocytes B-O I-cell_type
, B-O O
and B-O O
subtraction B-O O
potential B-O O
difference B-O O
( B-O O
SPD B-O O
; B-O O
rectal B-O O
minus B-O O
oral B-O O
values B-O O
) B-O O
. B-O O

Mean B-O O
values B-O O
for B-O O
plasma B-O O
aldosterone B-O O
were B-O O
not B-O O
different B-O O
between B-O O
the B-O O
two B-O O
groups B-O O
, B-O O
but B-O O
significant B-O O
differences B-O O
were B-O O
observed B-O O
for B-O O
MR B-O B-protein
( B-O O
preeclampsia B-O O
, B-O O
81 B-O O
+/- B-O O
44 B-O O
receptors/cell B-O O
; B-O O
controls B-O O
, B-O O
306 B-O O
+/- B-O O
168 B-O O
) B-O O
and B-O O
SPD B-O O
( B-O O
preeclampsia B-O O
, B-O O
65 B-O O
+/- B-O O
7 B-O O
mV B-O O
; B-O O
controls B-O O
, B-O O
12 B-O O
+/- B-O O
5 B-O O
mV B-O O
) B-O O
. B-O O

In B-O O
six B-O O
cases B-O O
we B-O O
determined B-O O
MR B-O B-protein
, B-O O
plasma B-O O
aldosterone B-O O
, B-O O
and B-O O
SPD B-O O
in B-O O
patients B-O O
with B-O O
preeclampsia B-O O
before B-O O
and B-O O
3 B-O O
months B-O O
after B-O O
delivery B-O O
. B-O O

MR B-O B-protein
were B-O O
reduced B-O O
before B-O O
delivery B-O O
( B-O O
96 B-O O
+/- B-O O
27 B-O O
receptors/cell B-O O
) B-O O
, B-O O
and B-O O
SPD B-O O
increased B-O O
( B-O O
64 B-O O
+/- B-O O
8 B-O O
mV B-O O
) B-O O
, B-O O
with B-O O
both B-O O
parameters B-O O
normalizing B-O O
after B-O O
delivery B-O O
( B-O O
MR B-O B-protein
, B-O O
242 B-O O
+/- B-O O
79 B-O O
; B-O O
SPD B-O O
, B-O O
14.0 B-O O
+/- B-O O
4 B-O O
mV B-O O
) B-O O
. B-O O

Aldosterone B-O O
levels B-O O
returned B-O O
to B-O O
normal B-O O
nonpregnant B-O O
values B-O O
after B-O O
delivery B-O O
. B-O O

These B-O O
data B-O O
suggest B-O O
an B-O O
important B-O O
role B-O O
for B-O O
abnormalities B-O O
in B-O O
mineralocorticoid B-O O
effector B-O O
mechanisms B-O O
in B-O O
the B-O O
etiology B-O O
of B-O O
preeclampsia B-O O
and B-O O
could B-O O
be B-O O
an B-O O
useful B-O O
marker B-O O
for B-O O
diagnosis B-O O
. B-O O

Kinetics B-O O
of B-O O
nuclear B-O O
translocation B-O O
and B-O O
turnover B-O O
of B-O O
the B-O O
vitamin B-O B-protein
D B-O I-protein
receptor B-O I-protein
in B-O O
human B-O B-cell_line
HL60 B-O I-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
and B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
lymphocytes B-O I-cell_type
-- B-O O
coincident B-O O
rise B-O O
of B-O O
DNA-relaxing B-O O
activity B-O O
in B-O O
nuclear B-O O
extracts B-O O
. B-O O

High B-O B-protein
affinity B-O I-protein
receptors B-O I-protein
( B-O O
VDR B-O B-protein
) B-O O
for B-O O
1 B-O O
, B-O O
25-dihydroxycholecalciferol B-O O
( B-O O
calcitriol B-O O
) B-O O
are B-O O
expressed B-O O
in B-O O
HL60 B-O B-cell_line
human B-O I-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
and B-O O
in B-O O
low B-O O
numbers B-O O
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
lymphocytes B-O I-cell_type
( B-O O
PBL B-O B-cell_type
) B-O O
. B-O O

HL60 B-O B-cell_line
cells B-O I-cell_line
, B-O O
expressing B-O O
some B-O O
characteristics B-O O
of B-O O
promyelocytes B-O B-cell_type
, B-O O
can B-O O
be B-O O
induced B-O O
to B-O O
monocytoid B-O O
differentiation B-O O
by B-O O
calcitriol B-O O
. B-O O

Specific B-O O
nuclear B-O O
translocation B-O O
of B-O O
[ B-O B-protein
3H B-O I-protein
] B-O I-protein
calcitriol/VDR B-O I-protein
was B-O O
examined B-O O
after B-O O
exposure B-O O
of B-O O
whole B-O B-cell_type
cells B-O I-cell_type
to B-O O
10 B-O O
( B-O O
-9 B-O O
) B-O O
M/l B-O O
calcitriol B-O O
in B-O O
the B-O O
presence B-O O
and B-O O
absence B-O O
of B-O O
a B-O O
500-fold B-O O
excess B-O O
of B-O O
unlabeled B-O O
ligand B-O O
and B-O O
subsequent B-O O
isolation B-O O
of B-O O
nuclei B-O O
. B-O O

Specific B-O O
nuclear B-O O
translocation B-O O
of B-O O
[ B-O B-protein
3H B-O I-protein
] B-O I-protein
calcitriol/VDR B-O I-protein
was B-O O
found B-O O
to B-O O
be B-O O
time B-O O
dependent B-O O
reaching B-O O
a B-O O
maximum B-O O
of B-O O
approximately B-O O
2100 B-O O
binding B-O O
sites/nucleus B-O O
after B-O O
3 B-O O
h B-O O
of B-O O
incubation B-O O
in B-O O
HL60 B-O B-cell_line
cells B-O I-cell_line
, B-O O
whereas B-O O
a B-O O
maximum B-O O
of B-O O
approximately B-O O
310 B-O O
binding B-O O
sites/nucleus B-O O
was B-O O
found B-O O
after B-O O
3 B-O O
h B-O O
in B-O O
PBL B-O B-cell_type
. B-O O

Pulse B-O O
exposure B-O O
of B-O O
HL60 B-O B-cell_line
to B-O O
radiolabeled B-O O
hormone B-O O
for B-O O
3 B-O O
h B-O O
followed B-O O
by B-O O
culture B-O O
in B-O O
medium B-O O
without B-O O
serum B-O O
and B-O O
calcitriol B-O O
lead B-O O
to B-O O
nuclear B-O O
retention B-O O
of B-O O
approximately B-O O
1600 B-O O
radiolabeled B-O O
VDR B-O B-protein
by B-O O
8 B-O O
h B-O O
and B-O O
approximately B-O O
1000 B-O O
VDR B-O B-protein
by B-O O
24 B-O O
h B-O O
. B-O O

Radiolabeled B-O B-protein
VDR B-O I-protein
disappeared B-O O
from B-O O
the B-O O
nuclear B-O O
compartment B-O O
with B-O O
a B-O O
halflife B-O O
of B-O O
approximately B-O O
30 B-O O
min B-O O
if B-O O
cells B-O O
were B-O O
cultured B-O O
with B-O O
identical B-O O
concentrations B-O O
of B-O O
unlabeled B-O O
hormone B-O O
after B-O O
the B-O O
pulse B-O O
( B-O O
pulse/chase-experiments B-O O
) B-O O
. B-O O

No B-O O
difference B-O O
of B-O O
VDR B-O B-protein
retention B-O O
in B-O O
pulse B-O O
and B-O O
pulse/chase-experiments B-O O
was B-O O
seen B-O O
in B-O O
PBL B-O B-cell_type
, B-O O
where B-O O
VDR B-O B-protein
halflife B-O O
was B-O O
approximately B-O O
30 B-O O
min B-O O
. B-O O

No B-O O
specific B-O O
translocation B-O O
into B-O O
the B-O O
nuclear B-O O
compartment B-O O
was B-O O
seen B-O O
when B-O O
isolated B-O O
nuclei B-O O
were B-O O
incubated B-O O
in B-O O
[ B-O O
3H B-O O
] B-O O
calcitriol B-O O
. B-O O

Radiolabeled B-O B-protein
hormone/receptor B-O I-protein
complexes B-O I-protein
of B-O O
nuclei B-O O
isolated B-O O
from B-O O
cells B-O O
exposed B-O O
for B-O O
3 B-O O
h B-O O
to B-O O
radiolabeled B-O O
hormone B-O O
-- B-O O
in B-O O
contrast B-O O
to B-O O
identical B-O O
experiments B-O O
with B-O O
intact B-O O
cells B-O O
-- B-O O
did B-O O
not B-O O
disappear B-O O
from B-O O
the B-O O
nuclear B-O O
compartment B-O O
upon B-O O
incubation B-O O
of B-O O
nuclei B-O O
with B-O O
identical B-O O
concentrations B-O O
of B-O O
the B-O O
unlabeled B-O O
compound B-O O
. B-O O

The B-O O
activity B-O O
of B-O O
DNA B-O B-protein
relaxing B-O I-protein
enzymes B-O I-protein
( B-O O
e.g. B-O O
topoisomerases B-O B-protein
I B-O I-protein
and B-O I-protein
II B-O I-protein
) B-O O
in B-O O
nuclear B-O O
extracts B-O O
was B-O O
measured B-O O
using B-O O
a B-O O
PBR B-O O
322-relaxation-assay B-O O
. B-O O

Enhanced B-O O
overall B-O O
enzyme B-O O
activity B-O O
was B-O O
found B-O O
in B-O O
nuclear B-O O
extracts B-O O
by B-O O
1 B-O O
h B-O O
after B-O O
incubation B-O O
with B-O O
calcitriol B-O O
( B-O O
final B-O O
ethanol B-O O
concentration B-O O
0.0001 B-O O
% B-O O
v/v B-O O
) B-O O
in B-O O
HL60 B-O B-cell_line
and B-O O
PBL B-O B-cell_type
. B-O O

The B-O O
enhanced B-O O
activity B-O O
disappeared B-O O
after B-O O
2 B-O O
h B-O O
in B-O O
PBL B-O B-cell_type
, B-O O
whereas B-O O
it B-O O
was B-O O
still B-O O
enhanced B-O O
by B-O O
4 B-O O
h B-O O
in B-O O
HL60 B-O B-cell_line
. B-O O

No B-O O
effect B-O O
was B-O O
seen B-O O
in B-O O
ethanol B-O B-cell_line
treated B-O I-cell_line
controls B-O I-cell_line
. B-O O

We B-O O
conclude B-O O
that B-O O
a B-O O
specific B-O O
nuclear B-O O
translocation B-O O
mechanism B-O O
exists B-O O
for B-O O
calcitriol B-O O
in B-O O
both B-O O
cell B-O O
types B-O O
examined B-O O
, B-O O
most B-O O
likely B-O O
due B-O O
to B-O O
translocation B-O O
of B-O O
receptor B-O B-protein
proteins B-O I-protein
after B-O O
hormone B-O O
binding B-O O
. B-O O

Translocated B-O B-protein
hormone/receptor B-O I-protein
complexes B-O I-protein
compete B-O O
for B-O O
a B-O O
limited B-O O
number B-O O
of B-O O
specific B-O O
nuclear B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
. B-O O

Enhanced B-O O
activity B-O O
of B-O O
topoisomerases B-O B-protein
in B-O O
nuclear B-O O
extracts B-O O
upon B-O O
translocation B-O O
of B-O O
VDR B-O B-protein
might B-O O
reflect B-O O
interaction B-O O
of B-O O
both B-O O
within B-O O
the B-O O
nuclear B-O O
compartment B-O O
, B-O O
thus B-O O
initiating B-O O
DNA-unwinding B-O O
, B-O O
a B-O O
prerequisite B-O O
of B-O O
transcription B-O O
initiation B-O O
. B-O O

Influence B-O O
of B-O O
estradiol B-O O
and B-O O
tamoxifen B-O O
on B-O O
susceptibility B-O O
of B-O O
human B-O B-cell_line
breast B-O I-cell_line
cancer B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
to B-O O
lysis B-O O
by B-O O
lymphokine-activated B-O B-cell_type
killer B-O I-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
design B-O O
of B-O O
combination B-O O
hormonal B-O O
and B-O O
immunotherapeutic B-O O
protocols B-O O
for B-O O
breast B-O O
cancer B-O O
patients B-O O
may B-O O
be B-O O
facilitated B-O O
by B-O O
analysis B-O O
of B-O O
preclinical B-O O
in B-O O
vitro B-O O
model B-O O
systems B-O O
. B-O O

Estrogen B-O B-cell_line
receptor B-O I-cell_line
positive B-O I-cell_line
( B-O I-cell_line
ER+ B-O I-cell_line
: B-O I-cell_line
MCF-7 B-O I-cell_line
) B-O I-cell_line
and B-O I-cell_line
negative B-O I-cell_line
( B-O I-cell_line
ER- B-O I-cell_line
: B-O I-cell_line
MDA-MB-231 B-O I-cell_line
) B-O I-cell_line
human B-O I-cell_line
breast B-O I-cell_line
cancer B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
were B-O O
utilized B-O O
to B-O O
evaluate B-O O
the B-O O
effects B-O O
of B-O O
tamoxifen B-O O
( B-O O
TAM B-O O
) B-O O
and B-O O
estradiol B-O O
( B-O O
E2 B-O O
) B-O O
on B-O O
modulation B-O O
of B-O O
breast B-O O
cancer B-O O
target B-O O
susceptibility B-O O
to B-O O
lysis B-O O
by B-O O
lymphokine-activated B-O B-cell_type
killer B-O I-cell_type
( B-O I-cell_type
LAK B-O I-cell_type
) B-O I-cell_type
cells B-O I-cell_type
. B-O O

E2 B-O B-cell_line
-stimulated B-O I-cell_line
ER+ B-O I-cell_line
cells B-O I-cell_line
were B-O O
more B-O O
susceptible B-O O
to B-O O
lysis B-O O
by B-O O
LAK B-O B-cell_type
cells B-O I-cell_type
than B-O O
corresponding B-O O
TAM B-O O
-treated B-O O
or B-O O
control B-O B-cell_type
cells B-O I-cell_type
, B-O O
while B-O O
treatment B-O O
of B-O O
with B-O O
either B-O O
E2 B-O B-protein
or B-O O
TAM B-O O
alone B-O O
did B-O O
not B-O O
alter B-O O
from B-O O
control B-O O
their B-O O
susceptibility B-O O
to B-O O
this B-O O
immune-mediated B-O O
lysis B-O O
. B-O O

All B-O O
ER+ B-O B-cell_line
and B-O I-cell_line
ER- B-O I-cell_line
cells B-O I-cell_line
tested B-O O
remained B-O O
sensitive B-O O
after B-O O
treatment B-O O
with B-O O
TAM B-O O
to B-O O
lysis B-O O
by B-O O
LAK B-O B-cell_type
cells B-O I-cell_type
. B-O O

In B-O O
addition B-O O
, B-O O
an B-O O
adenocarcinoma B-O B-protein
reactive B-O I-protein
human-mouse B-O I-protein
chimeric B-O I-protein
monoclonal B-O I-protein
antibody B-O I-protein
( B-O O
ING-1 B-O B-protein
) B-O O
was B-O O
able B-O O
to B-O O
significantly B-O O
boost B-O O
in B-O O
vivo B-O O
generated B-O O
LAK B-O O
cell-mediated B-O O
lysis B-O O
of B-O O
control B-O O
, B-O O
E2-treated B-O O
, B-O O
and B-O O
TAM-treated B-O B-cell_line
ER+ B-O I-cell_line
and B-O I-cell_line
ER- B-O I-cell_line
cells B-O I-cell_line
. B-O O

These B-O O
in B-O O
vitro B-O O
results B-O O
provide B-O O
a B-O O
preclinical B-O O
rationale B-O O
for B-O O
in B-O O
vivo B-O O
testing B-O O
of B-O O
TAM B-O O
, B-O O
interleukin-2 B-O B-protein
( B-O O
IL-2 B-O B-protein
) B-O O
, B-O O
and B-O O
breast B-O O
cancer B-O O
reactive B-O O
antibody-dependent B-O O
cellular B-O O
cytotoxicity B-O O
facilitating B-O O
antibody B-O O
in B-O O
patients B-O O
with B-O O
refractory B-O O
or B-O O
high B-O O
risk B-O O
breast B-O O
cancer B-O O
. B-O O

The B-O O
cellular B-O B-DNA
oncogene B-O I-DNA
c-myb B-O B-DNA
can B-O O
interact B-O O
synergistically B-O O
with B-O O
the B-O O
Epstein-Barr B-O B-protein
virus B-O I-protein
BZLF1 B-O I-protein
transactivator B-O I-protein
in B-O O
lymphoid B-O B-cell_type
cells B-O I-cell_type
. B-O O

Regulation B-O O
of B-O O
replicative B-O O
functions B-O O
in B-O O
the B-O O
Epstein-Barr B-O B-DNA
virus B-O I-DNA
( B-O I-DNA
EBV B-O I-DNA
) B-O I-DNA
genome B-O I-DNA
is B-O O
mediated B-O O
through B-O O
activation B-O O
of B-O O
a B-O O
virally B-O B-protein
encoded B-O I-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
Z B-O B-protein
( B-O O
BZLF1 B-O B-protein
) B-O O
. B-O O

We B-O O
have B-O O
shown B-O O
that B-O O
the B-O O
Z B-O B-protein
gene B-O I-protein
product B-O I-protein
, B-O O
which B-O O
binds B-O O
to B-O O
AP-1 B-O B-DNA
sites B-O I-DNA
as B-O O
a B-O O
homodimer B-O B-protein
and B-O O
has B-O O
sequence B-O O
similarity B-O O
to B-O O
c-Fos B-O B-protein
, B-O O
can B-O O
efficiently B-O O
activate B-O O
the B-O O
EBV B-O B-DNA
early B-O I-DNA
promoter B-O I-DNA
, B-O O
BMRF1 B-O B-DNA
, B-O O
in B-O O
certain B-O O
cell B-O O
types B-O O
( B-O O
i.e. B-O O
, B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
) B-O O
but B-O O
not B-O O
others B-O O
( B-O O
i.e. B-O O
, B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
) B-O O
. B-O O

Here B-O O
we B-O O
demonstrate B-O O
that B-O O
the B-O O
c-myb B-O B-protein
proto-oncogene B-O I-protein
product B-O I-protein
, B-O O
which B-O O
is B-O O
itself B-O O
a B-O O
DNA-binding B-O B-protein
protein B-O I-protein
and B-O O
transcriptional B-O B-protein
transactivator B-O I-protein
, B-O O
can B-O O
interact B-O O
synergistically B-O O
with B-O O
Z B-O B-protein
in B-O O
activating B-O O
the B-O O
BMRF1 B-O B-DNA
promoter B-O I-DNA
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
( B-O O
a B-O O
T-cell B-O B-cell_line
line B-O I-cell_line
) B-O O
or B-O O
Raji B-O B-cell_line
cells B-O I-cell_line
( B-O O
an B-O O
EBV B-O B-cell_line
-positive B-O I-cell_line
B-cell B-O I-cell_line
) B-O O
, B-O O
whereas B-O O
the B-O O
c-myb B-O B-protein
gene B-O I-protein
product B-O I-protein
by B-O O
itself B-O O
has B-O O
little B-O O
effect B-O O
. B-O O

The B-O O
simian B-O B-DNA
virus B-O I-DNA
40 B-O I-DNA
early B-O I-DNA
promoter B-O I-DNA
is B-O O
also B-O O
synergistically B-O O
activated B-O O
by B-O O
the B-O O
Z/c-myb B-O B-protein
combination B-O I-protein
. B-O O

Synergistic B-O O
transactivation B-O O
of B-O O
the B-O O
BMRF1 B-O B-DNA
promoter B-O I-DNA
by B-O O
the B-O O
Z/c-myb B-O B-protein
combination B-O I-protein
appears B-O O
to B-O O
involve B-O O
direct B-O O
binding B-O O
by B-O O
the B-O O
Z B-O B-protein
protein B-O I-protein
but B-O O
not B-O O
the B-O O
c-myb B-O B-protein
protein B-O I-protein
. B-O O

A B-O O
30-bp B-O B-DNA
sequence B-O I-DNA
in B-O O
the B-O O
BMRF1 B-O B-DNA
promoter B-O I-DNA
which B-O O
contains B-O O
a B-O O
Z B-O B-DNA
binding B-O I-DNA
site B-O I-DNA
( B-O O
a B-O O
consensus B-O B-DNA
AP-1 B-O I-DNA
site B-O I-DNA
) B-O O
is B-O O
sufficient B-O O
to B-O O
transfer B-O O
high-level B-O O
lymphoid-specific B-O O
responsiveness B-O O
to B-O O
the B-O O
Z/c-myb B-O B-protein
combination B-O I-protein
to B-O O
a B-O O
heterologous B-O B-DNA
promoter B-O I-DNA
. B-O O

That B-O O
the B-O O
c-myb B-O B-protein
oncogene B-O I-protein
product B-O I-protein
can B-O O
interact B-O O
synergistically B-O O
with B-O O
an B-O O
EBV B-O B-protein
-encoded B-O I-protein
member B-O I-protein
of B-O O
the B-O O
leucine B-O B-protein
zipper B-O I-protein
protein B-O I-protein
family B-O I-protein
suggests B-O O
c-myb B-O B-DNA
is B-O O
likely B-O O
to B-O O
engage B-O O
in B-O O
similar B-O O
interactions B-O O
with B-O O
cellularly B-O O
encoded B-O O
transcription B-O B-protein
factors B-O I-protein
. B-O O

Alpha-lipoic B-O O
acid B-O O
is B-O O
a B-O O
potent B-O O
inhibitor B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
in B-O O
human B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Acquired B-O O
immunodeficiency B-O O
syndrome B-O O
( B-O O
AIDS B-O O
) B-O O
results B-O O
from B-O O
infection B-O O
with B-O O
a B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
( B-O O
HIV B-O O
) B-O O
. B-O O

The B-O O
long B-O B-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
LTR B-O B-DNA
) B-O O
region B-O O
of B-O O
HIV B-O B-DNA
proviral B-O I-DNA
DNA B-O I-DNA
contains B-O O
binding B-O B-DNA
sites B-O I-DNA
for B-O O
nuclear B-O B-protein
factor B-O I-protein
kappa B-O I-protein
B B-O I-protein
( B-O O
NF-kappa B-O B-protein
B B-O I-protein
) B-O O
, B-O O
and B-O O
this B-O O
transcriptional B-O B-protein
activator B-O I-protein
appears B-O O
to B-O O
regulate B-O O
HIV B-O O
activation B-O O
. B-O O

Recent B-O O
findings B-O O
suggest B-O O
an B-O O
involvement B-O O
of B-O O
reactive B-O O
oxygen B-O O
species B-O O
( B-O O
ROS B-O O
) B-O O
in B-O O
signal B-O O
transduction B-O O
pathways B-O O
leading B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
. B-O O

The B-O O
present B-O O
study B-O O
was B-O O
based B-O O
on B-O O
reports B-O O
that B-O O
antioxidants B-O O
which B-O O
eliminate B-O O
ROS B-O O
should B-O O
block B-O O
the B-O O
activation B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
and B-O O
subsequently B-O O
HIV B-O O
transcription B-O O
, B-O O
and B-O O
thus B-O O
antioxidants B-O O
can B-O O
be B-O O
used B-O O
as B-O O
therapeutic B-O O
agents B-O O
for B-O O
AIDS B-O O
. B-O O

Incubation B-O O
of B-O O
Jurkat B-O B-cell_line
T B-O I-cell_line
cells B-O I-cell_line
( B-O O
1 B-O O
x B-O O
10 B-O O
( B-O O
6 B-O O
) B-O O
cells/ml B-O O
) B-O O
with B-O O
a B-O O
natural B-O O
thiol B-O O
antioxidant B-O O
, B-O O
alpha-lipoic B-O O
acid B-O O
, B-O O
prior B-O O
to B-O O
the B-O O
stimulation B-O O
of B-O O
cells B-O O
was B-O O
found B-O O
to B-O O
inhibit B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
induced B-O O
by B-O O
tumor B-O B-protein
necrosis B-O I-protein
factor-alpha B-O I-protein
( B-O O
25 B-O O
ng/ml B-O O
) B-O O
or B-O O
by B-O O
phorbol B-O O
12-myristate B-O O
13-acetate B-O O
( B-O O
50 B-O O
ng/ml B-O O
) B-O O
. B-O O

The B-O O
inhibitory B-O O
action B-O O
of B-O O
alpha-lipoic B-O O
acid B-O O
was B-O O
found B-O O
to B-O O
be B-O O
very B-O O
potent B-O O
as B-O O
only B-O O
4 B-O O
mM B-O O
was B-O O
needed B-O O
for B-O O
a B-O O
complete B-O O
inhibition B-O O
, B-O O
whereas B-O O
20 B-O O
mM B-O O
was B-O O
required B-O O
for B-O O
N-acetylcysteine B-O O
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
alpha-lipoic B-O O
acid B-O O
may B-O O
be B-O O
effective B-O O
in B-O O
AIDS B-O O
therapeutics B-O O
. B-O O

Reticuloendotheliosis B-O B-DNA
virus B-O I-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
elements B-O I-DNA
are B-O O
efficient B-O O
promoters B-O B-DNA
in B-O O
cells B-O O
of B-O O
various B-O O
species B-O O
and B-O O
tissue B-O O
origin B-O O
, B-O O
including B-O O
human B-O B-cell_type
lymphoid B-O I-cell_type
cells B-O I-cell_type
. B-O O

Promiscuous B-O O
transcriptional B-O O
activity B-O O
of B-O O
the B-O O
reticuloendotheliosis B-O B-DNA
virus B-O I-DNA
( B-O I-DNA
REV B-O I-DNA
) B-O I-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
LTR B-O B-DNA
) B-O O
was B-O O
detected B-O O
in B-O O
transient B-O O
expression B-O O
assays B-O O
using B-O O
LTR- B-O B-DNA
chloramphenicol B-O I-DNA
acetyltransferase B-O I-DNA
-encoding B-O I-DNA
gene B-O I-DNA
chimeras B-O I-DNA
, B-O O
and B-O O
cells B-O O
of B-O O
diverse B-O O
species B-O O
and B-O O
tissue B-O O
type B-O O
; B-O O
levels B-O O
of B-O O
expression B-O O
from B-O O
two B-O O
different B-O O
REV B-O B-DNA
LTRs B-O I-DNA
correlate B-O O
with B-O O
reports B-O O
of B-O O
pathogenicity B-O O
of B-O O
the B-O O
respective B-O O
viruses B-O O
in B-O O
vivo B-O O
. B-O O

REVs B-O O
do B-O O
not B-O O
encode B-O O
a B-O O
transactivator B-O B-protein
targeted B-O O
to B-O O
the B-O O
viral B-O B-DNA
LTR B-O I-DNA
, B-O O
and B-O O
cells B-O O
infected B-O O
with B-O O
Marek B-O O
's B-O O
disease B-O O
virus B-O O
, B-O O
a B-O O
herpesvirus B-O O
with B-O O
an B-O O
overlapping B-O O
host B-O O
range B-O O
, B-O O
do B-O O
not B-O O
express B-O O
factors B-O O
that B-O O
preferentially B-O O
enhance B-O O
expression B-O O
from B-O O
REV B-O O
or B-O O
avian B-O B-DNA
sarcoma/leukemia B-O I-DNA
virus B-O I-DNA
LTRs B-O I-DNA
. B-O O

REV B-O B-DNA
LTRs B-O I-DNA
work B-O O
efficiently B-O O
in B-O O
human B-O B-cell_type
lymphoid B-O I-cell_type
cells B-O I-cell_type
, B-O O
and B-O O
are B-O O
viable B-O O
alternatives B-O O
to B-O O
promoters B-O B-DNA
commonly B-O O
used B-O O
for B-O O
expression B-O O
of B-O O
cloned B-O B-DNA
genes B-O I-DNA
. B-O O

They B-O O
may B-O O
also B-O O
prove B-O O
useful B-O O
in B-O O
the B-O O
identification B-O O
of B-O O
new B-O O
, B-O O
ubiquitous B-O B-protein
cellular B-O I-protein
transcription B-O I-protein
factors B-O I-protein
. B-O O

A B-O O
novel B-O O
Ets-related B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
Elf-1 B-O B-protein
, B-O O
binds B-O O
to B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
type B-O I-DNA
2 B-O I-DNA
regulatory B-O I-DNA
elements B-O I-DNA
that B-O O
are B-O O
required B-O O
for B-O O
inducible B-O O
trans B-O O
activation B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

Human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
and B-O O
HIV-2 B-O O
are B-O O
structurally B-O O
related B-O O
retroviruses B-O O
which B-O O
both B-O O
cause B-O O
AIDS B-O O
in B-O O
humans B-O O
. B-O O

Although B-O O
both B-O O
viruses B-O O
establish B-O O
latency B-O O
in B-O O
quiescent B-O O
human-peripheral-blood B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
, B-O O
the B-O O
asymptomatic B-O O
phase B-O O
of B-O O
HIV-2 B-O O
infection B-O O
may B-O O
be B-O O
more B-O O
prolonged B-O O
than B-O O
that B-O O
of B-O O
HIV-1 B-O O
. B-O O

The B-O O
latent B-O O
phases B-O O
of B-O O
both B-O O
HIV-1 B-O O
and B-O O
HIV-2 B-O O
infection B-O O
have B-O O
been B-O O
shown B-O O
to B-O O
be B-O O
disrupted B-O O
by B-O O
T-cell B-O O
activation B-O O
, B-O O
a B-O O
process B-O O
that B-O O
requires B-O O
host B-O O
cell B-O O
transcription B-O O
factors B-O O
. B-O O

In B-O O
the B-O O
case B-O O
of B-O O
HIV-1 B-O O
, B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
is B-O O
sufficient B-O O
for B-O O
inducible B-O O
transcriptional B-O O
activation B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
factors B-O O
in B-O O
addition B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
are B-O O
required B-O O
to B-O O
activate B-O O
HIV-2 B-O O
transcription B-O O
in B-O O
infected B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

In B-O O
this B-O O
report B-O O
, B-O O
we B-O O
demonstrate B-O O
that B-O O
a B-O O
novel B-O O
Ets-related B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
Elf-1 B-O B-protein
, B-O O
binds B-O O
specifically B-O O
to B-O O
two B-O O
purine-rich B-O B-DNA
motifs B-O I-DNA
in B-O O
the B-O O
HIV-2 B-O B-DNA
enhancer B-O I-DNA
. B-O O

Mutagenesis B-O O
experiments B-O O
demonstrated B-O O
that B-O O
these B-O O
Elf-1 B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
are B-O O
required B-O O
for B-O O
induction B-O O
of B-O O
HIV-2 B-O O
transcription B-O O
following B-O O
T-cell-receptor-mediated B-O O
T-cell B-O O
activation B-O O
. B-O O

Moreover B-O O
, B-O O
Elf-1 B-O B-protein
is B-O O
the B-O O
only B-O O
factor B-O O
present B-O O
in B-O O
activated B-O O
T-cell B-O O
nuclear B-O O
extracts B-O O
that B-O O
binds B-O O
to B-O O
these B-O O
sites B-O O
in B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
. B-O O

Thus B-O O
, B-O O
Elf-1 B-O B-protein
is B-O O
a B-O O
novel B-O O
transcription B-O B-protein
factor B-O I-protein
that B-O O
appears B-O O
to B-O O
be B-O O
required B-O O
for B-O O
the B-O O
T-cell-receptor-mediated B-O O
trans B-O O
activation B-O O
of B-O O
HIV-2 B-O B-DNA
gene B-O I-DNA
expression B-O O
. B-O O

These B-O O
results B-O O
may B-O O
explain B-O O
differences B-O O
in B-O O
the B-O O
clinical B-O O
spectra B-O O
of B-O O
diseases B-O O
caused B-O O
by B-O O
HIV-1 B-O O
and B-O O
HIV-2 B-O O
and B-O O
may B-O O
also B-O O
have B-O O
implications B-O O
for B-O O
the B-O O
design B-O O
of B-O O
therapeutic B-O O
approaches B-O O
to B-O O
HIV-2 B-O O
infection B-O O
. B-O O

Okadaic B-O O
acid B-O O
is B-O O
a B-O O
potent B-O O
inducer B-O O
of B-O O
AP-1 B-O B-protein
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
and B-O O
tumor B-O B-protein
necrosis B-O I-protein
factor-alpha B-O I-protein
in B-O O
human B-O B-cell_type
B B-O I-cell_type
lymphocytes B-O I-cell_type
. B-O O

Treatment B-O O
of B-O O
human B-O B-cell_type
B B-O I-cell_type
lymphocytes B-O I-cell_type
with B-O O
an B-O O
optimal B-O O
concentration B-O O
of B-O O
okadaic B-O O
acid B-O O
, B-O O
an B-O O
inhibitor B-O O
of B-O O
phosphatases B-O B-protein
1 B-O I-protein
and B-O I-protein
2A B-O I-protein
, B-O O
resulted B-O O
in B-O O
the B-O O
induction B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
, B-O O
AP-1 B-O B-protein
and B-O O
a B-O O
marked B-O O
increase B-O O
in B-O O
NF-kappa B-O B-protein
B B-O I-protein
levels B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
no B-O O
effect B-O O
on B-O O
the B-O O
levels B-O O
of B-O O
the B-O O
octamer B-O B-protein
binding B-O I-protein
proteins B-O I-protein
, B-O O
Oct-1 B-O B-protein
or B-O O
Oct-2 B-O B-protein
, B-O O
were B-O O
found B-O O
. B-O O

Since B-O O
both B-O O
AP-1 B-O B-protein
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
have B-O O
been B-O O
reported B-O O
to B-O O
be B-O O
important B-O O
in B-O O
the B-O O
induction B-O O
of B-O O
the B-O O
tumor B-O B-DNA
necrosis B-O I-DNA
factor-alpha B-O I-DNA
( B-O I-DNA
TNF-alpha B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
we B-O O
examined B-O O
the B-O O
effects B-O O
of B-O O
okadaic B-O O
acid B-O O
on B-O O
TNF-alpha B-O B-RNA
mRNA B-O I-RNA
levels B-O O
. B-O O

Treatment B-O O
with B-O O
okadaic B-O O
acid B-O O
resulted B-O O
in B-O O
a B-O O
striking B-O O
increase B-O O
in B-O O
TNF-alpha B-O B-RNA
mRNA B-O I-RNA
transcripts B-O O
within B-O O
1 B-O O
h B-O O
of B-O O
stimulation B-O O
and B-O O
large B-O O
amounts B-O O
of B-O O
TNF-alpha B-O B-protein
were B-O O
released B-O O
into B-O O
the B-O O
culture B-O O
media B-O O
. B-O O

Although B-O O
okadaic B-O O
acid B-O O
provides B-O O
a B-O O
potent B-O O
inductive B-O O
signal B-O O
for B-O O
AP-1 B-O B-protein
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
it B-O O
did B-O O
not B-O O
induce B-O O
either B-O O
B B-O O
cell B-O O
proliferation B-O O
or B-O O
immunoglobulin B-O B-protein
secretion B-O O
. B-O O

Heterodimerization B-O O
and B-O O
transcriptional B-O O
activation B-O O
in B-O O
vitro B-O O
by B-O O
NF-kappa B-O B-protein
B B-O I-protein
proteins B-O I-protein
. B-O O

The B-O O
NF-kappa B-O B-protein
B B-O I-protein
family B-O I-protein
of B-O O
transcription B-O B-protein
proteins B-O I-protein
represents B-O O
multiple B-O O
DNA B-O O
binding B-O O
, B-O O
rel B-O B-protein
related B-O I-protein
polypeptides B-O I-protein
that B-O O
contribute B-O O
to B-O O
regulation B-O O
of B-O O
genes B-O O
involved B-O O
in B-O O
immune B-O O
responsiveness B-O O
and B-O O
inflammation B-O O
, B-O O
as B-O O
well B-O O
as B-O O
activation B-O O
of B-O O
the B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
. B-O O

In B-O O
this B-O O
study B-O O
multiple B-O O
NF-kappa B-O B-protein
B B-O I-protein
related B-O O
polypeptides B-O O
ranging B-O O
from B-O O
85 B-O O
to B-O O
45 B-O O
kDa B-O O
were B-O O
examined B-O O
for B-O O
their B-O O
capacity B-O O
to B-O O
interact B-O O
with B-O O
the B-O O
PRDII B-O B-DNA
regulatory B-O I-DNA
element B-O I-DNA
of B-O O
interferon B-O B-protein
beta B-O I-protein
and B-O O
were B-O O
shown B-O O
to B-O O
possess B-O O
distinct B-O O
intrinsic B-O O
DNA B-O O
binding B-O O
affinities B-O O
for B-O O
this B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
and B-O O
form B-O O
multiple B-O O
DNA B-O O
binding B-O O
homo- B-O O
and B-O O
hetero B-O B-protein
dimer B-O I-protein
complexes B-O I-protein
in B-O O
co-renaturation B-O O
experiments B-O O
. B-O O

Furthermore B-O O
, B-O O
using B-O O
DNA B-O B-DNA
templates B-O I-DNA
containing B-O O
two B-O O
copies B-O O
of B-O O
the B-O O
PRDII B-O B-DNA
domain B-O I-DNA
linked B-O O
to B-O O
the B-O O
rabbit B-O B-DNA
beta B-O I-DNA
globin B-O I-DNA
gene B-O I-DNA
, B-O O
the B-O O
purified B-O O
polypeptides B-O O
specifically B-O O
stimulated B-O O
NF-kappa B-O B-protein
B B-O I-protein
dependent B-O O
transcription B-O O
in B-O O
an B-O O
in B-O O
vitro B-O O
reconstitution B-O O
assay B-O O
as B-O O
heterodimers B-O B-protein
but B-O O
not B-O O
as B-O O
p50 B-O B-protein
homodimers B-O I-protein
. B-O O

These B-O O
experiments B-O O
emphasize B-O O
the B-O O
role B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
dimerization B-O O
as B-O O
a B-O O
distinct B-O O
level B-O O
of B-O O
transcriptional B-O O
control B-O O
that B-O O
may B-O O
permit B-O O
functional B-O O
diversification B-O O
of B-O O
a B-O O
limited B-O O
number B-O O
of B-O O
regulatory B-O B-protein
proteins B-O I-protein
. B-O O

c-myc B-O B-RNA
mRNA B-O I-RNA
expression B-O O
in B-O O
minor B-O O
salivary B-O O
glands B-O O
of B-O O
patients B-O O
with B-O O
Sjogren B-O O
's B-O O
syndrome B-O O
. B-O O

c-myc B-O B-DNA
protooncogene B-O I-DNA
is B-O O
implicated B-O O
in B-O O
the B-O O
pathogenesis B-O O
of B-O O
B B-O O
cell B-O O
lymphoid B-O O
malignancies B-O O
and B-O O
high B-O O
levels B-O O
of B-O O
c-myc B-O B-RNA
mRNA B-O I-RNA
expression B-O O
are B-O O
observed B-O O
in B-O O
activated B-O B-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
. B-O O

Sjogren B-O O
's B-O O
syndrome B-O O
( B-O O
SS B-O O
) B-O O
is B-O O
characterized B-O O
by B-O O
lymphocytic B-O B-cell_type
infiltrates B-O I-cell_type
of B-O O
exocrine B-O O
glands B-O O
, B-O O
remarkable B-O O
B B-O O
cell B-O O
hyperreactivity B-O O
and B-O O
a B-O O
strong B-O O
predisposition B-O O
to B-O O
B B-O O
cell B-O O
neoplasia B-O O
. B-O O

In B-O O
this B-O O
study B-O O
, B-O O
c-myc B-O B-RNA
protooncogene B-O I-RNA
mRNA B-O I-RNA
expression B-O O
in B-O O
29 B-O O
labial B-O O
minor B-O O
salivary B-O O
gland B-O O
biopsies B-O O
from B-O O
patients B-O O
with B-O O
primary B-O O
SS B-O O
and B-O O
15 B-O O
controls B-O O
was B-O O
examined B-O O
using B-O O
in B-O O
situ B-O O
hybridization B-O O
histochemistry B-O O
. B-O O

Two B-O O
40mer B-O O
oligonucleotides B-O O
from B-O O
the B-O O
1st B-O O
and B-O O
the B-O O
2nd B-O B-DNA
exon B-O I-DNA
of B-O O
the B-O O
c-myc B-O B-DNA
gene B-O I-DNA
, B-O O
labeled B-O O
with B-O O
35S B-O O
, B-O O
were B-O O
used B-O O
as B-O O
probes B-O O
. B-O O

To B-O O
detect B-O O
the B-O O
origin B-O O
of B-O O
the B-O O
cell B-O O
hybridized B-O O
with B-O O
a B-O O
c-myc B-O B-DNA
probe B-O I-DNA
, B-O O
a B-O O
combined B-O O
immunochemistry B-O O
in B-O O
situ B-O O
hybridization B-O O
histochemistry B-O O
technique B-O O
was B-O O
used B-O O
. B-O O

High B-O O
c-myc B-O B-RNA
mRNA B-O I-RNA
expression B-O O
was B-O O
detected B-O O
on B-O O
acinar B-O B-cell_type
epithelial B-O I-cell_type
cells B-O I-cell_type
. B-O O

c-myc B-O B-DNA
did B-O O
not B-O O
correlate B-O O
with B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-protein
protein B-O O
expression B-O O
. B-O O

Stronger B-O O
c-myc B-O B-RNA
mRNA B-O I-RNA
expression B-O O
was B-O O
detected B-O O
in B-O O
labial B-O O
salivary B-O O
glands B-O O
of B-O O
patients B-O O
with B-O O
longer B-O O
disease B-O O
duration B-O O
( B-O O
p B-O O
less B-O O
than B-O O
or B-O O
equal B-O O
to B-O O
0.002 B-O O
) B-O O
and B-O O
more B-O O
intense B-O O
T B-O O
lymphocyte B-O O
infiltrates B-O O
( B-O O
p B-O O
less B-O O
than B-O O
0.05 B-O O
) B-O O
although B-O O
these B-O O
patients B-O O
revealed B-O O
no B-O O
hypergammaglobulinemia B-O O
. B-O O

No B-O O
correlation B-O O
was B-O O
observed B-O O
between B-O O
c-myc B-O B-RNA
mRNA B-O I-RNA
and B-O O
B B-O O
lymphocyte B-O O
monoclonicity B-O O
or B-O O
lymphoma B-O O
. B-O O

In B-O O
conclusion B-O O
, B-O O
strong B-O O
c-myc B-O B-RNA
mRNA B-O I-RNA
expression B-O O
was B-O O
observed B-O O
on B-O O
epithelial B-O B-cell_type
cells B-O I-cell_type
of B-O O
labial B-O O
salivary B-O O
glands B-O O
from B-O O
patients B-O O
with B-O O
primary B-O O
SS B-O O
. B-O O

Our B-O O
findings B-O O
may B-O O
indicate B-O O
the B-O O
presence B-O O
of B-O O
a B-O O
reactivated B-O O
virus B-O O
hosted B-O O
in B-O O
these B-O O
cells B-O O
. B-O O

Corticosteroid B-O B-protein
receptors B-O I-protein
and B-O O
lymphocyte B-O B-cell_type
subsets B-O I-cell_type
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
in B-O O
aging B-O O
. B-O O

Plasma B-O O
cortisol B-O O
and B-O O
aldosterone B-O O
levels B-O O
and B-O O
number B-O O
of B-O O
related B-O O
receptors B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
were B-O O
measured B-O O
in B-O O
49 B-O O
healthy B-O O
aged B-O O
subjects B-O O
( B-O O
62-97 B-O O
yr B-O O
) B-O O
and B-O O
in B-O O
21 B-O O
adult B-O O
controls B-O O
( B-O O
21-50 B-O O
yr B-O O
) B-O O
. B-O O

In B-O O
all B-O O
subjects B-O O
, B-O O
in B-O O
addition B-O O
, B-O O
lymphocyte B-O B-cell_type
subsets B-O I-cell_type
were B-O O
determined B-O O
as B-O O
an B-O O
index B-O O
of B-O O
corticosteroid B-O O
action B-O O
. B-O O

The B-O O
mean B-O O
number B-O O
of B-O O
type B-O B-protein
I B-O I-protein
and B-O I-protein
type B-O I-protein
II B-O I-protein
receptors B-O I-protein
was B-O O
significantly B-O O
lower B-O O
in B-O O
aged B-O O
subjects B-O O
than B-O O
in B-O O
controls B-O O
( B-O O
respectively B-O O
, B-O O
198 B-O O
+/- B-O O
96 B-O O
and B-O O
272 B-O O
+/- B-O O
97 B-O O
receptors B-O O
/cell B-O O
for B-O O
type B-O B-protein
I B-O I-protein
, B-O O
and B-O O
1 B-O O
, B-O O
794 B-O O
+/- B-O O
803 B-O O
and B-O O
3 B-O O
, B-O O
339 B-O O
+/- B-O O
918 B-O O
for B-O O
type B-O B-protein
II B-O I-protein
receptors B-O I-protein
) B-O O
. B-O O

Plasma B-O O
aldosterone B-O O
and B-O O
cortisol B-O O
and B-O O
lymphocyte B-O B-cell_type
subsets B-O I-cell_type
were B-O O
not B-O O
different B-O O
in B-O O
the B-O O
two B-O O
groups B-O O
. B-O O

All B-O O
of B-O O
the B-O O
parameters B-O O
were B-O O
also B-O O
tested B-O O
for B-O O
correlation B-O O
, B-O O
and B-O O
a B-O O
significant B-O O
inverse B-O O
correlation B-O O
was B-O O
found B-O O
between B-O O
age B-O O
and B-O O
type B-O B-protein
I B-O I-protein
and B-O I-protein
type B-O I-protein
II B-O I-protein
receptors B-O I-protein
when B-O O
all B-O O
subjects B-O O
were B-O O
plotted B-O O
and B-O O
between B-O O
aged B-O O
and B-O O
CD4 B-O B-protein
and B-O O
age B-O O
and B-O O
CD4/CD8 B-O B-protein
in B-O O
the B-O O
aged B-O O
group B-O O
. B-O O

These B-O O
data B-O O
show B-O O
that B-O O
aged B-O O
subjects B-O O
have B-O O
reductions B-O O
of B-O O
corticosteroid B-O B-protein
receptors B-O I-protein
that B-O O
are B-O O
not B-O O
associated B-O O
with B-O O
increase B-O O
of B-O O
related B-O O
steroids B-O O
and B-O O
that B-O O
this B-O O
situation B-O O
probably B-O O
represents B-O O
a B-O O
concomitant B-O O
of B-O O
the B-O O
normal B-O O
aging B-O O
process B-O O
. B-O O

T B-O O
cell-specific B-O O
negative B-O O
regulation B-O O
of B-O O
transcription B-O O
of B-O O
the B-O O
human B-O O
cytokine B-O O
IL-4 B-O B-protein
. B-O O

IL-4 B-O B-protein
secreted B-O O
by B-O O
activated B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
is B-O O
a B-O O
pleiotropic B-O B-protein
cytokine B-O I-protein
affecting B-O O
growth B-O O
and B-O O
differentiation B-O O
of B-O O
diverse B-O O
cell B-O O
types B-O O
such B-O O
as B-O O
T B-O B-cell_type
cells B-O I-cell_type
, B-O O
B B-O B-cell_type
cells B-O I-cell_type
, B-O O
and B-O O
mast B-O B-cell_type
cells B-O I-cell_type
. B-O O

We B-O O
investigated B-O O
the B-O O
upstream B-O B-DNA
regulatory B-O I-DNA
elements B-O I-DNA
of B-O O
the B-O O
human B-O B-DNA
IL-4 B-O I-DNA
promoter B-O I-DNA
. B-O O

A B-O O
novel B-O O
T B-O B-DNA
cell-specific B-O I-DNA
negative B-O I-DNA
regulatory B-O I-DNA
element B-O I-DNA
( B-O O
NRE B-O B-DNA
) B-O O
composed B-O O
of B-O O
two B-O O
protein-binding B-O B-DNA
sites B-O I-DNA
were B-O O
mapped B-O O
in B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
flanking B-O I-DNA
region B-O I-DNA
of B-O O
the B-O O
IL-4 B-O B-DNA
gene B-O I-DNA
: B-O O
-311CTCCCTTCT-303 B-O O
( B-O O
NRE-I B-O B-DNA
) B-O O
and B-O O
-288CTTTTTGCTT-TGC-300 B-O O
( B-O O
NRE-II B-O B-DNA
) B-O O
. B-O O

A B-O O
T B-O B-protein
cell-specific B-O I-protein
protein B-O I-protein
Neg-1 B-O B-protein
and B-O O
a B-O O
ubiquitous B-O B-protein
protein B-O I-protein
Neg-2 B-O B-protein
binding B-O O
to B-O O
NRE-I B-O B-DNA
and B-O O
NRE-II B-O B-DNA
, B-O O
respectively B-O O
, B-O O
were B-O O
identified B-O O
. B-O O

Furthermore B-O O
, B-O O
a B-O O
positive B-O B-DNA
regulatory B-O I-DNA
element B-O I-DNA
was B-O O
found B-O O
45 B-O B-DNA
bp B-O I-DNA
downstream B-O I-DNA
of B-O O
the B-O O
NRE B-O B-DNA
. B-O O

The B-O O
enhancer B-O O
activity B-O O
of B-O O
the B-O O
PRE B-O B-DNA
was B-O O
completely B-O O
suppressed B-O O
when B-O O
the B-O O
NRE B-O B-DNA
was B-O O
present B-O O
. B-O O

These B-O O
data B-O O
suggest B-O O
that B-O O
IL-4 B-O B-DNA
promoter B-O I-DNA
activity B-O O
is B-O O
normally B-O O
down-regulated B-O O
by B-O O
an B-O O
NRE B-O B-DNA
via B-O O
repression B-O O
of B-O O
the B-O O
enhancer B-O B-DNA
positive B-O I-DNA
regulatory B-O I-DNA
element B-O I-DNA
. B-O O

These B-O O
data B-O O
may B-O O
have B-O O
implications B-O O
for B-O O
the B-O O
stringent B-O O
control B-O O
of B-O O
IL-4 B-O B-protein
expression B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

Interleukin B-O O
6-induced B-O O
differentiation B-O O
of B-O O
a B-O O
human B-O B-cell_line
B B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
into B-O O
IgM-secreting B-O B-cell_type
plasma B-O I-cell_type
cells B-O I-cell_type
is B-O O
mediated B-O O
by B-O O
c-fos B-O B-DNA
. B-O O

The B-O O
role B-O O
of B-O O
the B-O O
protooncogene B-O B-DNA
c-fos B-O I-DNA
in B-O O
interleukin B-O B-protein
( B-O I-protein
IL B-O I-protein
) B-O I-protein
6 B-O I-protein
-induced B-O O
B B-O O
cell B-O O
differentiation B-O O
was B-O O
assessed B-O O
. B-O O

Treatment B-O O
of B-O O
SKW B-O B-cell_line
6.4 B-O I-cell_line
cells B-O I-cell_line
with B-O O
IL B-O B-protein
6 B-O I-protein
induced B-O O
a B-O O
transient B-O O
and B-O O
early B-O O
stimulation B-O O
of B-O O
c-fos B-O B-RNA
sense B-O I-RNA
mRNA B-O I-RNA
expression B-O O
. B-O O

The B-O O
effect B-O O
appeared B-O O
within B-O O
30 B-O O
min B-O O
and B-O O
returned B-O O
to B-O O
basal B-O O
levels B-O O
after B-O O
2 B-O O
h B-O O
. B-O O

The B-O O
addition B-O O
of B-O O
antisense B-O O
oligonucleotides B-O O
to B-O O
c-fos B-O B-DNA
significantly B-O O
inhibited B-O O
IL B-O B-protein
6 B-O I-protein
-induced B-O O
IgM B-O B-protein
production B-O O
by B-O O
SKW B-O B-cell_line
6.4 B-O I-cell_line
cells B-O I-cell_line
( B-O O
p B-O O
less B-O O
than B-O O
0.001 B-O O
) B-O O
, B-O O
whereas B-O O
control B-O O
oligonucleotides B-O O
had B-O O
no B-O O
inhibitory B-O O
effect B-O O
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
activation B-O O
of B-O O
c-fos B-O B-DNA
is B-O O
involved B-O O
in B-O O
IL B-O B-protein
6 B-O I-protein
-induced B-O O
differentiation B-O O
of B-O O
SKW B-O B-cell_line
6.4 B-O I-cell_line
cells B-O I-cell_line
into B-O O
IgM-secreting B-O B-cell_line
cells B-O I-cell_line
. B-O O

Transcriptional B-O O
regulation B-O O
during B-O O
T-cell B-O B-cell_type
development B-O O
: B-O O
the B-O O
alpha B-O B-DNA
TCR B-O I-DNA
gene B-O I-DNA
as B-O O
a B-O O
molecular B-O O
model B-O O
. B-O O

The B-O O
regulation B-O O
of B-O O
gene B-O O
expression B-O O
during B-O O
lymphocyte B-O B-cell_type
differentiation B-O O
is B-O O
a B-O O
complex B-O O
process B-O O
involving B-O O
interactions B-O O
between B-O O
multiple B-O B-DNA
positive B-O I-DNA
and B-O I-DNA
negative B-O I-DNA
transcriptional B-O I-DNA
regulatory B-O I-DNA
elements B-O I-DNA
. B-O O

In B-O O
this B-O O
article B-O O
, B-O O
transcriptional B-O O
regulation B-O O
of B-O O
the B-O O
archetypal B-O B-DNA
T-cell B-O I-DNA
-specific B-O I-DNA
gene B-O I-DNA
, B-O O
alpha B-O B-DNA
TCR B-O I-DNA
, B-O O
is B-O O
discussed B-O O
. B-O O

Major B-O O
recent B-O O
developments B-O O
, B-O O
including B-O O
the B-O O
identification B-O O
of B-O O
novel B-O O
families B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
that B-O O
regulate B-O O
multiple B-O O
T-cell B-O B-DNA
genes B-O I-DNA
during B-O O
thymocyte B-O O
ontogeny B-O O
and B-O O
T-cell B-O O
activation B-O O
, B-O O
are B-O O
described B-O O
. B-O O

Photoaffinity B-O O
labeling B-O O
of B-O O
plasma B-O B-protein
membrane B-O I-protein
receptors B-O I-protein
for B-O O
aldosterone B-O O
from B-O O
human B-O B-cell_type
mononuclear B-O I-cell_type
leukocytes B-O I-cell_type
. B-O O

Non-genomic B-O O
effects B-O O
of B-O O
aldosterone B-O O
on B-O O
the B-O O
sodium-proton-antiport B-O B-protein
have B-O O
been B-O O
shown B-O O
in B-O O
human B-O B-cell_type
mononuclear B-O I-cell_type
leukocytes B-O I-cell_type
which B-O O
could B-O O
be B-O O
related B-O O
to B-O O
a B-O O
new B-O O
aldosterone B-O B-protein
membrane B-O I-protein
receptor B-O I-protein
. B-O O

In B-O O
the B-O O
present B-O O
paper B-O O
plasma B-O O
membranes B-O O
from B-O O
human B-O B-cell_type
mononuclear B-O I-cell_type
leukocytes B-O I-cell_type
were B-O O
covalently B-O O
photolabeled B-O O
with B-O O
a B-O O
[ B-O O
125I B-O O
] B-O O
-aldosterone B-O O
derivative B-O O
. B-O O

Sodium B-O O
dodecyl B-O O
sulfate-polyacrylamide B-O O
gel B-O O
electrophoresis B-O O
showed B-O O
significant B-O O
aldosterone B-O O
binding B-O O
at B-O O
a B-O O
molecular B-O O
weight B-O O
of B-O O
approximately B-O O
50000 B-O O
Dalton B-O O
which B-O O
was B-O O
absent B-O O
with B-O O
1 B-O O
microM B-O O
cold B-O O
aldosterone B-O O
, B-O O
but B-O O
not B-O O
cortisol B-O O
in B-O O
the B-O O
binding B-O O
media B-O O
. B-O O

The B-O O
presence B-O O
of B-O O
the B-O O
sulfhydryl B-O O
agent B-O O
dithiothreitol B-O O
did B-O O
not B-O O
affect B-O O
results B-O O
suggesting B-O O
the B-O O
absence B-O O
of B-O O
disulfide B-O B-protein
bridges B-O I-protein
in B-O O
the B-O O
steroid B-O B-protein
binding B-O I-protein
domain B-O I-protein
of B-O O
the B-O O
receptor B-O O
. B-O O

These B-O O
data B-O O
are B-O O
the B-O O
first B-O O
to B-O O
define B-O O
the B-O O
molecular B-O O
weight B-O O
of B-O O
the B-O O
membrane B-O B-protein
receptor B-O I-protein
for B-O O
aldosterone B-O O
. B-O O

Redox B-O O
status B-O O
of B-O O
cells B-O O
influences B-O O
constitutive B-O O
or B-O O
induced B-O O
NF-kappa B-O B-protein
B B-O I-protein
translocation B-O O
and B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
activity B-O O
in B-O O
human B-O B-cell_line
T B-O I-cell_line
and B-O I-cell_line
monocytic B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

We B-O O
have B-O O
tested B-O O
the B-O O
hypothesis B-O O
that B-O O
cellular B-O O
activation B-O O
events B-O O
occurring B-O O
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
and B-O O
monocytes B-O B-cell_type
and B-O O
mediated B-O O
through B-O O
translocation B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
are B-O O
dependent B-O O
upon B-O O
the B-O O
constitutive B-O O
redox B-O O
status B-O O
of B-O O
these B-O O
cells B-O O
. B-O O

We B-O O
used B-O O
phenolic B-O O
, B-O O
lipid-soluble B-O O
, B-O O
chain-breaking B-O O
antioxidants B-O O
( B-O O
butylated B-O O
hydroxyanisole B-O O
( B-O O
BHA B-O O
) B-O O
, B-O O
nordihydroquairetic B-O O
acid B-O O
, B-O O
or B-O O
alpha-tocopherol B-O O
( B-O O
vitamin B-O O
E B-O O
) B-O O
to B-O O
show B-O O
that B-O O
peroxyl B-O O
radical B-O O
scavenging B-O O
in B-O O
unstimulated B-O O
and B-O O
PMA- B-O O
or B-O O
TNF- B-O B-cell_line
stimulated B-O I-cell_line
cells B-O I-cell_line
blocks B-O O
the B-O O
functions B-O O
depending B-O O
on B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
. B-O O

BHA B-O O
was B-O O
found B-O O
to B-O O
suppress B-O O
not B-O O
only B-O O
PMA- B-O O
or B-O O
TNF- B-O B-protein
induced B-O O
, B-O O
but B-O O
also B-O O
constitutive B-O O
, B-O O
HIV-enhancer B-O B-DNA
activity B-O O
concomitant B-O O
to B-O O
an B-O O
inhibition B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
activity B-O O
in B-O O
both B-O O
lymphoblastoid B-O B-cell_line
T B-O I-cell_line
( B-O O
J.Jhan B-O B-cell_line
) B-O O
and B-O O
monocytic B-O B-cell_line
( B-O I-cell_line
U937 B-O I-cell_line
) B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

This B-O O
was B-O O
also B-O O
true B-O O
for B-O O
KBF B-O B-protein
( B-O O
p50 B-O O
homodimer B-O O
) B-O O
binding B-O O
activity B-O O
in B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
. B-O O

Secretion B-O O
of B-O O
TNF B-O B-protein
, B-O O
the B-O O
product B-O O
of B-O O
another B-O O
NF-kappa B-O B-protein
B B-O I-protein
-dependent B-O O
gene B-O O
, B-O O
was B-O O
abolished B-O O
by B-O O
BHA B-O O
in B-O O
PMA-stimulated B-O B-cell_line
U937 B-O I-cell_line
cells B-O I-cell_line
. B-O O

The B-O O
anti-oxidative B-O O
effect B-O O
of B-O O
BHA B-O B-protein
was B-O O
accompanied B-O O
by B-O O
an B-O O
increase B-O O
in B-O O
thiol B-O O
, B-O O
but B-O O
not B-O O
glutathione B-O O
, B-O O
content B-O O
in B-O O
stimulated B-O O
and B-O O
unstimulated B-O O
T B-O O
cell B-O O
, B-O O
whereas B-O O
TNF B-O B-protein
stimulation B-O O
itself B-O O
barely B-O O
modified B-O O
the B-O O
cellular B-O O
thiol B-O O
level B-O O
. B-O O

Oxidative B-O O
stress B-O O
obtained B-O O
by B-O O
the B-O O
addition B-O O
of B-O O
H2O2 B-O O
to B-O O
the B-O O
culture B-O O
medium B-O O
of B-O O
J.Jhan B-O B-cell_line
or B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
could B-O O
not B-O O
by B-O O
itself B-O O
induce B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
. B-O O

These B-O O
observations B-O O
suggest B-O O
that B-O O
TNF B-O B-protein
and B-O O
PMA B-O O
do B-O O
not B-O O
lead B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
through B-O O
induction B-O O
of B-O O
changes B-O O
in B-O O
the B-O O
cell B-O O
redox B-O O
status B-O O
. B-O O

Rather B-O O
, B-O O
TNF B-O B-protein
and B-O O
PMA B-O O
can B-O O
exert B-O O
their B-O O
effect B-O O
only B-O O
if B-O O
cells B-O O
are B-O O
in B-O O
an B-O O
appropriate B-O O
redox B-O O
status B-O O
, B-O O
because B-O O
prior B-O O
modification B-O O
toward B-O O
reduction B-O O
with B-O O
BHA B-O O
treatment B-O O
prevents B-O O
this B-O O
activation B-O O
. B-O O

It B-O O
appears B-O O
that B-O O
a B-O O
basal B-O O
redox B-O O
equilibrium B-O O
tending B-O O
toward B-O O
oxidation B-O O
is B-O O
a B-O O
prerequisite B-O O
for B-O O
full B-O O
activation B-O O
of B-O O
transduction B-O O
pathways B-O O
regulating B-O O
the B-O O
activity B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
-dependent B-O O
genes B-O O
. B-O O

Selection B-O O
of B-O O
optimal B-O O
kappa B-O O
B/Rel B-O O
DNA-binding B-O O
motifs B-O O
: B-O O
interaction B-O O
of B-O O
both B-O O
subunits B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
with B-O O
DNA B-O O
is B-O O
required B-O O
for B-O O
transcriptional B-O O
activation B-O O
. B-O O

Analysis B-O O
of B-O O
the B-O O
p50 B-O B-protein
and B-O O
p65 B-O B-protein
subunits B-O I-protein
of B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
transcription B-O I-protein
factor B-O I-protein
complex B-O I-protein
has B-O O
revealed B-O O
that B-O O
both B-O O
proteins B-O O
can B-O O
interact B-O O
with B-O O
related B-O O
DNA B-O O
sequences B-O O
through B-O O
either B-O O
homo- B-O O
or B-O O
hetero B-O O
dimer B-O O
formation B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
the B-O O
product B-O O
of B-O O
the B-O O
proto-oncogene B-O B-DNA
c-rel B-O I-DNA
can B-O O
bind B-O O
to B-O O
similar B-O O
DNA B-O B-DNA
motifs B-O I-DNA
by B-O O
itself B-O O
or B-O O
as B-O O
a B-O O
heterodimer B-O B-protein
with B-O O
p50 B-O B-protein
or B-O O
p65 B-O B-protein
. B-O O

However B-O O
, B-O O
these B-O O
studies B-O O
have B-O O
used B-O O
a B-O O
limited B-O O
number B-O O
of B-O O
known B-O O
kappa B-O O
B B-O O
DNA B-O O
motifs B-O O
, B-O O
and B-O O
the B-O O
question B-O O
of B-O O
the B-O O
optimal B-O B-DNA
DNA B-O I-DNA
sequences B-O I-DNA
preferred B-O O
by B-O O
each B-O O
homodimer B-O B-protein
has B-O O
not B-O O
been B-O O
addressed B-O O
. B-O O

Using B-O O
purified B-O O
recombinant B-O O
p50 B-O B-protein
, B-O O
p65 B-O B-protein
, B-O O
and B-O O
c-Rel B-O B-protein
proteins B-O I-protein
, B-O O
optimal B-O O
DNA-binding B-O B-DNA
motifs B-O I-DNA
were B-O O
selected B-O O
from B-O O
a B-O O
pool B-O O
of B-O O
random B-O O
oligonucleotides B-O O
. B-O O

Alignment B-O O
of B-O O
the B-O O
selected B-O O
sequences B-O O
allowed B-O O
us B-O O
to B-O O
predict B-O O
a B-O O
consensus B-O B-DNA
sequence B-O I-DNA
for B-O O
binding B-O O
of B-O O
the B-O O
individual B-O O
homodimeric B-O B-protein
Rel-related B-O I-protein
proteins B-O I-protein
, B-O O
and B-O O
DNA-protein B-O O
binding B-O O
analysis B-O O
of B-O O
the B-O O
selected B-O O
DNA B-O B-DNA
sequences B-O I-DNA
revealed B-O O
sequence B-O O
specificity B-O O
of B-O O
the B-O O
proteins B-O O
. B-O O

Contrary B-O O
to B-O O
previous B-O O
assumptions B-O O
, B-O O
we B-O O
observed B-O O
that B-O O
p65 B-O B-protein
homodimers B-O I-protein
can B-O O
interact B-O O
with B-O O
a B-O O
subset B-O O
of B-O O
DNA B-O B-DNA
sequences B-O I-DNA
not B-O O
recognized B-O O
by B-O O
p50 B-O B-protein
homodimers B-O I-protein
. B-O O

Differential B-O O
binding B-O O
affinities B-O O
were B-O O
also B-O O
obtained B-O O
with B-O O
p50- B-O B-DNA
and B-O I-DNA
c-Rel- B-O I-DNA
selected B-O I-DNA
sequences B-O I-DNA
. B-O O

Using B-O O
either B-O O
a B-O O
p50- B-O B-protein
or B-O O
p65- B-O O
selected B-O O
kappa B-O B-DNA
B B-O I-DNA
motif B-O I-DNA
, B-O O
which B-O O
displayed B-O O
differential B-O O
binding B-O O
with B-O O
respect B-O O
to B-O O
the B-O O
other B-O O
protein B-O O
, B-O O
little B-O O
to B-O O
no B-O O
binding B-O O
was B-O O
observed B-O O
with B-O O
the B-O O
heterodimeric B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
complex B-O I-protein
. B-O O

Similarly B-O O
, B-O O
in B-O O
transfection B-O O
experiments B-O O
in B-O O
which B-O O
the B-O O
selective B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
binding B-O I-DNA
sites B-O I-DNA
were B-O O
used B-O O
to B-O O
drive B-O O
the B-O O
expression B-O O
of B-O O
a B-O O
chloramphenicol B-O B-DNA
acetyltransferase B-O I-DNA
reporter B-O I-DNA
construct B-O I-DNA
, B-O O
the B-O O
p65 B-O B-protein
- B-O O
and B-O O
p50 B-O B-protein
-selected B-O O
motifs B-O O
were B-O O
activated B-O O
only B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
p65 B-O B-protein
and B-O O
p50/65 B-O B-protein
( B-O O
a B-O O
chimeric B-O B-protein
protein B-O I-protein
with B-O O
the B-O O
p50 B-O B-protein
DNA B-O I-protein
binding B-O I-protein
domain B-O I-protein
and B-O O
p65 B-O B-protein
activation B-O I-protein
domain B-O I-protein
) B-O O
expression B-O O
vectors B-O O
, B-O O
respectively B-O O
, B-O O
and B-O O
neither B-O O
demonstrated B-O O
a B-O O
significant B-O O
response B-O O
to B-O O
stimuli B-O O
that B-O O
induce B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
. B-O O

These B-O O
findings B-O O
demonstrate B-O O
that B-O O
interaction B-O O
of B-O O
both B-O O
subunits B-O O
of B-O O
the B-O O
heterodimeric B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
complex B-O I-protein
with B-O O
DNA B-O O
is B-O O
required B-O O
for B-O O
DNA B-O O
binding B-O O
and B-O O
transcriptional B-O O
activation B-O O
and B-O O
suggest B-O O
that B-O O
transcriptional B-O O
activation B-O O
mediated B-O O
by B-O O
the B-O O
individual B-O O
rel-related B-O B-protein
proteins B-O I-protein
will B-O O
differ B-O O
dramatically B-O O
, B-O O
depending B-O O
on B-O O
the B-O O
specific B-O O
kappa B-O B-DNA
B B-O I-DNA
motifs B-O I-DNA
present B-O O
. B-O O

NF-kappa B-O B-protein
B B-O I-protein
-dependent B-O O
induction B-O O
of B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
p50 B-O I-DNA
subunit B-O I-DNA
gene B-O I-DNA
promoter B-O I-DNA
underlies B-O O
self-perpetuation B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
transcription B-O O
in B-O O
monocytic B-O B-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
molecular B-O O
mechanisms B-O O
underlying B-O O
the B-O O
sustained B-O O
nuclear B-O O
translocation B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
observed B-O O
in B-O O
U937 B-O B-cell_line
monocytic B-O I-cell_line
cells B-O I-cell_line
chronically B-O O
infected B-O O
with B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
( B-O O
HIV B-O O
) B-O O
were B-O O
studied B-O O
. B-O O

The B-O O
activity B-O O
of B-O O
the B-O O
promoter B-O B-DNA
regulating B-O O
the B-O O
synthesis B-O O
of B-O O
the B-O O
p105 B-O B-protein
precursor B-O I-protein
of B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
p50 B-O I-protein
subunit B-O I-protein
was B-O O
enhanced B-O O
in B-O O
these B-O O
cells B-O O
. B-O O

Deletions B-O O
in B-O O
this B-O O
promoter B-O B-DNA
indicated B-O O
that B-O O
this B-O O
upregulation B-O O
was B-O O
mediated B-O O
through B-O O
the B-O O
NF-kappa B-O B-protein
B- B-O I-protein
but B-O O
not B-O O
the B-O O
AP-1-binding B-O B-DNA
motif B-O I-DNA
, B-O O
by B-O O
bona B-O B-protein
fide B-O I-protein
p50/p65 B-O I-protein
heterodimers B-O I-protein
. B-O O

Analysis B-O O
of B-O O
cytosolic B-O O
extracts B-O O
indicated B-O O
that B-O O
NF-kappa B-O B-protein
B B-O I-protein
levels B-O O
were B-O O
increased B-O O
in B-O O
HIV B-O B-cell_type
-infected B-O I-cell_type
cells B-O I-cell_type
. B-O O

In B-O O
contrast B-O O
to B-O O
the B-O O
transient B-O O
NF-kappa B-O B-protein
B B-O I-protein
activation B-O O
induced B-O O
by B-O O
phorbol B-O O
ester B-O O
, B-O O
the B-O O
permanent B-O O
NF-kappa B-O B-protein
B B-O I-protein
translocation B-O O
induced B-O O
by B-O O
HIV B-O O
infection B-O O
was B-O O
not B-O O
dependent B-O O
on B-O O
PKC B-O B-protein
isoenzymes B-O I-protein
alpha B-O I-protein
and B-O I-protein
beta B-O I-protein
as B-O O
shown B-O O
by B-O O
the B-O O
use B-O O
of B-O O
a B-O O
specific B-O O
inhibitor B-O O
( B-O O
GF B-O O
109203X B-O O
) B-O O
. B-O O

These B-O O
observations B-O O
indicate B-O O
that B-O O
during B-O O
chronic B-O O
HIV B-O O
infection B-O O
of B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
, B-O O
continuous B-O O
NF-kappa B-O B-protein
B B-O I-protein
( B-O O
p50/p65 B-O B-protein
) B-O O
translocation B-O O
results B-O O
in B-O O
p105 B-O O
promoter B-O O
upregulation B-O O
with B-O O
subsequent B-O O
cytosolic B-O O
NF-kappa B-O B-protein
B B-O I-protein
accumulation B-O O
, B-O O
ready B-O O
for B-O O
further B-O O
translocation B-O O
. B-O O

This B-O O
HIV B-O O
-mediated B-O O
mechanism B-O O
results B-O O
in B-O O
a B-O O
self-perpetuating B-O O
loop B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
production B-O O
. B-O O

Activation B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
by B-O O
interleukin B-O B-protein
2 B-O I-protein
in B-O O
human B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
. B-O O

We B-O O
report B-O O
here B-O O
that B-O O
interleukin B-O B-protein
2 B-O I-protein
( B-O O
IL-2 B-O B-protein
) B-O O
acts B-O O
on B-O O
human B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
by B-O O
enhancing B-O O
binding B-O O
activity B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
to B-O O
its B-O O
consensus B-O B-DNA
sequence B-O I-DNA
in B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
regulatory B-O I-DNA
enhancer B-O I-DNA
region B-O I-DNA
of B-O O
the B-O O
IL-2 B-O B-protein
receptor B-O I-protein
alpha B-O I-protein
chain B-O I-protein
( B-O O
p55 B-O B-protein
) B-O O
. B-O O

Similarly B-O O
, B-O O
IL-2 B-O B-protein
activates B-O O
NF-kappa B-O B-protein
B B-O I-protein
in B-O O
the B-O O
human B-O B-cell_line
monocytic B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
U B-O I-cell_line
937 B-O I-cell_line
, B-O O
but B-O O
not B-O O
in B-O O
resting B-O B-cell_type
human B-O I-cell_type
T-cells B-O I-cell_type
. B-O O

This B-O O
effect B-O O
is B-O O
detectable B-O O
within B-O O
15 B-O O
min B-O O
and B-O O
peaks B-O O
1 B-O O
h B-O O
after B-O O
exposure B-O O
to B-O O
IL-2 B-O B-protein
. B-O O

Enhanced B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
activity B-O O
is B-O O
followed B-O O
by B-O O
functional B-O O
activation B-O O
in B-O O
that B-O O
inducibility B-O O
of B-O O
the B-O O
IL-2 B-O B-protein
receptor B-O I-protein
alpha B-O I-protein
chain B-O I-protein
is B-O O
mediated B-O O
by B-O O
enhanced B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
and B-O O
that B-O O
a B-O O
heterologous B-O B-DNA
promoter B-O I-DNA
containing B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
consensus B-O I-DNA
sequence B-O I-DNA
( B-O O
-291 B-O B-DNA
to B-O I-DNA
-245 B-O I-DNA
) B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
receptor B-O I-DNA
alpha B-O I-DNA
chain B-O I-DNA
gene B-O I-DNA
is B-O O
activated B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
IL-2 B-O B-protein
is B-O O
capable B-O O
of B-O O
increasing B-O O
transcript B-O O
levels B-O O
of B-O O
the B-O O
p50 B-O B-DNA
gene B-O I-DNA
coding B-O O
for B-O O
the B-O O
p50 B-O B-protein
subunit B-O I-protein
of B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
whereas B-O O
mRNA B-O B-RNA
levels B-O O
of B-O O
the B-O O
p65 B-O B-DNA
NF-kappa B-O I-DNA
B B-O I-DNA
gene B-O I-DNA
remained B-O O
unchanged B-O O
. B-O O

Studies B-O O
on B-O O
the B-O O
biological B-O O
activity B-O O
of B-O O
triiodothyronine B-O O
sulfate B-O O
. B-O O

Hepatic B-O B-cell_type
microsomes B-O I-cell_type
and B-O O
isolated B-O B-cell_type
hepatocytes B-O I-cell_type
in B-O O
short B-O O
term B-O O
culture B-O O
desulfate B-O O
T3 B-O O
sulfate B-O O
( B-O O
T3SO4 B-O O
) B-O O
. B-O O

We B-O O
, B-O O
therefore B-O O
, B-O O
wished B-O O
to B-O O
determine B-O O
whether B-O O
T3SO4 B-O O
could B-O O
mimic B-O O
the B-O O
action B-O O
of B-O O
thyroid B-O O
hormone B-O O
in B-O O
vitro B-O O
. B-O O

T3SO4 B-O O
had B-O O
no B-O O
thyromimetic B-O O
effect B-O O
on B-O O
the B-O O
activity B-O O
of B-O O
Ca B-O B-protein
( B-O I-protein
2+ B-O I-protein
) B-O I-protein
-ATPase B-O I-protein
in B-O O
human B-O O
erythrocyte B-O O
membranes B-O O
at B-O O
doses B-O O
up B-O O
to B-O O
10 B-O O
, B-O O
000 B-O O
times B-O O
the B-O O
maximally B-O O
effective B-O O
dose B-O O
of B-O O
T3 B-O O
( B-O O
10 B-O O
( B-O O
-10 B-O O
) B-O O
mol/L B-O O
) B-O O
. B-O O

In B-O O
GH4C1 B-O B-cell_line
pituitary B-O I-cell_line
cells B-O I-cell_line
, B-O O
T3SO4 B-O O
failed B-O O
to B-O O
displace B-O O
[ B-O O
125I B-O O
] B-O O
T3 B-O O
from B-O O
nuclear B-O B-protein
receptors B-O I-protein
in B-O O
intact B-O B-cell_type
cells B-O I-cell_type
or B-O O
soluble B-O O
preparations B-O O
. B-O O

Thus B-O O
, B-O O
T3SO4 B-O O
was B-O O
not B-O O
directly B-O O
thyromimetic B-O O
in B-O O
either B-O O
an B-O O
isolated B-O O
human B-O O
membrane B-O O
system B-O O
or B-O O
a B-O O
pituitary B-O O
cell B-O O
system B-O O
in B-O O
which B-O O
nuclear B-O O
receptor B-O O
occupancy B-O O
correlates B-O O
with B-O O
GH B-O O
synthesis B-O O
. B-O O

Thyroid B-O O
hormones B-O O
inhibit B-O O
[ B-O O
3H B-O O
] B-O O
glycosaminoglycan B-O O
synthesis B-O O
by B-O O
cultured B-O B-cell_line
human B-O I-cell_line
dermal B-O I-cell_line
fibroblasts B-O I-cell_line
, B-O O
and B-O O
T3SO4 B-O O
displayed B-O O
about B-O O
0.5 B-O O
% B-O O
the B-O O
activity B-O O
of B-O O
T3 B-O O
at B-O O
72 B-O O
h B-O O
. B-O O

Human B-O B-cell_type
fibroblasts B-O I-cell_type
contained B-O O
roughly B-O O
the B-O O
same B-O O
level B-O O
of B-O O
microsomal B-O O
p-nitrophenyl B-O B-protein
sulfatase B-O I-protein
activity B-O O
as B-O O
that B-O O
previously B-O O
observed B-O O
in B-O O
hepatic B-O B-cell_type
microsomes B-O I-cell_type
. B-O O

Propylthiouracil B-O O
( B-O O
50 B-O O
mumol/L B-O O
) B-O O
did B-O O
not B-O O
affect B-O O
the B-O O
action B-O O
of B-O O
T3SO4 B-O O
, B-O O
suggesting B-O O
that B-O O
deiodination B-O O
was B-O O
not B-O O
important B-O O
for B-O O
this B-O O
activity B-O O
of B-O O
T3SO4 B-O O
. B-O O

Thus B-O O
, B-O O
it B-O O
appears B-O O
T3SO4 B-O O
has B-O O
no B-O O
intrinsic B-O O
biological B-O O
activity B-O O
, B-O O
but B-O O
, B-O O
under B-O O
certain B-O O
circumstances B-O O
, B-O O
may B-O O
be B-O O
reactivated B-O O
by B-O O
desulfation B-O O
. B-O O

Human B-O O
T B-O O
cell B-O O
activation B-O O
through B-O O
the B-O O
activation-inducer B-O B-protein
molecule/CD69 B-O I-protein
enhances B-O O
the B-O O
activity B-O O
of B-O O
transcription B-O B-protein
factor B-O I-protein
AP-1 B-O I-protein
. B-O O

The B-O O
induction B-O O
of B-O O
the B-O O
AP-1 B-O B-protein
transcription B-O I-protein
factor B-O I-protein
has B-O O
been B-O O
ascribed B-O O
to B-O O
the B-O O
early B-O O
events B-O O
leading B-O O
to B-O O
T B-O O
cell B-O O
differentiation B-O O
and B-O O
activation B-O O
. B-O O

We B-O O
have B-O O
studied B-O O
the B-O O
regulation B-O O
of B-O O
AP-1 B-O B-protein
activity B-O O
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
stimulated B-O O
through B-O O
the B-O O
activation B-O O
inducer B-O O
molecule B-O O
( B-O O
AIM B-O O
) B-O O
/ B-O O
CD69 B-O B-protein
activation B-O O
pathway B-O O
. B-O O

Phorbol B-O O
esters B-O O
are B-O O
required B-O O
to B-O O
induce B-O O
AIM/CD69 B-O B-protein
cell-surface B-O O
expression B-O O
as B-O O
well B-O O
as B-O O
for B-O O
triggering B-O O
the B-O O
proliferation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
in B-O O
conjunction B-O O
with B-O O
anti-AIM B-O B-protein
mAb B-O I-protein
. B-O O

Mobility B-O O
shift B-O O
assays B-O O
showed B-O O
that B-O O
addition B-O O
of B-O O
anti-AIM B-O B-protein
mAb B-O I-protein
to B-O O
PMA B-O B-cell_type
-treated B-O I-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
markedly B-O O
enhanced B-O O
the B-O O
binding B-O O
activity B-O O
of B-O O
AP-1 B-O B-protein
to B-O O
its B-O O
cognate B-O B-DNA
sequence B-O I-DNA
, B-O O
the B-O O
phorbol B-O B-DNA
ester B-O I-DNA
response B-O I-DNA
element B-O I-DNA
. B-O O

In B-O O
contrast B-O O
, B-O O
anti-AIM B-O B-protein
mAb B-O I-protein
did B-O O
not B-O O
induce B-O O
any B-O O
change B-O O
in B-O O
the B-O O
binding B-O O
activity B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
a B-O O
transcription B-O B-protein
factor B-O I-protein
whose B-O O
activity B-O O
is B-O O
also B-O O
regulated B-O O
by B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
. B-O O

The B-O O
increase B-O O
in B-O O
AP-1 B-O B-protein
-binding B-O O
activity B-O O
was B-O O
accompanied B-O O
by B-O O
the B-O O
marked B-O O
stimulation B-O O
of B-O O
the B-O O
transcription B-O O
of B-O O
c-fos B-O B-DNA
but B-O O
not B-O O
that B-O O
of B-O O
c-jun B-O B-DNA
. B-O O

Blockade B-O O
of B-O O
the B-O O
DNA-binding B-O B-protein
complexes B-O I-protein
with B-O O
an B-O O
anti-Fos B-O B-protein
mAb B-O I-protein
demonstrated B-O O
a B-O O
direct B-O O
participation B-O O
of B-O O
c-Fos B-O B-protein
in B-O O
the B-O O
AP-1 B-O B-protein
complexes B-O I-protein
induced B-O O
by B-O O
anti-AIM B-O B-protein
mAb B-O I-protein
. B-O O

Most B-O O
of B-O O
the B-O O
AP-1 B-O B-protein
activity B-O O
could B-O O
be B-O O
eliminated B-O O
when B-O O
the B-O O
anti-AIM B-O B-protein
mAb B-O I-protein
was B-O O
added B-O O
to B-O O
the B-O O
culture B-O O
medium B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
cycloheximide B-O O
, B-O O
suggesting B-O O
that B-O O
de B-O O
novo B-O O
protein B-O O
synthesis B-O O
is B-O O
crucial B-O O
for B-O O
the B-O O
induction B-O O
of B-O O
AP-1 B-O B-protein
-binding B-O O
activity B-O O
. B-O O

These B-O O
data B-O O
provide B-O O
the B-O O
evidence B-O O
that B-O O
activation B-O O
of B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
through B-O O
the B-O O
AIM B-O O
activation B-O O
pathway B-O O
regulate B-O O
the B-O O
activity B-O O
of B-O O
AP-1 B-O B-protein
. B-O O

Therefore B-O O
, B-O O
this B-O O
pathway B-O O
appears B-O O
as B-O O
a B-O O
crucial B-O O
step B-O O
in B-O O
the B-O O
initiation B-O O
of B-O O
early B-O O
T B-O O
cell B-O O
activation B-O O
events B-O O
. B-O O

Gangliosides B-O O
suppress B-O O
tumor B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
production B-O O
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
. B-O O

Both B-O O
normal B-O B-cell_type
and B-O I-cell_type
malignant B-O I-cell_type
cells B-O I-cell_type
contain B-O O
gangliosides B-O O
as B-O O
important B-O O
cell B-O O
membrane B-O O
constituents B-O O
that B-O O
, B-O O
after B-O O
being B-O O
shed B-O O
, B-O O
may B-O O
influence B-O O
cells B-O O
of B-O O
the B-O O
immune B-O O
system B-O O
. B-O O

We B-O O
have B-O O
studied B-O O
the B-O O
impact B-O O
of B-O O
gangliosides B-O O
on B-O O
the B-O O
expression B-O O
of B-O O
TNF B-O B-protein
in B-O O
blood B-O B-cell_type
monocytes B-O I-cell_type
and B-O O
in B-O O
the B-O O
monocytic B-O B-cell_line
cell B-O I-cell_line
line B-O I-cell_line
Mono B-O B-cell_line
Mac B-O I-cell_line
6 B-O I-cell_line
. B-O O

Although B-O O
under B-O O
standard B-O O
culture B-O O
conditions B-O O
, B-O O
bovine B-O O
brain B-O O
gangliosides B-O O
( B-O O
100 B-O O
micrograms/ml B-O O
) B-O O
suppressed B-O O
LPS-stimulated B-O O
TNF B-O B-protein
production B-O O
5-fold B-O O
in B-O O
PBMC B-O B-cell_type
and B-O O
10-fold B-O O
in B-O O
Mono B-O B-cell_line
Mac B-O I-cell_line
6 B-O I-cell_line
cells B-O I-cell_line
, B-O O
suppression B-O O
was B-O O
more B-O O
efficient B-O O
under B-O O
serum-free B-O O
conditions B-O O
. B-O O

Looking B-O O
at B-O O
highly B-O O
purified B-O O
gangliosides B-O O
, B-O O
GD3 B-O B-protein
, B-O O
GD1a B-O B-protein
, B-O O
GM3 B-O B-DNA
, B-O O
GM2 B-O B-DNA
, B-O O
and B-O O
GM1 B-O B-DNA
were B-O O
all B-O O
effective B-O O
in B-O O
reducing B-O O
TNF B-O B-protein
production B-O O
in B-O O
PBMC B-O B-cell_type
, B-O O
and B-O O
in B-O O
Mono B-O B-cell_line
Mac B-O I-cell_line
6 B-O I-cell_line
by B-O O
factor B-O O
10 B-O O
to B-O O
50 B-O O
. B-O O

The B-O O
suppressive B-O O
activity B-O O
was B-O O
lost B-O O
in B-O O
molecules B-O O
, B-O O
lacking B-O O
the B-O O
sugar B-O O
moiety B-O O
or B-O O
the B-O O
lipid B-O O
moiety B-O O
. B-O O

Gangliosides B-O O
appear B-O O
to B-O O
act B-O O
at B-O O
an B-O O
early B-O O
step B-O O
of B-O O
activation B-O O
in B-O O
that B-O O
TNF B-O B-RNA
transcripts B-O I-RNA
were B-O O
reduced B-O O
and B-O O
the B-O O
mobilization B-O O
of B-O O
the B-O O
nuclear B-O B-protein
factor B-O I-protein
kappa B-O I-protein
B B-O I-protein
was B-O O
blocked B-O O
. B-O O

Furthermore B-O O
, B-O O
in B-O O
time B-O O
kinetics B-O O
, B-O O
gangliosides B-O O
were B-O O
effective B-O O
for B-O O
up B-O O
to B-O O
30 B-O O
min B-O O
after B-O O
addition B-O O
of B-O O
LPS B-O O
, B-O O
but B-O O
not B-O O
thereafter B-O O
. B-O O

However B-O O
, B-O O
the B-O O
expression B-O O
of B-O O
the B-O O
CD14 B-O B-protein
Ag B-O I-protein
, B-O O
a B-O O
receptor B-O B-protein
molecule B-O I-protein
for B-O O
LPS-LPS B-O B-protein
binding B-O I-protein
protein B-O I-protein
complexes B-O I-protein
, B-O O
was B-O O
unaffected B-O O
by B-O O
gangliosides B-O O
. B-O O

Finally B-O O
, B-O O
when B-O O
using B-O O
Staphylococcus B-O O
aureus B-O O
or B-O O
platelet B-O B-protein
activating B-O I-protein
factor B-O I-protein
as B-O O
a B-O O
stimulus B-O O
, B-O O
gangliosides B-O O
were B-O O
able B-O O
to B-O O
suppress B-O O
TNF B-O B-protein
production B-O O
in B-O O
Mono B-O B-cell_line
Mac B-O I-cell_line
6 B-O I-cell_line
cells B-O I-cell_line
by B-O O
factor B-O O
5 B-O O
to B-O O
10 B-O O
, B-O O
as B-O O
well B-O O
. B-O O

On B-O O
the B-O O
other B-O O
hand B-O O
, B-O O
phorbol B-O O
ester B-O O
-induced B-O O
production B-O O
of B-O O
O2- B-O O
was B-O O
similar B-O O
in B-O O
cells B-O O
treated B-O O
with B-O O
and B-O O
without B-O O
gangliosides B-O O
. B-O O

Taken B-O O
together B-O O
, B-O O
our B-O O
data B-O O
demonstrate B-O O
that B-O O
TNF B-O B-protein
gene B-O O
expression B-O O
in B-O O
monocytes B-O B-cell_type
induced B-O O
by B-O O
different B-O O
types B-O O
of B-O O
stimuli B-O O
can B-O O
be B-O O
blocked B-O O
by B-O O
gangliosides B-O O
at B-O O
an B-O O
early B-O O
step B-O O
of B-O O
signal B-O O
transduction B-O O
. B-O O

A B-O O
novel B-O O
mitogen-inducible B-O B-protein
gene B-O I-protein
product B-O I-protein
related B-O O
to B-O O
p50/p105-NF-kappa B-O B-protein
B B-O I-protein
participates B-O O
in B-O O
transactivation B-O O
through B-O O
a B-O O
kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
. B-O O

A B-O O
Rel-related B-O O
, B-O O
mitogen-inducible B-O O
, B-O O
kappa B-O B-protein
B-binding B-O I-protein
protein B-O I-protein
has B-O O
been B-O O
cloned B-O O
as B-O O
an B-O O
immediate-early B-O B-DNA
activation B-O I-DNA
gene B-O I-DNA
of B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
cDNA B-O B-DNA
has B-O O
an B-O O
open B-O B-DNA
reading B-O I-DNA
frame B-O I-DNA
of B-O O
900 B-O O
amino B-O O
acids B-O O
capable B-O O
of B-O O
encoding B-O O
a B-O O
97-kDa B-O B-protein
protein B-O I-protein
. B-O O

This B-O O
protein B-O O
is B-O O
most B-O O
similar B-O O
to B-O O
the B-O O
105-kDa B-O O
precursor B-O O
polypeptide B-O O
of B-O O
p50-NF-kappa B-O B-protein
B B-O I-protein
. B-O O

Like B-O O
the B-O O
105-kDa B-O B-protein
precursor B-O I-protein
, B-O O
it B-O O
contains B-O O
an B-O O
amino-terminal B-O B-protein
Rel-related B-O I-protein
domain B-O I-protein
of B-O O
about B-O O
300 B-O B-protein
amino B-O I-protein
acids B-O I-protein
and B-O O
a B-O O
carboxy-terminal B-O B-protein
domain B-O I-protein
containing B-O O
six B-O O
full B-O O
cell B-O O
cycle B-O O
or B-O O
ankyrin B-O B-protein
repeats B-O I-protein
. B-O O

In B-O O
vitro-translated B-O B-protein
proteins B-O I-protein
, B-O O
truncated B-O O
downstream B-O O
of B-O O
the B-O O
Rel B-O B-DNA
domain B-O I-DNA
and B-O O
excluding B-O O
the B-O O
repeats B-O O
, B-O O
bind B-O O
kappa B-O B-DNA
B B-O I-DNA
sites B-O I-DNA
. B-O O

We B-O O
refer B-O O
to B-O O
the B-O O
kappa B-O B-protein
B-binding B-O I-protein
, B-O I-protein
truncated B-O I-protein
protein B-O I-protein
as B-O O
p50B B-O B-protein
by B-O O
analogy B-O O
with B-O O
p50-NF-kappa B-O B-protein
B B-O I-protein
and B-O O
to B-O O
the B-O O
full-length B-O B-protein
protein B-O I-protein
as B-O O
p97 B-O B-protein
. B-O O

p50B B-O B-protein
is B-O O
able B-O O
to B-O O
form B-O O
heteromeric B-O B-protein
kappa B-O I-protein
B-binding B-O I-protein
complexes B-O I-protein
with B-O O
RelB B-O B-protein
, B-O O
as B-O O
well B-O O
as B-O O
with B-O O
p65 B-O B-protein
and B-O O
p50 B-O B-protein
, B-O O
the B-O O
two B-O O
subunits B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

Transient-transfection B-O O
experiments B-O O
in B-O O
embryonal B-O B-cell_line
carcinoma B-O I-cell_line
cells B-O I-cell_line
demonstrate B-O O
a B-O O
functional B-O O
cooperation B-O O
between B-O O
p50B B-O B-protein
and B-O O
RelB B-O B-protein
or B-O O
p65 B-O B-protein
in B-O O
transactivation B-O O
of B-O O
a B-O O
reporter B-O B-DNA
plasmid B-O I-DNA
dependent B-O O
on B-O O
a B-O O
kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
. B-O O

The B-O O
data B-O O
imply B-O O
the B-O O
existence B-O O
of B-O O
a B-O O
complex B-O O
family B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
-like B-O O
transcription B-O B-protein
factors B-O I-protein
. B-O O

Surrogate B-O O
thyroglobulin B-O B-protein
receptors B-O I-protein
and B-O O
T B-O O
cell B-O O
proliferation B-O O
in B-O O
Hashimoto B-O O
's B-O O
thyroiditis B-O O
. B-O O

Immunoglobulin B-O B-protein
molecules B-O I-protein
on B-O O
the B-O O
surface B-O O
of B-O O
a B-O O
B B-O B-cell_type
lymphocyte B-O I-cell_type
are B-O O
the B-O O
endogenous B-O B-protein
`` B-O I-protein
receptors B-O I-protein
`` B-O O
to B-O O
which B-O O
specific B-O O
antigens B-O O
bind B-O O
. B-O O

Studies B-O O
in B-O O
mice B-O O
have B-O O
shown B-O O
that B-O O
a B-O O
monoclonal B-O B-protein
antibody B-O I-protein
, B-O O
conjugated B-O O
with B-O O
palmitate B-O O
to B-O O
provide B-O O
a B-O O
lipid B-O O
tail B-O O
, B-O O
can B-O O
be B-O O
inserted B-O O
into B-O O
the B-O O
cell B-O O
membrane B-O O
to B-O O
provide B-O O
a B-O O
`` B-O O
surrogate B-O O
`` B-O O
antigen B-O B-protein
receptor B-O I-protein
. B-O O

We B-O O
have B-O O
investigated B-O O
whether B-O O
a B-O O
palmitate B-O B-protein
conjugate B-O I-protein
of B-O O
a B-O O
human B-O B-protein
monoclonal B-O I-protein
antibody B-O I-protein
specific B-O O
for B-O O
thyroglobulin B-O B-protein
( B-O O
TG B-O B-protein
) B-O O
could B-O O
function B-O O
as B-O O
a B-O O
surrogate B-O B-protein
TG B-O I-protein
receptor B-O I-protein
on B-O O
blood B-O B-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
separated B-O O
into B-O O
fractions B-O O
enriched B-O O
for B-O O
T B-O B-cell_type
cells B-O I-cell_type
or B-O O
depleted B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
( B-O O
non-T B-O B-cell_type
cells B-O I-cell_type
) B-O O
. B-O O

Using B-O O
flow B-O O
cytometry B-O O
, B-O O
we B-O O
detected B-O O
surrogate B-O B-protein
TG B-O I-protein
receptors B-O I-protein
on B-O O
non-T B-O O
( B-O O
but B-O O
not B-O O
on B-O O
T B-O O
) B-O O
cells B-O O
from B-O O
11 B-O O
of B-O O
11 B-O O
individuals B-O O
studied B-O O
( B-O O
5 B-O O
Hashimoto B-O O
patients B-O O
and B-O O
6 B-O O
control B-O O
donors B-O O
) B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
endogenous B-O B-protein
TG B-O I-protein
receptors B-O I-protein
could B-O O
only B-O O
be B-O O
detected B-O O
on B-O O
non- B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
from B-O O
1 B-O O
of B-O O
3 B-O O
Hashimoto B-O O
patients B-O O
and B-O O
from B-O O
0 B-O O
of B-O O
4 B-O O
control B-O O
donors B-O O
. B-O O

Because B-O O
of B-O O
the B-O O
efficient B-O O
binding B-O O
of B-O O
TG B-O B-protein
by B-O O
surrogate B-O B-protein
receptors B-O I-protein
on B-O O
non-T B-O B-cell_type
cells B-O I-cell_type
, B-O O
we B-O O
assessed B-O O
the B-O O
ability B-O O
of B-O O
such B-O O
cells B-O O
to B-O O
present B-O O
TG B-O B-protein
to B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

Proliferation B-O O
in B-O O
response B-O O
to B-O O
TG B-O B-protein
was B-O O
observed B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
from B-O O
only B-O O
1 B-O O
of B-O O
5 B-O O
Hashimoto B-O O
patients B-O O
. B-O O

This B-O O
low B-O O
frequency B-O O
of B-O O
response B-O O
was B-O O
no B-O O
different B-O O
from B-O O
that B-O O
previously B-O O
detected B-O O
using B-O O
cultures B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
and B-O O
autologous B-O B-cell_type
dendritic B-O I-cell_type
cells B-O I-cell_type
. B-O O

Therefore B-O O
, B-O O
the B-O O
successful B-O O
generation B-O O
of B-O O
surrogate B-O B-protein
receptors B-O I-protein
on B-O O
non-T B-O B-cell_type
cells B-O I-cell_type
is B-O O
not B-O O
associated B-O O
with B-O O
more B-O O
efficient B-O O
TG B-O O
presentation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

Furthermore B-O O
, B-O O
the B-O O
significance B-O O
of B-O O
the B-O O
present B-O O
study B-O O
is B-O O
that B-O O
the B-O O
T B-O B-cell_type
cells B-O I-cell_type
, B-O O
not B-O O
the B-O O
antigen-presenting B-O B-cell_type
cells B-O I-cell_type
, B-O O
are B-O O
likely B-O O
to B-O O
be B-O O
the B-O O
limiting B-O O
element B-O O
in B-O O
the B-O O
T B-O O
cell B-O O
proliferative B-O O
response B-O O
to B-O O
TG B-O B-protein
and B-O O
other B-O O
thyroid B-O B-protein
autoantigens B-O I-protein
. B-O O

Targeted B-O O
degradation B-O O
of B-O O
c-Fos B-O B-protein
, B-O O
but B-O O
not B-O O
v-Fos B-O B-protein
, B-O O
by B-O O
a B-O O
phosphorylation-dependent B-O B-protein
signal B-O I-protein
on B-O O
c-Jun B-O B-protein
. B-O O

The B-O O
proto-oncogene B-O B-protein
products B-O I-protein
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
heterodimerize B-O O
through B-O O
their B-O O
leucine B-O B-protein
zippers B-O I-protein
to B-O O
form B-O O
the B-O O
AP-1 B-O B-protein
transcription B-O I-protein
factor B-O I-protein
. B-O O

The B-O O
transcriptional B-O O
activity B-O O
of B-O O
the B-O O
heterodimer B-O B-protein
is B-O O
regulated B-O O
by B-O O
signal-dependent B-O O
phosphorylation B-O O
and B-O O
dephosphorylation B-O O
events B-O O
. B-O O

The B-O O
stability B-O O
of B-O O
c-Fos B-O B-protein
was B-O O
found B-O O
to B-O O
also B-O O
be B-O O
controlled B-O O
by B-O O
intracellular B-O O
signal B-O O
transduction B-O O
. B-O O

In B-O O
transient B-O O
expression B-O O
and B-O O
in B-O O
vitro B-O O
degradation B-O O
experiments B-O O
, B-O O
the B-O O
stability B-O O
of B-O O
c-Fos B-O B-protein
was B-O O
decreased B-O O
when B-O O
the B-O O
protein B-O O
was B-O O
dimerized B-O O
with B-O O
phosphorylated B-O O
c-Jun B-O B-protein
. B-O O

c-Jun B-O B-protein
protein B-O O
isolated B-O O
from B-O O
phorbol B-O B-cell_line
ester-induced B-O I-cell_line
cells B-O I-cell_line
did B-O O
not B-O O
target B-O O
c-Fos B-O B-protein
for B-O O
degradation B-O O
, B-O O
which B-O O
suggests B-O O
that B-O O
c-Fos B-O B-protein
is B-O O
transiently B-O O
stabilized B-O O
after B-O O
stimulation B-O O
of B-O O
cell B-O O
growth B-O O
. B-O O

v-Fos B-O B-protein
protein B-O I-protein
, B-O O
the B-O O
retroviral B-O O
counterpart B-O O
of B-O O
c-Fos B-O B-protein
, B-O O
was B-O O
not B-O O
susceptible B-O O
to B-O O
degradation B-O O
targeted B-O O
by B-O O
c-Jun B-O B-protein
. B-O O

The B-O O
regulation B-O O
of B-O O
the B-O O
human B-O B-DNA
tumor B-O I-DNA
necrosis B-O I-DNA
factor B-O I-DNA
alpha B-O I-DNA
promoter B-O I-DNA
region B-O I-DNA
in B-O O
macrophage B-O B-cell_type
, B-O O
T B-O B-cell_type
cell B-O I-cell_type
, B-O O
and B-O O
B B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

The B-O O
1311-base B-O B-DNA
pair B-O I-DNA
human B-O I-DNA
tumor B-O I-DNA
necrosis B-O I-DNA
factor B-O I-DNA
( B-O I-DNA
TNF B-O I-DNA
) B-O I-DNA
alpha B-O I-DNA
promoter B-O I-DNA
region B-O I-DNA
was B-O O
fused B-O O
to B-O O
the B-O O
luciferase B-O B-DNA
( B-O I-DNA
Luc B-O I-DNA
) B-O I-DNA
reporter B-O I-DNA
gene B-O I-DNA
and B-O O
studied B-O O
in B-O O
a B-O O
transient B-O O
transfection B-O O
system B-O O
in B-O O
three B-O O
TNF B-O B-cell_line
producing B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
the B-O O
U937 B-O B-cell_line
macrophage B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
the B-O O
MLA B-O B-cell_line
144 B-O I-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
and B-O O
the B-O O
729-6 B-O B-cell_line
B B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
. B-O O

This B-O O
full B-O O
length B-O O
promoter B-O O
construct B-O O
can B-O O
be B-O O
induced B-O O
by B-O O
phorbol B-O O
13-myristate B-O O
acetate B-O O
( B-O O
PMA B-O O
) B-O O
in B-O O
each B-O O
of B-O O
these B-O O
cell B-O O
types B-O O
. B-O O

Analysis B-O O
of B-O O
a B-O O
series B-O O
of B-O O
5'-truncations B-O B-DNA
showed B-O O
several B-O O
peaks B-O O
of B-O O
basal B-O O
and B-O O
PMA B-O O
induced B-O O
activity B-O O
suggesting B-O O
the B-O O
presence B-O O
of B-O O
several B-O O
positive B-O O
and B-O O
negative B-O B-DNA
regulatory B-O I-DNA
elements B-O I-DNA
. B-O O

A B-O O
PMA B-O B-DNA
responsive B-O I-DNA
element B-O I-DNA
was B-O O
localized B-O O
to B-O O
a B-O O
region B-O O
between B-O O
-95 B-O B-DNA
and B-O I-DNA
-36 B-O I-DNA
bp B-O I-DNA
relative B-O O
to B-O O
the B-O O
transcription B-O B-DNA
start B-O I-DNA
site B-O I-DNA
. B-O O

Within B-O O
this B-O O
region B-O O
, B-O O
single B-O O
AP-2- B-O B-DNA
and B-O I-DNA
AP-1- B-O I-DNA
like B-O I-DNA
consensus B-O I-DNA
sequences B-O I-DNA
were B-O O
noted B-O O
. B-O O

These B-O O
AP-2 B-O B-protein
and B-O O
AP-1 B-O B-DNA
sites B-O I-DNA
were B-O O
each B-O O
modified B-O O
with B-O O
a B-O O
double B-O O
point B-O O
mutation B-O O
. B-O O

A B-O O
modest B-O O
( B-O O
20-50 B-O O
% B-O O
) B-O O
reduction B-O O
in B-O O
TNF B-O B-DNA
promoter B-O I-DNA
activity B-O O
was B-O O
observed B-O O
with B-O O
the B-O O
AP-2 B-O B-DNA
site B-O I-DNA
mutation B-O O
. B-O O

However B-O O
, B-O O
mutation B-O O
of B-O O
the B-O O
AP-1 B-O B-DNA
site B-O I-DNA
markedly B-O O
diminished B-O O
both B-O O
the B-O O
basal B-O O
and B-O O
PMA-activated B-O O
promoter B-O O
activity B-O O
. B-O O

Also B-O O
co-transfections B-O O
of B-O O
the B-O O
wild-type B-O B-DNA
promoter B-O I-DNA
construct B-O I-DNA
with B-O O
an B-O O
AP-1/c-jun B-O B-DNA
expression B-O I-DNA
vector B-O I-DNA
resulted B-O O
in B-O O
augmented B-O O
basal B-O O
and B-O O
PMA B-O O
-induced B-O O
promoter B-O O
activity B-O O
. B-O O

Stable B-O O
expression B-O O
of B-O O
transdominant B-O B-protein
Rev B-O I-protein
protein B-O I-protein
in B-O O
human B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
inhibits B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
replication B-O O
. B-O O

The B-O O
human B-O B-protein
immunodeficiency B-O I-protein
virus B-O I-protein
( B-O I-protein
HIV B-O I-protein
) B-O I-protein
Rev B-O I-protein
protein B-O I-protein
is B-O O
essential B-O O
for B-O O
viral B-O B-protein
structural B-O I-protein
protein B-O I-protein
expression B-O O
( B-O O
Gag B-O B-protein
, B-O O
Pol B-O B-protein
, B-O O
and B-O O
Env B-O B-protein
) B-O O
and B-O O
, B-O O
hence B-O O
, B-O O
for B-O O
viral B-O O
replication B-O O
. B-O O

In B-O O
transient B-O O
transfection B-O O
assays B-O O
, B-O O
mutant B-O O
forms B-O O
of B-O O
Rev B-O B-protein
have B-O O
been B-O O
identified B-O O
that B-O O
inhibit B-O O
wild-type B-O O
Rev B-O O
activity B-O O
and B-O O
therefore B-O O
suppress B-O O
viral B-O O
replication B-O O
. B-O O

To B-O O
determine B-O O
whether B-O O
such B-O O
transdominant B-O B-protein
Rev B-O I-protein
proteins B-O I-protein
could B-O O
provide B-O O
long-term B-O O
protection B-O O
against B-O O
HIV B-O O
infection B-O O
without B-O O
affecting B-O O
T B-O O
cell B-O O
function B-O O
, B-O O
T B-O B-cell_line
leukemia B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
were B-O O
stably B-O O
transduced B-O O
with B-O O
a B-O O
retroviral B-O B-DNA
vector B-O I-DNA
encoding B-O O
a B-O O
transdominant B-O B-protein
mutant B-O I-protein
of B-O O
the B-O O
Rev B-O B-protein
protein B-O I-protein
, B-O O
M10 B-O B-protein
. B-O O

While B-O O
all B-O O
the B-O O
M10 B-O B-cell_line
-expressing B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
remained B-O O
infectable B-O O
by B-O O
HIV-1 B-O O
, B-O O
these B-O O
same B-O O
cells B-O O
failed B-O O
to B-O O
support B-O O
a B-O O
productive B-O O
replication B-O O
cycle B-O O
when B-O O
infected B-O O
with B-O O
a B-O O
cloned B-O O
isolate B-O O
of B-O O
HIV-1 B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
two B-O O
out B-O O
of B-O O
three B-O O
M10 B-O B-cell_line
-expressing B-O I-cell_line
CEM B-O I-cell_line
clones B-O I-cell_line
were B-O O
also B-O O
resistant B-O O
to B-O O
highly B-O O
productive B-O O
infection B-O O
by B-O O
a B-O O
heterogeneous B-O O
HIV-1 B-O O
pool B-O O
. B-O O

Expression B-O O
of B-O O
M10 B-O B-protein
did B-O O
not B-O O
affect B-O O
induction B-O O
of B-O O
HIV B-O O
transcription B-O O
mediated B-O O
by B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
regulatory B-O I-DNA
element B-O I-DNA
or B-O O
Tat B-O B-protein
. B-O O

Importantly B-O O
, B-O O
constitutive B-O O
expression B-O O
of B-O O
Rev B-O B-protein
M10 B-O I-protein
did B-O O
not B-O O
alter B-O O
the B-O O
secretion B-O O
of B-O O
interleukin B-O B-protein
2 B-O I-protein
in B-O O
response B-O O
to B-O O
mitogen B-O B-protein
stimulation B-O O
of B-O O
EL-4 B-O B-cell_line
and B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
. B-O O

The B-O O
inhibition B-O O
of B-O O
HIV B-O O
infection B-O O
in B-O O
cells B-O O
stably B-O O
expressing B-O O
a B-O O
transdominant B-O B-protein
Rev B-O I-protein
protein B-O I-protein
, B-O O
in B-O O
the B-O O
absence B-O O
of B-O O
any B-O O
deleterious B-O O
effect B-O O
on B-O O
T B-O O
cell B-O O
function B-O O
, B-O O
suggests B-O O
that B-O O
such B-O O
a B-O O
strategy B-O O
could B-O O
provide B-O O
a B-O O
therapeutic B-O O
effect B-O O
in B-O O
the B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
of B-O O
acquired B-O O
immunodeficiency B-O O
syndrome B-O O
patients B-O O
. B-O O

Simple B-O O
derivation B-O O
of B-O O
TFIID-dependent B-O O
RNA B-O B-protein
polymerase B-O I-protein
II B-O I-protein
transcription B-O O
systems B-O O
from B-O O
Schizosaccharomyces B-O O
pombe B-O O
and B-O O
other B-O O
organisms B-O O
, B-O O
and B-O O
factors B-O O
required B-O O
for B-O O
transcriptional B-O O
activation B-O O
. B-O O

Resolution B-O O
of B-O O
whole B-O O
cell B-O O
extract B-O O
through B-O O
two B-O O
chromatographic B-O O
steps B-O O
yields B-O O
a B-O O
single B-O O
protein B-O O
fraction B-O O
requiring B-O O
only B-O O
the B-O O
addition B-O O
of B-O O
TFIID B-O B-protein
for B-O O
the B-O O
initiation B-O O
of B-O O
transcription B-O O
at B-O O
RNA B-O B-DNA
polymerase B-O I-DNA
II B-O I-DNA
promoters B-O I-DNA
. B-O O

This B-O O
approach B-O O
allows B-O O
the B-O O
convenient B-O O
generation B-O O
of B-O O
RNA B-O B-protein
polymerase B-O I-protein
II B-O I-protein
transcription B-O O
systems B-O O
from B-O O
Saccharomyces B-O O
cerevisiae B-O O
, B-O O
human B-O B-cell_type
lymphocytes B-O I-cell_type
, B-O O
and B-O O
Schizosaccharomyces B-O O
pombe B-O O
. B-O O

TFIIDs B-O B-protein
from B-O O
all B-O O
three B-O O
organisms B-O O
are B-O O
interchangeable B-O O
among B-O O
all B-O O
three B-O O
systems B-O O
. B-O O

The B-O O
S. B-O O
cerevisiae B-O O
and B-O O
Sch. B-O O
pombe B-O O
systems B-O O
support B-O O
effects B-O O
of B-O O
acidic B-O B-protein
activator B-O I-protein
proteins B-O I-protein
, B-O O
provided B-O O
a B-O O
further B-O O
protein B-O O
fraction B-O O
from B-O O
S. B-O O
cerevisiae B-O O
is B-O O
supplied B-O O
. B-O O

This B-O O
further B-O O
fraction B-O O
is B-O O
distinct B-O O
from B-O O
the B-O O
mediator B-O O
of B-O O
transcriptional B-O O
activation B-O O
described B-O O
previously B-O O
and B-O O
represents B-O O
a B-O O
second B-O O
component B-O O
in B-O O
addition B-O O
to B-O O
general B-O B-protein
initiation B-O I-protein
factors B-O I-protein
that B-O O
may B-O O
facilitate B-O O
a B-O O
response B-O O
to B-O O
acidic B-O B-protein
activators B-O I-protein
. B-O O

Regulation B-O O
of B-O O
c-jun B-O B-DNA
expression B-O O
during B-O O
induction B-O O
of B-O O
monocytic B-O O
differentiation B-O O
by B-O O
okadaic B-O O
acid B-O O
. B-O O

The B-O O
present B-O O
work B-O O
has B-O O
examined B-O O
the B-O O
effects B-O O
of B-O O
okadaic B-O O
acid B-O O
, B-O O
an B-O O
inhibitor B-O O
of B-O O
type B-O B-protein
1 B-O I-protein
and B-O I-protein
2A B-O I-protein
protein B-O I-protein
phosphatases B-O I-protein
, B-O O
on B-O O
the B-O O
regulation B-O O
of B-O O
c-jun B-O B-DNA
expression B-O O
during B-O O
monocytic B-O O
differentiation B-O O
of B-O O
U-937 B-O B-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
. B-O O

The B-O O
results B-O O
demonstrate B-O O
that B-O O
okadaic B-O O
acid B-O O
treatment B-O O
is B-O O
associated B-O O
with B-O O
induction B-O O
of B-O O
a B-O O
differentiated B-O O
monocyte B-O O
phenotype B-O O
characterized B-O O
by B-O O
: B-O O
( B-O O
a B-O O
) B-O O
growth B-O O
arrest B-O O
; B-O O
( B-O O
b B-O O
) B-O O
increases B-O O
in B-O O
Mac-1 B-O B-protein
cell B-O I-protein
surface B-O I-protein
antigen B-O I-protein
expression B-O O
; B-O O
( B-O O
c B-O O
) B-O O
down-regulation B-O O
of B-O O
c-myc B-O B-RNA
transcripts B-O I-RNA
; B-O O
and B-O O
( B-O O
d B-O O
) B-O O
induction B-O O
of B-O O
tumor B-O B-DNA
necrosis B-O I-DNA
factor B-O I-DNA
gene B-O I-DNA
expression B-O O
. B-O O

This B-O O
induction B-O O
of B-O O
monocytic B-O O
differentiation B-O O
was B-O O
associated B-O O
with B-O O
transient B-O O
increases B-O O
in B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
levels B-O O
, B-O O
which B-O O
were B-O O
maximal B-O O
at B-O O
6 B-O O
h B-O O
. B-O O

Similar B-O O
effects B-O O
were B-O O
obtained B-O O
for B-O O
the B-O O
c-fos B-O B-DNA
gene B-O I-DNA
. B-O O

Run-on B-O O
analysis B-O O
demonstrated B-O O
detectable B-O O
levels B-O O
of B-O O
c-jun B-O B-DNA
transcription B-O O
in B-O O
U-937 B-O B-cell_line
cells B-O I-cell_line
and B-O O
that B-O O
this B-O O
rate B-O O
is B-O O
increased B-O O
approximately B-O O
40-fold B-O O
following B-O O
okadaic B-O O
acid B-O O
exposure B-O O
. B-O O

c-jun B-O B-RNA
mRNA B-O I-RNA
levels B-O O
were B-O O
superinduced B-O O
in B-O O
cells B-O O
treated B-O O
with B-O O
both B-O O
okadaic B-O O
acid B-O O
and B-O O
cycloheximide B-O O
, B-O O
whereas B-O O
inhibition B-O O
of B-O O
protein B-O O
synthesis B-O O
had B-O O
little B-O O
, B-O O
if B-O O
any B-O O
, B-O O
effect B-O O
on B-O O
okadaic B-O O
acid B-O O
-induced B-O O
c-jun B-O B-DNA
transcription B-O O
. B-O O

The B-O O
half-life B-O O
of B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
was B-O O
similar B-O O
( B-O O
45-50 B-O O
min B-O O
) B-O O
in B-O O
both B-O O
untreated B-O O
and B-O O
okadaic B-O B-cell_line
acid B-O I-cell_line
-induced B-O I-cell_line
cells B-O I-cell_line
. B-O O

In B-O O
contrast B-O O
, B-O O
treatment B-O O
with B-O O
both B-O O
okadaic B-O O
acid B-O O
and B-O O
cycloheximide B-O O
was B-O O
associated B-O O
with B-O O
stabilization B-O O
( B-O O
t B-O O
1/2 B-O O
= B-O O
90 B-O O
min B-O O
) B-O O
of B-O O
c-jun B-O B-protein
transcripts B-O I-protein
. B-O O

Taken B-O O
together B-O O
, B-O O
these B-O O
findings B-O O
indicate B-O O
that B-O O
the B-O O
induction B-O O
of B-O O
c-jun B-O B-DNA
transcription B-O O
by B-O O
okadaic B-O O
acid B-O O
is B-O O
controlled B-O O
primarily B-O O
by B-O O
a B-O O
transcriptional B-O O
mechanism B-O O
. B-O O

Since B-O O
previous B-O O
studies B-O O
have B-O O
demonstrated B-O O
that B-O O
the B-O O
c-jun B-O B-DNA
gene B-O I-DNA
is B-O O
autoinduced B-O O
by B-O O
Jun/AP-1 B-O B-protein
, B-O O
we B-O O
also B-O O
studied B-O O
transcription B-O O
of B-O O
c-jun B-O B-DNA
promoter B-O I-DNA
( B-O I-DNA
positions B-O I-DNA
-132/+170 B-O I-DNA
) B-O I-DNA
-reporter B-O I-DNA
gene B-O I-DNA
constructs B-O I-DNA
with B-O O
and B-O O
without B-O O
a B-O O
mutated B-O B-DNA
AP-1 B-O I-DNA
element B-O I-DNA
. B-O O

( B-O O
ABSTRACT B-O O
TRUNCATED B-O O
AT B-O O
250 B-O O
WORDS B-O O
) B-O O

Mitogen B-O B-protein
stimulation B-O O
of B-O O
T-cells B-O B-cell_type
increases B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
protein B-O O
levels B-O O
, B-O O
AP-1 B-O B-protein
binding B-O O
and B-O O
AP-1 B-O B-protein
transcriptional B-O O
activity B-O O
. B-O O

We B-O O
have B-O O
analysed B-O O
the B-O O
effect B-O O
of B-O O
mitogenic B-O B-protein
lectins B-O I-protein
on B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
protein B-O O
levels B-O O
as B-O O
well B-O O
as B-O O
on B-O O
activator B-O B-protein
protein-1 B-O I-protein
( B-O O
AP-1 B-O B-protein
) B-O O
binding B-O O
and B-O O
enhancer B-O O
activity B-O O
in B-O O
Jurkat B-O B-cell_line
T-cells B-O I-cell_line
. B-O O

Both B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
protein B-O O
levels B-O O
were B-O O
increased B-O O
after B-O O
Con B-O O
A B-O O
and B-O O
PHA B-O B-protein
stimulation B-O O
. B-O O

Since B-O O
T-cell B-O O
stimulation B-O O
increases B-O O
both B-O O
intracellular B-O O
Ca2+ B-O O
and B-O O
cAMP B-O O
levels B-O O
and B-O O
activates B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
, B-O O
the B-O O
possible B-O O
involvement B-O O
of B-O O
these B-O O
intracellular B-O O
messengers B-O O
in B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
induction B-O O
was B-O O
tested B-O O
. B-O O

PMA B-O O
, B-O O
which B-O O
directly B-O O
activates B-O O
PKC B-O B-protein
, B-O O
mimicked B-O O
the B-O O
effect B-O O
of B-O O
the B-O O
lectins B-O B-protein
on B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
, B-O O
but B-O O
elevation B-O O
of B-O O
either B-O O
intracellular B-O O
Ca2+ B-O O
or B-O O
cAMP B-O O
levels B-O O
had B-O O
little B-O O
or B-O O
no B-O O
effect B-O O
. B-O O

The B-O O
mitogen-induced B-O O
increase B-O O
of B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
immunoreactivity B-O O
was B-O O
inhibited B-O O
by B-O O
H-7 B-O B-protein
, B-O O
a B-O O
kinase B-O O
inhibitor B-O O
with B-O O
relatively B-O O
high B-O O
specificity B-O O
for B-O O
PKC B-O B-protein
, B-O O
and B-O O
less B-O O
efficiently B-O O
by B-O O
H-8 B-O B-protein
, B-O O
a B-O O
structurally B-O O
related B-O O
kinase B-O O
inhibitor B-O O
less B-O O
active B-O O
on B-O O
PKC B-O B-protein
, B-O O
but B-O O
more B-O O
active B-O O
on B-O O
cyclic B-O B-protein
nucleotide-dependent B-O I-protein
kinases B-O I-protein
. B-O O

Con B-O O
A B-O O
stimulation B-O O
was B-O O
found B-O O
to B-O O
increase B-O O
both B-O O
binding B-O O
of B-O O
AP-1 B-O B-protein
to B-O O
the B-O O
AP-1 B-O B-DNA
consensus B-O I-DNA
sequence B-O I-DNA
, B-O O
TRE B-O B-DNA
, B-O O
and B-O O
AP-1 B-O B-DNA
enhancer B-O I-DNA
activity B-O O
, B-O O
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
. B-O O

PMA B-O O
was B-O O
also B-O O
found B-O O
to B-O O
increase B-O O
the B-O O
AP-1 B-O B-DNA
enhancer B-O I-DNA
activity B-O O
, B-O O
whereas B-O O
elevation B-O O
of B-O O
Ca2+ B-O O
or B-O O
cAMP B-O O
had B-O O
only B-O O
minor B-O O
effects B-O O
. B-O O

We B-O O
conclude B-O O
that B-O O
stimulation B-O O
with B-O O
mitogenic B-O O
lectins B-O B-protein
is B-O O
sufficient B-O O
to B-O O
increase B-O O
both B-O O
c-Fos B-O B-protein
and B-O O
c-Jun B-O B-protein
protein B-O O
levels B-O O
, B-O O
AP-1 B-O B-protein
binding B-O O
and B-O O
AP-1 B-O B-DNA
enhancer B-O I-DNA
activity B-O O
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
and B-O O
that B-O O
they B-O O
act B-O O
via B-O O
mechanisms B-O O
that B-O O
could B-O O
involve B-O O
the B-O O
activation B-O O
of B-O O
PKC B-O B-protein
. B-O O

An B-O O
11-base-pair B-O B-DNA
DNA B-O I-DNA
sequence B-O I-DNA
motif B-O I-DNA
apparently B-O O
unique B-O O
to B-O O
the B-O O
human B-O B-DNA
interleukin B-O I-DNA
4 B-O I-DNA
gene B-O I-DNA
confers B-O O
responsiveness B-O O
to B-O O
T-cell B-O O
activation B-O O
signals B-O O
. B-O O

We B-O O
have B-O O
identified B-O O
a B-O O
DNA B-O B-DNA
segment B-O I-DNA
that B-O O
confers B-O O
responsiveness B-O O
to B-O O
antigen B-O O
stimulation B-O O
signals B-O O
on B-O O
the B-O O
human B-O B-DNA
interleukin B-O I-DNA
( B-O I-DNA
IL B-O I-DNA
) B-O I-DNA
4 B-O I-DNA
gene B-O I-DNA
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
. B-O O

The B-O O
human B-O B-DNA
IL-4 B-O I-DNA
gene B-O I-DNA
, B-O O
of B-O O
10 B-O B-protein
kilobases B-O I-protein
, B-O O
is B-O O
composed B-O O
of B-O O
four B-O O
exons B-O B-DNA
and B-O O
three B-O O
introns B-O B-DNA
. B-O O

A B-O O
cis-acting B-O B-DNA
element B-O I-DNA
( B-O O
P B-O B-DNA
sequence B-O I-DNA
) B-O O
resides B-O O
in B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
upstream B-O I-DNA
region B-O I-DNA
; B-O O
no B-O O
additional B-O O
DNA B-O B-DNA
segments B-O I-DNA
with B-O O
enhancer B-O O
activity B-O O
were B-O O
identified B-O O
in B-O O
the B-O O
human B-O B-DNA
IL-4 B-O I-DNA
gene B-O I-DNA
. B-O O

For B-O O
further B-O O
mapping B-O O
purposes B-O O
, B-O O
a B-O O
fusion B-O B-DNA
promoter B-O I-DNA
was B-O O
constructed B-O O
with B-O O
the B-O O
granulocyte/macrophage B-O B-DNA
colony-stimulating B-O I-DNA
factor B-O I-DNA
basic B-O I-DNA
promoter B-O I-DNA
containing B-O O
60 B-O B-DNA
base B-O I-DNA
pairs B-O I-DNA
of B-O I-DNA
sequence B-O I-DNA
upstream B-O O
from B-O O
the B-O O
cap B-O B-DNA
site B-O I-DNA
of B-O O
the B-O O
mouse B-O B-DNA
granulocyte/macrophage B-O I-DNA
colony-stimulating B-O I-DNA
factor B-O I-DNA
gene B-O I-DNA
and B-O O
various B-O O
lengths B-O O
of B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
upstream B-O I-DNA
sequence B-O I-DNA
of B-O O
the B-O O
IL-4 B-O B-DNA
gene B-O I-DNA
. B-O O

The B-O O
P B-O B-DNA
sequence B-O I-DNA
was B-O O
located B-O O
between B-O O
positions B-O O
-79 B-O O
and B-O O
-69 B-O O
relative B-O O
to B-O O
the B-O O
transcription B-O B-DNA
start B-O I-DNA
site B-O I-DNA
of B-O O
the B-O O
human B-O B-DNA
IL-4 B-O I-DNA
gene B-O I-DNA
, B-O O
and B-O O
this B-O O
location B-O O
was B-O O
confirmed B-O O
by B-O O
base-substitution B-O O
mutations B-O O
. B-O O

The B-O O
plasmids B-O B-DNA
carrying B-O O
multiple B-O O
copies B-O O
of B-O O
the B-O O
P B-O B-DNA
sequence B-O I-DNA
showed B-O O
higher B-O O
responsiveness B-O O
to B-O O
the B-O O
stimulation B-O O
. B-O O

The B-O O
binding B-O B-protein
protein B-O I-protein
( B-O O
s B-O O
) B-O O
that B-O O
recognize B-O O
the B-O O
P B-O B-DNA
sequence B-O I-DNA
of B-O O
the B-O O
IL-4 B-O B-DNA
gene B-O I-DNA
were B-O O
identified B-O O
by B-O O
DNA-mobility-shift B-O O
assays B-O O
. B-O O

The B-O O
binding B-O O
of B-O O
NF B-O B-protein
( B-O I-protein
P B-O I-protein
) B-O I-protein
( B-O O
a B-O O
DNA B-O B-protein
binding B-O I-protein
protein B-O I-protein
that B-O O
specifically B-O O
recognizes B-O O
the B-O O
P B-O B-DNA
sequence B-O I-DNA
) B-O O
to B-O O
the B-O O
P B-O B-DNA
sequence B-O I-DNA
was B-O O
abolished B-O O
when B-O O
oligonucleotides B-O O
carrying B-O O
base B-O O
substitutions B-O O
were B-O O
used B-O O
, B-O O
indicating B-O O
that B-O O
the B-O O
NF B-O B-protein
( B-O I-protein
P B-O I-protein
) B-O I-protein
interaction B-O O
is B-O O
sequence-specific B-O O
and B-O O
that B-O O
binding B-O O
specificity B-O O
of B-O O
the B-O O
protein B-O O
paralleled B-O O
the B-O O
sequence B-O O
requirements B-O O
for B-O O
IL-4 B-O B-protein
expression B-O O
in B-O O
vivo B-O O
. B-O O

The B-O O
P B-O B-DNA
sequence B-O I-DNA
does B-O O
not B-O O
share B-O O
homology B-O O
with B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
upstream B-O I-DNA
sequence B-O I-DNA
of B-O O
the B-O O
IL-2 B-O B-DNA
gene B-O I-DNA
, B-O O
even B-O O
though B-O O
surrounding B-O O
sequences B-O O
of B-O O
the B-O O
IL-4 B-O B-DNA
gene B-O I-DNA
share B-O O
high B-O O
homology B-O O
with B-O O
the B-O O
IL-2 B-O B-DNA
gene B-O I-DNA
. B-O O

We B-O O
conclude B-O O
that B-O O
a B-O O
different B-O O
set B-O O
of B-O O
proteins B-O O
recognize B-O O
IL-2 B-O B-protein
and B-O O
IL-4 B-O B-DNA
genes B-O I-DNA
. B-O O

Leukotriene B-O O
B4 B-O O
stimulates B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O O
gene B-O O
transcription B-O O
and B-O O
AP-1 B-O B-protein
binding B-O O
activity B-O O
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
. B-O O

We B-O O
have B-O O
examined B-O O
the B-O O
effect B-O O
of B-O O
leukotriene B-O O
B4 B-O O
( B-O O
LTB4 B-O B-protein
) B-O O
, B-O O
a B-O O
potent B-O O
lipid B-O O
proinflammatory B-O B-protein
mediator B-O I-protein
, B-O O
on B-O O
the B-O O
expression B-O O
of B-O O
the B-O O
proto-oncogenes B-O B-DNA
c-jun B-O B-DNA
and B-O O
c-fos B-O B-DNA
. B-O O

In B-O O
addition B-O O
, B-O O
we B-O O
looked B-O O
at B-O O
the B-O O
modulation B-O O
of B-O O
nuclear B-O B-protein
factors B-O I-protein
binding B-O O
specifically B-O O
to B-O O
the B-O O
AP-1 B-O B-DNA
element B-O I-DNA
after B-O O
LTB4 B-O O
stimulation B-O O
. B-O O

LTB4 B-O O
increased B-O O
the B-O O
expression B-O O
of B-O O
the B-O O
c-fos B-O B-DNA
gene B-O I-DNA
in B-O O
a B-O O
time- B-O O
and B-O O
concentration-dependent B-O O
manner B-O O
. B-O O

The B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
, B-O O
which B-O O
is B-O O
constitutively B-O O
expressed B-O O
in B-O O
human B-O B-cell_type
peripheral-blood B-O I-cell_type
monocytes B-O I-cell_type
at B-O O
relatively B-O O
high B-O O
levels B-O O
, B-O O
was B-O O
also B-O O
slightly B-O O
augmented B-O O
by B-O O
LTB4 B-O O
, B-O O
although B-O O
to B-O O
a B-O O
much B-O O
lower B-O O
extent B-O O
than B-O O
c-fos B-O B-DNA
. B-O O

The B-O O
kinetics B-O O
of B-O O
expression B-O O
of B-O O
the B-O O
two B-O O
genes B-O O
were B-O O
also B-O O
slightly B-O O
different B-O O
, B-O O
with B-O O
c-fos B-O B-RNA
mRNA B-O I-RNA
reaching B-O O
a B-O O
peak B-O O
at B-O O
15 B-O O
min B-O O
after B-O O
stimulation B-O O
and B-O O
c-jun B-O B-DNA
at B-O O
30 B-O O
min B-O O
. B-O O

Both B-O O
messages B-O O
rapidly B-O O
declined B-O O
thereafter B-O O
. B-O O

Stability B-O O
of B-O O
the B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
was B-O O
not B-O O
affected B-O O
by B-O O
LTB4 B-O O
, B-O O
as B-O O
assessed B-O O
after B-O O
actinomycin B-O O
D B-O O
treatment B-O O
. B-O O

Nuclear B-O O
transcription B-O O
studies B-O O
in B-O O
vitro B-O O
showed B-O O
that B-O O
LTB4 B-O O
increased B-O O
the B-O O
transcription B-O O
of B-O O
the B-O O
c-fos B-O B-DNA
gene B-O I-DNA
7-fold B-O O
and B-O O
the B-O O
c-jun B-O B-DNA
gene B-O I-DNA
1.4-fold B-O O
. B-O O

Resting B-O B-cell_type
monocytes B-O I-cell_type
contained B-O O
nuclear B-O B-protein
factors B-O I-protein
binding B-O O
to B-O O
the B-O O
AP-1 B-O B-DNA
element B-O I-DNA
, B-O O
but B-O O
stimulation B-O O
of B-O O
monocytes B-O B-cell_type
with B-O O
LTB4 B-O O
induced B-O O
greater B-O O
AP-1 B-O B-protein
-binding B-O O
activity B-O O
of B-O O
nuclear B-O B-protein
proteins B-O I-protein
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
LTB4 B-O O
may B-O O
regulate B-O O
the B-O O
production B-O O
of B-O O
different B-O O
cytokines B-O B-protein
by B-O O
modulating B-O O
the B-O O
yield B-O O
and/or B-O O
the B-O O
function B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
such B-O O
as B-O O
AP-1 B-O B-protein
-binding B-O O
proto-oncogene B-O B-protein
products B-O I-protein
. B-O O

Modulation B-O O
of B-O O
normal B-O O
erythroid B-O O
differentiation B-O O
by B-O O
the B-O O
endogenous B-O O
thyroid B-O O
hormone B-O O
and B-O O
retinoic B-O B-protein
acid B-O I-protein
receptors B-O I-protein
: B-O O
a B-O O
possible B-O O
target B-O O
for B-O O
v-erbA B-O B-DNA
oncogene B-O I-DNA
action B-O O
. B-O O

The B-O O
v-erbA B-O B-DNA
oncogene B-O I-DNA
, B-O O
a B-O O
mutated B-O O
version B-O O
of B-O O
the B-O O
thyroid B-O B-protein
hormone B-O I-protein
receptor B-O I-protein
alpha B-O I-protein
( B-O O
c-erbA/TR-alpha B-O B-protein
) B-O O
, B-O O
inhibits B-O O
erythroid B-O O
differentiation B-O O
and B-O O
constitutively B-O O
represses B-O O
transcription B-O O
of B-O O
certain B-O O
erythrocyte B-O B-DNA
genes B-O I-DNA
, B-O O
suggesting B-O O
a B-O O
normal B-O O
function B-O O
of B-O O
the B-O O
proto-oncogene B-O B-DNA
c-erbA B-O I-DNA
in B-O O
erythropoiesis B-O O
. B-O O

Here B-O O
we B-O O
demonstrate B-O O
that B-O O
the B-O O
endogenous B-O O
thyroid B-O B-protein
hormone B-O I-protein
receptor B-O I-protein
alpha B-O I-protein
( B-O O
c-erbA/TR-alpha B-O B-protein
) B-O O
and B-O O
the B-O O
closely B-O O
related B-O O
retinoic B-O B-protein
acid B-O I-protein
receptor B-O I-protein
alpha B-O I-protein
( B-O O
RAR-alpha B-O B-protein
) B-O O
play B-O O
a B-O O
role B-O O
in B-O O
the B-O O
regulation B-O O
of B-O O
normal B-O O
erythroid B-O O
differentiation B-O O
. B-O O

Retinoic B-O O
acid B-O O
( B-O O
RA B-O O
) B-O O
distinctly B-O O
modulated B-O O
the B-O O
erythroid B-O O
differentiation B-O O
program B-O O
of B-O O
normal B-O B-cell_type
erythroid B-O I-cell_type
progenitors B-O I-cell_type
and B-O O
erythroblasts B-O B-cell_type
reversibly B-O O
transformed B-O O
by B-O O
a B-O O
conditional B-O O
tyrosine B-O B-DNA
kinase B-O I-DNA
oncogene B-O I-DNA
. B-O O

When B-O O
added B-O O
pulsewise B-O O
to B-O O
immature B-O B-cell_type
cells B-O I-cell_type
, B-O O
differentiation B-O O
was B-O O
accelerated B-O O
while B-O O
more B-O O
mature B-O B-cell_type
cells B-O I-cell_type
underwent B-O O
premature B-O O
cell B-O O
death B-O O
. B-O O

Thyroid B-O O
hormone B-O O
( B-O O
T3 B-O O
) B-O O
alone B-O O
caused B-O O
similar B-O O
but B-O O
weaker B-O O
effects B-O O
. B-O O

Interestingly B-O O
, B-O O
T3 B-O O
strongly B-O O
enhanced B-O O
the B-O O
action B-O O
of B-O O
RA B-O B-protein
, B-O O
suggesting B-O O
cooperative B-O O
action B-O O
of B-O O
the B-O O
two B-O O
receptors B-O O
in B-O O
modulating B-O O
erythroid B-O O
differentiation B-O O
. B-O O

Expression B-O O
of B-O O
the B-O O
human B-O B-protein
RAR-alpha B-O I-protein
in B-O O
receptor-negative B-O B-cell_line
erythroblasts B-O I-cell_line
conferred B-O O
RA B-O O
-induced B-O O
regulation B-O O
of B-O O
differentiation B-O O
to B-O O
the B-O O
otherwise B-O O
unresponsive B-O B-cell_type
cells B-O I-cell_type
, B-O O
thus B-O O
showing B-O O
that B-O O
the B-O O
RAR-alpha B-O B-protein
is B-O O
essential B-O O
for B-O O
the B-O O
RA B-O O
effect B-O O
. B-O O

Likewise B-O O
, B-O O
enhanced B-O O
expression B-O O
of B-O O
exogenous B-O B-protein
c-erbA/TR-alpha B-O I-protein
in B-O O
erythroblasts B-O B-cell_type
rendered B-O O
them B-O O
susceptible B-O O
to B-O O
modulation B-O O
of B-O O
differentiation B-O O
by B-O O
T3 B-O O
, B-O O
suggesting B-O O
a B-O O
similar B-O O
function B-O O
of B-O O
both B-O O
receptors B-O O
. B-O O

Activation B-O O
of B-O O
lymphokine B-O B-DNA
genes B-O I-DNA
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
: B-O O
role B-O O
of B-O O
cis-acting B-O B-DNA
DNA B-O I-DNA
elements B-O I-DNA
that B-O O
respond B-O O
to B-O O
T B-O O
cell B-O O
activation B-O O
signals B-O O
. B-O O

Activation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
is B-O O
initiated B-O O
by B-O O
the B-O O
recognition B-O O
of B-O O
antigen B-O O
on B-O O
antigen B-O B-cell_type
presenting B-O I-cell_type
cells B-O I-cell_type
to B-O O
exert B-O O
the B-O O
effector B-O O
functions B-O O
in B-O O
immune B-O O
and B-O O
inflammatory B-O O
responses B-O O
. B-O O

Two B-O O
types B-O O
of B-O O
helper B-O B-cell_line
T B-O I-cell_line
cell B-O I-cell_line
( B-O I-cell_line
Th B-O I-cell_line
) B-O I-cell_line
clones B-O I-cell_line
( B-O O
Th1 B-O B-cell_line
and B-O O
Th2 B-O B-cell_line
) B-O O
are B-O O
defined B-O O
on B-O O
the B-O O
basis B-O O
of B-O O
different B-O O
patterns B-O O
of B-O O
cytokine B-O B-protein
( B-O O
lymphokine B-O B-protein
) B-O O
secretion B-O O
. B-O O

They B-O O
determine B-O O
the B-O O
outcome B-O O
of B-O O
an B-O O
antigenic B-O O
response B-O O
toward B-O O
humoral B-O O
or B-O O
cell-mediated B-O O
immunity B-O O
. B-O O

Although B-O O
lymphokine B-O B-DNA
genes B-O I-DNA
are B-O O
coordinately B-O O
regulated B-O B-protein
upon B-O I-protein
antigen B-O I-protein
stimulation B-O O
, B-O O
they B-O O
are B-O O
regulated B-O O
by B-O O
the B-O O
mechanisms B-O O
common B-O O
to B-O O
all B-O O
as B-O O
well B-O O
as B-O O
those B-O O
which B-O O
are B-O O
unique B-O O
to B-O O
each B-O O
gene B-O O
. B-O O

For B-O O
most B-O O
lymphokine B-O B-DNA
genes B-O I-DNA
, B-O O
a B-O O
combination B-O O
of B-O O
phorbol B-O O
esters B-O O
( B-O O
phorbol B-O O
12-myristate B-O O
13 B-O O
acetate B-O O
, B-O O
PMA B-O O
) B-O O
and B-O O
calcium B-O O
ionophores B-O O
( B-O O
A23187 B-O O
) B-O O
is B-O O
required B-O O
for B-O O
their B-O O
maximal B-O O
induction B-O O
. B-O O

Yet B-O O
phorbol B-O O
ester B-O O
alone B-O O
or B-O O
calcium B-O O
ionophore B-O O
alone B-O O
produce B-O O
several B-O O
lymphokines B-O B-protein
. B-O O

The B-O O
production B-O O
of B-O O
the B-O O
granulocyte-macrophage B-O B-protein
colony B-O I-protein
stimulating B-O I-protein
factor B-O I-protein
( B-O O
GM-CSF B-O B-protein
) B-O O
is B-O O
completely B-O O
dependent B-O O
on B-O O
the B-O O
two B-O O
signals B-O O
. B-O O

We B-O O
have B-O O
previously B-O O
found B-O O
a B-O O
cis-acting B-O B-DNA
region B-O I-DNA
spanning B-O O
the B-O O
GM-CSF B-O B-DNA
promoter B-O I-DNA
region B-O I-DNA
( B-O O
positions B-O B-DNA
-95 B-O I-DNA
to B-O I-DNA
+27 B-O I-DNA
) B-O O
that B-O O
confers B-O O
inducibility B-O O
to B-O O
reporter B-O B-DNA
genes B-O I-DNA
in B-O O
transient B-O O
transfection B-O O
assays B-O O
. B-O O

Further B-O O
analysis B-O O
identified B-O O
three B-O O
elements B-O O
required B-O O
for B-O O
efficient B-O O
induction B-O O
, B-O O
referred B-O O
to B-O O
as B-O O
GM2 B-O B-DNA
, B-O O
GC-box B-O B-DNA
and B-O O
conserved B-O B-DNA
lymphokine B-O I-DNA
element B-O I-DNA
( B-O O
CLE0 B-O B-DNA
) B-O O
. B-O O

GM2 B-O B-DNA
defines B-O O
a B-O O
binding B-O B-DNA
site B-O I-DNA
for B-O O
protein B-O O
( B-O O
s B-O O
) B-O O
whose B-O O
binding B-O O
is B-O O
inducible B-O O
by B-O O
PMA B-O O
. B-O O

One B-O O
protein B-O O
, B-O O
NF-GM2 B-O B-protein
is B-O O
similar B-O O
to B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kB B-O B-protein
. B-O O

GC-box B-O B-DNA
is B-O O
a B-O O
binding B-O B-DNA
site B-O I-DNA
for B-O O
constitutively B-O B-protein
bound B-O I-protein
proteins B-O I-protein
. B-O O

CLEO B-O B-protein
defines B-O O
a B-O O
binding B-O B-DNA
site B-O I-DNA
for B-O O
protein B-O O
( B-O O
s B-O O
) B-O O
whose B-O O
optimum B-O O
binding B-O O
is B-O O
stimulated B-O O
by B-O O
PMA B-O O
and B-O O
A23187 B-O O
. B-O O

Viral B-O B-protein
trans-activators B-O I-protein
such B-O O
as B-O O
Tax B-O B-protein
( B-O O
human B-O O
T B-O O
cell B-O O
leukemia B-O O
virus-1 B-O O
, B-O O
HTLV-1 B-O O
) B-O O
and B-O O
E2 B-O B-protein
( B-O O
bovine B-O O
papilloma B-O O
virus B-O O
, B-O O
BPV B-O O
) B-O O
proteins B-O O
are B-O O
other B-O O
agents B-O O
which B-O O
activate B-O O
lymphokine B-O B-DNA
gene B-O I-DNA
expression B-O O
by B-O O
bypassing B-O O
T B-O B-protein
cell B-O I-protein
receptor B-O I-protein
( B-O O
TCR B-O B-protein
) B-O O
mediated B-O O
signaling B-O O
. B-O O

The B-O O
trans-activation B-O B-protein
domain B-O I-protein
of B-O O
E2 B-O B-protein
and B-O O
Tax B-O B-protein
is B-O O
interchangeable B-O O
although B-O O
they B-O O
have B-O O
no B-O O
obvious B-O O
sequence B-O O
homology B-O O
between B-O O
them B-O O
. B-O O

The B-O O
viral B-O B-protein
trans-activators B-O I-protein
appear B-O O
to B-O O
target B-O O
specific B-O O
DNA B-O B-protein
binding B-O I-protein
protein B-O I-protein
such B-O O
as B-O O
NF-kB B-O B-protein
and B-O O
Sp1 B-O B-protein
to B-O O
cis-acting B-O B-DNA
DNA B-O I-DNA
site B-O I-DNA
and B-O O
promote B-O O
lymphokine B-O B-DNA
gene B-O I-DNA
expression B-O O
without B-O O
TCR B-O B-protein
-mediated B-O O
stimulation B-O O
. B-O O

Mutations B-O O
in B-O O
the B-O O
Pit-1 B-O B-DNA
gene B-O I-DNA
in B-O O
children B-O O
with B-O O
combined B-O O
pituitary B-O O
hormone B-O O
deficiency B-O O
. B-O O

Pit-1 B-O B-protein
is B-O O
a B-O O
pituitary-specific B-O B-protein
transcription B-O I-protein
factor B-O I-protein
that B-O O
binds B-O O
to B-O O
and B-O O
transactivates B-O O
promoters B-O B-DNA
of B-O O
growth B-O B-DNA
hormone B-O I-DNA
and B-O I-DNA
prolactin B-O I-DNA
genes B-O I-DNA
. B-O O

In B-O O
three B-O O
unrelated B-O O
Japanese B-O O
children B-O O
with B-O O
combined B-O O
pituitary B-O O
hormone B-O O
deficiency B-O O
, B-O O
we B-O O
identified B-O O
three B-O O
point B-O O
mutations B-O O
in B-O O
the B-O O
Pit-1 B-O B-DNA
gene B-O I-DNA
, B-O O
Pro24Leu B-O B-DNA
, B-O O
Arg143Gln B-O B-DNA
, B-O O
and B-O O
Arg271Trp B-O B-DNA
, B-O O
located B-O O
on B-O O
the B-O O
major B-O B-DNA
transactivation B-O I-DNA
region B-O I-DNA
, B-O O
POU-specific B-O B-protein
domain B-O I-protein
, B-O O
and B-O O
POU-homeodomain B-O B-protein
, B-O O
respectively B-O O
. B-O O

Activation B-O O
of B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
and B-O O
elevation B-O O
of B-O O
cAMP B-O O
interact B-O O
synergistically B-O O
to B-O O
raise B-O O
c-Fos B-O B-protein
and B-O O
AP-1 B-O B-protein
activity B-O O
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
. B-O O

We B-O O
have B-O O
earlier B-O O
found B-O O
that B-O O
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
activation B-O O
of B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
enhances B-O O
the B-O O
cyclic B-O O
adenosine B-O O
monophosphate B-O O
( B-O O
cAMP B-O O
) B-O O
accumulation B-O O
induced B-O O
by B-O O
adenosine B-O B-protein
receptor B-O I-protein
stimulation B-O O
or B-O O
activation B-O O
of B-O O
Gs B-O B-protein
. B-O O

Here B-O O
we B-O O
have B-O O
therefore B-O O
examined B-O O
the B-O O
effect B-O O
of B-O O
the B-O O
phorbol B-O O
ester B-O O
PMA B-O O
( B-O O
phorbol B-O O
12-myristate B-O O
13-acetate B-O O
) B-O O
which B-O O
stimulates B-O O
PKC B-O B-protein
and B-O O
a B-O O
combination B-O O
of B-O O
the B-O O
adenosine B-O B-protein
receptor B-O I-protein
agonist B-O O
NECA B-O O
( B-O O
5'- B-O O
( B-O O
N-ethyl B-O O
) B-O O
-carboxamido B-O O
adenosine B-O O
) B-O O
and B-O O
forskolin B-O O
to B-O O
raise B-O O
cAMP B-O O
, B-O O
on B-O O
the B-O O
levels B-O O
of B-O O
c-Fos B-O B-protein
and B-O O
Jun B-O B-protein
and B-O O
on B-O O
the B-O O
binding B-O O
and B-O O
transcriptional B-O O
activity B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
, B-O O
activator B-O B-protein
protein-1 B-O I-protein
( B-O O
AP-1 B-O B-protein
) B-O O
. B-O O

PMA B-O O
treatment B-O O
caused B-O O
a B-O O
concentration- B-O O
and B-O O
time-dependent B-O O
increase B-O O
in B-O O
both B-O O
c-Fos B-O B-protein
and B-O O
Jun B-O B-protein
immunoreactivity B-O O
in B-O O
contrast B-O O
to B-O O
cAMP B-O O
elevation B-O O
that B-O O
had B-O O
only B-O O
a B-O O
slight B-O O
effect B-O O
. B-O O

Both B-O O
PMA B-O O
and B-O O
the B-O O
combination B-O O
of B-O O
NECA B-O B-protein
and B-O O
forskolin B-O O
acted B-O O
together B-O O
either B-O O
to B-O O
increase B-O O
( B-O O
c-Fos B-O B-protein
) B-O O
or B-O O
decrease B-O O
( B-O O
Jun B-O B-protein
) B-O O
protein B-O O
levels B-O O
as B-O O
well B-O O
as B-O O
increasing B-O O
AP-1 B-O B-protein
binding B-O O
, B-O O
as B-O O
judged B-O O
by B-O O
gel-shift B-O O
assay B-O O
, B-O O
and B-O O
AP-1 B-O B-protein
transcriptional B-O O
activity B-O O
. B-O O

Furthermore B-O O
there B-O O
was B-O O
a B-O O
clear-cut B-O O
synergy B-O O
between B-O O
the B-O O
PKC B-O B-protein
stimulator B-O O
and B-O O
the B-O O
cAMP B-O O
elevating B-O O
agents B-O O
. B-O O

The B-O O
results B-O O
demonstrate B-O O
that B-O O
the B-O O
simultaneous B-O O
activation B-O O
of B-O O
PKC B-O B-protein
and B-O O
elevation B-O O
of B-O O
cAMP B-O O
leads B-O O
to B-O O
an B-O O
enhanced B-O O
AP-1 B-O B-protein
transcriptional B-O O
activity B-O O
in B-O O
a B-O O
T-leukemia B-O B-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
suggesting B-O O
that B-O O
the B-O O
previously B-O O
observed B-O O
interaction B-O O
between B-O O
the B-O O
parallel B-O O
signal B-O O
transduction B-O O
pathways B-O O
may B-O O
have B-O O
functional B-O O
consequences B-O O
at B-O O
the B-O O
level B-O O
of B-O O
gene B-O O
transcription B-O O
. B-O O

Inhibition B-O O
of B-O O
anti-CD3 B-O B-protein
monoclonal B-O I-protein
antibody B-O I-protein
-induced B-O O
T-cell B-O O
proliferation B-O O
by B-O O
dexamethasone B-O O
, B-O O
isoproterenol B-O O
, B-O O
or B-O O
prostaglandin B-O O
E2 B-O O
either B-O O
alone B-O O
or B-O O
in B-O O
combination B-O O
. B-O O

1 B-O O
. B-O O

The B-O O
purpose B-O O
of B-O O
these B-O O
studies B-O O
was B-O O
to B-O O
investigate B-O O
the B-O O
modulation B-O O
of B-O O
the B-O O
proliferation B-O O
of B-O O
human B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
obtained B-O O
from B-O O
peripheral B-O O
blood B-O O
by B-O O
dexamethasone B-O O
( B-O O
DEX B-O O
) B-O O
, B-O O
isoproterenol B-O O
( B-O O
ISO B-O O
) B-O O
, B-O O
and B-O O
prostaglandin B-O B-protein
E2 B-O I-protein
( B-O O
PGE2 B-O B-protein
) B-O O
. B-O O

The B-O O
former B-O O
two B-O O
substances B-O O
interact B-O O
with B-O O
T B-O B-cell_type
cells B-O I-cell_type
via B-O O
the B-O O
glucocorticoid B-O B-protein
and B-O I-protein
beta-adrenergic B-O I-protein
receptors B-O I-protein
respectively B-O O
. B-O O

When B-O O
occupied B-O O
by B-O O
their B-O O
natural B-O O
ligands B-O O
, B-O O
glucocorticosteroids B-O O
and B-O O
catecholamines B-O O
, B-O O
these B-O O
receptors B-O O
have B-O O
a B-O O
role B-O O
in B-O O
modulating B-O O
T-cell B-O O
function B-O O
during B-O O
stress B-O O
. B-O O

During B-O O
the B-O O
inflammatory B-O O
response B-O O
increased B-O O
levels B-O O
of B-O O
PGE2 B-O B-protein
bind B-O O
to B-O O
their B-O O
receptors B-O O
on B-O O
T B-O B-cell_type
cells B-O I-cell_type
and B-O O
thus B-O O
alter B-O O
responsiveness B-O O
. B-O O

Proliferation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
was B-O O
induced B-O O
by B-O O
immobilized B-O O
anti-CD3 B-O B-protein
monoclonal B-O I-protein
antibody B-O I-protein
( B-O O
mAb B-O B-protein
) B-O O
in B-O O
the B-O O
presence B-O O
or B-O O
absence B-O O
of B-O O
an B-O O
additional B-O O
costimulatory B-O O
signal B-O O
delivered B-O O
by B-O O
anti-CD28 B-O B-protein
mAb B-O I-protein
. B-O O

2 B-O O
. B-O O

Various B-O O
physiologic B-O O
concentrations B-O O
of B-O O
DEX B-O O
, B-O O
ISO B-O O
, B-O O
or B-O O
PGE2 B-O O
were B-O O
added B-O O
at B-O O
the B-O O
time B-O O
of B-O O
initiation B-O O
of B-O O
the B-O O
cultures B-O O
and B-O O
subsequent B-O O
proliferation B-O O
of B-O O
the B-O O
unstimulated B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
was B-O O
determined B-O O
. B-O O

The B-O O
results B-O O
demonstrate B-O O
that B-O O
physiologic B-O O
concentrations B-O O
of B-O O
all B-O O
three B-O O
of B-O O
these B-O O
agents B-O O
inhibit B-O O
the B-O O
anti-CD3 B-O B-protein
mAb B-O I-protein
-induced B-O O
proliferation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

3 B-O O
. B-O O

Although B-O O
DEX B-O O
and B-O O
PGE2 B-O O
were B-O O
equipotent B-O O
in B-O O
suppressing B-O O
T-cell B-O O
proliferation B-O O
, B-O O
ISO B-O O
was B-O O
much B-O O
less B-O O
effective B-O O
. B-O O

4 B-O O
. B-O O

Because B-O O
concomitant B-O O
elevations B-O O
in B-O O
the B-O O
peripheral B-O O
levels B-O O
of B-O O
these B-O O
substances B-O O
may B-O O
occur B-O O
, B-O O
experiments B-O O
were B-O O
performed B-O O
to B-O O
determine B-O O
the B-O O
T-cell B-O O
inhibitory B-O O
effects B-O O
of B-O O
DEX B-O O
together B-O O
with B-O O
either B-O O
PGE2 B-O O
or B-O O
ISO B-O O
. B-O O

Synergistic B-O O
suppression B-O O
of B-O O
T-cell B-O O
proliferation B-O O
was B-O O
observed B-O O
when B-O O
various B-O O
concentrations B-O O
of B-O O
DEX B-O O
and B-O O
PGE2 B-O O
, B-O O
but B-O O
not B-O O
DEX B-O O
and B-O O
ISO B-O O
, B-O O
were B-O O
added B-O O
to B-O O
cultures B-O O
. B-O O

This B-O O
synergistic B-O O
suppression B-O O
could B-O O
not B-O O
be B-O O
explained B-O O
by B-O O
an B-O O
increase B-O O
in B-O O
cAMP B-O O
accumulation B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
stimulated B-O O
with B-O O
DEX B-O O
and B-O O
PGE2 B-O O
. B-O O

5 B-O O
. B-O O

Finally B-O O
, B-O O
the B-O O
addition B-O O
of B-O O
anti-CD28 B-O B-protein
mAb B-O I-protein
to B-O O
anti-CD3 B-O B-cell_type
mAb-stimulated B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
overcame B-O O
much B-O O
of B-O O
the B-O O
suppression B-O O
of B-O O
proliferation B-O O
induced B-O O
by B-O O
PGE2 B-O B-protein
or B-O O
ISO B-O O
but B-O O
less B-O O
so B-O O
than B-O O
that B-O O
induced B-O O
by B-O O
DEX B-O O
. B-O O

In B-O O
vivo B-O O
footprint B-O O
analysis B-O O
of B-O O
the B-O O
HLA-DRA B-O B-DNA
gene B-O I-DNA
promoter B-O I-DNA
: B-O O
cell-specific B-O O
interaction B-O O
at B-O O
the B-O O
octamer B-O B-DNA
site B-O I-DNA
and B-O O
up-regulation B-O O
of B-O O
X B-O O
box B-O O
binding B-O O
by B-O O
interferon B-O B-protein
gamma B-O I-protein
. B-O O

Analysis B-O O
of B-O O
the B-O O
major B-O B-DNA
histocompatibility B-O I-DNA
complex B-O I-DNA
class B-O I-DNA
II B-O I-DNA
gene B-O I-DNA
promoter B-O I-DNA
DRA B-O B-DNA
has B-O O
previously B-O O
identified B-O O
at B-O O
least B-O O
five B-O O
cis-acting B-O B-DNA
regions B-O I-DNA
required B-O O
for B-O O
maximal B-O O
expression B-O O
. B-O O

We B-O O
have B-O O
examined B-O O
the B-O O
DRA B-O B-DNA
promoter B-O I-DNA
for B-O O
protein-DNA B-O O
interactions B-O O
in B-O O
the B-O O
intact B-O O
cell B-O O
, B-O O
which B-O O
may B-O O
mediate B-O O
transcriptional B-O O
activation B-O O
. B-O O

Using B-O O
in B-O O
vivo B-O O
genomic B-O O
footprinting B-O O
we B-O O
identified B-O O
interactions B-O O
in B-O O
B-cell B-O B-cell_line
lines B-O I-cell_line
at B-O O
the B-O O
octamer B-O B-DNA
site B-O I-DNA
and B-O O
the B-O O
Y B-O B-DNA
, B-O I-DNA
X1 B-O I-DNA
, B-O I-DNA
and B-O I-DNA
X2 B-O I-DNA
boxes B-O I-DNA
. B-O O

Class B-O B-cell_line
II B-O I-cell_line
antigen B-O I-cell_line
expressing B-O I-cell_line
T-cell B-O I-cell_line
lines B-O I-cell_line
maintained B-O O
contacts B-O O
identical B-O O
to B-O O
B-cell B-O B-cell_line
lines B-O I-cell_line
, B-O O
while B-O O
class B-O B-cell_line
II-negative B-O I-cell_line
T-cell B-O I-cell_line
lines B-O I-cell_line
exhibited B-O O
no B-O O
interactions B-O O
. B-O O

In B-O O
lymphoid B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
the B-O O
octamer B-O B-DNA
site B-O I-DNA
is B-O O
occupied B-O O
and B-O O
required B-O O
for B-O O
maximal B-O O
expression B-O O
. B-O O

This B-O O
is B-O O
most B-O O
likely B-O O
due B-O O
to B-O O
the B-O O
presence B-O O
of B-O O
the B-O O
lymphoid-specific B-O B-protein
OTF-2 B-O I-protein
factor B-O I-protein
. B-O O

In B-O O
contrast B-O O
, B-O O
the B-O O
class B-O B-cell_line
II-positive B-O I-cell_line
nonlymphoid B-O I-cell_line
glioblastoma B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
does B-O O
not B-O O
exhibit B-O O
interactions B-O O
at B-O O
the B-O O
octamer B-O B-DNA
site B-O I-DNA
despite B-O O
the B-O O
presence B-O O
of B-O O
the B-O O
ubiquitous B-O B-protein
OTF-1 B-O I-protein
factor B-O I-protein
and B-O O
an B-O O
open B-O B-DNA
binding B-O I-DNA
site B-O I-DNA
. B-O O

Thus B-O O
, B-O O
the B-O O
DRA B-O B-DNA
promoter B-O I-DNA
discriminates B-O O
against B-O O
OTF-1 B-O B-protein
activation B-O O
at B-O O
the B-O O
level B-O O
of B-O O
DNA B-O O
binding B-O O
in B-O O
the B-O O
glioblastoma B-O B-cell_line
line B-O I-cell_line
. B-O O

Interferon B-O B-protein
gamma B-O I-protein
induces B-O O
class B-O O
II B-O O
expression B-O O
in B-O O
this B-O O
glioblastoma B-O B-cell_line
cell B-O I-cell_line
line B-O I-cell_line
and B-O O
, B-O O
in B-O O
parallel B-O O
, B-O O
up-regulates B-O O
X1 B-O B-DNA
and B-O O
X2 B-O B-DNA
box B-O I-DNA
protein-DNA B-O O
interactions B-O O
, B-O O
while B-O O
all B-O O
other B-O O
interactions B-O O
remain B-O O
unchanged B-O O
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
interferon B-O B-protein
gamma B-O I-protein
functions B-O O
on B-O O
a B-O O
poised B-O B-DNA
promoter B-O I-DNA
by B-O O
altering B-O O
weak B-O O
, B-O O
nonproductive B-O O
interactions B-O O
at B-O O
the B-O O
X B-O B-DNA
boxes B-O I-DNA
to B-O O
strong B-O O
interactions B-O O
. B-O O

These B-O O
findings B-O O
provide B-O O
direct B-O O
in B-O O
vivo B-O O
evidence B-O O
to B-O O
strongly B-O O
suggest B-O O
that B-O O
the B-O O
modulation B-O O
of B-O O
X1 B-O B-DNA
and B-O O
X2 B-O B-DNA
interactions B-O O
is B-O O
an B-O O
important B-O O
constituent B-O O
of B-O O
the B-O O
interferon B-O B-protein
gamma B-O I-protein
induction B-O O
pathway B-O O
. B-O O

Estrogen B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
and B-O O
effects B-O O
of B-O O
danazol B-O O
on B-O O
their B-O O
sites B-O O
in B-O O
vitro B-O O
. B-O O

1 B-O O
. B-O O

This B-O O
study B-O O
was B-O O
designed B-O O
to B-O O
investigate B-O O
the B-O O
presence B-O O
of B-O O
estrogen B-O O
type B-O O
I B-O O
( B-O O
high B-O O
affinity B-O O
, B-O O
low B-O O
capacity B-O O
) B-O O
and B-O O
type B-O O
II B-O O
( B-O O
low B-O O
affinity B-O O
, B-O O
high B-O O
capacity B-O O
) B-O O
binding B-O O
sites B-O O
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
and B-O O
the B-O O
effects B-O O
of B-O O
danazol B-O O
on B-O O
these B-O O
sites B-O O
. B-O O

2 B-O O
. B-O O

These B-O O
two B-O O
types B-O O
of B-O O
estrogen B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
existed B-O O
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
. B-O O

3 B-O O
. B-O O

Danazol B-O O
bound B-O O
to B-O O
these B-O O
sites B-O O
in B-O O
high B-O O
concentration B-O O
( B-O O
10 B-O O
( B-O O
-6 B-O O
) B-O O
M B-O O
, B-O O
clinical B-O O
serum B-O O
concentration B-O O
during B-O O
danazol B-O O
therapy B-O O
) B-O O
and B-O O
decreased B-O O
the B-O O
number B-O O
of B-O O
both B-O O
sites B-O O
. B-O O

4 B-O O
. B-O O

It B-O O
is B-O O
suggested B-O O
that B-O O
danazol B-O O
has B-O O
an B-O O
anti-estrogenic B-O O
action B-O O
to B-O O
the B-O O
monocytes B-O B-cell_type
through B-O O
the B-O O
competition B-O O
and B-O O
suppression B-O O
of B-O O
estrogen B-O O
binding B-O O
sites B-O O
as B-O O
seen B-O O
in B-O O
the B-O O
estrogen B-O O
target B-O O
organ B-O O
. B-O O

A B-O O
microtitre B-O O
assay B-O O
system B-O O
for B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
: B-O O
decreased B-O O
receptor B-O O
concentration B-O O
in B-O O
myocardial B-O O
infarction B-O O
. B-O O

A B-O O
major B-O O
difficulty B-O O
in B-O O
determination B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
sites B-O O
is B-O O
the B-O O
very B-O O
complicated B-O O
assay B-O O
procedure B-O O
. B-O O

Therefore B-O O
, B-O O
we B-O O
describe B-O O
a B-O O
microtitre B-O O
assay B-O O
system B-O O
for B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
which B-O O
is B-O O
a B-O O
whole-cell B-O O
competitive B-O O
binding B-O O
radioassay B-O O
using B-O O
[ B-O O
3H B-O O
] B-O O
-dexamethasone B-O O
as B-O O
radioligand B-O O
. B-O O

This B-O O
modification B-O O
of B-O O
a B-O O
previously B-O O
described B-O O
protocol B-O O
simplifies B-O O
and B-O O
reduces B-O O
laboratory B-O O
work B-O O
and B-O O
allows B-O O
assay B-O O
reproducibility B-O O
to B-O O
be B-O O
controlled B-O O
more B-O O
reliably B-O O
. B-O O

Thus B-O O
enabled B-O O
to B-O O
perform B-O O
the B-O O
test B-O O
on B-O O
multiple B-O O
blood B-O O
samples B-O O
in B-O O
parallel B-O O
, B-O O
we B-O O
investigated B-O O
cardiac B-O O
infarction B-O O
patients B-O O
over B-O O
a B-O O
12-day B-O O
period B-O O
to B-O O
test B-O O
if B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
binding B-O O
is B-O O
altered B-O O
in B-O O
this B-O O
' B-O O
stressful B-O O
' B-O O
disease B-O O
. B-O O

On B-O O
the B-O O
first B-O O
day B-O O
of B-O O
the B-O O
disease B-O O
, B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
capacity B-O O
was B-O O
significantly B-O O
decreased B-O O
without B-O O
alteration B-O O
of B-O O
the B-O O
receptor-ligand B-O O
affinity B-O O
, B-O O
whereas B-O O
on B-O O
days B-O O
4 B-O O
and B-O O
12 B-O O
the B-O O
number B-O O
of B-O O
receptor B-O O
sites B-O O
was B-O O
normal B-O O
again B-O O
. B-O O

This B-O O
result B-O O
fits B-O O
well B-O O
into B-O O
the B-O O
general B-O O
observation B-O O
of B-O O
stress-induced B-O O
down-regulation B-O O
of B-O O
immune B-O O
responses B-O O
. B-O O

SRC-related B-O B-DNA
proto-oncogenes B-O I-DNA
and B-O O
transcription B-O B-protein
factors B-O I-protein
in B-O O
primary B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
: B-O O
modulation B-O O
by B-O O
cyclosporin B-O O
A B-O O
and B-O O
FK506 B-O O
. B-O O

Activation B-O O
of B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
induces B-O O
transcription B-O O
of B-O O
genes B-O B-DNA
encoding B-O O
for B-O O
lymphokines B-O B-protein
. B-O O

Interleukin-2 B-O B-protein
( B-O O
IL-2 B-O B-protein
) B-O O
gene B-O O
expression B-O O
is B-O O
controlled B-O O
transcriptionally B-O O
by B-O O
the B-O O
cooperative B-O O
activity B-O O
of B-O O
specific B-O O
trans-activating B-O B-protein
factors B-O I-protein
that B-O O
bind B-O O
to B-O O
the B-O O
IL-2 B-O B-DNA
enhancer B-O I-DNA
. B-O O

Cyclosporin B-O O
A B-O O
( B-O O
CsA B-O O
) B-O O
and B-O O
FK506 B-O O
inhibit B-O O
the B-O O
production B-O O
of B-O O
IL-2 B-O B-protein
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
at B-O O
the B-O O
level B-O O
of B-O O
gene B-O O
transcription B-O O
. B-O O

A B-O O
member B-O O
of B-O O
the B-O O
src B-O B-DNA
gene B-O I-DNA
family B-O I-DNA
, B-O O
the B-O O
lymphocyte-specific B-O B-protein
protein B-O I-protein
tyrosine B-O I-protein
kinase B-O I-protein
, B-O O
p56lck B-O B-protein
, B-O O
has B-O O
been B-O O
implicated B-O O
in B-O O
IL-2 B-O B-protein
production B-O O
. B-O O

CsA B-O O
was B-O O
found B-O O
not B-O O
to B-O O
inhibit B-O O
lck B-O B-DNA
gene B-O I-DNA
expression B-O O
, B-O O
nor B-O O
the B-O O
activity B-O O
of B-O O
the B-O O
lck B-O B-protein
gene B-O I-protein
product B-O I-protein
. B-O O

However B-O O
, B-O O
CsA B-O O
and B-O O
FK506 B-O O
inhibit B-O O
the B-O O
appearance B-O O
of B-O O
DNA B-O O
binding B-O O
activity B-O O
of B-O O
factors B-O O
that B-O O
bind B-O O
to B-O O
the B-O O
NF-AT B-O B-DNA
and B-O I-DNA
AP-1 B-O I-DNA
sites B-O I-DNA
in B-O O
the B-O O
IL-2 B-O B-DNA
enhancer B-O I-DNA
. B-O O

Since B-O O
the B-O O
induction B-O O
of B-O O
NF-AT B-O B-protein
and B-O O
AP-1 B-O B-protein
is B-O O
induced B-O O
by B-O O
the B-O O
same B-O O
stimuli B-O O
that B-O O
stimulate B-O O
IL-2 B-O B-protein
production B-O O
, B-O O
these B-O O
results B-O O
indicate B-O O
that B-O O
the B-O O
immunosuppressant B-O O
action B-O O
of B-O O
CsA B-O O
and B-O O
FK506 B-O O
is B-O O
exerted B-O O
at B-O O
the B-O O
level B-O O
of B-O O
these B-O O
trans-activating B-O B-protein
factors B-O I-protein
. B-O O

The B-O O
AP-1 B-O B-DNA
site B-O I-DNA
at B-O O
-150 B-O B-DNA
bp B-O I-DNA
, B-O O
but B-O O
not B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
, B-O O
is B-O O
likely B-O O
to B-O O
represent B-O O
the B-O O
major B-O O
target B-O O
of B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
in B-O O
the B-O O
interleukin B-O B-DNA
2 B-O I-DNA
promoter B-O I-DNA
. B-O O

Stimulation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
with B-O O
antigen B-O O
results B-O O
in B-O O
activation B-O O
of B-O O
several B-O O
kinases B-O B-protein
, B-O O
including B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
, B-O O
that B-O O
may B-O O
mediate B-O O
the B-O O
later B-O O
induction B-O O
of B-O O
activation-related B-O B-DNA
genes B-O I-DNA
. B-O O

We B-O O
have B-O O
examined B-O O
the B-O O
potential B-O O
role B-O O
of B-O O
PKC B-O B-protein
in B-O O
induction B-O O
of B-O O
the B-O O
interleukin B-O B-DNA
2 B-O I-DNA
( B-O I-DNA
IL-2 B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
stimulated B-O O
through B-O O
the B-O O
T B-O B-protein
cell B-O I-protein
receptor/CD3 B-O I-protein
complex B-O I-protein
. B-O O

We B-O O
have B-O O
previously B-O O
shown B-O O
that B-O O
prolonged B-O O
treatment B-O O
of B-O O
the B-O O
untransformed B-O B-protein
T B-O I-protein
cell B-O I-protein
clone B-O I-protein
Ar-5 B-O I-protein
with B-O O
phorbol B-O O
esters B-O O
results B-O O
in B-O O
downmodulation B-O O
of B-O O
the B-O O
alpha B-O B-protein
and B-O I-protein
beta B-O I-protein
isozymes B-O I-protein
of B-O O
PKC B-O B-protein
, B-O O
and B-O O
abrogates B-O O
induction B-O O
of B-O O
IL-2 B-O B-RNA
mRNA B-O I-RNA
and B-O O
protein B-O O
. B-O O

Here B-O O
we B-O O
show B-O O
that B-O O
phorbol B-O O
ester B-O O
treatment B-O O
also B-O O
abolishes B-O O
induction B-O O
of B-O O
chloramphenicol B-O B-protein
acetyltransferase B-O I-protein
activity B-O O
in B-O O
Ar-5 B-O B-cell_line
cells B-O I-cell_line
transfected B-O O
with B-O O
a B-O O
plasmid B-O B-DNA
containing B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
linked B-O O
to B-O O
this B-O O
reporter B-O B-DNA
gene B-O I-DNA
. B-O O

The B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
contains B-O O
binding B-O B-DNA
sites B-O I-DNA
for B-O O
nuclear B-O B-protein
factors B-O I-protein
including B-O O
NFAT-1 B-O B-protein
, B-O O
Oct B-O B-protein
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
and B-O O
AP-1 B-O B-protein
, B-O O
which B-O O
are B-O O
all B-O O
potentially B-O O
sensitive B-O O
to B-O O
activation B-O O
of B-O O
PKC B-O B-protein
. B-O O

We B-O O
show B-O O
that B-O O
induction B-O O
of B-O O
a B-O O
trimer B-O O
of B-O O
the B-O O
NFAT B-O B-DNA
and B-O I-DNA
Oct B-O I-DNA
sites B-O I-DNA
is B-O O
not B-O O
sensitive B-O O
to B-O O
phorbol B-O O
ester B-O O
treatment B-O O
, B-O O
and B-O O
that B-O O
mutations B-O O
in B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
have B-O O
no B-O O
effect B-O O
on B-O O
inducibility B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
. B-O O

In B-O O
contrast B-O O
, B-O O
mutations B-O O
in B-O O
the B-O O
AP-1 B-O B-DNA
site B-O I-DNA
located B-O O
at B-O O
-150 B-O B-DNA
bp B-O I-DNA
almost B-O O
completely B-O O
abrogate B-O O
induction B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
, B-O O
and B-O O
appearance B-O O
of B-O O
an B-O O
inducible B-O B-protein
nuclear B-O I-protein
factor B-O I-protein
binding B-O O
to B-O O
this B-O O
site B-O O
is B-O O
sensitive B-O O
to B-O O
PKC B-O B-protein
depletion B-O O
. B-O O

Moreover B-O O
, B-O O
cotransfections B-O O
with B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
expression B-O O
plasmids B-O O
markedly B-O O
enhance B-O O
induction B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
in B-O O
minimally B-O B-cell_line
stimulated B-O I-cell_line
T B-O I-cell_line
cells B-O I-cell_line
. B-O O

Our B-O O
results B-O O
indicate B-O O
that B-O O
the B-O O
AP-1 B-O B-DNA
site B-O I-DNA
at B-O O
-150 B-O B-DNA
bp B-O I-DNA
represents B-O O
a B-O O
major B-O O
, B-O O
if B-O O
not B-O O
the B-O O
only B-O O
, B-O O
site B-O O
of B-O O
PKC B-O B-protein
responsiveness B-O O
in B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
. B-O O

[ B-O O
Effect B-O O
of B-O O
antihypertensive B-O O
therapy B-O O
with B-O O
captopril B-O O
on B-O O
gluco- B-O B-protein
and B-O I-protein
mineralo B-O I-protein
corticoid B-O I-protein
receptors B-O I-protein
of B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
lymphocytes B-O I-cell_type
in B-O O
hypertensive B-O O
patients B-O O
of B-O O
various B-O O
age B-O O
] B-O O

Binding B-O O
of B-O O
3H-dexamethasone B-O O
and B-O O
3H-aldosterone B-O O
by B-O O
peripheral B-O B-protein
lymphocyte B-O I-protein
receptors B-O I-protein
was B-O O
investigated B-O O
in B-O O
healthy B-O O
persons B-O O
and B-O O
hypertensive B-O O
patients B-O O
before B-O O
and B-O O
after B-O O
2-week B-O O
captopril B-O O
treatment B-O O
. B-O O

The B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
and B-O I-protein
mineralocorticoid B-O I-protein
binding B-O I-protein
sites B-O I-protein
was B-O O
increased B-O O
in B-O O
hypertensives B-O O
vs B-O O
normotensives B-O O
. B-O O

The B-O O
treatment B-O O
with B-O O
the B-O O
ACE B-O O
inhibitor B-O O
captopril B-O O
led B-O O
to B-O O
activation B-O O
of B-O O
hormone-receptor B-O O
interactions B-O O
. B-O O

There B-O O
was B-O O
a B-O O
more B-O O
marked B-O O
rise B-O O
of B-O O
the B-O O
number B-O O
of B-O O
receptors B-O B-protein
in B-O O
middle-aged B-O O
( B-O O
44-55 B-O O
years B-O O
) B-O O
hypertensives B-O O
vs B-O O
elderly B-O O
( B-O O
61-80 B-O O
years B-O O
) B-O O
subjects B-O O
after B-O O
captopril B-O O
treatment B-O O
. B-O O

The B-O O
use B-O O
of B-O O
interferon-gamma-treated B-O B-cell_line
U937 B-O I-cell_line
cells B-O I-cell_line
in B-O O
chemiluminescence B-O O
assays B-O O
to B-O O
detect B-O O
red B-O B-cell_type
cell B-O I-cell_type
, B-O O
platelet B-O B-cell_type
and B-O O
granulocyte B-O B-protein
antibodies B-O I-protein
of B-O O
potential B-O O
clinical B-O O
significance B-O O
. B-O O

The B-O O
chemiluminescent B-O O
( B-O O
CL B-O O
) B-O O
response B-O O
of B-O O
interferon-gamma-treated B-O B-cell_line
U937 B-O I-cell_line
( B-O I-cell_line
IFN-U937 B-O I-cell_line
) B-O I-cell_line
cells B-O I-cell_line
to B-O O
sensitized B-O B-cell_type
target B-O I-cell_type
cells B-O I-cell_type
has B-O O
been B-O O
used B-O O
to B-O O
detect B-O O
red B-O B-cell_type
cell B-O I-cell_type
, B-O O
platelet B-O B-cell_type
and B-O O
granulocyte B-O B-protein
antibodies B-O I-protein
. B-O O

A B-O O
clone B-O O
of B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
was B-O O
selected B-O O
which B-O O
expressed B-O O
Fc B-O B-protein
receptor B-O I-protein
I B-O I-protein
( B-O O
Fc B-O B-protein
gamma B-O I-protein
RI B-O I-protein
) B-O O
and B-O O
which B-O O
, B-O O
after B-O O
incubation B-O O
with B-O O
IFN-gamma B-O B-protein
for B-O O
72 B-O O
h B-O O
, B-O O
was B-O O
capable B-O O
of B-O O
generating B-O O
high B-O O
levels B-O O
of B-O O
lucigenin-enhanced B-O O
CL B-O O
. B-O O

The B-O O
CL B-O O
responses B-O O
of B-O O
IFN-U937 B-O B-cell_line
cells B-O I-cell_line
and B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
human B-O I-cell_type
monocytes B-O I-cell_type
to B-O O
sensitized B-O B-cell_type
red B-O I-cell_type
cells B-O I-cell_type
, B-O O
platelets B-O B-cell_type
or B-O O
granulocytes B-O B-cell_type
were B-O O
then B-O O
compared B-O O
. B-O O

Assays B-O O
using B-O O
monocytes B-O B-cell_type
or B-O O
IFN-U937 B-O B-cell_line
cells B-O I-cell_line
were B-O O
of B-O O
comparable B-O O
sensitivity B-O O
for B-O O
detection B-O O
of B-O O
antibodies B-O B-protein
against B-O O
all B-O O
three B-O O
types B-O O
of B-O O
target B-O B-cell_type
cell B-O I-cell_type
. B-O O

In B-O O
addition B-O O
, B-O O
the B-O O
use B-O O
of B-O O
IFN-U937 B-O B-cell_line
cells B-O I-cell_line
reduced B-O O
interassay B-O O
variation B-O O
and B-O O
simplified B-O O
assay B-O O
performance B-O O
. B-O O

The B-O O
potential B-O O
clinical B-O O
usefulness B-O O
of B-O O
these B-O O
CL B-O O
assays B-O O
was B-O O
suggested B-O O
by B-O O
the B-O O
ability B-O O
of B-O O
both B-O O
monocytes B-O B-cell_type
and B-O O
IFN-U937 B-O B-cell_line
cells B-O I-cell_line
to B-O O
respond B-O O
to B-O O
red B-O B-cell_type
cells B-O I-cell_type
, B-O O
platelets B-O B-cell_type
or B-O O
granulocytes B-O B-cell_type
sensitized B-O O
with B-O O
sera B-O O
from B-O O
pregnant B-O O
women B-O O
whose B-O O
babies B-O O
had B-O O
either B-O O
haemolytic B-O O
disease B-O O
of B-O O
the B-O O
newborn B-O O
( B-O O
HDN B-O B-protein
) B-O O
, B-O O
alloimmune B-O O
thrombocytopenia B-O O
or B-O O
alloimmune B-O O
neutropenia B-O O
respectively B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
monocytes B-O B-cell_type
and B-O O
IFN-U937 B-O B-cell_line
cells B-O I-cell_line
both B-O O
responded B-O O
to B-O O
red B-O B-cell_type
cells B-O I-cell_type
sensitized B-O O
with B-O O
antibodies B-O B-protein
against B-O O
a B-O O
variety B-O O
of B-O O
specificities B-O O
of B-O O
assumed B-O O
( B-O O
although B-O O
not B-O O
documented B-O O
) B-O O
clinical B-O O
significance B-O O
for B-O O
blood B-O O
transfusion B-O O
recipients B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
monocytes B-O B-cell_type
and B-O O
IFN-U937 B-O B-cell_line
cells B-O I-cell_line
responded B-O O
only B-O O
weakly B-O O
to B-O O
red B-O B-cell_type
cells B-O I-cell_type
sensitized B-O O
with B-O O
either B-O O
anti-D B-O B-protein
in B-O O
sera B-O O
from B-O O
mothers B-O O
of B-O O
babies B-O O
unaffected B-O O
by B-O O
HDN B-O O
, B-O O
or B-O O
with B-O O
antisera B-O O
containing B-O O
high B-O B-protein
titre B-O I-protein
antibodies B-O I-protein
with B-O O
specificities B-O O
not B-O O
normally B-O O
associated B-O O
with B-O O
significantly B-O O
reduced B-O O
red B-O B-cell_type
cell B-O I-cell_type
survival B-O O
. B-O O

Ablation B-O O
of B-O O
transplanted B-O O
HTLV-I B-O O
Tax-transformed B-O O
tumors B-O O
in B-O O
mice B-O O
by B-O O
antisense B-O O
inhibition B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
[ B-O O
published B-O O
erratum B-O O
appears B-O O
in B-O O
Science B-O O
1993 B-O O
Mar B-O O
12 B-O O
; B-O O
259 B-O O
( B-O O
5101 B-O O
) B-O O
: B-O O
1523 B-O O
] B-O O

Mice B-O O
transgenic B-O O
for B-O O
the B-O O
human B-O B-DNA
T B-O I-DNA
cell B-O I-DNA
leukemia B-O I-DNA
virus B-O I-DNA
( B-O I-DNA
HTLV-I B-O I-DNA
) B-O I-DNA
Tax B-O I-DNA
gene B-O I-DNA
develop B-O O
fibroblastic B-O O
tumors B-O O
that B-O O
express B-O O
NF-kappa B-O B-DNA
B-inducible B-O I-DNA
early B-O I-DNA
genes B-O I-DNA
. B-O O

In B-O O
vitro B-O O
inhibition B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
expression B-O O
by B-O O
antisense B-O O
oligodeoxynucleotides B-O O
( B-O O
ODNs B-O O
) B-O O
inhibited B-O O
growth B-O O
of B-O O
these B-O O
culture-adapted B-O B-cell_line
Tax-transformed B-O I-cell_line
fibroblasts B-O I-cell_line
as B-O O
well B-O O
as B-O O
an B-O O
HTLV-I B-O B-cell_line
-transformed B-O I-cell_line
human B-O I-cell_line
lymphocyte B-O I-cell_line
line B-O I-cell_line
. B-O O

In B-O O
contrast B-O O
, B-O O
antisense B-O O
inhibition B-O O
of B-O O
Tax B-O B-protein
itself B-O O
had B-O O
no B-O O
apparent B-O O
effect B-O O
on B-O O
cell B-O O
growth B-O O
. B-O O

Mice B-O O
treated B-O O
with B-O O
antisense B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
ODNs B-O O
showed B-O O
rapid B-O O
regression B-O O
of B-O O
transplanted B-O O
fibrosarcomas B-O O
. B-O O

This B-O O
suggests B-O O
that B-O O
NF-kappa B-O B-protein
B B-O I-protein
expression B-O O
may B-O O
be B-O O
necessary B-O O
for B-O O
the B-O O
maintenance B-O O
of B-O O
the B-O O
malignant B-O O
phenotype B-O O
and B-O O
provides B-O O
a B-O O
therapeutic B-O O
approach B-O O
for B-O O
HTLV-I B-O O
-associated B-O O
disease B-O O
. B-O O

Membrane B-O B-protein
receptors B-O I-protein
for B-O O
aldosterone B-O O
: B-O O
a B-O O
novel B-O O
pathway B-O O
for B-O O
mineralocorticoid B-O O
action B-O O
. B-O O

Rapid B-O O
nongenomic B-O O
in B-O O
vitro B-O O
effects B-O O
of B-O O
aldosterone B-O O
on B-O O
intracellular B-O O
electrolytes B-O O
, B-O O
cell B-O O
volume B-O O
, B-O O
and B-O O
Na B-O B-protein
( B-O I-protein
+ B-O I-protein
) B-O I-protein
-H+ B-O I-protein
antiport B-O I-protein
have B-O O
been B-O O
found B-O O
in B-O O
human B-O B-cell_type
mononuclear B-O I-cell_type
leukocytes B-O I-cell_type
( B-O O
HML B-O B-cell_type
) B-O O
. B-O O

Binding B-O O
of B-O O
125I-labeled B-O O
aldosterone B-O O
to B-O O
plasma B-O O
membranes B-O O
of B-O O
HML B-O B-cell_type
shares B-O O
important B-O O
features B-O O
with B-O O
these B-O O
functional B-O O
data B-O O
. B-O O

This B-O O
includes B-O O
a B-O O
very B-O O
low B-O O
apparent B-O O
dissociation B-O O
constant B-O O
( B-O O
Kd B-O O
) B-O O
of B-O O
0.1 B-O O
nM B-O O
for B-O O
both B-O O
aldosterone B-O O
and B-O O
the B-O O
effect B-O O
on B-O O
the B-O O
Na B-O B-protein
( B-O I-protein
+ B-O I-protein
) B-O I-protein
-H B-O I-protein
( B-O I-protein
+ B-O I-protein
) B-O I-protein
-antiport B-O I-protein
, B-O O
a B-O O
high B-O O
turnover B-O O
rate B-O O
, B-O O
and B-O O
the B-O O
almost B-O O
exclusive B-O O
binding B-O O
selectivity B-O O
for B-O O
aldosterone B-O O
. B-O O

Dexamethasone B-O O
, B-O O
RU B-O O
26988 B-O O
, B-O O
corticosterone B-O O
, B-O O
ouabain B-O O
, B-O O
amiloride B-O O
, B-O O
and B-O O
18-hydroxyprogesterone B-O O
were B-O O
inactive B-O O
as B-O O
ligands B-O O
. B-O O

Deoxycorticosterone B-O O
acetate B-O O
had B-O O
an B-O O
intermediate B-O O
activity B-O O
with B-O O
an B-O O
apparent B-O O
Kd B-O O
of B-O O
100 B-O O
nM B-O O
. B-O O

These B-O O
findings B-O O
are B-O O
the B-O O
first B-O O
to B-O O
demonstrate B-O O
membrane B-O O
binding B-O O
of B-O O
aldosterone B-O O
being B-O O
compatible B-O O
with B-O O
major B-O O
aspects B-O O
of B-O O
its B-O O
nongenomic B-O O
effects B-O O
. B-O O

Leukotriene B-O O
B4 B-O O
transcriptionally B-O O
activates B-O O
interleukin-6 B-O B-protein
expression B-O O
involving B-O O
NK-chi B-O B-protein
B B-O I-protein
and B-O O
NF-IL6 B-O B-protein
. B-O O

Leukotriene B-O O
B4 B-O O
( B-O O
LTB4 B-O O
) B-O O
is B-O O
a B-O O
notable B-O O
participant B-O O
in B-O O
inflammation B-O O
and B-O O
chemotaxis B-O O
. B-O O

It B-O O
is B-O O
, B-O O
however B-O O
, B-O O
still B-O O
unclear B-O O
whether B-O O
LTB4 B-O B-protein
acts B-O O
in B-O O
this B-O O
regard B-O O
directly B-O O
or B-O O
indirectly B-O O
by B-O O
stimulating B-O O
the B-O O
release B-O O
of B-O O
chemotactic B-O O
and B-O O
inflammatory B-O B-protein
cytokines B-O I-protein
. B-O O

Here B-O O
we B-O O
report B-O O
that B-O O
LTB4 B-O O
induces B-O O
synthesis B-O O
of B-O O
interleukin B-O B-protein
( B-O I-protein
IL B-O I-protein
) B-O I-protein
-6 B-O I-protein
by B-O O
human B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
through B-O O
transcriptional B-O O
activation B-O O
of B-O O
the B-O O
IL-6 B-O B-DNA
gene B-O I-DNA
. B-O O

We B-O O
furthermore B-O O
demonstrate B-O O
that B-O O
this B-O O
process B-O O
involves B-O O
activation B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-chi B-O B-protein
B B-O I-protein
and B-O O
, B-O O
to B-O O
a B-O O
lesser B-O O
extent B-O O
, B-O O
of B-O O
NF-IL6 B-O B-protein
, B-O O
while B-O O
the B-O O
activity B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
AP-1 B-O B-protein
, B-O O
shown B-O O
to B-O O
otherwise B-O O
confer B-O O
IL-6 B-O B-protein
inducibility B-O O
, B-O O
appeared B-O O
to B-O O
be B-O O
unaffected B-O O
by B-O O
LTB4 B-O O
. B-O O

Involvement B-O O
of B-O O
NF-chi B-O B-protein
B B-O I-protein
and B-O O
NF-IL6 B-O B-protein
in B-O O
induction B-O O
of B-O O
IL-6 B-O B-protein
transcription B-O O
by B-O O
monocytes B-O B-cell_type
was B-O O
demonstrated B-O O
using B-O O
deleted B-O O
forms B-O O
of B-O O
the B-O O
IL-6 B-O B-DNA
promoter B-O I-DNA
. B-O O

Activation B-O O
of B-O O
the B-O O
IL-6 B-O B-DNA
promoter B-O I-DNA
by B-O O
LTB4 B-O O
was B-O O
not B-O O
only B-O O
associated B-O O
with B-O O
accumulation B-O O
of B-O O
the B-O O
respective B-O O
transcripts B-O O
but B-O O
resulted B-O O
in B-O O
synthesis B-O O
of B-O O
functional B-O O
IL-6 B-O B-protein
protein B-O I-protein
as B-O O
well B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
LTB4 B-O B-protein
mediated B-O O
transactivation B-O O
of B-O O
a B-O O
heterologous B-O B-DNA
promoter B-O I-DNA
construct B-O I-DNA
containing B-O O
the B-O O
NF-chi B-O B-protein
B B-O I-protein
or B-O O
the B-O O
NF-IL6 B-O B-DNA
enhancer B-O I-DNA
, B-O O
but B-O O
not B-O O
the B-O O
AP-1 B-O B-DNA
enhancer B-O I-DNA
. B-O O

The B-O O
signaling B-O O
events B-O O
mediating B-O O
this B-O O
effect B-O O
appeared B-O O
to B-O O
involve B-O O
the B-O O
release B-O O
of B-O O
H2O2 B-O O
, B-O O
since B-O O
LTB4 B-O O
failed B-O O
to B-O O
induce B-O O
NF-chi B-O B-protein
B B-O I-protein
or B-O O
NF-IL6 B-O B-protein
in B-O O
the B-O O
presence B-O O
of B-O O
the B-O O
scavenger B-O O
of B-O O
H2O2 B-O O
, B-O O
N-acetyl-L-cysteine B-O O
. B-O O

Bcl-2 B-O B-protein
: B-O O
a B-O O
repressor B-O O
of B-O O
lymphocyte B-O B-cell_type
death B-O O
. B-O O

The B-O O
genes B-O O
and B-O O
mechanisms B-O O
that B-O O
control B-O O
programmed B-O O
cell B-O O
death B-O O
are B-O O
currently B-O O
the B-O O
subject B-O O
of B-O O
intense B-O O
study B-O O
. B-O O

The B-O O
bcl-2 B-O B-DNA
gene B-O I-DNA
, B-O O
a B-O O
repressor B-O O
of B-O O
lymphocyte B-O B-cell_type
death B-O O
, B-O O
is B-O O
perhaps B-O O
the B-O O
best B-O O
understood B-O O
of B-O O
the B-O O
programmed B-O O
cell B-O O
death B-O O
associated B-O O
genes B-O O
. B-O O

Here B-O O
, B-O O
Stanley B-O O
Korsmeyer B-O O
provides B-O O
a B-O O
brief B-O O
overview B-O O
of B-O O
bcl-2 B-O B-protein
, B-O O
concentrating B-O O
on B-O O
its B-O O
roles B-O O
in B-O O
B- B-O O
and B-O O
T- B-O O
cell B-O O
development B-O O
and B-O O
in B-O O
oncogenesis B-O O
. B-O O

Cytoplasmic B-O B-protein
domain B-O I-protein
heterogeneity B-O O
and B-O O
functions B-O O
of B-O O
IgG B-O B-protein
Fc B-O I-protein
receptors B-O I-protein
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

B B-O B-cell_type
lymphocytes B-O I-cell_type
and B-O O
macrophages B-O B-cell_type
express B-O O
closely B-O O
related B-O O
immunoglobulin B-O B-protein
G B-O I-protein
( B-O I-protein
IgG B-O I-protein
) B-O I-protein
Fc B-O I-protein
receptors B-O I-protein
( B-O O
Fc B-O B-protein
gamma B-O I-protein
RII B-O I-protein
) B-O O
that B-O O
differ B-O O
only B-O O
in B-O O
the B-O O
structures B-O O
of B-O O
their B-O O
cytoplasmic B-O B-protein
domains B-O I-protein
. B-O O

Because B-O O
of B-O O
cell B-O O
type-specific B-O O
alternative B-O O
messenger B-O O
RNA B-O O
splicing B-O O
, B-O O
B-cell B-O B-protein
Fc B-O I-protein
gamma B-O I-protein
RII B-O I-protein
contains B-O O
an B-O O
insertion B-O O
of B-O O
47 B-O B-protein
amino B-O I-protein
acids B-O I-protein
that B-O O
participates B-O O
in B-O O
determining B-O O
receptor B-O O
function B-O O
in B-O O
these B-O O
cells B-O O
. B-O O

Transfection B-O O
of B-O O
an B-O O
Fc B-O B-cell_line
gamma B-O I-cell_line
RII B-O I-cell_line
-negative B-O I-cell_line
B-cell B-O I-cell_line
line B-O I-cell_line
with B-O O
complementary B-O B-DNA
DNA B-O I-DNA
's B-O O
encoding B-O O
the B-O O
two B-O O
splice B-O O
products B-O O
and B-O O
various B-O O
receptor B-O O
mutants B-O O
indicated B-O O
that B-O O
the B-O O
insertion B-O O
was B-O O
responsible B-O O
for B-O O
preventing B-O O
both B-O O
Fc B-O B-protein
gamma B-O I-protein
RII B-O I-protein
-mediated B-O O
endocytosis B-O O
and B-O O
Fc B-O B-protein
gamma B-O I-protein
RII B-O I-protein
-mediated B-O O
antigen B-O O
presentation B-O O
. B-O O

The B-O O
insertion B-O O
was B-O O
not B-O O
required B-O O
for B-O O
Fc B-O B-protein
gamma B-O I-protein
RII B-O I-protein
to B-O O
modulate B-O O
surface B-O B-protein
immunoglobulin B-O I-protein
-triggered B-O O
B-cell B-O O
activation B-O O
. B-O O

Instead B-O O
, B-O O
regulation B-O O
of B-O O
activation B-O O
involved B-O O
a B-O O
region B-O O
of B-O O
the B-O O
cytoplasmic B-O B-protein
domain B-O I-protein
common B-O O
to B-O O
both B-O O
the B-O O
lymphocyte B-O B-cell_type
and B-O O
macrophage B-O B-protein
receptor B-O I-protein
isoforms B-O I-protein
. B-O O

In B-O O
contrast B-O O
, B-O O
the B-O O
insertion B-O O
did B-O O
contribute B-O O
to B-O O
the B-O O
formation B-O O
of B-O O
caps B-O O
in B-O O
response B-O O
to B-O O
receptor B-O O
cross-linking B-O O
, B-O O
consistent B-O O
with B-O O
suggestions B-O O
that B-O O
the B-O O
lymphocyte B-O B-cell_type
but B-O O
not B-O O
macrophage B-O O
form B-O O
of B-O O
the B-O O
receptor B-O O
can B-O O
associate B-O O
with B-O O
the B-O O
detergent-insoluble B-O O
cytoskeleton B-O O
. B-O O

[ B-O O
Age-related B-O O
changes B-O O
in B-O O
glucocorticoid B-O B-protein
and B-O I-protein
mineralocorticoid B-O I-protein
receptors B-O I-protein
in B-O O
lymphocytes B-O B-cell_type
of B-O O
healthy B-O O
persons B-O O
and B-O O
patients B-O O
with B-O O
hypertension B-O O
] B-O O

It B-O O
has B-O O
been B-O O
found B-O O
that B-O O
the B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
lymphocytes B-O B-cell_type
of B-O O
the B-O O
peripheral B-O O
blood B-O O
of B-O O
healthy B-O O
elderly B-O O
subjects B-O O
increases B-O O
, B-O O
while B-O O
the B-O O
number B-O O
of B-O O
mineralocorticoid B-O B-protein
receptors B-O I-protein
decreases B-O O
. B-O O

The B-O O
mechanisms B-O O
of B-O O
hormone-receptor B-O O
interactions B-O O
in B-O O
hypertension B-O O
are B-O O
activated B-O O
: B-O O
the B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
and B-O I-protein
mineralocorticoid B-O I-protein
binding B-O I-protein
sites B-O I-protein
grows B-O O
in B-O O
hypertensive B-O O
patients B-O O
. B-O O

Still B-O O
a B-O O
more B-O O
essential B-O O
rise B-O O
in B-O O
the B-O O
number B-O O
of B-O O
receptors B-O B-protein
is B-O O
observed B-O O
in B-O O
mid-age B-O O
hypertensive B-O O
patients B-O O
than B-O O
in B-O O
elderly B-O O
ones B-O O
. B-O O

The B-O O
mechanism B-O O
of B-O O
action B-O O
of B-O O
cyclosporin B-O O
A B-O O
and B-O O
FK506 B-O O
. B-O O

CsA B-O O
and B-O O
FK506 B-O O
are B-O O
powerful B-O O
suppressors B-O O
of B-O O
the B-O O
immune B-O O
system B-O O
, B-O O
most B-O O
notably B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

They B-O O
act B-O O
at B-O O
a B-O O
point B-O O
in B-O O
activation B-O O
that B-O O
lies B-O O
between B-O O
receptor B-O O
ligation B-O O
and B-O O
the B-O O
transcription B-O O
of B-O O
early B-O B-DNA
genes B-O I-DNA
. B-O O

Here B-O O
, B-O O
Stuart B-O O
Schreiber B-O O
and B-O O
Gerald B-O O
Crabtree B-O O
review B-O O
recent B-O O
findings B-O O
that B-O O
indicate B-O O
CsA B-O O
and B-O O
FK506 B-O O
operate B-O O
as B-O O
prodrugs B-O O
: B-O O
they B-O O
bind B-O O
endogenous B-O B-protein
intracellular B-O I-protein
receptors B-O I-protein
, B-O O
the B-O O
immunophilins B-O B-protein
, B-O O
and B-O O
the B-O O
resulting B-O O
complex B-O O
targets B-O O
the B-O O
protein B-O B-protein
phosphatase B-O I-protein
, B-O O
calcineurin B-O B-protein
, B-O O
to B-O O
exert B-O O
the B-O O
immunosuppressive B-O O
effect B-O O
. B-O O

Induction B-O O
of B-O O
monocytic B-O O
differentiation B-O O
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
-like B-O O
activities B-O O
by B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
1 B-O O
infection B-O O
of B-O O
myelomonoblastic B-O B-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
effects B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
infection B-O O
on B-O O
cellular B-O O
differentiation B-O O
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
DNA B-O O
binding B-O O
activity B-O O
have B-O O
been B-O O
investigated B-O O
in B-O O
a B-O O
new B-O O
model B-O O
of B-O O
myeloid B-O O
differentiation B-O O
. B-O O

PLB-985 B-O B-cell_line
cells B-O I-cell_line
represent B-O O
a B-O O
bipotential B-O B-cell_line
myelomonoblastic B-O I-cell_line
cell B-O I-cell_line
population B-O I-cell_line
capable B-O O
of B-O O
either B-O O
granulocytic B-O O
or B-O O
monocytic B-O O
differentiation B-O O
after B-O O
induction B-O O
with B-O O
appropriate B-O O
inducers B-O O
. B-O O

By B-O O
virtue B-O O
of B-O O
the B-O O
presence B-O O
of B-O O
CD4 B-O B-protein
on B-O O
the B-O O
cell B-O O
surface B-O O
, B-O O
PLB-985 B-O B-cell_line
cells B-O I-cell_line
were B-O O
chronically B-O O
infected B-O O
with B-O O
HIV-1 B-O O
strain B-O O
IIIB B-O O
. B-O O

PLB-IIIB B-O B-cell_line
cells B-O I-cell_line
clearly B-O O
possessed B-O O
a B-O O
more B-O O
monocytic B-O O
phenotype B-O O
than B-O O
the B-O O
parental B-O B-cell_type
myeloblasts B-O I-cell_type
, B-O O
as B-O O
determined B-O O
by B-O O
differential B-O O
staining B-O O
, B-O O
increased B-O O
expression B-O O
of B-O O
the B-O O
myeloid-specific B-O B-protein
surface B-O I-protein
markers B-O I-protein
, B-O O
and B-O O
transcription B-O O
of B-O O
the B-O O
c-fms B-O B-DNA
proto-oncogene B-O I-DNA
. B-O O

NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
activity B-O O
was B-O O
inducible B-O O
by B-O O
tumor B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
and B-O O
phorbol B-O O
myristate B-O O
acetate B-O O
in B-O O
PLB-985 B-O B-cell_line
. B-O O

However B-O O
, B-O O
in B-O O
PLB-IIIB B-O B-cell_line
cells B-O I-cell_line
, B-O O
constitutive B-O O
expression B-O O
of B-O O
a B-O O
novel B-O O
NF-kappa B-O B-protein
B B-O I-protein
complex B-O I-protein
was B-O O
detected B-O O
, B-O O
composed B-O O
of B-O O
proteins B-O O
ranging B-O O
between B-O O
70 B-O O
and B-O O
110 B-O O
kD B-O O
. B-O O

These B-O O
proteins B-O O
interacted B-O O
specifically B-O O
with B-O O
the B-O O
symmetric B-O B-DNA
NF-kappa B-O I-DNA
B B-O I-DNA
site B-O I-DNA
from B-O O
the B-O O
interferon B-O B-DNA
beta B-O I-DNA
( B-O I-DNA
IFN-beta B-O I-DNA
) B-O I-DNA
promoter B-O I-DNA
. B-O O

Mutations B-O O
affecting B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
guanine B-O I-DNA
residues B-O I-DNA
of B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
were B-O O
unable B-O O
to B-O O
compete B-O O
for B-O O
these B-O O
NF-kappa B-O B-protein
B B-O I-protein
-related B-O I-protein
proteins B-O I-protein
. B-O O

Inducibility B-O O
of B-O O
endogenous B-O O
IFN-beta B-O B-protein
and B-O O
IFN-alpha B-O B-protein
RNA B-O O
was B-O O
also B-O O
increased B-O O
in B-O O
PLB-IIIB B-O B-cell_line
cells B-O I-cell_line
. B-O O

These B-O O
studies B-O O
indicate B-O O
that B-O O
HIV-1 B-O O
infection B-O O
of B-O O
myelomonoblastic B-O B-cell_type
cells B-O I-cell_type
may B-O O
select B-O O
for B-O O
a B-O O
more B-O O
mature B-O O
monocytic B-O O
phenotype B-O O
and B-O O
that B-O O
unique B-O O
subunit B-O O
associations B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
DNA B-O B-protein
binding B-O I-protein
proteins B-O I-protein
may B-O O
contribute B-O O
to B-O O
differential B-O O
NF-kappa B-O B-protein
B B-O I-protein
-mediated B-O O
gene B-O O
expression B-O O
. B-O O

Cortisol B-O O
receptor B-O O
resistance B-O O
: B-O O
the B-O O
variability B-O O
of B-O O
its B-O O
clinical B-O O
presentation B-O O
and B-O O
response B-O O
to B-O O
treatment B-O O
. B-O O

Primary B-O O
( B-O O
partial B-O O
) B-O O
cortisol B-O O
receptor B-O O
resistance B-O O
was B-O O
previously B-O O
reported B-O O
in B-O O
a B-O O
total B-O O
of B-O O
7 B-O O
patients B-O O
and B-O O
14 B-O O
asymptomatic B-O O
family B-O O
members B-O O
. B-O O

Its B-O O
occurrence B-O O
is B-O O
considered B-O O
to B-O O
be B-O O
extremely B-O O
rare B-O O
. B-O O

In B-O O
the B-O O
present B-O O
study B-O O
we B-O O
report B-O O
on B-O O
6 B-O O
patients B-O O
( B-O O
2 B-O O
males B-O O
and B-O O
4 B-O O
females B-O O
) B-O O
with B-O O
the B-O O
syndrome B-O O
. B-O O

The B-O O
first B-O O
male B-O O
patient B-O O
presented B-O O
with B-O O
mild B-O O
hypertension B-O O
. B-O O

Hydrochlorothiazide B-O O
therapy B-O O
resulted B-O O
in B-O O
life-threatening B-O O
hypokalemia B-O O
. B-O O

The B-O O
second B-O O
male B-O O
patient B-O O
had B-O O
slight B-O O
hypertension B-O O
without B-O O
hypokalemia B-O O
. B-O O

All B-O O
four B-O O
female B-O O
patients B-O O
presented B-O O
between B-O O
the B-O O
age B-O O
of B-O O
20-30 B-O O
yr B-O O
with B-O O
acne B-O O
, B-O O
hirsutism B-O O
, B-O O
and B-O O
irregular B-O O
menstruations B-O O
. B-O O

Low B-O O
dose B-O O
dexamethasone B-O O
therapy B-O O
( B-O O
1-1.5 B-O O
mg/day B-O O
) B-O O
was B-O O
of B-O O
clinical B-O O
benefit B-O O
in B-O O
these B-O O
patients B-O O
. B-O O

All B-O O
patients B-O O
showed B-O O
insufficient B-O O
suppression B-O O
of B-O O
serum B-O O
cortisol B-O O
concentrations B-O O
in B-O O
the B-O O
overnight B-O O
1-mg B-O O
dexamethasone B-O O
test B-O O
. B-O O

The B-O O
diurnal B-O O
rhythm B-O O
of B-O O
ACTH B-O B-protein
and B-O O
cortisol B-O O
was B-O O
intact B-O O
, B-O O
albeit B-O O
at B-O O
an B-O O
elevated B-O O
level B-O O
. B-O O

There B-O O
was B-O O
a B-O O
normal B-O O
increase B-O O
in B-O O
ACTH B-O O
, B-O O
cortisol B-O O
, B-O O
and B-O O
GH B-O B-protein
( B-O O
except B-O O
in B-O O
one B-O O
obese B-O O
patient B-O O
) B-O O
in B-O O
response B-O O
to B-O O
insulin-induced B-O O
hypoglycemia B-O O
, B-O O
while B-O O
cortisol B-O O
production B-O O
was B-O O
elevated B-O O
in B-O O
three B-O O
patients B-O O
. B-O O

Circulating B-O O
adrenal B-O O
androgen B-O O
levels B-O O
were B-O O
increased B-O O
in B-O O
all B-O O
patients B-O O
. B-O O

Glucocorticoid B-O B-protein
receptors B-O I-protein
were B-O O
investigated B-O O
in B-O O
a B-O O
whole B-O O
cell B-O O
dexamethasone B-O O
binding B-O O
assay B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
. B-O O

In B-O O
the B-O O
first B-O O
male B-O O
patient B-O O
, B-O O
the B-O O
number B-O O
of B-O O
receptors B-O B-protein
was B-O O
very B-O O
low B-O O
, B-O O
while B-O O
the B-O O
affinity B-O O
was B-O O
lower B-O O
than B-O O
that B-O O
in B-O O
controls B-O O
. B-O O

A B-O O
lowered B-O O
affinity B-O O
to B-O O
dexamethasone B-O O
was B-O O
found B-O O
in B-O O
one B-O O
female B-O O
patient B-O O
, B-O O
while B-O O
a B-O O
lowered B-O O
number B-O O
of B-O O
receptors B-O B-protein
was B-O O
found B-O O
in B-O O
three B-O O
patients B-O O
. B-O O

In B-O O
the B-O O
second B-O O
male B-O O
patient B-O O
, B-O O
no B-O O
abnormalities B-O O
were B-O O
found B-O O
. B-O O

As B-O O
a B-O O
bioassay B-O O
for B-O O
glucocorticoid B-O O
action B-O O
we B-O O
also B-O O
measured B-O O
dexamethasone B-O O
suppressibility B-O O
of B-O O
mitogen-stimulated B-O O
incorporation B-O O
of B-O O
[ B-O O
3H B-O O
] B-O O
thymidine B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
. B-O O

In B-O O
the B-O O
male B-O O
patient B-O O
with B-O O
normal B-O O
receptor B-O O
status B-O O
, B-O O
dexamethasone B-O O
suppressibility B-O O
of B-O O
[ B-O O
3H B-O O
] B-O O
thymidine B-O O
incorporation B-O O
was B-O O
significantly B-O O
lower B-O O
than B-O O
that B-O O
in B-O O
healthy B-O O
controls B-O O
with B-O O
respect B-O O
to B-O O
both B-O O
maximal B-O O
suppression B-O O
and B-O O
IC50 B-O O
. B-O O

Partial B-O O
cortisol B-O O
receptor B-O O
resistance B-O O
might B-O O
be B-O O
less B-O O
rare B-O O
than B-O O
previously B-O O
thought B-O O
. B-O O

In B-O O
the B-O O
six B-O O
patients B-O O
presented B-O O
, B-O O
at B-O O
least B-O O
three B-O O
different B-O O
forms B-O O
can B-O O
be B-O O
recognized B-O O
. B-O O

Therapy B-O O
with B-O O
dexamethasone B-O O
was B-O O
successful B-O O
in B-O O
female B-O O
patients B-O O
with B-O O
acne B-O O
and B-O O
hirsutism B-O O
, B-O O
as B-O O
the B-O O
secondary B-O O
increase B-O O
in B-O O
the B-O O
production B-O O
of B-O O
adrenal B-O O
androgens B-O O
was B-O O
effectively B-O O
controlled B-O O
. B-O O

The B-O O
development B-O O
of B-O O
functionally B-O O
responsive B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
work B-O O
reviewed B-O O
in B-O O
this B-O O
article B-O O
separates B-O O
T B-O O
cell B-O O
development B-O O
into B-O O
four B-O O
phases B-O O
. B-O O

First B-O O
is B-O O
an B-O O
expansion B-O O
phase B-O O
prior B-O O
to B-O O
TCR B-O B-protein
rearrangement B-O O
, B-O O
which B-O O
appears B-O O
to B-O O
be B-O O
correlated B-O O
with B-O O
programming B-O O
of B-O O
at B-O O
least B-O O
some B-O O
response B-O O
genes B-O O
for B-O O
inducibility B-O O
. B-O O

This B-O O
phase B-O O
can B-O O
occur B-O O
to B-O O
some B-O O
extent B-O O
outside B-O O
of B-O O
the B-O O
thymus B-O O
. B-O O

However B-O O
, B-O O
the B-O O
profound B-O O
T B-O O
cell B-O O
deficit B-O O
of B-O O
nude B-O O
mice B-O O
indicates B-O O
that B-O O
the B-O O
thymus B-O O
is B-O O
by B-O O
far B-O O
the B-O O
most B-O O
potent B-O O
site B-O O
for B-O O
inducing B-O O
the B-O O
expansion B-O O
per B-O O
se B-O O
, B-O O
even B-O O
if B-O O
other B-O O
sites B-O O
can B-O O
induce B-O O
some B-O O
response B-O O
acquisition B-O O
. B-O O

Second B-O O
is B-O O
a B-O O
controlled B-O O
phase B-O O
of B-O O
TCR B-O B-DNA
gene B-O I-DNA
rearrangement B-O O
. B-O O

The B-O O
details B-O O
of B-O O
the B-O O
regulatory B-O O
mechanism B-O O
that B-O O
selects B-O O
particular B-O O
loci B-O O
for B-O O
rearrangement B-O O
are B-O O
still B-O O
not B-O O
known B-O O
. B-O O

It B-O O
seems B-O O
that B-O O
the B-O O
rearrangement B-O O
of B-O O
the B-O O
TCR B-O B-DNA
gamma B-O I-DNA
loci B-O I-DNA
in B-O O
the B-O O
gamma B-O B-cell_type
delta B-O I-cell_type
lineage B-O I-cell_type
may B-O O
not B-O O
always B-O O
take B-O O
place B-O O
at B-O O
a B-O O
developmental B-O O
stage B-O O
strictly B-O O
equivalent B-O O
to B-O O
the B-O O
rearrangement B-O O
of B-O O
TCR B-O B-DNA
beta B-O I-DNA
in B-O O
the B-O O
alpha B-O B-cell_type
beta B-O I-cell_type
lineage B-O I-cell_type
, B-O O
and B-O O
it B-O O
is B-O O
not B-O O
clear B-O O
just B-O O
how B-O O
early B-O O
the B-O O
two B-O O
lineages B-O O
diverge B-O O
. B-O O

In B-O O
the B-O O
TCR B-O B-cell_type
alpha B-O I-cell_type
beta B-O I-cell_type
lineage B-O I-cell_type
, B-O O
however B-O O
, B-O O
the B-O O
final B-O O
gene B-O O
rearrangement B-O O
events B-O O
are B-O O
accompanied B-O O
by B-O O
rapid B-O O
proliferation B-O O
and B-O O
an B-O O
interruption B-O O
in B-O O
cellular B-O O
response B-O O
gene B-O O
inducibility B-O O
. B-O O

The B-O O
loss B-O O
of B-O O
conventional B-O O
responsiveness B-O O
is B-O O
probably B-O O
caused B-O O
by B-O O
alterations B-O O
at B-O O
the B-O O
level B-O O
of B-O O
signaling B-O O
, B-O O
and B-O O
may B-O O
be B-O O
a B-O O
manifestation B-O O
of B-O O
the B-O O
physiological B-O O
state B-O O
that B-O O
is B-O O
a B-O O
precondition B-O O
for B-O O
selection B-O O
. B-O O

Third B-O O
is B-O O
the B-O O
complex B-O O
process B-O O
of B-O O
selection B-O O
. B-O O

Whereas B-O O
peripheral B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
can B-O O
undergo B-O O
forms B-O O
of B-O O
positive B-O O
selection B-O O
( B-O O
by B-O O
antigen-driven B-O O
clonal B-O O
expansion B-O O
) B-O O
and B-O O
negative B-O O
selection B-O O
( B-O O
by B-O O
abortive B-O O
stimulation B-O O
leading B-O O
to B-O O
anergy B-O O
or B-O O
death B-O O
) B-O O
, B-O O
neither B-O O
is B-O O
exactly B-O O
the B-O O
same B-O O
phenomenon B-O O
that B-O O
occurs B-O O
in B-O O
the B-O O
thymic B-O O
cortex B-O O
. B-O O

Negative B-O O
selection B-O O
in B-O O
the B-O O
cortex B-O O
appears B-O O
to B-O O
be B-O O
a B-O O
suicidal B-O O
inversion B-O O
of B-O O
antigen B-O O
responsiveness B-O O
: B-O O
instead B-O O
of B-O O
turning B-O O
on B-O O
IL-2 B-O B-protein
expression B-O O
, B-O O
the B-O O
activated B-O B-cell_type
cell B-O I-cell_type
destroys B-O O
its B-O O
own B-O O
chromatin B-O B-DNA
. B-O O

The B-O O
genes B-O O
that B-O O
need B-O O
to B-O O
be B-O O
induced B-O O
for B-O O
this B-O O
response B-O O
are B-O O
not B-O O
yet B-O O
identified B-O O
, B-O O
but B-O O
it B-O O
is B-O O
unquestionably B-O O
a B-O O
form B-O O
of B-O O
activation B-O O
. B-O O

It B-O O
is B-O O
interesting B-O O
that B-O O
in B-O O
humans B-O O
and B-O O
rats B-O O
, B-O O
cortical B-O B-cell_type
thymocytes B-O I-cell_type
undergoing B-O O
negative B-O O
selection B-O O
can B-O O
still B-O O
induce B-O O
IL-2R B-O B-protein
alpha B-O I-protein
expression B-O O
and B-O O
even B-O O
be B-O O
rescued B-O O
in B-O O
vitro B-O O
, B-O O
if B-O O
exogenous B-O O
IL-2 B-O B-protein
is B-O O
provided B-O O
. B-O O

Perhaps B-O O
murine B-O B-cell_type
thymocytes B-O I-cell_type
are B-O O
denied B-O O
this B-O O
form B-O O
of B-O O
rescue B-O O
because B-O O
they B-O O
shut B-O O
off B-O O
IL-2R B-O B-protein
beta B-O I-protein
chain B-O I-protein
expression B-O O
at B-O O
an B-O O
earlier B-O O
stage B-O O
or B-O O
because B-O O
they B-O O
may B-O O
be B-O O
uncommonly B-O O
Bcl-2 B-O B-protein
deficient B-O O
( B-O O
cf. B-O O
Sentman B-O O
et B-O O
al. B-O O
, B-O O
1991 B-O O
; B-O O
Strasser B-O O
et B-O O
al. B-O O
, B-O O
1991 B-O O
) B-O O
. B-O O

Even B-O O
so B-O O
, B-O O
medullary B-O B-cell_type
thymocytes B-O I-cell_type
remain B-O O
at B-O O
least B-O O
partially B-O O
susceptible B-O O
to B-O O
negative B-O O
selection B-O O
even B-O O
as B-O O
they B-O O
continue B-O O
to B-O O
mature B-O O
. B-O O

I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
masks B-O O
the B-O O
nuclear B-O O
localization B-O O
signal B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
and B-O O
requires B-O O
the B-O O
transactivation B-O B-protein
domain B-O I-protein
to B-O O
inhibit B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
DNA B-O O
binding B-O O
. B-O O

The B-O O
active B-O O
nuclear B-O O
form B-O O
of B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
transcription B-O I-protein
factor B-O I-protein
complex B-O I-protein
is B-O O
composed B-O O
of B-O O
two B-O O
DNA B-O B-protein
binding B-O I-protein
subunits B-O I-protein
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
p50 B-O I-protein
, B-O O
both B-O O
of B-O O
which B-O O
share B-O O
extensive B-O O
N-terminal B-O O
sequence B-O O
homology B-O O
with B-O O
the B-O O
v-rel B-O B-protein
oncogene B-O I-protein
product B-O I-protein
. B-O O

The B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
subunit B-O I-protein
provides B-O O
the B-O O
transactivation B-O O
activity B-O O
in B-O O
this B-O O
complex B-O O
and B-O O
serves B-O O
as B-O O
an B-O O
intracellular B-O B-protein
receptor B-O I-protein
for B-O O
a B-O O
cytoplasmic B-O B-protein
inhibitor B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
termed B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

In B-O O
contrast B-O O
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
p50 B-O I-protein
alone B-O O
fails B-O O
to B-O O
stimulate B-O O
kappa B-O O
B-directed B-O O
transcription B-O O
, B-O O
and B-O O
based B-O O
on B-O O
prior B-O O
in B-O O
vitro B-O O
studies B-O O
, B-O O
is B-O O
not B-O O
directly B-O O
regulated B-O O
by B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

To B-O O
investigate B-O O
the B-O O
molecular B-O O
basis B-O O
for B-O O
the B-O O
critical B-O O
regulatory B-O O
interaction B-O O
between B-O O
NF-kappa B-O B-protein
B B-O I-protein
and B-O O
I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
, B-O O
a B-O O
series B-O O
of B-O O
human B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
p65 B-O I-protein
mutants B-O I-protein
was B-O O
identified B-O O
that B-O O
functionally B-O O
segregated B-O O
DNA B-O O
binding B-O O
, B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
-mediated B-O O
inhibition B-O O
, B-O O
and B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
-induced B-O O
nuclear B-O O
exclusion B-O O
of B-O O
this B-O O
transcription B-O B-protein
factor B-O I-protein
. B-O O

Results B-O O
from B-O O
in B-O O
vivo B-O O
expression B-O O
studies B-O O
performed B-O O
with B-O O
these B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
mutants B-O I-protein
revealed B-O O
the B-O O
following B-O O
: B-O O
1 B-O O
) B-O O
I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
completely B-O O
inhibits B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
-dependent B-O O
transcriptional B-O O
activation B-O O
mediated B-O O
through B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
type B-O I-DNA
1 B-O I-DNA
kappa B-O I-DNA
B B-O I-DNA
enhancer B-O I-DNA
in B-O O
human B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
, B-O O
2 B-O O
) B-O O
the B-O O
binding B-O O
of B-O O
I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
is B-O O
sufficient B-O O
to B-O O
retarget B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
from B-O O
the B-O O
nucleus B-O O
to B-O O
the B-O O
cytoplasm B-O O
, B-O O
3 B-O O
) B-O O
selective B-O O
deletion B-O O
of B-O O
the B-O O
functional B-O O
nuclear B-O O
localization B-O O
signal B-O O
present B-O O
in B-O O
the B-O O
Rel B-O B-protein
homology B-O I-protein
domain B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
disrupts B-O O
its B-O O
ability B-O O
to B-O O
engage B-O O
I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
, B-O O
and B-O O
4 B-O O
) B-O O
the B-O O
unique B-O O
C-terminus B-O B-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
attenuates B-O O
its B-O O
own B-O O
nuclear B-O O
localization B-O O
and B-O O
contains B-O O
sequences B-O O
that B-O O
are B-O O
required B-O O
for B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
-mediated B-O O
inhibition B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
DNA B-O O
binding B-O O
activity B-O O
. B-O O

Together B-O O
, B-O O
these B-O O
findings B-O O
suggest B-O O
that B-O O
the B-O O
nuclear B-O O
localization B-O O
signal B-O O
and B-O O
transactivation B-O B-protein
domain B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
constitute B-O O
a B-O O
bipartite B-O O
system B-O O
that B-O O
is B-O O
critically B-O O
involved B-O O
in B-O O
the B-O O
inhibitory B-O O
function B-O O
of B-O O
I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
. B-O O

Unexpectedly B-O O
, B-O O
our B-O O
in B-O O
vivo B-O O
studies B-O O
also B-O O
demonstrate B-O O
that B-O O
I B-O B-protein
kappa B-O I-protein
B/MAD-3 B-O I-protein
binds B-O O
directly B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
p50 B-O I-protein
. B-O O

This B-O O
interaction B-O O
is B-O O
functional B-O O
as B-O O
it B-O O
leads B-O O
to B-O O
retargeting B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
p50 B-O I-protein
from B-O O
the B-O O
nucleus B-O O
to B-O O
the B-O O
cytoplasm B-O O
. B-O O

However B-O O
, B-O O
no B-O O
loss B-O O
of B-O O
DNA B-O O
binding B-O O
activity B-O O
is B-O O
observed B-O O
, B-O O
presumably B-O O
reflecting B-O O
the B-O O
unique B-O O
C-terminal B-O B-protein
domain B-O I-protein
that B-O O
is B-O O
distinct B-O O
from B-O O
that B-O O
present B-O O
in B-O O
NF-kappa B-O B-protein
B B-O I-protein
p65 B-O I-protein
. B-O O

Characterization B-O O
of B-O O
a B-O O
new B-O O
tissue-specific B-O O
transcription B-O B-protein
factor B-O I-protein
binding B-O O
to B-O O
the B-O O
simian B-O B-DNA
virus B-O I-DNA
40 B-O I-DNA
enhancer B-O I-DNA
TC-II B-O I-DNA
( B-O I-DNA
NF-kappa B-O I-DNA
B B-O I-DNA
) B-O I-DNA
element B-O I-DNA
. B-O O

We B-O O
have B-O O
biochemically B-O O
and B-O O
functionally B-O O
characterized B-O O
a B-O O
new B-O O
transcription B-O B-protein
factor B-O I-protein
, B-O O
NP-TCII B-O B-protein
, B-O O
which B-O O
is B-O O
present B-O O
in B-O O
nuclei B-O O
from B-O O
unstimulated B-O B-cell_line
T B-O I-cell_line
and B-O I-cell_line
B B-O I-cell_line
lymphocytes B-O I-cell_line
but B-O O
is B-O O
not B-O O
found B-O O
in B-O O
nonhematopoietic B-O B-cell_type
cells B-O I-cell_type
. B-O O

This B-O O
factor B-O O
has B-O O
a B-O O
DNA-binding B-O O
specificity B-O O
similar B-O O
to B-O O
that B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
but B-O O
is B-O O
unrelated B-O O
to B-O O
this B-O O
or B-O O
other B-O O
Rel B-O B-protein
proteins B-O I-protein
by B-O O
functional B-O O
and B-O O
biochemical B-O O
criteria B-O O
. B-O O

It B-O O
can B-O O
also B-O O
be B-O O
distinguished B-O O
from B-O O
other B-O O
previously B-O O
described B-O O
lymphocyte-specific B-O B-protein
DNA-binding B-O I-protein
proteins B-O I-protein
. B-O O

The B-O O
candidate B-O B-protein
oncoprotein B-O I-protein
Bcl-3 B-O B-protein
is B-O O
an B-O O
antagonist B-O O
of B-O O
p50/NF-kappa B-O B-protein
B B-O I-protein
-mediated B-O O
inhibition B-O O
. B-O O

The B-O O
candidate B-O B-DNA
oncogene B-O I-DNA
bcl-3 B-O I-DNA
was B-O O
discovered B-O O
as B-O O
a B-O O
translocation B-O O
into B-O O
the B-O O
immunoglobulin B-O B-DNA
alpha-locus B-O I-DNA
in B-O O
some B-O O
cases B-O O
of B-O O
B-cell B-O O
chronic B-O O
lymphocytic B-O O
leukaemias B-O O
. B-O O

The B-O O
protein B-O O
Bcl-3 B-O B-protein
contains B-O O
seven B-O O
so-called B-O O
ankyrin B-O B-protein
repeats B-O I-protein
. B-O O

Similar B-O O
repeat B-O B-protein
motifs B-O I-protein
are B-O O
found B-O O
in B-O O
a B-O O
number B-O O
of B-O O
diverse B-O B-protein
regulatory B-O I-protein
proteins B-O I-protein
but B-O O
the B-O O
motifs B-O O
of B-O O
Bcl-3 B-O B-protein
are B-O O
most B-O O
closely B-O O
related B-O O
to B-O O
those B-O O
found B-O O
in B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
proteins B-O I-protein
in B-O O
which B-O O
the B-O O
ankyrin B-O B-protein
repeat B-O I-protein
domain B-O I-protein
is B-O O
thought B-O O
to B-O O
be B-O O
directly B-O O
involved B-O O
in B-O O
inhibition B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
. B-O O

No B-O O
biological B-O O
function B-O O
has B-O O
yet B-O O
been B-O O
described B-O O
for B-O O
Bcl-3 B-O B-protein
, B-O O
but B-O O
it B-O O
was B-O O
noted B-O O
recently B-O O
that B-O O
Bcl-3 B-O B-protein
interferes B-O O
with B-O O
DNA-binding B-O O
of B-O O
the B-O O
p50 B-O B-protein
subunit B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
in B-O O
vitro B-O O
. B-O O

Here B-O O
we B-O O
demonstrate B-O O
that B-O O
Bcl-3 B-O B-protein
can B-O O
aid B-O O
kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
-dependent B-O O
transcription B-O O
in B-O O
vivo B-O O
by B-O O
counteracting B-O O
the B-O O
inhibitory B-O O
effects B-O O
of B-O O
p50/NF-kappa B-O B-protein
B B-O I-protein
homodimers B-O I-protein
. B-O O

Bcl-3 B-O B-protein
may B-O O
therefore B-O O
aid B-O O
activation B-O O
of B-O O
select B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
-regulated B-O I-DNA
genes B-O I-DNA
, B-O O
including B-O O
those B-O O
of B-O O
the B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
. B-O O

[ B-O O
Mechanism B-O O
of B-O O
action B-O O
of B-O O
steroid B-O O
hormones B-O O
. B-O O
I B-O O
. B-O O
Estrogens B-O O
] B-O O

The B-O O
steroid B-O O
hormone B-O O
are B-O O
very B-O O
versatile B-O O
molecules B-O O
: B-O O
although B-O O
they B-O O
are B-O O
related B-O O
among B-O O
them B-O O
by B-O O
their B-O O
chemical B-O O
structure B-O O
, B-O O
they B-O O
have B-O O
very B-O O
diverse B-O O
functions B-O O
and B-O O
including B-O O
antagonic B-O O
. B-O O

Their B-O O
action B-O O
mechanism B-O O
is B-O O
not B-O O
completely B-O O
cleared B-O O
. B-O O

The B-O O
estrogens B-O O
participate B-O O
in B-O O
the B-O O
regulation B-O O
of B-O O
practically B-O O
all B-O O
the B-O O
reproductive B-O O
and B-O O
sexual B-O O
events B-O O
of B-O O
the B-O O
female B-O O
, B-O O
although B-O O
the B-O O
intracellular B-O O
actions B-O O
by B-O O
which B-O O
they B-O O
take B-O O
place B-O O
are B-O O
not B-O O
well B-O O
known B-O O
and B-O O
the B-O O
proposed B-O O
models B-O O
do B-O O
not B-O O
adequately B-O O
satisfy B-O O
the B-O O
questions B-O O
. B-O O

Currently B-O O
it B-O O
is B-O O
accepted B-O O
the B-O O
existence B-O O
of B-O O
a B-O O
cytoplasmic B-O B-protein
and/or B-O I-protein
nuclear B-O I-protein
receptor B-O I-protein
, B-O O
without B-O O
explaining B-O O
satisfactorily B-O O
how B-O O
the B-O O
hormones B-O O
come B-O O
to B-O O
the B-O O
nucleus B-O O
. B-O O

The B-O O
endocrine B-O O
events B-O O
that B-O O
are B-O O
rapidly B-O O
expressed B-O O
( B-O O
seconds B-O O
) B-O O
are B-O O
due B-O O
to B-O O
a B-O O
possible B-O O
interaction B-O O
with B-O O
cellular B-O O
membrane B-O O
. B-O O

The B-O O
purpose B-O O
of B-O O
this B-O O
review B-O O
is B-O O
to B-O O
analyze B-O O
and B-O O
concilliate B-O O
the B-O O
reported B-O O
data B-O O
on B-O O
the B-O O
mechanism B-O O
of B-O O
action B-O O
of B-O O
estrogens B-O O
. B-O O

Reduced B-O O
susceptibility B-O O
to B-O O
HIV-1 B-O O
infection B-O O
of B-O O
ethyl-methanesulfonate-treated B-O B-cell_line
CEM B-O I-cell_line
subclones B-O I-cell_line
correlates B-O O
with B-O O
a B-O O
blockade B-O O
in B-O O
their B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
signaling B-O O
pathway B-O O
. B-O O

We B-O O
have B-O O
described B-O O
the B-O O
isolation B-O O
of B-O O
chemically B-O O
induced B-O O
CEM B-O B-cell_line
subclones B-O I-cell_line
that B-O O
express B-O O
CD4 B-O B-protein
receptors B-O I-protein
and B-O O
bind B-O O
soluble B-O O
gp120 B-O B-protein
, B-O O
yet B-O O
show B-O O
a B-O O
markedly B-O O
reduced B-O O
susceptibility B-O O
to B-O O
infection B-O O
with B-O O
HIV-1 B-O O
. B-O O

Two B-O O
subclones B-O O
were B-O O
found B-O O
to B-O O
have B-O O
an B-O O
abnormal B-O O
response B-O O
to B-O O
the B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
activator B-O O
PMA B-O O
. B-O O

PMA B-O O
treatment B-O O
induced B-O O
CD3 B-O B-protein
and B-O I-protein
CD25 B-O I-protein
( B-O I-protein
IL-2R B-O I-protein
) B-O I-protein
receptors B-O I-protein
on B-O O
the B-O O
parental B-O O
line B-O O
and B-O O
on B-O O
other B-O O
ethyl-methanesulfonate-derived B-O B-cell_line
subclones B-O I-cell_line
, B-O O
but B-O O
not B-O O
on B-O O
these B-O O
two B-O O
mutants B-O O
. B-O O

Direct B-O O
assays B-O O
of B-O O
PKC B-O B-protein
activity B-O O
were B-O O
conducted B-O O
. B-O O

Total B-O O
cellular B-O O
PKC B-O B-protein
enzymatic B-O O
activity B-O O
was B-O O
found B-O O
to B-O O
be B-O O
normal B-O O
in B-O O
these B-O O
subclones B-O O
. B-O O

PMA B-O O
-induced B-O O
CD4 B-O B-protein
down-modulation B-O O
occurred B-O O
normally B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
activation B-O O
of B-O O
c-raf B-O B-protein
kinase B-O I-protein
was B-O O
normal B-O O
. B-O O

Since B-O O
HIV-1 B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
contains B-O O
two B-O O
functional B-O O
nuclear B-O B-DNA
factor B-O I-DNA
kB B-O I-DNA
( B-O I-DNA
NF-kB B-O I-DNA
) B-O I-DNA
regulatory B-O I-DNA
elements B-O I-DNA
, B-O O
we B-O O
studied B-O O
the B-O O
ability B-O O
of B-O O
PMA B-O O
to B-O O
induce B-O O
NF-kB B-O B-protein
binding B-O O
activity B-O O
by B-O O
different B-O O
assays B-O O
. B-O O

Chloramphenicol B-O B-protein
acetyl B-O I-protein
transferase B-O I-protein
( B-O O
CAT B-O B-protein
) B-O O
assays B-O O
using B-O O
the B-O O
HIV-1 B-O B-DNA
( B-O I-DNA
-139 B-O I-DNA
) B-O I-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat-CAT B-O I-DNA
construct B-O I-DNA
showed B-O O
no B-O O
PMA B-O O
induction B-O O
of B-O O
CAT B-O B-protein
activity B-O O
in B-O O
these B-O O
subclones B-O O
( B-O O
unlike B-O O
the B-O O
parental B-O O
line B-O O
and B-O O
other B-O O
subclones B-O O
) B-O O
. B-O O

Okadaic B-O O
acid B-O O
, B-O O
an B-O O
inhibitor B-O O
of B-O O
phosphatases B-O B-protein
1 B-O I-protein
and B-O I-protein
2A B-O I-protein
, B-O O
did B-O O
not B-O O
overcome B-O O
the B-O O
defect B-O O
in B-O O
these B-O O
subclones B-O O
. B-O O

Gel B-O O
retardation B-O O
assays B-O O
, B-O O
using B-O O
a B-O O
32P-probe B-O O
containing B-O O
the B-O O
HIV-1 B-O O
NF-kB B-O O
probe B-O O
and B-O O
nuclear B-O O
extracts B-O O
from B-O O
PMA B-O B-cell_line
-treated B-O I-cell_line
cells B-O I-cell_line
, B-O O
showed B-O O
significantly B-O O
reduced B-O O
induction B-O O
of B-O O
nuclear B-O B-protein
NF-kB B-O I-protein
binding B-O I-protein
proteins B-O I-protein
in B-O O
these B-O O
two B-O O
subclones B-O O
compared B-O O
with B-O O
wild B-O B-protein
type B-O I-protein
CEM B-O I-protein
and B-O O
a B-O O
control B-O O
subclone B-O O
. B-O O

Deoxycholate B-O O
treatment B-O O
of B-O O
cytoplasmic B-O O
extracts B-O O
from B-O O
these B-O O
subclones B-O O
released B-O O
much B-O O
reduced B-O O
NF-kB B-O B-protein
binding B-O I-protein
proteins B-O I-protein
from B-O O
their B-O O
cytoplasmic B-O O
pools B-O O
. B-O O

Thus B-O O
, B-O O
reduced B-O O
levels B-O O
of B-O O
PKC B-O B-protein
-induced B-O O
nuclear B-O O
NF-kB B-O B-protein
activity B-O O
in B-O O
two B-O O
T B-O O
cell B-O O
subclones B-O O
did B-O O
not B-O O
affect B-O O
their B-O O
normal B-O O
cell B-O O
growth B-O O
, B-O O
but B-O O
correlated B-O O
with B-O O
a B-O O
pronounced B-O O
reduction B-O O
in B-O O
their B-O O
susceptibility B-O O
to B-O O
HIV-1 B-O O
infection B-O O
. B-O O

Nuclear B-O B-protein
factor B-O I-protein
of B-O I-protein
activated B-O I-protein
T B-O I-protein
cells B-O I-protein
contains B-O O
Fos B-O B-protein
and B-O O
Jun B-O B-protein
. B-O O

The B-O O
nuclear B-O B-protein
factor B-O I-protein
NF-AT B-O I-protein
( B-O O
ref. B-O O
1 B-O O
) B-O O
is B-O O
induced B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
stimulated B-O O
through B-O O
the B-O O
T-cell B-O B-protein
receptor/CD3 B-O I-protein
complex B-O I-protein
, B-O O
and B-O O
is B-O O
required B-O O
for B-O O
interleukin-2 B-O B-DNA
( B-O I-DNA
IL-2 B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
induction B-O O
. B-O O

Although B-O O
NF-AT B-O B-protein
has B-O O
not B-O O
been B-O O
cloned B-O O
or B-O O
purified B-O O
, B-O O
there B-O O
is B-O O
evidence B-O O
that B-O O
it B-O O
is B-O O
a B-O O
major B-O O
target B-O O
for B-O O
immunosuppression B-O O
by B-O O
cyclosporin B-O O
A B-O O
( B-O O
CsA B-O O
) B-O O
and B-O O
FK506 B-O O
( B-O O
refs B-O O
2-7 B-O O
) B-O O
. B-O O

NF-AT B-O B-protein
induction B-O O
may B-O O
require B-O O
two B-O O
activation-dependent B-O O
events B-O O
: B-O O
the B-O O
CsA B-O O
-sensitive B-O O
translocation B-O O
of B-O O
a B-O O
pre-existing B-O O
component B-O O
and B-O O
the B-O O
CsA B-O O
-resistant B-O O
synthesis B-O O
of B-O O
a B-O O
nuclear B-O B-protein
component B-O I-protein
. B-O O

Here B-O O
we B-O O
report B-O O
that B-O O
the B-O O
newly B-O O
synthesized B-O O
nuclear B-O B-protein
component B-O I-protein
of B-O O
NF-AT B-O B-protein
is B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
AP-1 B-O B-protein
. B-O O

We B-O O
show B-O O
that B-O O
the B-O O
inducible B-O O
nuclear B-O O
form B-O O
of B-O O
NF-AT B-O B-protein
contains B-O O
Fos B-O B-protein
and B-O O
Jun B-O B-protein
proteins B-O I-protein
. B-O O

Furthermore B-O O
, B-O O
we B-O O
identify B-O O
a B-O O
pre-existing B-O B-protein
NF-AT B-O I-protein
-binding B-O I-protein
factor B-O I-protein
that B-O O
is B-O O
present B-O O
in B-O O
hypotonic B-O O
extracts B-O O
of B-O O
unstimulated B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

On B-O O
the B-O O
basis B-O O
of B-O O
binding B-O O
, B-O O
reconstitution B-O O
and B-O O
cotransfection B-O O
experiments B-O O
, B-O O
we B-O O
propose B-O O
that B-O O
activation B-O O
of B-O O
NF-AT B-O B-protein
occurs B-O O
in B-O O
at B-O O
least B-O O
two B-O O
stages B-O O
: B-O O
a B-O O
CsA B-O O
-sensitive B-O O
stage B-O O
involving B-O O
modification B-O O
and/or B-O O
translocation B-O O
of B-O O
the B-O O
pre-existing B-O O
NF-AT B-O B-protein
complex B-O I-protein
, B-O O
and B-O O
a B-O O
CsA B-O O
-insensitive B-O O
stage B-O O
involving B-O O
the B-O O
addition B-O O
of B-O O
newly B-O O
synthesized B-O O
Fos B-O B-protein
or B-O O
Fos/Jun B-O B-protein
proteins B-O I-protein
to B-O O
the B-O O
pre-existing B-O B-protein
complex B-O I-protein
. B-O O

A B-O O
lymphoid B-O B-protein
cell-specific B-O I-protein
nuclear B-O I-protein
factor B-O I-protein
containing B-O O
c-Rel-like B-O B-protein
proteins B-O I-protein
preferentially B-O O
interacts B-O O
with B-O O
interleukin-6 B-O B-DNA
kappa B-O I-DNA
B-related B-O I-DNA
motifs B-O I-DNA
whose B-O O
activities B-O O
are B-O O
repressed B-O O
in B-O O
lymphoid B-O B-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
proto-oncoprotein B-O O
c-Rel B-O B-protein
is B-O O
a B-O O
member B-O O
of B-O O
the B-O O
nuclear B-O B-protein
factor B-O I-protein
kappa B-O I-protein
B B-O I-protein
transcription B-O I-protein
factor B-O I-protein
family B-O I-protein
, B-O O
which B-O O
includes B-O O
the B-O O
p50 B-O B-protein
and B-O O
p65 B-O B-protein
subunits B-O I-protein
of B-O O
nuclear B-O B-protein
factor B-O I-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

We B-O O
show B-O O
here B-O O
that B-O O
c-Rel B-O B-protein
binds B-O O
to B-O O
kappa B-O B-DNA
B B-O I-DNA
sites B-O I-DNA
as B-O O
homodimers B-O B-protein
as B-O O
well B-O O
as B-O O
heterodimers B-O B-protein
with B-O O
p50 B-O B-protein
. B-O O

These B-O O
homodimers B-O B-protein
and B-O O
heterodimers B-O B-protein
show B-O O
distinct B-O O
DNA-binding B-O O
specificities B-O O
and B-O O
affinities B-O O
for B-O O
various B-O O
kappa B-O B-DNA
B B-O I-DNA
motifs B-O I-DNA
. B-O O

In B-O O
particular B-O O
, B-O O
the B-O O
c-Rel B-O B-protein
homodimer B-O I-protein
has B-O O
a B-O O
high B-O O
affinity B-O O
for B-O O
interleukin-6 B-O B-protein
( B-O O
IL-6 B-O B-protein
) B-O O
and B-O O
beta B-O B-DNA
interferon B-O I-DNA
kappa B-O I-DNA
B B-O I-DNA
sites B-O I-DNA
. B-O O

In B-O O
spite B-O O
of B-O O
its B-O O
association B-O O
with B-O O
p50 B-O B-protein
in B-O O
vitro B-O O
, B-O O
however B-O O
, B-O O
we B-O O
found B-O O
a B-O O
lymphoid B-O B-protein
cell-specific B-O I-protein
nuclear B-O I-protein
factor B-O I-protein
in B-O O
vivo B-O O
that B-O O
contains B-O O
c-Rel B-O B-protein
but B-O O
not B-O O
p50 B-O B-protein
epitopes B-O I-protein
; B-O O
this B-O O
factor B-O O
, B-O O
termed B-O O
IL-6 B-O B-protein
kappa B-O I-protein
B B-O I-protein
binding B-O I-protein
factor B-O I-protein
II B-O I-protein
, B-O O
appears B-O O
to B-O O
contain B-O O
the B-O O
c-Rel B-O B-protein
homodimer B-O I-protein
and B-O O
preferentially B-O O
recognizes B-O O
several B-O O
IL-6 B-O B-DNA
kappa B-O I-DNA
B-related B-O I-DNA
kappa B-O I-DNA
B B-O I-DNA
motifs B-O I-DNA
. B-O O

Although B-O O
it B-O O
has B-O O
been B-O O
previously B-O O
shown B-O O
that B-O O
the B-O O
IL-6 B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
motif B-O I-DNA
functions B-O O
as B-O O
a B-O O
potent B-O O
IL-1/tumor B-O B-DNA
necrosis B-O I-DNA
factor-responsive B-O I-DNA
element B-O I-DNA
in B-O O
nonlymphoid B-O B-cell_type
cells B-O I-cell_type
, B-O O
its B-O O
activity B-O O
was B-O O
found B-O O
to B-O O
be B-O O
repressed B-O O
in B-O O
lymphoid B-O B-cell_type
cells B-O I-cell_type
such B-O O
as B-O O
a B-O O
Jurkat B-O B-cell_line
T-cell B-O I-cell_line
line B-O I-cell_line
. B-O O

We B-O O
also B-O O
present B-O O
evidence B-O O
that B-O O
IL-6 B-O B-protein
kappa B-O I-protein
B B-O I-protein
binding B-O I-protein
factor B-O I-protein
II B-O I-protein
functions B-O O
as B-O O
a B-O O
repressor B-O O
specific B-O O
for B-O O
IL-6 B-O B-DNA
kappa B-O I-DNA
B-related B-O I-DNA
kappa B-O I-DNA
B B-O I-DNA
motifs B-O I-DNA
in B-O O
lymphoid B-O B-cell_type
cells B-O I-cell_type
. B-O O

Cortisol B-O O
resistance B-O O
in B-O O
acquired B-O O
immunodeficiency B-O O
syndrome B-O O
. B-O O

This B-O O
study B-O O
concerns B-O O
9 B-O O
iv B-O O
drug B-O O
abusers B-O O
with B-O O
acquired B-O O
immunodeficiency B-O O
syndrome B-O O
( B-O O
AIDS B-O O
) B-O O
who B-O O
developed B-O O
hypercortisolism B-O O
without B-O O
the B-O O
clinical B-O O
signs B-O O
or B-O O
metabolic B-O O
consequences B-O O
of B-O O
hypercortisolism B-O O
. B-O O

All B-O O
patients B-O O
were B-O O
characterized B-O O
by B-O O
an B-O O
Addisonian B-O O
picture B-O O
( B-O O
weakness B-O O
, B-O O
weight B-O O
loss B-O O
, B-O O
hypotension B-O O
, B-O O
hyponatremia B-O O
, B-O O
and B-O O
intense B-O O
mucocutaneous B-O O
melanosis B-O O
) B-O O
. B-O O

An B-O O
acquired B-O O
form B-O O
of B-O O
peripheral B-O O
resistance B-O O
to B-O O
glucocorticoids B-O O
was B-O O
suspected B-O O
. B-O O

We B-O O
, B-O O
therefore B-O O
, B-O O
examined B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
characteristics B-O O
on B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
by B-O O
measuring B-O O
[ B-O O
3H B-O O
] B-O O
dexamethasone B-O O
binding B-O O
and B-O O
the B-O O
effect B-O O
of B-O O
dexamethasone B-O O
on B-O O
[ B-O O
3H B-O O
] B-O O
thymidine B-O O
incorporation B-O O
, B-O O
which B-O O
is B-O O
one B-O O
of B-O O
the B-O O
effects B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
activation B-O O
. B-O O

Glucocorticoid B-O B-protein
receptor B-O I-protein
density B-O O
was B-O O
increased B-O O
in B-O O
AIDS B-O O
patients B-O O
with B-O O
an B-O O
Addisonian B-O O
picture B-O O
( B-O O
group B-O O
1 B-O O
; B-O O
16.2 B-O O
+/- B-O O
9.4 B-O O
fmol/million B-O O
cells B-O O
) B-O O
compared B-O O
to B-O O
values B-O O
in B-O O
12 B-O O
AIDS B-O O
patients B-O O
without B-O O
an B-O O
Addisonian B-O O
picture B-O O
( B-O O
group B-O O
2 B-O O
; B-O O
6.05 B-O O
+/- B-O O
2.6 B-O O
fmol/million B-O O
cells B-O O
; B-O O
P B-O O
less B-O O
than B-O O
0.01 B-O O
) B-O O
and B-O O
sex- B-O O
and B-O O
age-matched B-O O
controls B-O O
( B-O O
3.15 B-O O
+/- B-O O
2.3 B-O O
fmol/million B-O O
cells B-O O
; B-O O
P B-O O
less B-O O
than B-O O
0.01 B-O O
) B-O O
. B-O O

The B-O O
affinity B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
( B-O O
Kd B-O O
) B-O O
was B-O O
strikingly B-O O
decreased B-O O
( B-O O
9.36 B-O O
+/- B-O O
3.44 B-O O
nM B-O O
in B-O O
group B-O O
1 B-O O
; B-O O
3.2 B-O O
+/- B-O O
1.5 B-O O
nM B-O O
in B-O O
group B-O O
2 B-O O
; B-O O
2.0 B-O O
+/- B-O O
0.8 B-O O
nM B-O O
in B-O O
controls B-O O
; B-O O
P B-O O
less B-O O
than B-O O
0.01 B-O O
) B-O O
. B-O O

[ B-O O
3H B-O O
] B-O O
Thymidine B-O O
incorporation B-O O
was B-O O
decreased B-O O
dose-dependently B-O O
by B-O O
dexamethasone B-O O
in B-O O
controls B-O O
and B-O O
patients B-O O
; B-O O
the B-O O
effect B-O O
was B-O O
significantly B-O O
blunted B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.05 B-O O
) B-O O
in B-O O
group B-O O
1 B-O O
patients B-O O
, B-O O
which B-O O
suggests B-O O
that B-O O
activation B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
is B-O O
impaired B-O O
as B-O O
a B-O O
result B-O O
of B-O O
the B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
abnormality B-O O
. B-O O

In B-O O
conclusion B-O O
, B-O O
AIDS B-O O
patients B-O O
with B-O O
hypercortisolism B-O O
and B-O O
clinical B-O O
features B-O O
of B-O O
peripheral B-O O
resistance B-O O
to B-O O
glucocorticoids B-O O
are B-O O
characterized B-O O
by B-O O
abnormal B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
on B-O O
lymphocytes B-O B-cell_type
. B-O O

Resistance B-O O
to B-O O
glucocorticoids B-O O
implies B-O O
a B-O O
complex B-O O
change B-O O
in B-O O
immune-endocrine B-O O
function B-O O
, B-O O
which B-O O
may B-O O
be B-O O
important B-O O
in B-O O
the B-O O
course B-O O
of B-O O
immunodeficiency B-O O
syndrome B-O O
. B-O O

A B-O O
novel B-O O
primer B-O O
extension B-O O
method B-O O
to B-O O
detect B-O O
the B-O O
number B-O O
of B-O O
CAG B-O B-DNA
repeats B-O I-DNA
in B-O O
the B-O O
androgen B-O B-DNA
receptor B-O I-DNA
gene B-O I-DNA
in B-O O
families B-O O
with B-O O
X-linked B-O O
spinal B-O O
and B-O O
bulbar B-O O
muscular B-O O
atrophy B-O O
. B-O O

X-linked B-O O
spinal B-O O
and B-O O
bulbar B-O O
muscular B-O O
atrophy B-O O
( B-O O
SBMA B-O O
) B-O O
, B-O O
an B-O O
adult-onset B-O O
form B-O O
of B-O O
motor B-O O
neuron B-O O
disease B-O O
, B-O O
was B-O O
recently B-O O
reported B-O O
to B-O O
be B-O O
caused B-O O
by B-O O
amplification B-O O
of B-O O
the B-O O
CAG B-O B-DNA
repeats B-O I-DNA
in B-O O
the B-O O
androgen B-O B-DNA
receptor B-O I-DNA
gene B-O I-DNA
. B-O O

We B-O O
report B-O O
here B-O O
a B-O O
simple B-O O
and B-O O
rapid B-O O
strategy B-O O
to B-O O
detect B-O O
the B-O O
precise B-O O
number B-O O
of B-O O
the B-O O
CAGs B-O B-protein
. B-O O

After B-O O
the B-O O
DNA B-O B-DNA
fragment B-O I-DNA
containing B-O O
the B-O O
CAG B-O B-DNA
repeats B-O I-DNA
is B-O O
amplified B-O O
by B-O O
the B-O O
polymerase B-O O
chain B-O O
reaction B-O O
, B-O O
a B-O O
primer B-O O
extension B-O O
is B-O O
carried B-O O
out B-O O
; B-O O
the B-O O
extension B-O O
of B-O O
the B-O O
end-labelled B-O B-DNA
reverse B-O I-DNA
primer B-O I-DNA
adjacent B-O O
to B-O O
3 B-O B-DNA
' B-O I-DNA
end B-O I-DNA
of B-O O
CAG B-O B-DNA
repeats B-O I-DNA
stops B-O O
at B-O O
the B-O O
first B-O O
T B-O O
after B-O O
CAG B-O B-DNA
repeats B-O I-DNA
with B-O O
the B-O O
incorporation B-O O
of B-O O
dideoxy B-O O
ATP B-O O
in B-O O
the B-O O
reaction B-O O
mixture B-O O
. B-O O

The B-O O
resultant B-O O
primer B-O B-DNA
products B-O I-DNA
are B-O O
analysed B-O O
by B-O O
denaturing B-O O
polyacrylamide B-O O
gel B-O O
electrophoresis B-O O
and B-O O
autoradiography B-O O
. B-O O

This B-O O
method B-O O
could B-O O
be B-O O
quite B-O O
useful B-O O
to B-O O
detect B-O O
not B-O O
only B-O O
CAG B-O B-DNA
repeats B-O I-DNA
in B-O O
SBMA B-O O
but B-O O
also B-O O
other B-O O
polymorphic B-O B-DNA
dinucleotide B-O I-DNA
and B-O O
trinucleotide B-O B-DNA
repeats B-O I-DNA
. B-O O

Cellular B-O O
immune B-O O
and B-O O
cytokine B-O B-protein
pathways B-O O
resulting B-O O
in B-O O
tissue B-O B-protein
factor B-O I-protein
expression B-O O
and B-O O
relevance B-O O
to B-O O
septic B-O O
shock B-O O
. B-O O

Cells B-O O
of B-O O
monocyte B-O O
lineage B-O O
serve B-O O
as B-O O
effector B-O B-cell_type
cells B-O I-cell_type
in B-O O
the B-O O
cellular B-O O
immune B-O O
response B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
they B-O O
respond B-O O
to B-O O
LPS B-O O
and B-O O
cytokines B-O B-protein
with B-O O
activation B-O O
and B-O O
expression B-O O
of B-O O
inflammatory B-O B-protein
effector B-O I-protein
gene B-O I-protein
products B-O I-protein
similar B-O O
to B-O O
those B-O O
elicited B-O O
by B-O O
the B-O O
antigen B-O O
driven B-O O
response B-O O
. B-O O

The B-O O
response B-O O
to B-O O
antigen B-O O
proceeds B-O O
at B-O O
the B-O O
T B-O B-cell_type
helper B-O I-cell_type
cell B-O I-cell_type
level B-O O
through B-O O
two B-O O
independent B-O O
forms B-O O
of B-O O
cellular B-O O
collaboration B-O O
, B-O O
contact B-O O
and B-O O
lymphokine B-O B-protein
. B-O O

We B-O O
review B-O O
the B-O O
control B-O O
of B-O O
expression B-O O
of B-O O
the B-O O
Tissue B-O B-DNA
Factor B-O I-DNA
( B-O I-DNA
TF B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
and B-O O
the B-O O
function B-O O
of B-O O
the B-O O
TF B-O B-protein
protein B-O I-protein
. B-O O

The B-O O
enhanced B-O O
initiation B-O O
of B-O O
transcription B-O O
of B-O O
the B-O O
TF B-O B-DNA
gene B-O I-DNA
appears B-O O
to B-O O
require B-O O
engagement B-O O
of B-O O
a B-O O
56 B-O B-DNA
bp B-O I-DNA
LPS B-O I-DNA
Response B-O I-DNA
Element B-O I-DNA
, B-O O
an B-O O
enhancer B-O B-DNA
that B-O O
is B-O O
engaged B-O O
by B-O O
both B-O O
AP-1 B-O B-protein
type B-O I-protein
heterodimeric B-O I-protein
complexes B-O I-protein
as B-O O
well B-O O
as B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
like B-O O
heterodimeric B-O B-protein
complexes B-O I-protein
. B-O O

Dissociation B-O O
of B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
from B-O O
Ig B-O B-protein
kappa B-O I-protein
B B-O I-protein
by B-O O
cytokine B-O B-protein
and B-O O
LPS B-O O
stimulation B-O O
, B-O O
and B-O O
possibly B-O O
activated B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
, B-O O
may B-O O
represent B-O O
a B-O O
common B-O O
pathway B-O O
to B-O O
induction B-O O
of B-O O
the B-O O
TF B-O B-DNA
and B-O I-DNA
other B-O I-DNA
inflammatory B-O I-DNA
genes B-O I-DNA
. B-O O

Enhancement B-O O
of B-O O
expression B-O O
of B-O O
TF B-O B-protein
is B-O O
observed B-O O
upon B-O O
adhesion B-O O
of B-O O
Mo B-O B-protein
to B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
and B-O O
extracellular B-O B-protein
matrix B-O I-protein
proteins B-O I-protein
, B-O O
as B-O O
well B-O O
as B-O O
upon B-O O
engagement B-O O
of B-O O
leukocyte B-O B-protein
integrins B-O I-protein
. B-O O

The B-O O
biological B-O O
effects B-O O
that B-O O
follow B-O O
from B-O O
expression B-O O
of B-O O
TF B-O B-protein
by B-O O
vascular B-O B-cell_type
cells B-O I-cell_type
have B-O O
been B-O O
resolved B-O O
by B-O O
analysis B-O O
of B-O O
function B-O O
aided B-O O
by B-O O
the B-O O
use B-O O
of B-O O
recombinant B-O B-protein
full B-O I-protein
length B-O I-protein
TF B-O I-protein
and B-O O
truncated B-O B-protein
surface B-O I-protein
domain B-O I-protein
of B-O O
TF B-O B-protein
. B-O O

The B-O O
rules B-O O
of B-O O
assembly B-O O
of B-O O
the B-O O
cognate B-O B-protein
ligands B-O I-protein
of B-O O
TF B-O B-protein
, B-O O
namely B-O O
the B-O O
zymogen B-O B-protein
plasma B-O I-protein
factors B-O I-protein
VII B-O I-protein
and B-O O
the B-O O
serine B-O B-protein
protease B-O I-protein
factor B-O I-protein
VIIa B-O I-protein
, B-O O
with B-O O
the B-O O
soluble B-O B-protein
surface B-O I-protein
domain B-O I-protein
of B-O O
TF B-O B-protein
in B-O O
free B-O O
solution B-O O
, B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
phospholipid B-O O
surfaces B-O O
and B-O O
cell B-O O
surface B-O O
and B-O O
of B-O O
the B-O O
anchored B-O B-protein
TF B-O I-protein
molecule B-O I-protein
have B-O O
been B-O O
described B-O O
. B-O O

It B-O O
is B-O O
evident B-O O
that B-O O
assembly B-O O
of B-O O
the B-O O
surface B-O B-protein
domain B-O I-protein
of B-O O
TF B-O B-protein
with B-O O
VIIa B-O B-protein
to B-O O
form B-O O
the B-O O
binary B-O O
TF.VIIa B-O B-protein
complex B-O I-protein
induces B-O O
a B-O O
significant B-O O
increase B-O O
in B-O O
the B-O O
Kcat B-O O
of B-O O
the B-O O
catalytic B-O B-protein
domain B-O I-protein
of B-O O
VIIa B-O B-protein
for B-O O
small B-O O
peptidyl B-O O
substrates B-O O
and B-O O
more B-O O
profoundly B-O O
for B-O O
protein B-O B-protein
substrate B-O I-protein
. B-O O

This B-O O
provides B-O O
substantial B-O O
evidence B-O O
for B-O O
an B-O O
allosteric B-O O
effect B-O O
on B-O O
the B-O O
catalytic B-O O
cleft B-O O
of B-O O
VIIa B-O B-protein
that B-O O
is B-O O
imparted B-O O
by B-O O
binding B-O O
to B-O O
TF B-O B-protein
, B-O O
its B-O O
cognate B-O B-protein
catalytic B-O I-protein
cofactor B-O I-protein
. B-O O

It B-O O
is B-O O
also B-O O
evident B-O O
that B-O O
the B-O O
TF.VIIa B-O B-protein
complex B-O I-protein
is B-O O
proteolytically B-O O
active B-O O
and B-O O
can B-O O
activate B-O O
the B-O O
zymogen B-O B-protein
plasma B-O I-protein
factor B-O I-protein
X B-O I-protein
to B-O O
the B-O O
serine B-O B-protein
protease B-O I-protein
Xa B-O I-protein
in B-O O
free B-O O
solution B-O O
, B-O O
inferring B-O O
that B-O O
extended B-O O
substrate B-O O
recognition B-O O
by B-O O
induced B-O O
structural B-O O
loci B-O O
of B-O O
the B-O O
TF.VIIa B-O B-protein
complex B-O I-protein
are B-O O
created B-O O
from B-O O
either B-O O
or B-O O
both B-O O
proteins B-O O
to B-O O
constitute B-O O
a B-O O
new B-O B-protein
recognition B-O I-protein
structure B-O I-protein
. B-O O

It B-O O
is B-O O
also B-O O
evident B-O O
that B-O O
association B-O O
of B-O O
X B-O B-protein
with B-O O
charged B-O O
phospholipid B-O O
surfaces B-O O
enhances B-O O
the B-O O
proteolytic B-O O
activation B-O O
of B-O O
this B-O O
zymogen B-O B-protein
by B-O O
increasing B-O O
recognition B-O O
and B-O O
susceptibility B-O O
of B-O O
the B-O O
sessile B-O O
peptide B-O O
bond B-O O
deduced B-O O
from B-O O
the B-O O
markedly B-O O
decreased B-O O
Km B-O O
and B-O O
increased B-O O
Kcat B-O O
. B-O O

Phorbol B-O O
ester B-O O
reduces B-O O
constitutive B-O B-protein
nuclear B-O I-protein
NF B-O I-protein
kappa B-O I-protein
B B-O I-protein
and B-O O
inhibits B-O O
HIV-1 B-O O
production B-O O
in B-O O
mature B-O B-cell_type
human B-O I-cell_type
monocytic B-O I-cell_type
cells B-O I-cell_type
. B-O O

NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
is B-O O
a B-O O
potent B-O O
mediator B-O O
of B-O O
specific B-O O
gene B-O O
expression B-O O
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
and B-O O
has B-O O
been B-O O
shown B-O O
to B-O O
play B-O O
a B-O O
role B-O O
in B-O O
transcription B-O O
of B-O O
the B-O O
HIV-1 B-O B-DNA
genome B-O I-DNA
in B-O O
promonocytic B-O O
leukemias B-O O
. B-O O

There B-O O
is B-O O
little B-O O
information B-O O
available B-O O
on B-O O
the B-O O
response B-O O
of B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
to B-O O
cytokines B-O B-protein
in B-O O
normal B-O B-cell_type
human B-O I-cell_type
monocytes B-O I-cell_type
. B-O O

We B-O O
have B-O O
used B-O O
a B-O O
32P-labeled B-O B-DNA
oligonucleotide B-O I-DNA
derived B-O O
from B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
( B-O I-DNA
HIV-1 B-O I-DNA
) B-O I-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
, B-O O
which B-O O
contains B-O O
a B-O O
tandem B-O B-DNA
repeat B-O I-DNA
of B-O O
the B-O O
NF B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
binding B-O I-DNA
sequence B-O I-DNA
, B-O O
as B-O O
a B-O O
probe B-O O
in B-O O
a B-O O
gel B-O O
retardation B-O O
assay B-O O
to B-O O
study B-O O
this B-O O
transcription B-O B-protein
factor B-O I-protein
. B-O O

Using B-O O
this B-O O
assay B-O O
, B-O O
we B-O O
have B-O O
detected B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
in B-O O
extracts B-O O
of B-O O
nuclei B-O O
from B-O O
normal B-O B-cell_type
human B-O I-cell_type
monocytes B-O I-cell_type
. B-O O

Treatment B-O O
of B-O O
normal B-O B-cell_type
monocytes B-O I-cell_type
with B-O O
12-0- B-O O
tetradecanoyl B-O O
phorbol-13-acetate B-O O
( B-O O
TPA B-O O
) B-O O
for B-O O
4-24 B-O O
h B-O O
caused B-O O
the B-O O
complete B-O O
disappearance B-O O
of B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
from B-O O
nuclear B-O O
extracts B-O O
of B-O O
monocytes B-O B-cell_type
. B-O O

A B-O O
similar B-O O
result B-O O
was B-O O
obtained B-O O
with B-O O
the B-O O
mature B-O B-cell_line
monocytic B-O I-cell_line
leukemia B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
THP-1 B-O B-cell_line
. B-O O

The B-O O
constitutive B-O B-protein
transcription B-O I-protein
factor B-O I-protein
SP1 B-O B-protein
was B-O O
unaffected B-O O
by B-O O
addition B-O O
of B-O O
TPA B-O O
. B-O O

The B-O O
disappearance B-O O
of B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
from B-O O
the B-O O
nucleus B-O O
was B-O O
concentration B-O O
dependent B-O O
between B-O O
10 B-O O
and B-O O
50 B-O O
ng/ml B-O O
of B-O O
phorbol B-O O
ester B-O O
. B-O O

In B-O O
THP-1 B-O B-cell_line
cells B-O I-cell_line
, B-O O
TPA B-O O
also B-O O
induced B-O O
a B-O O
new B-O O
, B-O O
faster-migrating B-O B-protein
NF B-O I-protein
kappa B-O I-protein
B B-O I-protein
species B-O I-protein
not B-O O
induced B-O O
in B-O O
monocytes B-O B-cell_type
. B-O O

Protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
inhibitor B-O O
staurosporine B-O O
, B-O O
but B-O O
not B-O O
cyclic B-O O
nucleotide-dependent B-O O
protein B-O O
kinase B-O O
inhibitor B-O O
HA-1004 B-O O
, B-O O
also B-O O
dramatically B-O O
reduced B-O O
constitutive B-O O
levels B-O O
of B-O O
nuclear B-O B-protein
NF B-O I-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

Finally B-O O
, B-O O
TPA B-O O
addition B-O O
to B-O O
monocytes B-O B-cell_type
infected B-O O
with B-O O
HIV-1 B-O O
inhibited B-O O
HIV-1 B-O O
replication B-O O
, B-O O
as B-O O
determined B-O O
by B-O O
reverse B-O B-protein
transcriptase B-O I-protein
assays B-O O
, B-O O
in B-O O
a B-O O
concentration-dependent B-O O
manner B-O O
. B-O O

These B-O O
results B-O O
are B-O O
in B-O O
striking B-O O
contrast B-O O
to B-O O
the B-O O
increase B-O O
in B-O O
nuclear B-O B-protein
NF B-O I-protein
kappa B-O I-protein
B B-O I-protein
and B-O O
HIV-1 B-O O
replication B-O O
induced B-O O
by B-O O
phorbol B-O O
esters B-O O
in B-O O
promonocytic B-O B-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
U937 B-O I-cell_line
and B-O O
HL-60 B-O B-cell_line
, B-O O
and B-O O
emphasize B-O O
the B-O O
importance B-O O
of B-O O
studying B-O O
cytokine B-O B-protein
regulation B-O O
of B-O O
HIV-1 B-O O
in B-O O
normal B-O B-cell_type
monocytes B-O I-cell_type
. B-O O

A B-O O
mechanism B-O O
for B-O O
the B-O O
antiinflammatory B-O O
effects B-O O
of B-O O
corticosteroids B-O O
: B-O O
the B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
regulates B-O O
leukocyte B-O O
adhesion B-O O
to B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
and B-O O
expression B-O O
of B-O O
endothelial-leukocyte B-O B-protein
adhesion B-O I-protein
molecule B-O I-protein
1 B-O I-protein
and B-O O
intercellular B-O B-protein
adhesion B-O I-protein
molecule B-O I-protein
1 B-O I-protein
. B-O O

Corticosteroids B-O O
are B-O O
the B-O O
preeminent B-O O
antiinflammatory B-O O
agents B-O O
although B-O O
the B-O O
molecular B-O O
mechanisms B-O O
that B-O O
impart B-O O
their B-O O
efficacy B-O O
have B-O O
not B-O O
been B-O O
defined B-O O
. B-O O

The B-O O
endothelium B-O O
plays B-O O
a B-O O
critical B-O O
role B-O O
in B-O O
inflammation B-O O
by B-O O
directing B-O O
circulating B-O B-cell_type
leukocytes B-O I-cell_type
into B-O O
extravascular B-O O
tissues B-O O
by B-O O
expressing B-O O
adhesive B-O B-protein
molecules B-O I-protein
for B-O O
leukocytes B-O B-cell_type
[ B-O O
e.g. B-O O
, B-O O
endothelial-leukocyte B-O B-protein
adhesion B-O I-protein
molecule B-O I-protein
1 B-O I-protein
( B-O O
ELAM-1 B-O B-protein
) B-O O
and B-O O
intercellular B-O B-protein
adhesion B-O I-protein
molecule B-O I-protein
1 B-O I-protein
( B-O O
ICAM-1 B-O B-protein
) B-O O
] B-O O
. B-O O

We B-O O
therefore B-O O
determined B-O O
whether B-O O
corticosteroids B-O O
suppress B-O O
inflammation B-O O
by B-O O
inhibiting B-O O
endothelial B-O O
expression B-O O
of B-O O
adhesion B-O B-protein
molecules B-O I-protein
for B-O O
neutrophils B-O B-cell_type
( B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
) B-O O
. B-O O

Preincubation B-O O
of B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
with B-O O
endotoxin B-O B-protein
[ B-O O
lipopolysaccharide B-O O
( B-O O
LPS B-O O
) B-O O
, B-O O
1 B-O O
microgram/ml B-O O
] B-O O
led B-O O
to B-O O
a B-O O
4-fold B-O O
increase B-O O
in B-O O
subsequent B-O O
adherence B-O O
of B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
( B-O O
P B-O O
& B-O O
lt B-O O
; B-O O
0.0001 B-O O
, B-O O
n B-O O
= B-O O
10 B-O O
) B-O O
to B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
, B-O O
an B-O O
increase B-O O
that B-O O
was B-O O
markedly B-O O
attenuated B-O O
when B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
were B-O O
treated B-O O
with B-O O
dexamethasone B-O O
( B-O O
IC50 B-O O
& B-O O
lt B-O O
; B-O O
1 B-O O
nM B-O O
, B-O O
P B-O B-protein
& B-O I-protein
lt B-O I-protein
; B-O O
0.0001 B-O O
, B-O O
n B-O O
= B-O O
6 B-O O
or B-O O
7 B-O O
) B-O O
during B-O O
preincubation B-O O
with B-O O
LPS B-O O
. B-O O

Moreover B-O O
, B-O O
the B-O O
steroid B-O B-protein
receptor B-O I-protein
agonist B-O O
cortisol B-O O
( B-O O
10 B-O O
microM B-O O
) B-O O
, B-O O
but B-O O
not B-O O
its B-O O
inactive B-O O
metabolite B-O O
tetrahydrocortisol B-O O
( B-O O
10 B-O O
microM B-O O
) B-O O
, B-O O
diminished B-O O
LPS B-O O
-induced B-O O
endothelial B-O O
cell B-O O
adhesiveness B-O O
. B-O O

Further B-O O
evidence B-O O
that B-O O
the B-O O
action B-O O
of B-O O
dexamethasone B-O O
was B-O O
mediated B-O O
through B-O O
ligation B-O O
of B-O O
corticosteroid B-O B-protein
receptors B-O I-protein
[ B-O O
human B-O B-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
( B-O O
hGRs B-O B-protein
) B-O O
] B-O O
was B-O O
provided B-O O
by B-O O
experiments B-O O
utilizing B-O O
the B-O O
steroid B-O O
antagonist B-O O
RU-486 B-O O
. B-O O

RU-486 B-O O
( B-O O
10 B-O O
microM B-O O
) B-O O
, B-O O
which B-O O
prevents B-O O
translocation B-O O
of B-O O
ligated B-O O
hGR B-O B-protein
to B-O O
the B-O O
nucleus B-O O
by B-O O
inhibiting B-O O
dissociation B-O O
of B-O O
hGR B-O B-protein
from B-O O
heat B-O B-protein
shock B-O I-protein
protein B-O I-protein
90 B-O I-protein
, B-O O
completely B-O O
aborted B-O O
the B-O O
effect B-O O
of B-O O
dexamethasone B-O O
on B-O O
adhesiveness B-O O
of B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
( B-O O
P B-O O
& B-O O
lt B-O O
; B-O O
0.0005 B-O O
, B-O O
n B-O O
= B-O O
3 B-O O
) B-O O
. B-O O

Treatment B-O O
of B-O O
endothelial B-O B-cell_type
cells B-O I-cell_type
with B-O O
LPS B-O O
( B-O O
1 B-O O
microgram/ml B-O O
) B-O O
stimulated B-O O
transcription B-O O
of B-O O
ELAM-1 B-O B-protein
, B-O O
as B-O O
shown B-O O
by B-O O
Northern B-O O
blot B-O O
analysis B-O O
, B-O O
and B-O O
expression B-O O
of B-O O
membrane-associated B-O B-protein
ELAM-1 B-O I-protein
and B-O O
ICAM-1 B-O B-protein
, B-O O
as B-O O
shown B-O O
by B-O O
quantitative B-O O
immunofluorescence B-O O
( B-O O
both B-O O
P B-O B-protein
& B-O I-protein
lt B-O I-protein
; B-O O
0.001 B-O O
, B-O O
n B-O O
= B-O O
9 B-O O
) B-O O
. B-O O

Dexamethasone B-O O
markedly B-O O
inhibited B-O O
LPS B-O O
-stimulated B-O O
accumulation B-O O
of B-O O
mRNA B-O B-RNA
for B-O O
ELAM-1 B-O B-protein
and B-O O
expression B-O O
of B-O O
ELAM-1 B-O B-protein
and B-O O
ICAM-1 B-O B-protein
( B-O O
IC50 B-O O
& B-O O
lt B-O O
; B-O O
10 B-O O
nM B-O O
, B-O O
both B-O O
P B-O O
& B-O O
lt B-O O
; B-O O
0.001 B-O O
, B-O O
n B-O O
= B-O O
4-9 B-O O
) B-O O
; B-O O
inhibition B-O O
of B-O O
expression B-O O
by B-O O
dexamethasone B-O O
was B-O O
reversed B-O O
by B-O O
RU-486 B-O O
( B-O O
both B-O O
P B-O B-protein
& B-O I-protein
lt B-O I-protein
; B-O O
0.005 B-O O
, B-O O
n B-O O
= B-O O
4-6 B-O O
) B-O O
. B-O O

As B-O O
in B-O O
the B-O O
adhesion B-O O
studies B-O O
, B-O O
cortisol B-O O
but B-O O
not B-O O
tetrahydrocortisol B-O O
inhibited B-O O
expression B-O O
of B-O O
ELAM-1 B-O B-protein
and B-O O
ICAM-1 B-O B-protein
( B-O O
both B-O O
P B-O B-protein
& B-O I-protein
lt B-O I-protein
; B-O O
0.005 B-O O
, B-O O
n B-O O
= B-O O
3 B-O O
or B-O O
4 B-O O
) B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
sodium B-O O
salicylate B-O O
( B-O O
1 B-O O
mM B-O O
) B-O O
inhibited B-O O
neither B-O O
adhesion B-O O
nor B-O O
expression B-O O
of B-O O
these B-O O
adhesion B-O B-protein
molecules B-O I-protein
. B-O O

These B-O O
studies B-O O
suggest B-O O
that B-O O
antagonism B-O O
by B-O O
dexamethasone B-O O
of B-O O
endotoxin B-O B-protein
-induced B-O O
inflammation B-O O
is B-O O
a B-O O
specific B-O O
instance B-O O
of B-O O
the B-O O
general B-O O
biological B-O O
principle B-O O
that B-O O
the B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
is B-O O
a B-O O
hormone-dependent B-O O
regulator B-O O
of B-O O
transcription B-O O
. B-O O

Pax-5 B-O B-DNA
encodes B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
BSAP B-O B-protein
and B-O O
is B-O O
expressed B-O O
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
, B-O O
the B-O O
developing B-O O
CNS B-O B-protein
, B-O O
and B-O O
adult B-O O
testis B-O O
. B-O O

BSAP B-O B-protein
has B-O O
been B-O O
identified B-O O
previously B-O O
as B-O O
a B-O O
transcription B-O B-protein
factor B-O I-protein
that B-O O
is B-O O
expressed B-O O
at B-O O
early B-O O
, B-O O
but B-O O
not B-O O
late B-O O
, B-O O
stages B-O O
of B-O O
B-cell B-O O
differentiation B-O O
. B-O O

Biochemical B-O O
purification B-O O
and B-O O
cDNA B-O O
cloning B-O O
has B-O O
now B-O O
revealed B-O O
that B-O O
BSAP B-O B-protein
belongs B-O O
to B-O O
the B-O O
family B-O O
of B-O O
paired B-O B-protein
domain B-O I-protein
proteins B-O I-protein
. B-O O

BSAP B-O B-protein
is B-O O
encoded B-O O
by B-O O
the B-O O
Pax-5 B-O B-DNA
gene B-O I-DNA
and B-O O
has B-O O
been B-O O
highly B-O O
conserved B-O O
between B-O O
human B-O O
and B-O O
mouse B-O O
. B-O O

An B-O O
intact B-O O
paired B-O O
domain B-O O
was B-O O
shown B-O O
to B-O O
be B-O O
both B-O O
necessary B-O O
and B-O O
sufficient B-O O
for B-O O
DNA B-O O
binding B-O O
of B-O O
BSAP B-O B-protein
. B-O O

Binding B-O O
studies B-O O
with B-O O
several B-O O
BSAP B-O B-DNA
recognition B-O I-DNA
sequences B-O I-DNA
demonstrated B-O O
that B-O O
the B-O O
sequence B-O O
specificity B-O O
of B-O O
BSAP B-O B-protein
differs B-O O
from B-O O
that B-O O
of B-O O
the B-O O
distantly B-O O
related B-O O
paired B-O O
domain B-O O
protein B-O O
Pax-1 B-O B-protein
. B-O O

During B-O O
embryogenesis B-O O
, B-O O
the B-O O
BSAP B-O B-DNA
gene B-O I-DNA
is B-O O
transiently B-O O
expressed B-O O
in B-O O
the B-O O
mesencephalon B-O O
and B-O O
spinal B-O O
cord B-O O
with B-O O
a B-O O
spatial B-O O
and B-O O
temporal B-O O
expression B-O O
pattern B-O O
that B-O O
is B-O O
distinct B-O O
from B-O O
that B-O O
of B-O O
other B-O O
Pax B-O B-DNA
genes B-O I-DNA
in B-O O
the B-O O
developing B-O O
central B-O O
nervous B-O O
system B-O O
( B-O O
CNS B-O B-protein
) B-O O
. B-O O

Later B-O O
, B-O O
the B-O O
expression B-O O
of B-O O
the B-O O
BSAP B-O B-DNA
gene B-O I-DNA
shifts B-O O
to B-O O
the B-O O
fetal B-O O
liver B-O O
where B-O O
it B-O O
correlates B-O O
with B-O O
the B-O O
onset B-O O
of B-O O
B B-O O
lymphopoiesis B-O O
. B-O O

BSAP B-O B-protein
expression B-O O
persists B-O O
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
and B-O O
is B-O O
also B-O O
seen B-O O
in B-O O
the B-O O
testis B-O O
of B-O O
the B-O O
adult B-O O
mouse B-O O
. B-O O

All B-O O
of B-O O
this B-O O
evidence B-O O
indicates B-O O
that B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
BSAP B-O B-protein
may B-O O
not B-O O
only B-O O
play B-O O
an B-O O
important B-O O
role B-O O
in B-O O
B-cell B-O O
differentiation B-O O
but B-O O
also B-O O
in B-O O
neural B-O O
development B-O O
and B-O O
spermatogenesis B-O O
. B-O O

Cell B-O O
cycle-dependent B-O O
initiation B-O O
and B-O O
lineage-dependent B-O O
abrogation B-O O
of B-O O
GATA-1 B-O B-protein
expression B-O O
in B-O O
pure B-O B-cell_type
differentiating B-O I-cell_type
hematopoietic B-O I-cell_type
progenitors B-O I-cell_type
. B-O O

The B-O O
programmed B-O O
activation/repression B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
in B-O O
early B-O O
hematopoietic B-O O
differentiation B-O O
has B-O O
not B-O O
yet B-O O
been B-O O
explored B-O O
. B-O O

The B-O O
DNA-binding B-O B-protein
protein B-O I-protein
GATA-1 B-O B-protein
is B-O O
required B-O O
for B-O O
normal B-O O
erythroid B-O O
development B-O O
and B-O O
regulates B-O O
erythroid-expressed B-O B-DNA
genes B-O I-DNA
in B-O O
maturing B-O B-cell_type
erythroblasts B-O I-cell_type
. B-O O

We B-O O
analyzed B-O O
GATA-1 B-O B-protein
expression B-O O
in B-O O
early B-O O
human B-O O
adult B-O O
hematopoiesis B-O O
by B-O O
using B-O O
an B-O O
in B-O O
vitro B-O O
system B-O O
in B-O O
which B-O O
`` B-O B-cell_type
pure B-O I-cell_type
`` B-O I-cell_type
early B-O I-cell_type
hematopoietic B-O I-cell_type
progenitors B-O I-cell_type
are B-O O
induced B-O O
to B-O O
gradual B-O O
and B-O O
synchronized B-O O
differentiation B-O O
selectively B-O O
along B-O O
the B-O O
erythroid B-O O
or B-O O
granulocyte-macrophage B-O O
pathway B-O O
by B-O O
differential B-O O
treatment B-O O
with B-O O
hematopoietic B-O B-protein
growth B-O I-protein
factors B-O I-protein
. B-O O

The B-O O
GATA-1 B-O B-DNA
gene B-O I-DNA
, B-O O
though B-O O
virtually B-O O
silent B-O O
in B-O O
quiescent B-O B-cell_type
progenitors B-O I-cell_type
, B-O O
is B-O O
activated B-O O
after B-O O
entrance B-O O
into B-O O
the B-O O
cell B-O O
cycle B-O O
upon B-O O
stimulation B-O O
with B-O O
hematopoietic B-O B-protein
growth B-O I-protein
factors B-O I-protein
. B-O O

Subsequently B-O O
, B-O O
increasing B-O O
expression B-O O
along B-O O
the B-O O
erythroid B-O O
pathway B-O O
contrasts B-O O
with B-O O
an B-O O
abrupt B-O O
downregulation B-O O
in B-O O
the B-O O
granulocyte-macrophage B-O B-cell_type
lineage B-O I-cell_type
. B-O O

These B-O O
results B-O O
suggest B-O O
a B-O O
microenvironment-directed B-O O
, B-O O
two-step B-O O
model B-O O
for B-O O
GATA-1 B-O B-protein
expression B-O O
in B-O O
differentiating B-O B-cell_type
hematopoietic B-O I-cell_type
progenitors B-O I-cell_type
that B-O O
involves B-O O
( B-O O
i B-O O
) B-O O
cycle-dependent B-O O
initiation B-O O
and B-O O
( B-O O
ii B-O O
) B-O O
lineage-dependent B-O O
maintenance B-O O
or B-O O
suppression B-O O
. B-O O

Hypothetically B-O O
, B-O O
on/off B-O O
switches B-O O
of B-O O
lineage-restricted B-O B-protein
transactivators B-O I-protein
may B-O O
underlie B-O O
the B-O O
binary B-O O
fate B-O O
decisions B-O O
of B-O O
hematopoietic B-O B-cell_type
progenitors B-O I-cell_type
. B-O O

Specific B-O O
NF-kappa B-O B-protein
B B-O I-protein
subunits B-O I-protein
act B-O O
in B-O O
concert B-O O
with B-O O
Tat B-O B-protein
to B-O O
stimulate B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
transcription B-O O
. B-O O

NF-kappa B-O B-protein
B B-O I-protein
is B-O O
a B-O O
protein B-O B-protein
complex B-O I-protein
which B-O O
functions B-O O
in B-O O
concert B-O O
with B-O O
the B-O O
tat-I B-O B-protein
gene B-O I-protein
product B-O I-protein
to B-O O
stimulate B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
( B-O O
HIV B-O O
) B-O O
transcription B-O O
. B-O O

To B-O O
determine B-O O
whether B-O O
specific B-O O
members B-O O
of B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
family B-O I-protein
contribute B-O O
to B-O O
this B-O O
effect B-O O
, B-O O
we B-O O
have B-O O
examined B-O O
the B-O O
abilities B-O O
of B-O O
different B-O O
NF-kappa B-O B-protein
B B-O I-protein
subunits B-O I-protein
to B-O O
act B-O O
with B-O O
Tat-I B-O B-protein
to B-O O
stimulate B-O O
transcription B-O O
of B-O O
HIV B-O O
in B-O O
Jurkat B-O B-cell_line
T-leukemia B-O I-cell_line
cells B-O I-cell_line
. B-O O

We B-O O
have B-O O
found B-O O
that B-O O
the B-O O
p49 B-O B-protein
( B-O I-protein
100 B-O I-protein
) B-O I-protein
DNA B-O I-protein
binding B-O I-protein
subunit B-O I-protein
, B-O O
together B-O O
with B-O O
p65 B-O B-protein
, B-O O
can B-O O
act B-O O
in B-O O
concert B-O O
with B-O O
Tat-I B-O B-protein
to B-O O
stimulate B-O O
the B-O O
expression B-O O
of B-O O
HIV B-O B-DNA
-CAT B-O I-DNA
plasmid B-O I-DNA
. B-O O

Little B-O O
effect B-O O
was B-O O
observed B-O O
with B-O O
50-kDa B-O B-protein
forms B-O I-protein
of B-O O
p105 B-O B-protein
NF-kappa B-O B-protein
B B-O I-protein
or B-O O
rel B-O B-protein
, B-O O
in B-O O
combination B-O O
with B-O O
p65 B-O B-protein
or B-O O
full-length B-O B-protein
c-rel B-O I-protein
, B-O O
which B-O O
do B-O O
not B-O O
stimulate B-O O
the B-O O
HIV B-O B-DNA
enhancer B-O I-DNA
in B-O O
these B-O O
cells B-O O
. B-O O

These B-O O
findings B-O O
suggest B-O O
that B-O O
the B-O O
combination B-O O
of B-O O
p49 B-O B-protein
( B-O I-protein
100 B-O I-protein
) B-O I-protein
and B-O O
p65 B-O B-protein
NF-kappa B-O B-protein
B B-O I-protein
can B-O O
act B-O O
in B-O O
concert B-O O
with B-O O
the B-O O
tat-I B-O B-protein
gene B-O I-protein
product B-O I-protein
to B-O O
stimulate B-O O
the B-O O
synthesis B-O O
of B-O O
HIV B-O B-RNA
RNA B-O I-RNA
. B-O O

Stable B-O O
expression B-O O
of B-O O
HB24 B-O B-DNA
, B-O O
a B-O O
diverged B-O B-DNA
human B-O I-DNA
homeobox B-O I-DNA
gene B-O I-DNA
, B-O O
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
induces B-O O
genes B-O O
involved B-O O
in B-O O
T B-O B-cell_type
cell B-O I-cell_type
activation B-O O
and B-O O
growth B-O O
. B-O O

A B-O O
diverged B-O B-DNA
homeobox B-O I-DNA
gene B-O I-DNA
, B-O O
HB24 B-O B-DNA
, B-O O
which B-O O
is B-O O
known B-O O
to B-O O
be B-O O
induced B-O O
following B-O O
lymphocyte B-O O
activation B-O O
, B-O O
was B-O O
introduced B-O O
into B-O O
Jurkat B-O B-cell_line
T B-O I-cell_line
cells B-O I-cell_line
under B-O O
the B-O O
control B-O O
of B-O O
a B-O O
constitutive B-O B-DNA
promoter B-O I-DNA
. B-O O

Stable B-O O
transfectants B-O O
of B-O O
HB24 B-O B-DNA
were B-O O
established B-O O
that B-O O
expressed B-O O
high B-O O
levels B-O O
of B-O O
HB24 B-O B-RNA
mRNA B-O I-RNA
and B-O O
possessed B-O O
an B-O O
altered B-O O
phenotype B-O O
suggestive B-O O
of B-O O
activated B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

A B-O O
number B-O O
of B-O O
genes B-O O
known B-O O
to B-O O
be B-O O
induced B-O O
following B-O O
T B-O O
cell B-O O
activation B-O O
and B-O O
associated B-O O
with B-O O
cell B-O O
growth B-O O
were B-O O
increased B-O O
in B-O O
the B-O O
transfectants B-O B-cell_line
, B-O O
including B-O O
c-fos B-O B-DNA
, B-O O
c-myc B-O B-DNA
, B-O O
c-myb B-O B-DNA
, B-O O
HLA-DR B-O B-protein
, B-O O
lck B-O B-protein
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
interleukin-2 B-O B-protein
and B-O O
interleukin-2 B-O B-protein
receptor B-O I-protein
alpha B-O I-protein
( B-O O
IL-2R B-O B-protein
alpha B-O I-protein
) B-O O
. B-O O

Analysis B-O O
of B-O O
IL-2R B-O B-protein
alpha B-O I-protein
expression B-O O
by B-O O
transient B-O O
transfection B-O O
of B-O O
IL-2R B-O B-DNA
alpha B-O I-DNA
promoter B-O I-DNA
constructs B-O I-DNA
into B-O O
the B-O O
HB24 B-O B-cell_line
transfectants B-O I-cell_line
revealed B-O O
constitutive B-O O
expression B-O O
( B-O O
about B-O O
60 B-O O
% B-O O
of B-O O
phytohemagglutinin- B-O B-cell_line
and B-O I-cell_line
phorbol B-O I-cell_line
ester- B-O I-cell_line
activated B-O I-cell_line
Jurkat B-O I-cell_line
cells B-O I-cell_line
) B-O O
that B-O O
was B-O O
dependent B-O O
on B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
site B-O I-DNA
in B-O O
the B-O O
IL-2R B-O B-DNA
alpha B-O I-DNA
promoter B-O I-DNA
. B-O O

Furthermore B-O O
, B-O O
as B-O O
a B-O O
consequence B-O O
of B-O O
the B-O O
increased B-O O
HB24 B-O B-RNA
mRNA B-O I-RNA
levels B-O O
, B-O O
the B-O O
Jurkat B-O B-cell_line
HB24 B-O I-cell_line
transfectants B-O I-cell_line
proliferated B-O O
more B-O O
rapidly B-O O
than B-O O
control B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

Thus B-O O
, B-O O
stable B-O O
expression B-O O
of B-O O
HB24 B-O B-DNA
confers B-O O
an B-O O
activation B-O O
phenotype B-O O
on B-O O
a B-O O
human B-O B-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
implicating B-O O
this B-O O
gene B-O O
as B-O O
an B-O O
important B-O O
transcriptional B-O B-protein
factor B-O I-protein
during B-O O
T B-O O
cell B-O O
activation B-O O
and B-O O
growth B-O O
. B-O O

Functional B-O O
interaction B-O O
between B-O O
the B-O O
two B-O O
zinc B-O B-protein
finger B-O I-protein
domains B-O I-protein
of B-O O
the B-O O
v-erb B-O B-protein
A B-O I-protein
oncoprotein B-O I-protein
. B-O O

The B-O O
v-erb B-O B-DNA
A B-O I-DNA
oncogene B-O I-DNA
of B-O O
avian B-O O
erythroblastosis B-O O
virus B-O O
is B-O O
a B-O O
mutated B-O O
and B-O O
virally B-O O
transduced B-O O
copy B-O O
of B-O O
a B-O O
host B-O B-DNA
cell B-O I-DNA
gene B-O I-DNA
encoding B-O O
a B-O O
thyroid B-O B-protein
hormone B-O I-protein
receptor B-O I-protein
. B-O O

The B-O O
protein B-O O
expressed B-O O
by B-O O
the B-O O
v-erb B-O B-DNA
A B-O I-DNA
oncogene B-O I-DNA
binds B-O O
to B-O O
DNA B-O O
and B-O O
acts B-O O
as B-O O
a B-O O
dominant B-O O
negative B-O O
inhibitor B-O O
of B-O O
both B-O O
the B-O O
thyroid B-O B-protein
hormone B-O I-protein
receptor B-O I-protein
and B-O O
the B-O O
closely B-O O
related B-O O
retinoic B-O B-protein
acid B-O I-protein
receptor B-O I-protein
. B-O O

The B-O O
v-erb B-O B-protein
A B-O I-protein
protein B-O I-protein
has B-O O
sustained B-O O
two B-O O
amino B-O O
acid B-O O
alterations B-O O
within B-O O
its B-O O
DNA-binding B-O B-protein
domain B-O I-protein
relative B-O O
to B-O O
that B-O O
of B-O O
c-erb B-O B-protein
A B-O I-protein
, B-O O
one B-O O
of B-O O
which B-O O
, B-O O
at B-O O
serine B-O O
61 B-O O
, B-O O
is B-O O
known B-O O
to B-O O
be B-O O
important B-O O
for B-O O
v-erb B-O B-protein
A B-O I-protein
function B-O O
in B-O O
the B-O O
neoplastic B-O B-cell_type
cell B-O I-cell_type
. B-O O

We B-O O
report B-O O
here B-O O
that B-O O
the B-O O
second B-O O
alteration B-O O
, B-O O
at B-O O
threonine B-O O
78 B-O O
, B-O O
also B-O O
plays B-O O
an B-O O
important B-O O
, B-O O
although B-O O
more B-O O
indirect B-O O
, B-O O
role B-O O
: B-O O
alteration B-O O
of B-O O
the B-O O
sequence B-O O
at B-O O
threonine B-O O
78 B-O O
such B-O O
that B-O O
it B-O O
resembles B-O O
that B-O O
of B-O O
c-erb B-O B-protein
A B-O I-protein
can B-O O
act B-O O
as B-O O
an B-O O
intragenic B-O O
suppressor B-O O
and B-O O
can B-O O
partially B-O O
restore B-O O
function B-O O
to B-O O
a B-O O
v-erb B-O B-protein
A B-O I-protein
protein B-O I-protein
rendered B-O O
defective B-O O
due B-O O
to B-O O
a B-O O
mutation B-O O
at B-O O
position B-O B-protein
61 B-O I-protein
. B-O O

Threonine B-O O
78 B-O O
lies B-O O
within B-O O
the B-O O
D-box B-O B-DNA
of B-O O
the B-O O
v-erb B-O B-protein
A B-O I-protein
protein B-O I-protein
, B-O O
a B-O O
region B-O O
thought B-O O
to B-O O
mediate B-O O
receptor-receptor B-O O
dimerizations B-O O
, B-O O
and B-O O
is B-O O
not B-O O
in B-O O
physical B-O O
proximity B-O O
to B-O O
the B-O O
serine B-O O
at B-O O
position B-O B-protein
61 B-O I-protein
. B-O O

It B-O O
therefore B-O O
appears B-O O
that B-O O
an B-O O
indirect B-O O
interaction B-O O
occurs B-O O
between B-O O
these B-O O
two B-O O
sites B-O O
and B-O O
that B-O O
this B-O O
interaction B-O O
is B-O O
crucial B-O O
for B-O O
v-erb B-O B-protein
A B-O I-protein
function B-O O
. B-O O

cis-acting B-O B-DNA
sequences B-O I-DNA
required B-O O
for B-O O
inducible B-O O
interleukin-2 B-O B-DNA
enhancer B-O I-DNA
function B-O O
bind B-O O
a B-O O
novel B-O O
Ets-related B-O B-protein
protein B-O I-protein
, B-O O
Elf-1 B-O B-protein
. B-O O

The B-O O
recent B-O O
definition B-O O
of B-O O
a B-O O
consensus B-O B-DNA
DNA B-O I-DNA
binding B-O I-DNA
sequence B-O I-DNA
for B-O O
the B-O O
Ets B-O B-protein
family B-O I-protein
of B-O O
transcription B-O B-protein
factors B-O I-protein
has B-O O
allowed B-O O
the B-O O
identification B-O O
of B-O O
potential B-O O
Ets B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
in B-O O
the B-O O
promoters B-O B-DNA
and B-O O
enhancers B-O B-DNA
of B-O O
many B-O O
inducible B-O B-DNA
T-cell B-O I-DNA
genes B-O I-DNA
. B-O O

In B-O O
the B-O O
studies B-O O
described B-O O
in B-O O
this B-O O
report B-O O
, B-O O
we B-O O
have B-O O
identified B-O O
two B-O O
potential B-O O
Ets B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
, B-O O
EBS1 B-O B-DNA
and B-O O
EBS2 B-O B-DNA
, B-O O
which B-O O
are B-O O
conserved B-O O
in B-O O
both B-O O
the B-O O
human B-O B-DNA
and B-O I-DNA
murine B-O I-DNA
interleukin-2 B-O I-DNA
enhancers B-O I-DNA
. B-O O

Within B-O O
the B-O O
human B-O B-DNA
enhancer B-O I-DNA
, B-O O
these B-O O
two B-O O
sites B-O O
are B-O O
located B-O O
within B-O O
the B-O O
previously B-O O
defined B-O O
DNase B-O B-protein
I B-O I-protein
footprints B-O O
, B-O O
NFAT-1 B-O B-protein
and B-O O
NFIL-2B B-O B-DNA
, B-O O
respectively B-O O
. B-O O

Electrophoretic B-O O
mobility B-O O
shift B-O O
and B-O O
methylation B-O O
interference B-O O
analyses B-O O
demonstrated B-O O
that B-O O
EBS1 B-O B-DNA
and B-O O
EBS2 B-O B-DNA
are B-O O
essential B-O O
for B-O O
the B-O O
formation B-O O
of B-O O
the B-O O
NFAT-1 B-O B-protein
and B-O I-protein
NFIL-2B B-O I-protein
nuclear B-O I-protein
protein B-O I-protein
complexes B-O I-protein
. B-O O

Furthermore B-O O
, B-O O
in B-O O
vitro B-O O
mutagenesis B-O O
experiments B-O O
demonstrated B-O O
that B-O O
inducible B-O O
interleukin-2 B-O B-DNA
enhancer B-O I-DNA
function B-O O
requires B-O O
the B-O O
presence B-O O
of B-O O
either B-O O
EBS1 B-O B-DNA
or B-O O
EBS2 B-O B-DNA
. B-O O

Two B-O O
well-characterized B-O O
Ets B-O B-protein
family B-O I-protein
members B-O I-protein
, B-O O
Ets-1 B-O B-protein
and B-O O
Ets-2 B-O B-protein
, B-O O
are B-O O
reciprocally B-O O
expressed B-O O
during B-O O
T-cell B-O O
activation B-O O
. B-O O

Surprisingly B-O O
, B-O O
however B-O O
, B-O O
neither B-O O
of B-O O
these B-O O
proteins B-O O
bound B-O O
in B-O O
vitro B-O O
to B-O O
EBS1 B-O B-DNA
or B-O O
EBS2 B-O B-DNA
. B-O O

We B-O O
therefore B-O O
screened B-O O
a B-O O
T-cell B-O B-DNA
cDNA B-O I-DNA
library B-O O
under B-O O
low-stringency B-O O
conditions B-O O
with B-O O
a B-O O
probe B-O O
from B-O O
the B-O O
DNA B-O B-protein
binding B-O I-protein
domain B-O I-protein
of B-O O
Ets-1 B-O B-protein
and B-O O
isolated B-O O
a B-O O
novel B-O B-protein
Ets B-O I-protein
family B-O I-protein
member B-O I-protein
, B-O O
Elf-1 B-O B-protein
. B-O O

Elf-1 B-O B-protein
contains B-O O
a B-O O
DNA B-O B-protein
binding B-O I-protein
domain B-O I-protein
that B-O O
is B-O O
nearly B-O O
identical B-O O
to B-O O
that B-O O
of B-O O
E74 B-O B-protein
, B-O O
the B-O O
ecdysone-inducible B-O B-protein
Drosophila B-O I-protein
transcription B-O I-protein
factor B-O I-protein
required B-O O
for B-O O
metamorphosis B-O O
( B-O O
hence B-O O
the B-O O
name B-O O
Elf-1 B-O B-protein
, B-O O
for B-O O
E74-like B-O B-protein
factor B-O I-protein
1 B-O I-protein
) B-O O
. B-O O

Elf-1 B-O B-protein
bound B-O O
specifically B-O O
to B-O O
both B-O O
EBS1 B-O B-DNA
and B-O O
EBS2 B-O B-DNA
in B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
. B-O O

It B-O O
also B-O O
bound B-O O
to B-O O
the B-O O
purine-rich B-O B-DNA
CD3R B-O I-DNA
element B-O I-DNA
from B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
type B-O I-DNA
2 B-O I-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
, B-O O
which B-O O
is B-O O
required B-O O
for B-O O
inducible B-O O
virus B-O O
expression B-O O
in B-O O
response B-O O
to B-O O
signalling B-O O
through B-O O
the B-O O
T-cell B-O B-protein
receptor B-O I-protein
. B-O O

Taken B-O O
together B-O O
, B-O O
these B-O O
results B-O O
demonstrate B-O O
that B-O O
multiple B-O B-protein
Ets B-O I-protein
family B-O I-protein
members B-O I-protein
with B-O O
apparently B-O O
distinct B-O O
DNA B-O O
binding B-O O
specificities B-O O
regulate B-O O
differential B-O O
gene B-O O
expression B-O O
in B-O O
resting B-O B-cell_type
and B-O I-cell_type
activated B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Binding B-O O
of B-O O
erythroid B-O B-protein
and B-O I-protein
non-erythroid B-O I-protein
nuclear B-O I-protein
proteins B-O I-protein
to B-O O
the B-O O
silencer B-O B-DNA
of B-O O
the B-O O
human B-O B-DNA
epsilon-globin-encoding B-O I-DNA
gene B-O I-DNA
. B-O O

To B-O O
clarify B-O O
the B-O O
molecular B-O O
mechanisms B-O O
involved B-O O
in B-O O
the B-O O
developmental B-O O
control B-O O
of B-O O
hemoglobin-encoding B-O B-DNA
genes B-O I-DNA
we B-O O
have B-O O
been B-O O
studying B-O O
the B-O O
expression B-O O
of B-O O
these B-O O
genes B-O O
in B-O O
human B-O B-cell_type
cells B-O I-cell_type
in B-O O
continuous B-O B-cell_line
culture B-O I-cell_line
. B-O O

We B-O O
have B-O O
previously B-O O
reported B-O O
the B-O O
presence B-O O
of B-O O
a B-O O
transcriptional B-O B-DNA
control B-O I-DNA
element B-O I-DNA
with B-O O
the B-O O
properties B-O O
of B-O O
a B-O O
silencer B-O B-DNA
extending B-O O
from B-O O
-392 B-O B-DNA
to B-O I-DNA
-177 B-O I-DNA
bp B-O I-DNA
relative B-O O
to B-O O
the B-O O
cap B-O B-DNA
site B-O I-DNA
of B-O O
the B-O O
human B-O B-DNA
epsilon-globin-encoding B-O I-DNA
gene B-O I-DNA
[ B-O O
Cao B-O O
et B-O O
al. B-O O
, B-O O
Proc.Natl.Acad.Sci.USA B-O O
86 B-O O
( B-O O
1989 B-O O
) B-O O
5306-5309 B-O O
] B-O O
. B-O O

We B-O O
also B-O O
showed B-O O
that B-O O
this B-O O
silencer B-O B-DNA
has B-O O
stronger B-O O
inhibitory B-O O
activity B-O O
in B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
, B-O O
as B-O O
compared B-O O
to B-O O
K562 B-O B-cell_line
human B-O I-cell_line
erythroleukemia B-O I-cell_line
cells B-O I-cell_line
. B-O O

Using B-O O
deletion B-O B-DNA
mutants B-O I-DNA
and B-O O
cis-cloned B-O O
synthetic B-O O
oligodeoxyribonucleotides B-O O
in B-O O
transient B-O O
expression B-O O
assays B-O O
, B-O O
nucleotide B-O B-DNA
sequences B-O I-DNA
responsible B-O O
for B-O O
this B-O O
effect B-O O
have B-O O
now B-O O
been B-O O
further B-O O
delimited B-O O
to B-O O
44 B-O O
bp B-O O
located B-O O
from B-O O
-294 B-O B-DNA
to B-O I-DNA
-251 B-O I-DNA
bp B-O I-DNA
. B-O O

Gel B-O O
electrophoresis B-O O
mobility B-O O
shift B-O O
assays B-O O
and B-O O
DNaseI B-O B-protein
footprinting B-O O
assays B-O O
demonstrate B-O O
that B-O O
these B-O O
negative B-O B-DNA
regulatory B-O I-DNA
sequences B-O I-DNA
are B-O O
recognized B-O O
differently B-O O
by B-O O
proteins B-O O
present B-O O
in B-O O
nuclear B-O O
extracts B-O O
obtained B-O O
from B-O O
HeLa B-O B-cell_line
and B-O O
K562 B-O B-cell_line
cells B-O I-cell_line
. B-O O

Two B-O O
binding B-O O
proteins B-O O
are B-O O
detected B-O O
in B-O O
K562 B-O O
nuclear B-O O
extracts B-O O
, B-O O
while B-O O
only B-O O
one B-O O
is B-O O
found B-O O
in B-O O
extracts B-O O
from B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
. B-O O

Possible B-O O
mechanisms B-O O
by B-O O
which B-O O
these B-O O
proteins B-O O
may B-O O
regulate B-O O
transcription B-O O
of B-O O
the B-O O
epsilon-globin-encoding B-O B-DNA
gene B-O I-DNA
in B-O O
erythroid B-O B-cell_type
and B-O I-cell_type
non-erythroid B-O I-cell_type
cells B-O I-cell_type
are B-O O
discussed B-O O
. B-O O

Calcitriol B-O O
: B-O O
a B-O O
hematolymphopoietrope B-O O
? B-O O
[ B-O O
editorial B-O O
] B-O O

A B-O O
MEDLINE B-O O
search B-O O
of B-O O
the B-O O
English-language B-O O
literature B-O O
was B-O O
conducted B-O O
using B-O O
the B-O O
indexing B-O O
terms B-O O
' B-O O
immunology B-O O
, B-O O
calcitriol B-O O
and B-O O
vitamin B-O O
D B-O O
' B-O O
to B-O O
identify B-O O
studies B-O O
indicating B-O O
a B-O O
role B-O O
for B-O O
calcitriol B-O O
as B-O O
a B-O O
primary B-O O
immunomodulator B-O O
. B-O O

Sixty-six B-O O
papers B-O O
published B-O O
between B-O O
January B-O O
1956 B-O O
and B-O O
June B-O O
1991 B-O O
were B-O O
identified B-O O
. B-O O

Forty-five B-O O
of B-O O
these B-O O
reports B-O O
are B-O O
cited B-O O
in B-O O
this B-O O
review B-O O
. B-O O

The B-O O
data B-O O
strongly B-O O
suggest B-O O
an B-O O
endocrine B-O O
, B-O O
autocrine B-O O
and/or B-O O
paracrine B-O O
role B-O O
for B-O O
calcitriol B-O O
in B-O O
immune B-O O
regulation B-O O
. B-O O

No B-O O
unifying B-O O
hypothesis B-O O
has B-O O
yet B-O O
emerged B-O O
explaining B-O O
this B-O O
collection B-O O
of B-O O
data B-O O
. B-O O

This B-O O
paper B-O O
provides B-O O
a B-O O
brief B-O O
review B-O O
of B-O O
immune B-O O
properties B-O O
currently B-O O
attributed B-O O
to B-O O
calcitriol B-O O
. B-O O

Transcription B-O O
of B-O O
the B-O O
hypersensitive B-O B-DNA
site B-O I-DNA
HS2 B-O I-DNA
enhancer B-O I-DNA
in B-O O
erythroid B-O B-cell_type
cells B-O I-cell_type
. B-O O

In B-O O
the B-O O
human B-O B-DNA
genome B-O I-DNA
, B-O O
the B-O O
erythroid-specific B-O B-DNA
hypersensitive B-O I-DNA
site B-O I-DNA
HS2 B-O I-DNA
enhancer B-O I-DNA
regulates B-O O
the B-O O
transcription B-O O
of B-O O
the B-O O
downstream B-O B-DNA
beta-like B-O I-DNA
globin B-O I-DNA
genes B-O I-DNA
10-50 B-O B-DNA
kilobases B-O I-DNA
away B-O O
. B-O O

The B-O O
mechanism B-O O
of B-O O
HS2 B-O B-DNA
enhancer B-O I-DNA
function B-O O
is B-O O
not B-O O
known B-O O
. B-O O

The B-O O
present B-O O
study B-O O
employs B-O O
RNA B-O O
protection B-O O
assays B-O O
to B-O O
analyze B-O O
the B-O O
transcriptional B-O O
status B-O O
of B-O O
the B-O O
HS2 B-O B-DNA
enhancer B-O I-DNA
in B-O O
transfected B-O O
recombinant B-O O
chloramphenicol B-O O
acetyltransferase B-O O
( B-O O
CAT B-O B-protein
) B-O O
plasmids B-O O
. B-O O

In B-O O
erythroid B-O B-cell_line
K562 B-O I-cell_line
cells B-O I-cell_line
in B-O O
which B-O O
the B-O O
HS2 B-O B-DNA
enhancer B-O I-DNA
is B-O O
active B-O O
, B-O O
the B-O O
HS2 B-O B-DNA
sequence B-O I-DNA
directs B-O O
the B-O O
synthesis B-O O
of B-O O
long B-O B-RNA
enhancer B-O I-RNA
transcripts B-O I-RNA
that B-O O
are B-O O
initiated B-O O
apparently B-O O
from B-O O
within B-O O
the B-O O
enhancer B-O B-DNA
and B-O O
elongated B-O O
through B-O O
the B-O O
intervening B-O O
DNA B-O O
into B-O O
the B-O O
cis-linked B-O B-DNA
CAT B-O I-DNA
gene B-O I-DNA
. B-O O

In B-O O
nonerythroid B-O B-cell_line
HL-60 B-O I-cell_line
cells B-O I-cell_line
in B-O O
which B-O O
the B-O O
HS2 B-O B-DNA
enhancer B-O I-DNA
is B-O O
inactive B-O O
, B-O O
long B-O B-RNA
enhancer B-O I-RNA
transcripts B-O I-RNA
are B-O O
not B-O O
detectable B-O O
. B-O O

Splitting B-O O
the B-O O
HS2 B-O B-DNA
enhancer B-O I-DNA
between B-O O
two B-O O
tandem B-O B-DNA
Ap1 B-O I-DNA
sites B-O I-DNA
abolishes B-O O
the B-O O
synthesis B-O O
of B-O O
a B-O O
group B-O O
of B-O O
long B-O B-RNA
enhancer B-O I-RNA
transcripts B-O I-RNA
and B-O O
results B-O O
in B-O O
loss B-O O
of B-O O
enhancer B-O B-DNA
function B-O O
and B-O O
transcriptional B-O O
silencing B-O O
of B-O O
the B-O O
cis-linked B-O B-DNA
CAT B-O I-DNA
gene B-O I-DNA
. B-O O

In B-O O
directing B-O O
the B-O O
synthesis B-O O
of B-O O
RNA B-O B-RNA
through B-O O
the B-O O
intervening B-O O
DNA B-O O
and B-O O
the B-O O
gene B-O O
by B-O O
a B-O O
tracking B-O O
and B-O O
transcription B-O O
mechanism B-O O
, B-O O
the B-O O
HS2 B-O B-DNA
enhancer B-O I-DNA
may B-O O
( B-O O
i B-O O
) B-O O
open B-O O
up B-O O
the B-O O
chromatin B-O B-DNA
structure B-O O
of B-O O
a B-O O
gene B-O B-DNA
domain B-O I-DNA
and B-O O
( B-O O
ii B-O O
) B-O O
deliver B-O O
enhancer B-O B-protein
binding B-O I-protein
proteins B-O I-protein
to B-O O
the B-O O
promoter B-O B-DNA
sequence B-O I-DNA
where B-O O
they B-O O
may B-O O
stimulate B-O O
the B-O O
transcription B-O O
of B-O O
the B-O O
gene B-O O
at B-O O
the B-O O
cap B-O B-DNA
site B-O I-DNA
. B-O O

Characterization B-O O
of B-O O
a B-O O
novel B-O O
T B-O B-protein
lymphocyte B-O I-protein
protein B-O I-protein
which B-O O
binds B-O O
to B-O O
a B-O O
site B-O O
related B-O O
to B-O O
steroid/thyroid B-O B-DNA
hormone B-O I-DNA
receptor B-O I-DNA
response B-O I-DNA
elements B-O I-DNA
in B-O O
the B-O O
negative B-O B-DNA
regulatory B-O I-DNA
sequence B-O I-DNA
of B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
. B-O O

We B-O O
have B-O O
previously B-O O
identified B-O O
a B-O O
T B-O B-protein
lymphocyte B-O I-protein
protein B-O I-protein
which B-O O
binds B-O O
to B-O O
a B-O O
site B-O O
within B-O O
the B-O O
LTR B-O B-DNA
of B-O O
the B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
and B-O O
exerts B-O O
an B-O O
inhibitory B-O O
effect B-O O
on B-O O
virus B-O O
gene B-O O
expression B-O O
. B-O O

The B-O O
palindromic B-O B-DNA
site B-O I-DNA
( B-O O
site B-O B-DNA
B B-O I-DNA
) B-O O
recognized B-O O
by B-O O
this B-O O
protein B-O O
is B-O O
related B-O O
to B-O O
the B-O O
palindromic B-O B-DNA
binding B-O I-DNA
sites B-O I-DNA
of B-O O
members B-O O
of B-O O
the B-O O
steroid/thyroid B-O B-protein
hormone B-O I-protein
receptor B-O I-protein
family B-O I-protein
. B-O O

Here B-O O
we B-O O
characterize B-O O
the B-O O
T B-O B-protein
cell B-O I-protein
protein B-O I-protein
binding B-O O
to B-O O
this B-O O
site B-O O
as B-O O
a B-O O
100 B-O B-protein
kD B-O I-protein
protein B-O I-protein
which B-O O
is B-O O
most B-O O
abundant B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
and B-O O
which B-O O
binds B-O O
to B-O O
site B-O B-DNA
B B-O I-DNA
as B-O O
a B-O O
200 B-O B-protein
kD B-O I-protein
complex B-O I-protein
. B-O O

This B-O O
protein B-O O
is B-O O
distinct B-O O
from B-O O
other B-O O
members B-O O
of B-O O
the B-O O
steroid/thyroid B-O B-protein
hormone B-O I-protein
receptor B-O I-protein
family B-O I-protein
including B-O O
the B-O O
COUP B-O B-protein
protein B-O I-protein
which B-O O
has B-O O
a B-O O
closely B-O O
related B-O O
DNA B-O O
binding B-O O
specificity B-O O
. B-O O

TAR B-O B-DNA
-independent B-O O
transactivation B-O O
by B-O O
Tat B-O B-protein
in B-O O
cells B-O O
derived B-O O
from B-O O
the B-O O
CNS B-O B-protein
: B-O O
a B-O O
novel B-O O
mechanism B-O O
of B-O O
HIV-1 B-O B-DNA
gene B-O I-DNA
regulation B-O O
. B-O O

The B-O O
Tat B-O B-protein
protein B-O I-protein
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
is B-O O
essential B-O O
for B-O O
productive B-O O
infection B-O O
and B-O O
is B-O O
a B-O O
potential B-O O
target B-O O
for B-O O
antiviral B-O O
therapy B-O O
. B-O O

Tat B-O B-protein
, B-O O
a B-O O
potent B-O O
activator B-O O
of B-O O
HIV-1 B-O B-DNA
gene B-O I-DNA
expression B-O O
, B-O O
serves B-O O
to B-O O
greatly B-O O
increase B-O O
the B-O O
rate B-O O
of B-O O
transcription B-O O
directed B-O O
by B-O O
the B-O O
viral B-O B-DNA
promoter B-O I-DNA
. B-O O

This B-O O
induction B-O O
, B-O O
which B-O O
seems B-O O
to B-O O
be B-O O
an B-O O
important B-O O
component B-O O
in B-O O
the B-O O
progression B-O O
of B-O O
acquired B-O O
immune B-O O
deficiency B-O O
syndrome B-O O
( B-O O
AIDS B-O O
) B-O O
, B-O O
may B-O O
be B-O O
due B-O O
to B-O O
increased B-O O
transcriptional B-O O
initiation B-O O
, B-O O
increased B-O O
transcriptional B-O O
elongation B-O O
, B-O O
or B-O O
a B-O O
combination B-O O
of B-O O
these B-O O
processes B-O O
. B-O O

Much B-O O
attention B-O O
has B-O O
been B-O O
focused B-O O
on B-O O
the B-O O
interaction B-O O
of B-O O
Tat B-O B-protein
with B-O O
a B-O O
specific B-O O
RNA B-O B-RNA
target B-O I-RNA
termed B-O O
TAR B-O B-DNA
( B-O O
transactivation B-O O
responsive B-O O
) B-O O
which B-O O
is B-O O
present B-O O
in B-O O
the B-O O
leader B-O B-DNA
sequence B-O I-DNA
of B-O O
all B-O O
HIV-1 B-O B-RNA
mRNAs B-O I-RNA
. B-O O

This B-O O
interaction B-O O
is B-O O
believed B-O O
to B-O O
be B-O O
an B-O O
important B-O O
component B-O O
of B-O O
the B-O O
mechanism B-O O
of B-O O
transactivation B-O O
. B-O O

In B-O O
this B-O O
report B-O O
we B-O O
demonstrate B-O O
that B-O O
in B-O O
certain B-O O
CNS-derived B-O B-cell_line
cells B-O I-cell_line
Tat B-O B-protein
is B-O O
capable B-O O
of B-O O
activating B-O O
HIV-1 B-O O
through B-O O
a B-O O
TAR B-O B-DNA
-independent B-O O
pathway B-O O
. B-O O

A B-O O
Tat B-O B-DNA
-responsive B-O I-DNA
element B-O I-DNA
is B-O O
found B-O O
upstream B-O O
within B-O O
the B-O O
viral B-O B-DNA
promoter B-O I-DNA
that B-O O
in B-O O
glial-derived B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
allows B-O O
transactivation B-O O
in B-O O
the B-O O
absence B-O O
of B-O O
TAR B-O B-DNA
. B-O O

Deletion B-O O
mapping B-O O
and B-O O
hybrid B-O B-DNA
promoter B-O I-DNA
constructs B-O I-DNA
demonstrate B-O O
that B-O O
the B-O O
newly B-O O
identified B-O O
Tat B-O B-DNA
-responsive B-O I-DNA
element B-O I-DNA
corresponds B-O O
to B-O O
a B-O O
sequence B-O O
within B-O O
the B-O O
viral B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
LTR B-O B-DNA
) B-O O
previously B-O O
identified B-O O
as B-O O
the B-O O
HIV-1 B-O B-DNA
enhancer B-O I-DNA
, B-O O
or B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
domain B-O I-DNA
. B-O O

DNA B-O O
band-shift B-O O
analysis B-O O
reveals B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
activity B-O O
in B-O O
glial B-O B-cell_type
cells B-O I-cell_type
that B-O O
differs B-O O
from B-O O
that B-O O
present B-O O
in B-O O
T B-O B-cell_type
lymphoid B-O I-cell_type
cells B-O I-cell_type
. B-O O

Further B-O O
, B-O O
we B-O O
observe B-O O
that B-O O
TAR-deleted B-O B-DNA
mutants B-O I-DNA
of B-O O
HIV-1 B-O O
demonstrate B-O O
normal B-O O
late B-O O
gene B-O O
expression B-O O
in B-O O
glial B-O B-cell_type
cells B-O I-cell_type
as B-O O
evidenced B-O O
by B-O O
syncytia B-O O
formation B-O O
and B-O O
production B-O O
of B-O O
viral B-O B-protein
p24 B-O I-protein
antigen B-O I-protein
. B-O O

( B-O O
ABSTRACT B-O O
TRUNCATED B-O O
AT B-O O
250 B-O O
WORDS B-O O
) B-O O

Transcription B-O B-protein
factor B-O I-protein
AP-2 B-O B-protein
activates B-O O
gene B-O O
expression B-O O
of B-O O
HTLV-I B-O O
. B-O O

The B-O O
HTLV-I B-O B-DNA
LTR B-O I-DNA
contains B-O O
three B-O O
conserved B-O O
regulatory B-O B-DNA
elements B-O I-DNA
known B-O O
as B-O O
21 B-O B-DNA
base B-O I-DNA
pair B-O I-DNA
repeats B-O I-DNA
which B-O O
are B-O O
required B-O O
for B-O O
stimulation B-O O
of B-O O
gene B-O O
expression B-O O
by B-O O
the B-O O
transactivator B-O B-protein
protein B-O I-protein
tax B-O B-protein
. B-O O

Mutagenesis B-O O
indicates B-O O
that B-O O
the B-O O
21 B-O B-DNA
bp B-O I-DNA
repeats B-O I-DNA
can B-O O
be B-O O
subdivided B-O O
into B-O O
three B-O O
motifs B-O O
, B-O O
A B-O O
, B-O O
B B-O O
and B-O O
C B-O O
, B-O O
each B-O O
of B-O O
which B-O O
influences B-O O
the B-O O
level B-O O
of B-O O
tax B-O B-protein
activation B-O O
. B-O O

The B-O O
A B-O B-DNA
site B-O I-DNA
in B-O O
the B-O O
21 B-O B-DNA
bp B-O I-DNA
repeat B-O I-DNA
has B-O O
strong B-O O
homology B-O O
with B-O O
previously B-O O
described B-O O
binding B-O B-DNA
sites B-O I-DNA
for B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
AP-2 B-O B-protein
. B-O O

We B-O O
demonstrated B-O O
that B-O O
AP-2 B-O B-RNA
mRNA B-O I-RNA
was B-O O
present B-O O
in B-O O
T-lymphocytes B-O B-cell_type
and B-O O
that B-O O
cellular B-O B-protein
factors B-O I-protein
from B-O O
both B-O O
non-transformed B-O O
and B-O O
transformed B-O O
T-lymphocytes B-O B-cell_type
specifically B-O O
bound B-O O
to B-O O
the B-O O
consensus B-O B-DNA
motif B-O I-DNA
for B-O O
AP-2 B-O B-protein
in B-O O
each B-O O
21 B-O O
bp B-O O
. B-O O

To B-O O
determine B-O O
the B-O O
role B-O O
of B-O O
AP-2 B-O B-protein
in B-O O
the B-O O
regulation B-O O
of B-O O
the B-O O
HTLV-I B-O B-DNA
LTR B-O I-DNA
gene B-O O
expression B-O O
, B-O O
we B-O O
used B-O O
an B-O O
AP-2 B-O B-DNA
cDNA B-O I-DNA
in B-O O
DNA B-O O
binding B-O O
and B-O O
transient B-O O
expression B-O O
assays B-O O
. B-O O

Gel B-O O
retardation B-O O
and B-O O
methylation B-O O
interference B-O O
studies B-O O
revealed B-O O
that B-O O
bacterially B-O O
produced B-O O
AP-2 B-O B-protein
bound B-O O
specifically B-O O
and B-O O
with B-O O
high B-O O
affinity B-O O
to B-O O
all B-O O
three B-O O
21 B-O B-DNA
bp B-O I-DNA
repeats B-O I-DNA
, B-O O
and B-O O
that B-O O
it B-O O
required B-O O
the B-O O
core B-O B-DNA
sequence B-O I-DNA
AGGC B-O O
for B-O O
specific B-O O
binding B-O O
. B-O O

Binding B-O O
of B-O O
AP-2 B-O B-protein
prevented B-O O
the B-O O
subsequent B-O O
binding B-O O
of B-O O
members B-O O
of B-O O
the B-O O
CREB/ATF B-O B-protein
family B-O I-protein
to B-O O
an B-O O
adjacent B-O B-DNA
regulatory B-O I-DNA
motif B-O I-DNA
in B-O O
the B-O O
21 B-O B-DNA
bp B-O I-DNA
repeat B-O I-DNA
. B-O O

Transfection B-O O
of B-O O
an B-O O
AP-2 B-O B-DNA
expression B-O I-DNA
construct B-O I-DNA
into B-O O
T-lymphocytes B-O B-cell_type
activated B-O O
gene B-O O
expression B-O O
from B-O O
the B-O O
HTLV-I B-O B-DNA
LTR B-O I-DNA
. B-O O

At B-O O
least B-O O
two B-O O
21 B-O B-DNA
bp B-O I-DNA
repeats B-O I-DNA
were B-O O
required B-O O
for B-O O
high B-O O
levels B-O O
of B-O O
AP-2 B-O B-protein
activation B-O O
and B-O O
mutagenesis B-O O
of B-O O
the B-O O
AP-2 B-O B-DNA
consensus B-O I-DNA
binding B-O I-DNA
sequences B-O I-DNA
in B-O O
the B-O O
21 B-O B-DNA
bp B-O I-DNA
repeats B-O I-DNA
eliminate B-O O
this B-O O
activation B-O O
. B-O O

( B-O O
ABSTRACT B-O O
TRUNCATED B-O O
AT B-O O
250 B-O O
WORDS B-O O
) B-O O

Activation B-O O
of B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
type B-O I-DNA
1 B-O I-DNA
enhancer B-O I-DNA
is B-O O
not B-O O
dependent B-O O
on B-O O
NFAT-1 B-O B-protein
. B-O O

The B-O O
function B-O O
of B-O O
a B-O O
putative B-O B-DNA
NFAT-1 B-O I-DNA
site B-O I-DNA
in B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
type B-O I-DNA
1 B-O I-DNA
enhancer B-O I-DNA
has B-O O
been B-O O
analyzed B-O O
. B-O O

Activation B-O O
by B-O O
the B-O O
T-cell B-O B-protein
antigen B-O I-protein
receptor B-O I-protein
is B-O O
minimal B-O O
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
and B-O O
is B-O O
mediated B-O O
by B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
sites B-O I-DNA
. B-O O

The B-O O
putative B-O B-DNA
NFAT-1 B-O I-DNA
region B-O I-DNA
is B-O O
not B-O O
required B-O O
for B-O O
the B-O O
response B-O O
to B-O O
anti-CD3 B-O B-protein
or B-O O
to B-O O
mitogens B-O B-protein
in B-O O
T-cell B-O B-cell_type
, B-O O
B-cell B-O B-cell_type
, B-O O
or B-O O
monocyte/macrophage B-O B-cell_line
leukemia B-O I-cell_line
lines B-O I-cell_line
, B-O O
nor B-O O
is B-O O
it B-O O
a B-O O
cis-acting B-O B-DNA
negative B-O I-DNA
regulatory B-O I-DNA
element B-O I-DNA
. B-O O

The B-O O
B B-O B-protein
cell-specific B-O I-protein
nuclear B-O I-protein
factor B-O I-protein
OTF-2 B-O B-protein
positively B-O O
regulates B-O O
transcription B-O O
of B-O O
the B-O O
human B-O B-DNA
class B-O I-DNA
II B-O I-DNA
transplantation B-O I-DNA
gene B-O I-DNA
, B-O O
DRA B-O B-DNA
. B-O O

The B-O O
promoter B-O B-DNA
of B-O O
the B-O O
major B-O B-DNA
histocompatibility B-O I-DNA
class B-O I-DNA
II B-O I-DNA
gene B-O I-DNA
DRA B-O B-DNA
contains B-O O
an B-O O
octamer B-O B-DNA
element B-O I-DNA
( B-O O
ATTTGCAT B-O O
) B-O O
that B-O O
is B-O O
required B-O O
for B-O O
efficient B-O O
DRA B-O B-DNA
expression B-O O
in B-O O
B B-O B-cell_type
cells B-O I-cell_type
. B-O O

Several B-O O
DNA-binding B-O B-protein
proteins B-O I-protein
are B-O O
known B-O O
to B-O O
bind B-O O
this B-O O
sequence B-O O
. B-O O

The B-O O
best B-O O
characterized B-O O
are B-O O
the B-O O
B B-O B-protein
cell-specific B-O I-protein
OTF-2 B-O I-protein
and B-O O
the B-O O
ubiquitous B-O O
OTF-1 B-O B-protein
. B-O O

This B-O O
report B-O O
directly B-O O
demonstrates B-O O
that B-O O
OTF-2 B-O B-protein
but B-O O
not B-O O
OTF-1 B-O B-protein
regulates B-O O
the B-O O
DRA B-O B-DNA
gene B-O I-DNA
. B-O O

In B-O O
vitro B-O O
transcription B-O O
analysis B-O O
using B-O O
protein B-O O
fractions B-O O
enriched B-O O
for B-O O
the B-O O
octamer-binding B-O B-protein
protein B-O I-protein
OTF-2 B-O B-protein
demonstrate B-O O
a B-O O
positive B-O O
functional B-O O
role B-O O
for B-O O
OTF-2 B-O B-protein
in B-O O
DRA B-O B-DNA
gene B-O I-DNA
transcription B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
OTF-1 B-O B-protein
-enriched B-O O
protein B-O O
fractions B-O O
did B-O O
not B-O O
affect B-O O
DRA B-O B-DNA
gene B-O I-DNA
transcription B-O O
although B-O O
it B-O O
functionally B-O O
enhanced B-O O
the B-O O
transcription B-O O
of B-O O
another B-O O
gene B-O O
. B-O O

Recombinant B-O B-protein
OTF-2 B-O I-protein
protein B-O I-protein
produced B-O O
by B-O O
in B-O O
vitro B-O O
transcription B-O O
/translation B-O O
could B-O O
also B-O O
enhance B-O O
DRA B-O B-DNA
gene B-O I-DNA
transcription B-O O
in B-O O
vitro B-O O
. B-O O

In B-O O
vivo B-O O
transient B-O O
transfection B-O O
studies B-O O
utilizing B-O O
an B-O O
OTF-2 B-O B-DNA
expression B-O I-DNA
vector B-O I-DNA
resulted B-O O
in B-O O
similar B-O O
findings B-O O
: B-O O
that B-O O
OTF-2 B-O B-protein
protein B-O I-protein
enhanced B-O O
DRA B-O B-DNA
gene B-O I-DNA
transcription B-O O
, B-O O
and B-O O
that B-O O
this B-O O
effect B-O O
requires B-O O
an B-O O
intact B-O O
octamer B-O B-DNA
element B-O I-DNA
. B-O O

Together B-O O
these B-O O
results B-O O
constitute B-O O
the B-O O
first B-O O
direct B-O O
evidence B-O O
of B-O O
a B-O O
positive B-O O
role B-O O
for B-O O
the B-O O
lymphoid-specific B-O B-protein
octamer-binding B-O I-protein
factor B-O I-protein
in B-O O
DRA B-O B-DNA
gene B-O I-DNA
transcription B-O O
. B-O O

Interferon-gamma B-O B-protein
potentiates B-O O
the B-O O
antiviral B-O O
activity B-O O
and B-O O
the B-O O
expression B-O O
of B-O O
interferon-stimulated B-O B-DNA
genes B-O I-DNA
induced B-O O
by B-O O
interferon-alpha B-O B-protein
in B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
. B-O O

Binding B-O O
of B-O O
type B-O B-protein
I B-O I-protein
interferon B-O I-protein
( B-O O
IFN-alpha/beta B-O B-protein
) B-O O
to B-O O
specific B-O O
receptors B-O O
results B-O O
in B-O O
the B-O O
rapid B-O O
transcriptional B-O O
activation B-O O
, B-O O
independent B-O O
of B-O O
protein B-O O
synthesis B-O O
, B-O O
of B-O O
IFN-alpha-stimulated B-O B-DNA
genes B-O I-DNA
( B-O O
ISGs B-O B-DNA
) B-O O
in B-O O
human B-O B-cell_type
fibroblasts B-O I-cell_type
and B-O O
HeLa B-O B-cell_line
and B-O O
Daudi B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

The B-O O
binding B-O O
of B-O O
ISGF3 B-O B-protein
( B-O O
IFN-stimulated B-O B-protein
gene B-O I-protein
factor B-O I-protein
3 B-O I-protein
) B-O O
to B-O O
the B-O O
conserved B-O O
IFN-stimulated B-O B-DNA
response B-O I-DNA
element B-O I-DNA
( B-O O
ISRE B-O B-DNA
) B-O O
results B-O O
in B-O O
transcriptional B-O O
activation B-O O
. B-O O

This B-O O
factor B-O O
is B-O O
composed B-O O
of B-O O
a B-O O
DNA-binding B-O B-protein
protein B-O I-protein
( B-O O
ISGF3 B-O B-protein
gamma B-O I-protein
) B-O O
, B-O O
which B-O O
normally B-O O
is B-O O
present B-O O
in B-O O
the B-O O
cytoplasm B-O O
, B-O O
and B-O O
other B-O O
IFN-alpha-activated B-O B-protein
proteins B-O I-protein
which B-O O
preexist B-O O
as B-O O
latent B-O B-protein
cytoplasmic B-O I-protein
precursors B-O I-protein
( B-O O
ISGF3 B-O B-protein
alpha B-O I-protein
) B-O O
. B-O O

We B-O O
have B-O O
found B-O O
that B-O O
ISG B-O B-protein
expression B-O O
in B-O O
the B-O O
monocytic B-O B-cell_line
U937 B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
differs B-O O
from B-O O
most B-O O
cell B-O B-cell_line
lines B-O I-cell_line
previously B-O O
examined B-O O
. B-O O

U937 B-O B-cell_line
cells B-O I-cell_line
express B-O O
both B-O O
type B-O B-protein
I B-O I-protein
and B-O I-protein
type B-O I-protein
II B-O I-protein
IFN B-O I-protein
receptors B-O I-protein
, B-O O
but B-O O
only B-O O
IFN-alpha B-O B-protein
is B-O O
capable B-O O
of B-O O
inducing B-O O
antiviral B-O O
protection B-O O
in B-O O
these B-O O
cells B-O O
. B-O O

Pretreatment B-O O
with B-O O
IFN-gamma B-O B-protein
potentiates B-O O
the B-O O
IFN-alpha B-O B-protein
-induced B-O O
protection B-O O
, B-O O
but B-O O
IFN-gamma B-O B-protein
alone B-O O
does B-O O
not B-O O
have B-O O
any B-O O
antiviral B-O O
activity B-O O
. B-O O

ISG15 B-O B-RNA
mRNA B-O I-RNA
accumulation B-O O
in B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
is B-O O
not B-O O
detectable B-O O
before B-O O
6 B-O O
h B-O O
of B-O O
IFN-alpha B-O B-protein
treatment B-O O
, B-O O
peaks B-O O
at B-O O
24 B-O O
h B-O O
, B-O O
and B-O O
requires B-O O
protein B-O O
synthesis B-O O
. B-O O

Although B-O O
IFN-gamma B-O B-protein
alone B-O O
does B-O O
not B-O O
induce B-O O
ISG B-O B-protein
expression B-O O
, B-O O
IFN-gamma B-O B-protein
pretreatment B-O O
markedly B-O O
increases B-O O
and B-O O
hastens B-O O
ISG B-O B-protein
expression B-O O
and B-O O
transcriptional B-O O
induction B-O O
. B-O O

Nuclear B-O O
extracts B-O O
assayed B-O O
for B-O O
the B-O O
presence B-O O
of B-O O
ISRE B-O B-protein
binding B-O I-protein
factors B-O I-protein
by B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
show B-O O
that B-O O
ISGF3 B-O B-protein
is B-O O
induced B-O O
by B-O O
IFN-alpha B-O B-protein
within B-O O
6 B-O O
h B-O O
from B-O O
undetectable B-O O
basal B-O O
levels B-O O
in B-O O
untreated B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
. B-O O

Activation B-O O
of B-O O
ISGF3 B-O B-protein
alpha B-O I-protein
, B-O O
the B-O O
latent B-O O
component B-O O
of B-O O
ISGF3 B-O B-protein
, B-O O
occurs B-O O
rapidly B-O O
. B-O O

However B-O O
, B-O O
the B-O O
increase B-O O
in B-O O
ISGF3 B-O B-protein
activity B-O O
ultimately B-O O
correlates B-O O
with B-O O
the B-O O
accumulation B-O O
of B-O O
ISGF3 B-O B-protein
gamma B-O I-protein
induced B-O O
by B-O O
IFN-alpha B-O B-protein
or B-O O
IFN-gamma B-O B-protein
. B-O O

( B-O O
ABSTRACT B-O O
TRUNCATED B-O O
AT B-O O
250 B-O O
WORDS B-O O
) B-O O

Single B-O O
point B-O O
estimation B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
lymphocytes B-O B-cell_type
of B-O O
normal B-O O
subjects B-O O
and B-O O
of B-O O
children B-O O
under B-O O
long B-O O
term B-O O
glucocorticoid B-O O
treatment B-O O
. B-O O

A B-O O
single B-O O
point B-O O
assay B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
( B-O O
GR B-O B-protein
) B-O O
in B-O O
human B-O B-cell_type
lymphocytes B-O I-cell_type
based B-O O
on B-O O
the B-O O
measurement B-O O
of B-O O
specific B-O O
dexamethasone B-O O
binding B-O O
has B-O O
been B-O O
developed B-O O
and B-O O
compared B-O O
with B-O O
a B-O O
common B-O O
multi-point B-O O
Scatchard B-O O
analysis B-O O
. B-O O

The B-O O
assay B-O O
conditions-concentration B-O O
of B-O O
the B-O O
ligand B-O O
20 B-O O
nmol/l B-O O
, B-O O
incubation B-O O
time B-O O
2 B-O O
h B-O O
and B-O O
the B-O O
cell B-O O
count B-O O
2-6 B-O O
mil B-O O
. B-O O

cells/tube B-O O
in B-O O
the B-O O
assay B-O O
volume B-O O
0.25 B-O O
ml B-O O
were B-O O
found B-O O
to B-O O
be B-O O
optimal B-O O
. B-O O

An B-O O
attempt B-O O
was B-O O
also B-O O
undertaken B-O O
to B-O O
use B-O O
a B-O O
cell B-O O
harvester B-O O
for B-O O
the B-O O
separation B-O O
of B-O O
cells B-O O
from B-O O
unbound B-O O
ligand B-O O
. B-O O

Though B-O O
specifically B-O O
bound B-O O
dexamethasone B-O O
measured B-O O
by B-O O
whole-cell B-O O
assay B-O O
and B-O O
that B-O O
using B-O O
cell B-O O
harvester B-O O
correlated B-O O
well B-O O
, B-O O
almost B-O O
by B-O O
one B-O O
order B-O O
lower B-O O
values B-O O
obtained B-O O
with B-O O
the B-O O
latter B-O O
method B-O O
render B-O O
it B-O O
non-applicable B-O O
for B-O O
receptor B-O O
quantitation B-O O
. B-O O

The B-O O
results B-O O
from B-O O
9 B-O O
healthy B-O O
volunteers B-O O
( B-O O
average B-O O
GR B-O B-protein
concentration B-O O
7131 B-O O
+/- B-O O
1256 B-O O
sites/cell B-O O
) B-O O
correlated B-O O
excellently B-O O
with B-O O
those B-O O
obtained B-O O
by B-O O
the B-O O
Scatchard B-O O
analysis B-O O
. B-O O

The B-O O
single B-O O
point B-O O
assay B-O O
has B-O O
been B-O O
also B-O O
applied B-O O
for B-O O
determination B-O O
of B-O O
GH B-O B-protein
in B-O O
10 B-O O
children B-O O
treated B-O O
with B-O O
large B-O O
doses B-O O
of B-O O
prednisone B-O O
. B-O O

The B-O O
average B-O O
values B-O O
from B-O O
healthy B-O O
volunteers B-O O
did B-O O
not B-O O
differ B-O O
significantly B-O O
from B-O O
those B-O O
found B-O O
in B-O O
these B-O O
children B-O O
, B-O O
though B-O O
much B-O O
broader B-O O
range B-O O
was B-O O
found B-O O
in B-O O
patients B-O O
. B-O O

Glucocorticoid B-O B-protein
receptor B-O I-protein
and B-O O
inhibition B-O O
of B-O O
3-O-methyl-D-glucose B-O O
uptake B-O O
by B-O O
glucocorticoids B-O O
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
leukocytes B-O I-cell_type
from B-O O
normal B-O O
humans B-O O
: B-O O
correlation B-O O
between B-O O
receptor B-O O
level B-O O
and B-O O
hormone B-O O
effect B-O O
in B-O O
vitro B-O O
. B-O O

We B-O O
have B-O O
measured B-O O
the B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
concentration B-O O
in B-O O
mononuclear B-O B-cell_type
and B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
, B-O O
both B-O O
of B-O O
which B-O O
were B-O O
isolated B-O O
from B-O O
peripheral B-O O
blood B-O O
from B-O O
ten B-O O
healthy B-O O
male B-O O
volunteers B-O O
. B-O O

In B-O O
parallel B-O O
, B-O O
the B-O O
inhibitory B-O O
effect B-O O
of B-O O
dexamethasone B-O O
on B-O O
3-O-methyl-D-glucose B-O O
uptake B-O O
was B-O O
assayed B-O O
in B-O O
the B-O O
corresponding B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
. B-O O

The B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
levels B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
correlated B-O O
with B-O O
those B-O O
in B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
, B-O O
and B-O O
there B-O O
was B-O O
a B-O O
linear B-O O
relationship B-O O
between B-O O
the B-O O
cellular B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
levels B-O O
and B-O O
glucocorticoid B-O O
-mediated B-O O
inhibition B-O O
of B-O O
the B-O O
uptake B-O O
of B-O O
3-O-methyl-D-glucose B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
. B-O O

When B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
were B-O O
incubated B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
8-bromo-cAMP B-O O
, B-O O
cellular B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
levels B-O O
increased B-O O
and B-O O
a B-O O
more B-O O
pronounced B-O O
inhibitory B-O O
effect B-O O
of B-O O
dexamethasone B-O O
was B-O O
observed B-O O
on B-O O
the B-O O
transport B-O O
of B-O O
3-O-methyl-D-glucose B-O O
. B-O O

We B-O O
conclude B-O O
that B-O O
the B-O O
cellular B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
levels B-O O
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
leukocytes B-O I-cell_type
reflect B-O O
in B-O O
vitro B-O O
responsiveness B-O O
to B-O O
glucocorticoids B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
from B-O O
healthy B-O O
males B-O O
, B-O O
and B-O O
that B-O O
the B-O O
individual B-O O
responsiveness B-O O
may B-O O
alter B-O O
upon B-O O
changes B-O O
in B-O O
the B-O O
cellular B-O O
levels B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
. B-O O

Transcription B-O B-protein
factor B-O I-protein
activation B-O O
and B-O O
functional B-O O
stimulation B-O O
of B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
. B-O O

Activation B-O O
of B-O O
expression B-O O
of B-O O
genes B-O B-DNA
encoding B-O O
transcription B-O B-protein
factors B-O I-protein
: B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
and B-O O
formation B-O O
of B-O O
AP1 B-O B-protein
transcriptional B-O I-protein
complex B-O I-protein
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
was B-O O
investigated B-O O
. B-O O

It B-O O
was B-O O
found B-O O
that B-O O
lipopolysaccharide B-O O
induced B-O O
strongly B-O O
both B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
expression B-O O
as B-O O
well B-O O
as B-O O
AP1 B-O B-protein
formation B-O O
. B-O O

Interferon B-O B-protein
gamma B-O I-protein
activated B-O O
strongly B-O O
c-fos B-O B-DNA
and B-O O
weakly B-O O
c-jun B-O B-DNA
and B-O O
AP1 B-O B-protein
. B-O O

Tumor B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
induced B-O O
slightly B-O O
c-fos B-O B-DNA
and B-O O
had B-O O
almost B-O O
no B-O O
effect B-O O
on B-O O
c-jun B-O B-DNA
and B-O O
AP1 B-O B-protein
. B-O O

The B-O O
data B-O O
suggest B-O O
that B-O O
differences B-O O
in B-O O
functional B-O O
responses B-O O
elicited B-O O
in B-O O
monocytes B-O B-cell_type
by B-O O
all B-O O
three B-O O
factors B-O O
may B-O O
be B-O O
dependent B-O O
on B-O O
different B-O O
routes B-O O
on B-O O
nuclear B-O O
signalling B-O O
employed B-O O
by B-O O
the B-O O
factors B-O O
. B-O O

Regulation B-O O
of B-O O
interleukin-1 B-O B-protein
beta B-O I-protein
production B-O O
by B-O O
glucocorticoids B-O O
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
: B-O O
the B-O O
mechanism B-O O
of B-O O
action B-O O
depends B-O O
on B-O O
the B-O O
activation B-O O
signal B-O O
. B-O O

Glucocorticoids B-O O
are B-O O
known B-O O
to B-O O
downregulate B-O O
interleukin-1 B-O B-protein
beta B-O I-protein
production B-O O
in B-O O
monocytic B-O B-cell_type
cells B-O I-cell_type
by B-O O
two B-O O
different B-O O
mechanims B-O O
: B-O O
direct B-O O
inhibition B-O O
of B-O O
the B-O O
gene B-O O
transcription B-O O
and B-O O
destabilization B-O O
of B-O O
the B-O O
preformed B-O O
interleukin-1 B-O B-RNA
beta B-O I-RNA
mRNA B-O I-RNA
. B-O O

Now B-O O
we B-O O
have B-O O
examined B-O O
the B-O O
effect B-O O
of B-O O
the B-O O
nature B-O O
of B-O O
the B-O O
monocyte B-O B-cell_type
activating B-O O
signal B-O O
on B-O O
these B-O O
two B-O O
inhibitory B-O O
mechanims B-O O
. B-O O

When B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
were B-O O
preincubated B-O O
with B-O O
dexamethasone B-O O
for B-O O
1 B-O O
hour B-O O
and B-O O
then B-O O
stimulated B-O O
either B-O O
with B-O O
bacterial B-O O
lipopolysaccharide B-O O
or B-O O
phorbol B-O O
myristate B-O O
, B-O O
it B-O O
was B-O O
found B-O O
that B-O O
dexamethasone B-O O
inhibited B-O O
the B-O O
lipopolysaccharide-induced B-O O
interleukin-1 B-O B-protein
beta B-O I-protein
protein B-O O
production B-O O
, B-O O
but B-O O
the B-O O
phorbol B-O O
myristate B-O O
-induced B-O O
production B-O O
was B-O O
increased B-O O
3-10 B-O O
fold B-O O
. B-O O

This B-O O
difference B-O O
was B-O O
also B-O O
seen B-O O
at B-O O
the B-O O
mRNA B-O O
level B-O O
. B-O O

When B-O O
dexamethasone B-O O
was B-O O
added B-O O
to B-O O
the B-O O
cultures B-O O
3 B-O O
hours B-O O
after B-O O
the B-O O
stimulators B-O O
, B-O O
it B-O O
clearly B-O O
decreased B-O O
the B-O O
interleukin-1 B-O B-RNA
beta B-O I-RNA
mRNA B-O I-RNA
levels B-O O
regardless B-O O
of B-O O
the B-O O
stimulator B-O O
used B-O O
( B-O O
although B-O O
the B-O O
effect B-O O
was B-O O
clearly B-O O
weaker B-O O
on B-O O
the B-O O
PMA-induced B-O B-RNA
mRNA B-O I-RNA
) B-O O
. B-O O

Thus B-O O
these B-O O
data B-O O
suggest B-O O
that B-O O
the B-O O
phorbol B-O O
myristate-induced B-O O
signal B-O O
( B-O O
prolonged B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
activation B-O O
? B-O O
) B-O O
can B-O O
not B-O O
be B-O O
inhibited B-O O
by B-O O
prior B-O O
incubation B-O O
with B-O O
dexamethasone B-O O
and B-O O
it B-O O
also B-O O
protects B-O O
the B-O O
induced B-O O
mRNA B-O B-RNA
for B-O O
the B-O O
degradative B-O O
action B-O O
of B-O O
dexamethasone B-O O
. B-O O

Nuclear B-O B-protein
transcription B-O I-protein
factors B-O I-protein
that B-O O
bind B-O O
to B-O O
elements B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
. B-O O

Induction B-O O
requirements B-O O
in B-O O
primary B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Prior B-O O
studies B-O O
have B-O O
identified B-O O
several B-O O
elements B-O O
that B-O O
contribute B-O O
to B-O O
the B-O O
activity B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
promoter B-O I-DNA
in B-O O
the B-O O
stimulated B-O O
T B-O B-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
Jurkat B-O B-cell_line
. B-O O

The B-O O
sites B-O O
and B-O O
their B-O O
corresponding B-O O
nuclear B-O B-protein
binding B-O I-protein
factors B-O I-protein
include B-O O
: B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
AP-1 B-O B-protein
, B-O O
AP-3 B-O B-protein
, B-O O
OCT-1 B-O B-protein
, B-O O
and B-O O
NF-AT B-O B-protein
. B-O O

The B-O O
latter B-O O
`` B-O O
nuclear B-O B-protein
factor B-O I-protein
for B-O I-protein
activated B-O I-protein
T B-O I-protein
cells B-O I-protein
`` B-O O
likely B-O O
contributes B-O O
to B-O O
the B-O O
tissue B-O O
specificity B-O O
of B-O O
IL-2 B-O B-DNA
gene B-O I-DNA
expression B-O O
. B-O O

Using B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
, B-O O
we B-O O
have B-O O
studied B-O O
these B-O O
transcription B-O B-protein
factors B-O I-protein
in B-O O
primary B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
from B-O O
human B-O O
blood B-O O
to B-O O
verify B-O O
their B-O O
presence B-O O
in B-O O
a B-O O
physiologic B-O O
setting B-O O
and B-O O
to B-O O
identify B-O O
the B-O O
signals B-O O
that B-O O
stimulate B-O O
factor B-O O
activity B-O O
. B-O O

All B-O O
factors B-O O
are B-O O
induced B-O O
in B-O O
the B-O O
nuclei B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
upon B-O O
activation B-O O
with B-O O
mitogens B-O B-protein
but B-O O
not B-O O
with B-O O
exogenous B-O B-protein
IL-2 B-O I-protein
growth B-O I-protein
factor B-O I-protein
. B-O O

However B-O O
, B-O O
the B-O O
signaling B-O O
requirements B-O O
and B-O O
sensitivity B-O O
to B-O O
protein B-O O
synthesis B-O O
inhibitors B-O O
differ B-O O
considerably B-O O
. B-O O

Only B-O O
the B-O O
activities B-O O
for B-O O
NF-AT B-O B-protein
and B-O O
AP-1 B-O B-DNA
sites B-O I-DNA
require B-O O
two B-O O
signals B-O O
for B-O O
optimal B-O O
induction B-O O
, B-O O
i.e. B-O O
, B-O O
PMA B-O O
plus B-O O
either B-O O
lectin B-O B-protein
or B-O O
antibody B-O O
to B-O O
the B-O O
CD3 B-O B-protein
or B-O O
CD28 B-O B-protein
surface B-O I-protein
molecules B-O I-protein
. B-O O

Other B-O O
factors B-O O
are B-O O
induced B-O O
by B-O O
lectin B-O B-protein
, B-O O
antibody B-O B-protein
, B-O O
and/or B-O O
PMA B-O O
alone B-O O
. B-O O

After B-O O
appropriate B-O O
stimulation B-O O
, B-O O
both B-O O
NF-AT B-O B-protein
and B-O O
AP-1 B-O B-protein
are B-O O
peculiarly B-O O
sensitive B-O O
to B-O O
the B-O O
protein B-O O
synthesis B-O O
inhibitor B-O O
anisomycin B-O O
. B-O O

Our B-O O
data B-O O
correlate B-O O
the B-O O
activity B-O O
of B-O O
NF-AT B-O B-protein
and B-O O
AP-1 B-O B-protein
in B-O O
gel B-O O
shift B-O O
assays B-O O
with B-O O
the B-O O
two B-O O
signals B-O O
requirements B-O O
for B-O O
IL-2 B-O B-DNA
gene B-O I-DNA
expression B-O O
. B-O O

NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
stably B-O O
expressing B-O O
the B-O O
Tax B-O B-protein
protein B-O I-protein
of B-O O
human B-O O
T B-O O
cell B-O O
lymphotropic B-O O
virus B-O O
type B-O O
I B-O O
. B-O O

The B-O O
effect B-O O
of B-O O
constitutive B-O O
Tax B-O B-protein
expression B-O O
on B-O O
the B-O O
interaction B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
with B-O O
its B-O O
recognition B-O B-DNA
sequence B-O I-DNA
and B-O O
on B-O O
NF-kappa B-O B-protein
B B-O I-protein
-dependent B-O O
gene B-O O
expression B-O O
was B-O O
examined B-O O
in B-O O
T B-O B-cell_line
lymphoid B-O I-cell_line
Jurkat B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
( B-O O
19D B-O B-cell_line
and B-O O
9J B-O B-cell_line
) B-O O
stably B-O O
transformed B-O O
with B-O O
a B-O O
Tax B-O B-DNA
expression B-O I-DNA
vector B-O I-DNA
. B-O O

Tax B-O B-protein
expressing B-O O
T B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
contained B-O O
a B-O O
constitutive B-O O
level B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
activity B-O O
, B-O O
detectable B-O O
by B-O O
mobility B-O O
shift B-O O
assay B-O O
and B-O O
uv B-O O
cross-linking B-O O
using B-O O
a B-O O
palindromic B-O B-DNA
NF-kappa B-O I-DNA
B B-O I-DNA
probe B-O I-DNA
homologous B-O O
to B-O O
the B-O O
interferon B-O B-DNA
beta B-O I-DNA
PRDII B-O I-DNA
site B-O I-DNA
. B-O O

In B-O O
Jurkat B-O B-cell_line
and B-O O
NC2.10 B-O O
induction B-O O
with B-O O
phorbol B-O O
esters B-O O
resulted B-O O
in B-O O
the B-O O
appearance B-O O
of B-O O
new B-O O
DNA B-O B-protein
binding B-O I-protein
proteins B-O I-protein
of B-O O
85 B-O O
, B-O O
75 B-O O
, B-O O
and B-O O
54 B-O B-protein
kDa B-O I-protein
, B-O O
whereas B-O O
in B-O O
Tax B-O B-cell_line
expressing B-O I-cell_line
cells B-O I-cell_line
the B-O O
85-kDa B-O B-protein
protein B-O I-protein
and B-O O
a B-O O
92-kDa B-O B-protein
DNA B-O I-protein
binding B-O I-protein
protein B-O I-protein
were B-O O
constitutively B-O O
induced B-O O
. B-O O

Expression B-O O
of B-O O
Tax B-O B-protein
protein B-O I-protein
in B-O O
19D B-O B-cell_line
and B-O O
9J B-O B-cell_line
resulted B-O O
in B-O O
transcription B-O O
of B-O O
the B-O O
endogenous B-O O
NF-kappa B-O B-protein
B B-O I-protein
-dependent B-O O
granulocyte-macrophage B-O B-DNA
colony B-O I-DNA
stimulating B-O I-DNA
factor B-O I-DNA
gene B-O I-DNA
and B-O O
increased B-O O
basal B-O O
level B-O O
expression B-O O
of B-O O
transfected B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
-regulated B-O I-DNA
promoters B-O I-DNA
. B-O O

Nonetheless B-O O
transcription B-O O
of B-O O
both B-O O
the B-O O
endogenous B-O O
and B-O O
the B-O O
transfected B-O O
gene B-O O
was B-O O
inducible B-O O
by B-O O
PMA B-O O
treatment B-O O
. B-O O

Tax B-O B-protein
expression B-O O
in B-O O
Jurkat B-O B-cell_line
T B-O I-cell_line
cells B-O I-cell_line
may B-O O
alter B-O O
the B-O O
stoichiometry B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
DNA B-O B-protein
binding B-O I-protein
proteins B-O I-protein
and B-O O
thus B-O O
change B-O O
the B-O O
expression B-O O
of B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
-regulated B-O I-DNA
promoters B-O I-DNA
. B-O O

A B-O O
nuclear B-O B-protein
factor B-O I-protein
NF-GM2 B-O I-protein
that B-O O
interacts B-O O
with B-O O
a B-O O
regulatory B-O B-DNA
region B-O I-DNA
of B-O O
the B-O O
GM-CSF B-O B-DNA
gene B-O I-DNA
essential B-O O
for B-O O
its B-O O
induction B-O O
in B-O O
responses B-O O
to B-O O
T-cell B-O O
activation B-O O
: B-O O
purification B-O O
from B-O O
human B-O B-cell_line
T-cell B-O I-cell_line
leukemia B-O I-cell_line
line B-O I-cell_line
Jurkat B-O I-cell_line
cells B-O I-cell_line
and B-O O
similarity B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

Activation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
by B-O O
antigen B-O O
, B-O O
lectin B-O B-protein
, B-O O
or B-O O
a B-O O
combination B-O O
of B-O O
phorbol-12-myristate B-O O
acetate B-O O
( B-O O
PMA B-O O
) B-O O
and B-O O
calcium B-O O
ionophore B-O O
( B-O O
A23187 B-O O
) B-O O
leads B-O O
to B-O O
the B-O O
induction B-O O
of B-O O
genes B-O O
for B-O O
a B-O O
set B-O O
of B-O O
lymphokines B-O B-protein
, B-O O
including B-O O
granulocyte-macrophage B-O B-protein
colony-stimulating B-O I-protein
factor B-O I-protein
( B-O O
GM-CSF B-O B-protein
) B-O O
. B-O O

We B-O O
demonstrated B-O O
in B-O O
earlier B-O O
studies B-O O
that B-O O
the B-O O
upstream B-O B-DNA
region B-O I-DNA
of B-O O
the B-O O
mouse B-O B-DNA
GM-CSF B-O I-DNA
promoter B-O I-DNA
at B-O O
positions B-O O
between B-O O
-95 B-O B-DNA
and B-O I-DNA
-73 B-O I-DNA
is B-O O
essential B-O O
for B-O O
transcriptional B-O O
activation B-O O
in B-O O
response B-O O
to B-O O
PMA/A23187 B-O O
. B-O O

This B-O O
region B-O O
contains B-O O
two B-O O
DNA-binding B-O B-DNA
motifs B-O I-DNA
, B-O O
GM2 B-O B-DNA
and B-O O
GC-box B-O B-DNA
. B-O O

The B-O O
GM2 B-O B-DNA
sequence B-O I-DNA
( B-O O
GGTAGTTCCC B-O O
) B-O O
is B-O O
recognized B-O O
by B-O O
an B-O O
inducible B-O B-protein
factor B-O I-protein
NF-GM2 B-O B-protein
; B-O O
the B-O O
other B-O O
( B-O O
CCGCCC B-O O
) B-O O
by B-O O
constitutive B-O B-protein
factors B-O I-protein
A1 B-O B-protein
, B-O O
A2 B-O B-protein
, B-O O
and B-O O
B B-O O
. B-O O

To B-O O
elucidate B-O O
the B-O O
mechanism B-O O
of B-O O
GM-CSF B-O B-DNA
gene B-O I-DNA
activation B-O O
, B-O O
we B-O O
have B-O O
purified B-O O
the B-O O
inducible B-O B-protein
factor B-O I-protein
NF-GM2 B-O B-protein
from B-O O
the B-O O
nuclear B-O O
extract B-O O
of B-O O
stimulated B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
on B-O O
the B-O O
basis B-O O
of B-O O
specific B-O O
DNA-binding B-O O
activity B-O O
. B-O O

The B-O O
purified B-O O
NF-GM2 B-O B-protein
consists B-O O
of B-O O
50 B-O O
( B-O O
p50 B-O B-protein
) B-O O
and B-O O
65 B-O O
kDa B-O O
( B-O O
p65 B-O B-protein
) B-O O
polypeptides B-O O
and B-O O
has B-O O
a B-O O
binding B-O O
activity B-O O
specific B-O O
for B-O O
both B-O O
the B-O O
GM-CSF B-O B-protein
and B-O O
immunoglobulin B-O B-DNA
kappa B-O I-DNA
( B-O I-DNA
GGAAAGTCCC B-O I-DNA
) B-O I-DNA
enhancers B-O I-DNA
. B-O O

Electrophoretically B-O O
purified B-O O
p50 B-O B-protein
alone B-O O
can B-O O
form B-O O
a B-O O
protein-DNA B-O B-protein
complex B-O I-protein
, B-O O
but B-O O
in B-O O
the B-O O
mixture B-O O
, B-O O
p50 B-O B-protein
associates B-O O
preferentially B-O O
with B-O O
p65 B-O B-protein
to B-O O
form B-O O
the B-O O
NF-GM2 B-O B-protein
complex B-O I-protein
. B-O O

In B-O O
addition B-O O
, B-O O
p65 B-O B-protein
gave B-O O
per B-O O
se B-O O
, B-O O
with B-O O
low B-O O
affinity B-O O
, B-O O
a B-O O
protein-DNA B-O B-protein
complex B-O I-protein
that B-O O
migrated B-O O
more B-O O
slowly B-O O
than B-O O
native B-O O
NF-GM2 B-O B-protein
complex B-O I-protein
. B-O O

Furthermore B-O O
, B-O O
an B-O O
antiserum B-O O
against B-O O
KBF1 B-O B-protein
( B-O O
identical B-O O
to B-O O
50 B-O B-protein
kDa B-O I-protein
NF-kappa B-O I-protein
B B-O I-protein
protein B-O I-protein
) B-O O
reacted B-O O
with B-O O
the B-O O
p50 B-O B-protein
of B-O O
NF-GM2 B-O B-protein
, B-O O
indicating B-O O
that B-O O
the B-O O
NF-GM2 B-O B-protein
polypeptide B-O I-protein
can B-O O
not B-O O
be B-O O
immunologically B-O O
differentiated B-O O
from B-O O
the B-O O
50 B-O B-protein
kDa B-O I-protein
subunit B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

The B-O O
purified B-O O
NF-GM2 B-O B-protein
activated B-O O
in B-O O
vitro B-O O
transcription B-O O
from B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
enhancer B-O I-DNA
, B-O O
while B-O O
it B-O O
failed B-O O
to B-O O
stimulate B-O O
transcription B-O O
from B-O O
the B-O O
GM-CSF B-O B-DNA
promoter B-O I-DNA
harboring B-O O
the B-O O
GM2 B-O B-DNA
sequence B-O I-DNA
. B-O O

This B-O O
suggests B-O O
that B-O O
the B-O O
activation B-O O
mechanism B-O O
of B-O O
the B-O O
GM-CSF B-O B-DNA
gene B-O I-DNA
through B-O O
the B-O O
GM2/GC-box B-O B-DNA
sequence B-O I-DNA
is B-O O
different B-O O
from B-O O
that B-O O
of B-O O
genes B-O O
carrying B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
enhancer B-O I-DNA
alone B-O O
. B-O O

Characterization B-O O
of B-O O
an B-O O
immediate-early B-O B-DNA
gene B-O I-DNA
induced B-O O
in B-O O
adherent B-O B-cell_type
monocytes B-O I-cell_type
that B-O O
encodes B-O O
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
-like B-O O
activity B-O O
. B-O O

We B-O O
have B-O O
cloned B-O O
a B-O O
group B-O O
of B-O O
cDNAs B-O B-DNA
representing B-O O
mRNAs B-O B-RNA
that B-O O
are B-O O
rapidly B-O O
induced B-O O
following B-O O
adherence B-O O
of B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
. B-O O

One B-O O
of B-O O
the B-O O
induced B-O O
transcripts B-O O
( B-O O
MAD-3 B-O B-protein
) B-O O
encodes B-O O
a B-O O
protein B-O O
of B-O O
317 B-O B-protein
amino B-O I-protein
acids B-O I-protein
with B-O O
one B-O O
domain B-O O
containing B-O O
five B-O B-protein
tandem B-O I-protein
repeats B-O I-protein
of B-O O
the B-O O
cdc10/ankyrin B-O B-protein
motif B-O I-protein
, B-O O
which B-O O
is B-O O
60 B-O O
% B-O O
similar B-O O
( B-O O
46 B-O O
% B-O O
identical B-O O
) B-O O
to B-O O
the B-O O
ankyrin B-O B-protein
repeat B-O I-protein
region B-O I-protein
of B-O O
the B-O O
precursor B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
/KBF1 B-O B-protein
p50 B-O B-protein
. B-O O

The B-O O
C-terminus B-O B-protein
has B-O O
a B-O O
putative B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
phosphorylation B-O O
site B-O O
. B-O O

In B-O O
vitro B-O O
translated B-O O
MAD-3 B-O B-protein
protein B-O I-protein
was B-O O
found B-O O
to B-O O
specifically B-O O
inhibit B-O O
the B-O O
DNA-binding B-O O
activity B-O O
of B-O O
the B-O O
p50/p65 B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
complex B-O I-protein
but B-O O
not B-O O
that B-O O
of B-O O
the B-O O
p50/p50 B-O B-protein
KBF1 B-O I-protein
factor B-O I-protein
or B-O O
of B-O O
other B-O O
DNA-binding B-O B-protein
proteins B-O I-protein
. B-O O

The B-O O
MAD-3 B-O B-DNA
cDNA B-O I-DNA
encodes B-O O
an B-O O
I B-O B-protein
kappa B-O I-protein
B-like B-O I-protein
protein B-O I-protein
that B-O O
is B-O O
likely B-O O
to B-O O
be B-O O
involved B-O O
in B-O O
regulation B-O O
of B-O O
transcriptional B-O O
responses B-O O
to B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
including B-O O
adhesion-dependent B-O O
pathways B-O O
of B-O O
monocyte B-O O
activation B-O O
. B-O O

Cortivazol B-O O
mediated B-O O
induction B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
messenger B-O O
ribonucleic B-O O
acid B-O O
in B-O O
wild-type B-O B-cell_line
and B-O I-cell_line
dexamethasone B-O I-cell_line
-resistant B-O I-cell_line
human B-O I-cell_line
leukemic B-O I-cell_line
( B-O I-cell_line
CEM B-O I-cell_line
) B-O I-cell_line
cells B-O I-cell_line
. B-O O

Cortivazol B-O O
is B-O O
a B-O O
phenylpyrazolo B-O O
glucocorticoid B-O O
of B-O O
high B-O O
potency B-O O
and B-O O
unusual B-O O
structure B-O O
. B-O O

In B-O O
both B-O O
wild-type B-O B-cell_line
and B-O O
highly B-O O
dexamethasone B-O B-cell_line
( B-O I-cell_line
dex B-O I-cell_line
) B-O I-cell_line
-resistant B-O I-cell_line
clones B-O I-cell_line
of B-O O
the B-O O
human B-O B-cell_line
leukemic B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
CEM B-O I-cell_line
, B-O O
exposure B-O O
to B-O O
cortivazol B-O O
leads B-O O
to B-O O
cell B-O O
death B-O O
. B-O O

It B-O O
has B-O O
been B-O O
shown B-O O
recently B-O O
that B-O O
in B-O O
wild-type B-O B-cell_line
CEM B-O I-cell_line
cells B-O I-cell_line
but B-O O
not B-O O
in B-O O
a B-O O
dex-resistant B-O O
, B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
( B-O O
GR B-O B-protein
) B-O O
-defective B-O O
clone B-O O
ICR-27 B-O B-cell_line
TK-3 B-O I-cell_line
, B-O O
dex B-O O
induces B-O O
GR B-O B-RNA
mRNA B-O I-RNA
. B-O O

To B-O O
test B-O O
the B-O O
hypothesis B-O O
that B-O O
cortivazol B-O O
acts B-O O
in B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
cells B-O I-cell_line
by B-O O
making B-O O
use B-O O
of B-O O
the B-O O
residual B-O O
GR B-O B-protein
found B-O O
there B-O O
, B-O O
wild-type B-O O
and B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
clones B-O I-cell_line
were B-O O
treated B-O O
with B-O O
various B-O O
concentrations B-O O
of B-O O
cortivazol B-O O
and B-O O
induction B-O O
of B-O O
GR B-O B-RNA
mRNA B-O I-RNA
was B-O O
studied B-O O
. B-O O

Cortivazol B-O O
significantly B-O O
induced B-O O
GR B-O B-RNA
mRNA B-O I-RNA
in B-O O
the B-O O
normal B-O B-cell_line
CEM-C7 B-O I-cell_line
as B-O O
well B-O O
as B-O O
in B-O O
two B-O O
classes B-O O
of B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
clones B-O I-cell_line
, B-O O
although B-O O
the B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
clones B-O I-cell_line
needed B-O O
at B-O O
least B-O O
10 B-O O
times B-O O
more B-O O
cortivazol B-O O
than B-O O
the B-O O
normal B-O B-cell_type
cells B-O I-cell_type
for B-O O
significant B-O O
GR B-O B-RNA
mRNA B-O I-RNA
induction B-O O
. B-O O

Increased B-O O
levels B-O O
of B-O O
GR B-O B-RNA
mRNA B-O I-RNA
were B-O O
noticed B-O O
as B-O O
early B-O O
as B-O O
3 B-O O
h B-O O
after B-O O
treatment B-O O
. B-O O

A B-O O
general B-O O
correlation B-O O
between B-O O
induction B-O O
of B-O O
GR B-O B-RNA
mRNA B-O I-RNA
and B-O O
lysis B-O O
of B-O O
the B-O O
normal B-O O
and B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
cells B-O I-cell_line
was B-O O
found B-O O
. B-O O

Positive B-O O
induction B-O O
of B-O O
GR B-O B-RNA
mRNA B-O I-RNA
might B-O O
be B-O O
one B-O O
of B-O O
the B-O O
earliest B-O O
crucial B-O O
steps B-O O
in B-O O
the B-O O
lysis B-O O
of B-O O
normal B-O O
and B-O O
dex-resistant B-O B-cell_line
CEM B-O I-cell_line
cells B-O I-cell_line
, B-O O
or B-O O
might B-O O
serve B-O O
as B-O O
a B-O O
marker B-O O
for B-O O
the B-O O
process B-O O
. B-O O

However B-O O
, B-O O
the B-O O
lysis B-O O
pathway B-O O
in B-O O
the B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
cells B-O I-cell_line
is B-O O
defective B-O O
in B-O O
that B-O O
dex B-O B-cell_line
-resistant B-O I-cell_line
clones B-O I-cell_line
needed B-O O
significantly B-O O
more B-O O
cortivazol B-O O
than B-O O
the B-O O
normal B-O B-cell_type
cells B-O I-cell_type
for B-O O
lysis B-O O
of B-O O
the B-O O
cells B-O O
. B-O O

HIV B-O B-DNA
enhancer B-O I-DNA
activity B-O O
perpetuated B-O O
by B-O O
NF-kappa B-O B-protein
B B-O I-protein
induction B-O O
on B-O O
infection B-O O
of B-O O
monocytes B-O B-cell_type
[ B-O O
see B-O O
comments B-O O
] B-O O

Permissiveness B-O O
to B-O O
replication B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
( B-O O
HIV B-O O
) B-O O
differs B-O O
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
and B-O O
macrophages B-O B-cell_type
. B-O O

In B-O O
T B-O B-cell_type
cells B-O I-cell_type
, B-O O
HIV B-O O
transcription B-O O
is B-O O
poorly B-O O
detected B-O O
in B-O O
vivo B-O O
. B-O O

Cloned B-O O
, B-O O
normal B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
show B-O O
very B-O O
little B-O O
, B-O O
if B-O O
any B-O O
, B-O O
basal B-O O
activity B-O O
of B-O O
the B-O O
HIV B-O B-DNA
enhancer B-O I-DNA
and B-O O
low B-O O
nuclear B-O O
expression B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
a B-O O
potent B-O O
transcriptional B-O B-protein
activator B-O I-protein
of B-O O
the B-O O
HIV B-O B-DNA
enhancer B-O I-DNA
. B-O O

In B-O O
contrast B-O O
, B-O O
fixed B-O O
tissue B-O O
macrophages B-O B-cell_type
express B-O O
detectable B-O O
HIV B-O B-protein
proteins B-O I-protein
, B-O O
indicating B-O O
permanent B-O O
virus B-O O
transcription B-O O
. B-O O

One B-O O
explanation B-O O
for B-O O
the B-O O
perpetuation B-O O
of B-O O
virus B-O O
infection B-O O
in B-O O
macrophages B-O B-cell_type
could B-O O
be B-O O
sustained B-O O
nuclear B-O O
NF-kappa B-O B-protein
B B-O I-protein
expression B-O O
. B-O O

However B-O O
, B-O O
the B-O O
U937 B-O B-cell_line
monocytic B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
which B-O O
is B-O O
fully B-O O
permissive B-O O
to B-O O
HIV B-O O
replication B-O O
, B-O O
is B-O O
known B-O O
to B-O O
express B-O O
only B-O O
low B-O O
levels B-O O
of B-O O
nuclear B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
. B-O O

We B-O O
show B-O O
here B-O O
that B-O O
chronic B-O O
HIV B-O O
infection B-O O
results B-O O
in B-O O
both B-O O
induction B-O O
of B-O O
a B-O O
nuclear B-O B-protein
factor B-O I-protein
with B-O O
antigenic B-O O
properties B-O O
indistinguishable B-O O
from B-O O
those B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
and B-O O
permanently B-O O
increased B-O O
HIV B-O B-DNA
enhancer B-O I-DNA
activity B-O O
. B-O O

This B-O O
phenomenon B-O O
, B-O O
which B-O O
is B-O O
independent B-O O
of B-O O
tumour B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
, B-O O
is B-O O
associated B-O O
with B-O O
HIV B-O O
replication B-O O
, B-O O
and B-O O
is B-O O
thus B-O O
likely B-O O
to B-O O
explain B-O O
at B-O O
least B-O O
in B-O O
part B-O O
the B-O O
perpetuation B-O O
of B-O O
HIV B-O O
infection B-O O
in B-O O
monocytes B-O B-cell_type
. B-O O

Isolation B-O O
of B-O O
a B-O O
rel-related B-O B-DNA
human B-O I-DNA
cDNA B-O I-DNA
that B-O O
potentially B-O O
encodes B-O O
the B-O O
65-kD B-O B-protein
subunit B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
[ B-O O
published B-O O
erratum B-O O
appears B-O O
in B-O O
Science B-O O
1991 B-O O
Oct B-O O
4 B-O O
; B-O O
254 B-O O
( B-O O
5028 B-O O
) B-O O
: B-O O
11 B-O O
] B-O O

A B-O O
DNA B-O B-DNA
probe B-O I-DNA
that B-O O
spanned B-O O
a B-O O
domain B-O O
conserved B-O O
among B-O O
the B-O O
proto-oncogene B-O B-DNA
c-rel B-O I-DNA
, B-O O
the B-O O
Drosophila B-O B-protein
morphogen B-O I-protein
dorsal B-O I-protein
, B-O O
and B-O O
the B-O O
p50 B-O B-protein
DNA B-O I-protein
binding B-O I-protein
subunit B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
was B-O O
generated B-O O
from B-O O
Jurkat B-O B-DNA
T B-O I-DNA
cell B-O I-DNA
complementary B-O I-DNA
DNA B-O I-DNA
with B-O O
the B-O O
polymerase B-O O
chain B-O O
reaction B-O O
( B-O O
PCR B-O O
) B-O O
and B-O O
degenerate B-O O
oligonucleotides B-O O
. B-O O

This B-O O
probe B-O O
was B-O O
used B-O O
to B-O O
identify B-O O
a B-O O
rel-related B-O B-DNA
complementary B-O I-DNA
DNA B-O I-DNA
that B-O O
hybridized B-O O
to B-O O
a B-O O
2.6-kilobase B-O B-RNA
messenger B-O I-RNA
RNA B-O I-RNA
present B-O O
in B-O O
human B-O B-cell_type
T B-O I-cell_type
and B-O I-cell_type
B B-O I-cell_type
lymphocytes B-O I-cell_type
. B-O O

In B-O O
vitro B-O O
transcription B-O O
and B-O O
translation B-O O
of B-O O
the B-O O
complementary B-O B-DNA
DNA B-O I-DNA
resulted B-O O
in B-O O
the B-O O
synthesis B-O O
of B-O O
a B-O O
protein B-O O
with B-O O
an B-O O
apparent B-O O
molecular B-O O
size B-O O
of B-O O
65 B-O B-protein
kilodaltons B-O I-protein
( B-O O
kD B-O O
) B-O O
. B-O O

The B-O O
translated B-O B-protein
protein B-O I-protein
showed B-O O
weak B-O O
DNA B-O O
binding B-O O
with B-O O
a B-O O
specificity B-O O
for B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
binding B-O I-DNA
motif B-O I-DNA
. B-O O

This B-O O
protein-DNA B-O B-protein
complex B-O I-protein
comigrated B-O O
with B-O O
the B-O O
complex B-O O
obtained B-O O
with B-O O
the B-O O
purified B-O B-protein
human B-O I-protein
p65 B-O I-protein
NF-kappa B-O I-protein
B B-O I-protein
subunit B-O I-protein
and B-O O
binding B-O O
was B-O O
inhibited B-O O
by B-O O
I B-O B-protein
kappa B-O I-protein
B-alpha B-O I-protein
and B-O O
-beta B-O O
proteins B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
the B-O O
65-kD B-O B-protein
protein B-O I-protein
associated B-O O
with B-O O
the B-O O
p50 B-O B-protein
subunit B-O I-protein
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
and B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
probe B-O I-DNA
to B-O O
form B-O O
a B-O O
complex B-O O
with B-O O
the B-O O
same B-O O
electrophoretic B-O O
mobility B-O O
as B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
-DNA B-O I-protein
complex B-O I-protein
. B-O O

Therefore B-O O
the B-O O
rel-related B-O B-protein
65-kD B-O I-protein
protein B-O I-protein
may B-O O
represent B-O O
the B-O O
p65 B-O B-protein
subunit B-O I-protein
of B-O O
the B-O O
active B-O O
NF-kappa B-O B-protein
B B-O I-protein
transcription B-O O
factor B-O O
complex B-O O
. B-O O

The B-O O
human B-O B-cell_line
myelomonocytic B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
U-937 B-O I-cell_line
as B-O O
a B-O O
model B-O O
for B-O O
studying B-O O
alterations B-O O
in B-O O
steroid-induced B-O O
monokine B-O O
gene B-O O
expression B-O O
: B-O O
marked B-O O
enhancement B-O O
of B-O O
lipopolysaccharide-stimulated B-O B-RNA
interleukin-1 B-O I-RNA
beta B-O I-RNA
messenger B-O I-RNA
RNA B-O I-RNA
levels B-O O
by B-O O
1 B-O O
, B-O O
25-dihydroxyvitamin B-O O
D3 B-O O
. B-O O

The B-O O
active B-O O
metabolite B-O O
of B-O O
vitamin B-O O
D B-O O
, B-O O
1 B-O O
, B-O O
25-dihydroxyvitamin B-O O
D3 B-O O
[ B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
] B-O O
, B-O O
is B-O O
a B-O O
potent B-O O
regulator B-O O
of B-O O
human B-O O
monocyte/macrophage B-O O
function B-O O
in B-O O
vitro B-O O
. B-O O

To B-O O
establish B-O O
a B-O O
model B-O O
for B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
regulation B-O O
of B-O O
human B-O O
monocyte B-O O
monokine B-O O
synthesis B-O O
, B-O O
three B-O O
human B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
( B-O O
U-937 B-O B-cell_line
, B-O O
THP-1 B-O B-cell_line
, B-O O
and B-O O
HL-60 B-O B-cell_line
) B-O O
were B-O O
examined B-O O
for B-O O
: B-O O
1 B-O O
) B-O O
the B-O O
presence B-O O
of B-O O
functional B-O O
1 B-O B-protein
, B-O I-protein
25- B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
; B-O O
2 B-O O
) B-O O
the B-O O
accumulation B-O O
of B-O O
interleukin-1 B-O B-RNA
beta B-O I-RNA
( B-O I-RNA
IL-1 B-O I-RNA
beta B-O I-RNA
) B-O I-RNA
mRNA B-O I-RNA
and B-O O
IL-1 B-O B-protein
beta B-O I-protein
protein B-O I-protein
in B-O O
response B-O O
to B-O O
lipopolysaccharide B-O O
( B-O O
LPS B-O O
) B-O O
; B-O O
and B-O O
3 B-O O
) B-O O
the B-O O
regulation B-O O
of B-O O
this B-O O
response B-O O
by B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
. B-O O

All B-O O
three B-O O
cell B-O B-cell_line
lines B-O I-cell_line
expressed B-O O
vitamin B-O B-protein
D B-O I-protein
receptor B-O I-protein
and B-O O
had B-O O
increased B-O O
levels B-O O
of B-O O
IL-1 B-O B-RNA
beta B-O I-RNA
mRNA B-O I-RNA
in B-O O
response B-O O
to B-O O
LPS B-O O
. B-O O

Preincubation B-O O
of B-O O
cells B-O O
with B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
augmented B-O O
IL-1 B-O B-RNA
beta B-O I-RNA
mRNA B-O I-RNA
levels B-O O
only B-O O
in B-O O
U-937 B-O B-cell_line
and B-O O
HL-60 B-O B-cell_line
cells B-O I-cell_line
. B-O O

From B-O O
these B-O O
data B-O O
, B-O O
and B-O O
taking B-O O
into B-O O
consideration B-O O
their B-O O
state B-O O
of B-O O
differentiation B-O O
and B-O O
relative B-O O
ease B-O O
of B-O O
culture B-O O
, B-O O
U-937 B-O B-cell_line
was B-O O
chosen B-O O
over B-O O
HL-60 B-O B-cell_line
and B-O O
THP-1 B-O B-cell_line
as B-O O
the B-O O
cell B-O B-cell_line
line B-O I-cell_line
we B-O O
further B-O O
characterized B-O O
. B-O O

In B-O O
U-937 B-O B-cell_line
cells B-O I-cell_line
, B-O O
optimum B-O O
time B-O O
and B-O O
dose B-O O
of B-O O
pretreatment B-O O
with B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
were B-O O
determined B-O O
to B-O O
be B-O O
12-24 B-O O
h B-O O
at B-O O
a B-O O
receptor B-O O
saturating B-O O
concentration B-O O
of B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
( B-O O
10 B-O O
nM B-O O
) B-O O
. B-O O

Preincubation B-O O
of B-O O
cells B-O O
with B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
had B-O O
no B-O O
effect B-O O
on B-O O
the B-O O
time B-O O
course B-O O
of B-O O
IL-1 B-O B-RNA
beta B-O I-RNA
mRNA B-O I-RNA
appearance B-O O
in B-O O
response B-O O
to B-O O
LPS B-O O
. B-O O

However B-O O
, B-O O
exposure B-O O
of B-O O
U-937 B-O B-cell_line
cells B-O I-cell_line
to B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
increased B-O O
by B-O O
200 B-O O
% B-O O
the B-O O
level B-O O
of B-O O
IL-1 B-O B-RNA
beta B-O I-RNA
mRNA B-O I-RNA
detected B-O O
and B-O O
decreased B-O O
by B-O O
three B-O O
orders B-O O
of B-O O
magnitude B-O O
the B-O O
concentration B-O O
of B-O O
LPS B-O O
required B-O O
to B-O O
achieve B-O O
steady B-O O
state B-O O
mRNA B-O O
levels B-O O
equivalent B-O O
to B-O O
those B-O O
observed B-O O
in B-O O
U-937 B-O B-cell_line
cells B-O I-cell_line
not B-O O
preincubated B-O O
with B-O O
the B-O O
hormone.2+o B-O O

Regulation B-O O
of B-O O
M-CSF B-O B-protein
expression B-O O
by B-O O
M-CSF B-O B-protein
: B-O O
role B-O O
of B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
and B-O O
transcription B-O B-protein
factor B-O I-protein
NF B-O I-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

Macrophage-colony-stimulating B-O B-protein
factor B-O I-protein
( B-O O
M-CSF B-O B-protein
) B-O O
, B-O O
also B-O O
referred B-O O
to B-O O
as B-O O
CSF-1 B-O B-protein
, B-O O
regulates B-O O
the B-O O
survival B-O O
, B-O O
growth B-O O
, B-O O
differentiation B-O O
and B-O O
functional B-O O
activity B-O O
of B-O O
monocytes B-O B-cell_type
by B-O O
binding B-O O
to B-O O
a B-O O
single B-O O
class B-O O
of B-O O
high-affinity B-O B-protein
cell B-O I-protein
surface B-O I-protein
receptors B-O I-protein
, B-O O
known B-O O
to B-O O
be B-O O
the B-O O
product B-O O
of B-O O
the B-O O
c-fms B-O B-DNA
protooncogene B-O I-DNA
. B-O O

The B-O O
detection B-O O
of B-O O
both B-O O
M-CSF B-O B-protein
and B-O O
c-fms B-O O
expression B-O O
by B-O O
cells B-O O
of B-O O
the B-O O
monocyte B-O B-cell_type
lineage B-O I-cell_type
has B-O O
suggested B-O O
that B-O O
M-CSF B-O B-protein
may B-O O
act B-O O
by B-O O
an B-O O
autocrine B-O O
mechanism B-O O
. B-O O

Interestingly B-O O
, B-O O
it B-O O
has B-O O
been B-O O
shown B-O O
that B-O O
M-CSF B-O B-protein
can B-O O
induce B-O O
the B-O O
expression B-O O
of B-O O
its B-O O
own B-O O
gene B-O O
. B-O O

Although B-O O
sensitivity B-O O
to B-O O
M-CSF B-O B-protein
can B-O O
be B-O O
modulated B-O O
by B-O O
regulation B-O O
of B-O O
receptor B-O O
expression B-O O
and B-O O
function B-O O
, B-O O
M-CSF B-O B-protein
responsiveness B-O O
is B-O O
largely B-O O
determined B-O O
at B-O O
a B-O O
postreceptor B-O O
level B-O O
. B-O O

To B-O O
date B-O O
, B-O O
little B-O O
is B-O O
known B-O O
about B-O O
the B-O O
intracellular B-O O
pathway B-O O
of B-O O
M-CSF B-O B-protein
signal B-O O
transduction B-O O
. B-O O

We B-O O
have B-O O
therefore B-O O
investigated B-O O
the B-O O
changes B-O O
in B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
activity B-O O
upon B-O O
exposure B-O O
of B-O O
monocytes B-O B-cell_type
to B-O O
M-CSF B-O B-protein
. B-O O

We B-O O
show B-O O
that B-O O
M-CSF B-O B-protein
activates B-O O
and B-O O
translocates B-O O
PKC B-O B-protein
. B-O O

Inhibition B-O O
of B-O O
PKC B-O B-protein
by B-O O
the B-O O
isoquinoline B-O O
derivative B-O O
H7 B-O O
abolishes B-O O
induction B-O O
of B-O O
M-CSF B-O B-protein
by B-O O
M-CSF B-O B-protein
. B-O O

Furthermore B-O O
, B-O O
activation B-O O
of B-O O
PKC B-O B-protein
was B-O O
pertussis-toxin-sensitive B-O O
and B-O O
was B-O O
associated B-O O
with B-O O
the B-O O
detection B-O O
of B-O O
an B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
protein B-O I-protein
in B-O O
nuclear B-O O
extracts B-O O
of B-O O
M-CSF B-O B-protein
-induced B-O O
blood B-O B-cell_type
monocytes B-O I-cell_type
but B-O O
not B-O O
in B-O O
monocytes B-O B-cell_type
exposed B-O O
to B-O O
medium B-O O
treatment B-O O
only B-O O
. B-O O

The B-O O
results B-O O
suggest B-O O
that B-O O
M-CSF B-O B-protein
induction B-O O
of B-O O
M-CSF B-O B-protein
involves B-O O
G B-O B-protein
proteins B-O I-protein
, B-O O
PKC B-O B-protein
and B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

Clone B-O B-DNA
pAT B-O I-DNA
133 B-O I-DNA
identifies B-O O
a B-O O
gene B-O O
that B-O O
encodes B-O O
another B-O O
human B-O O
member B-O O
of B-O O
a B-O O
class B-O O
of B-O O
growth B-O B-DNA
factor-induced B-O I-DNA
genes B-O I-DNA
with B-O O
almost B-O O
identical B-O O
zinc-finger B-O B-protein
domains B-O I-protein
. B-O O

We B-O O
report B-O O
the B-O O
structure B-O O
and B-O O
regulation B-O O
of B-O O
a B-O O
gene B-O O
represented B-O O
by B-O O
clone B-O B-DNA
pAT B-O I-DNA
133 B-O I-DNA
, B-O O
which B-O O
is B-O O
induced B-O O
upon B-O O
transition B-O O
from B-O O
a B-O O
resting B-O O
state B-O O
( B-O O
G0 B-O O
) B-O O
through B-O O
the B-O O
early B-O O
phase B-O O
of B-O O
the B-O O
cell B-O O
cycle B-O O
( B-O O
G1 B-O O
) B-O O
. B-O O

The B-O O
pAT B-O B-DNA
133 B-O I-DNA
gene B-O I-DNA
is B-O O
immediately B-O O
induced B-O O
, B-O O
with B-O O
FOS B-O B-protein
-like B-O O
kinetics B-O O
, B-O O
in B-O O
human B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
and B-O O
in B-O O
fibroblasts B-O B-cell_type
. B-O O

Primary B-O O
structure B-O O
analysis B-O O
showed B-O O
that B-O O
the B-O O
encoded B-O O
protein B-O O
contains B-O O
three B-O O
tandem B-O B-DNA
zinc-finger B-O I-DNA
sequences B-O I-DNA
of B-O O
the B-O O
type B-O O
Cys2-Xaa12-His2 B-O B-protein
. B-O O

This B-O O
zinc-finger B-O B-protein
region B-O I-protein
, B-O O
which B-O O
is B-O O
thought B-O O
to B-O O
bind B-O O
DNA B-O O
in B-O O
a B-O O
sequence-specific B-O O
manner B-O O
, B-O O
is B-O O
similar B-O O
( B-O O
greater B-O O
than B-O O
80 B-O O
% B-O O
on B-O O
the B-O O
amino B-O O
acid B-O O
level B-O O
) B-O O
to B-O O
two B-O O
previously B-O O
described B-O O
transcription B-O B-protein
factors B-O I-protein
pAT B-O B-protein
225/EGR1 B-O I-protein
and B-O O
pAT B-O O
591/EGR2 B-O B-protein
. B-O O

Except B-O O
for B-O O
the B-O O
conserved B-O O
zinc-finger B-O B-protein
domains B-O I-protein
, B-O O
the B-O O
amino B-O B-protein
acid B-O I-protein
sequences B-O I-protein
of B-O O
the B-O O
three B-O O
proteins B-O O
are B-O O
distinct B-O O
. B-O O

This B-O O
structural B-O O
similarity B-O O
suggests B-O O
that B-O O
the B-O O
pAT B-O B-DNA
133 B-O I-DNA
gene B-O I-DNA
encodes B-O O
a B-O O
transcription B-O B-protein
factor B-O I-protein
with B-O O
a B-O O
specific B-O O
biological B-O O
function B-O O
. B-O O

Comparing B-O O
the B-O O
regulation B-O O
of B-O O
these B-O O
related B-O O
zinc-finger B-O B-DNA
-encoding B-O I-DNA
genes B-O I-DNA
showed B-O O
coordinate B-O O
induction B-O O
upon B-O O
mitogenic B-O O
stimulation B-O O
of B-O O
resting B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
and B-O O
of B-O O
resting B-O B-cell_type
fibroblasts B-O I-cell_type
. B-O O

However B-O O
, B-O O
upon B-O O
transition B-O O
from B-O O
a B-O O
proliferating B-O O
( B-O O
G1 B-O O
) B-O O
to B-O O
a B-O O
resting B-O O
state B-O O
of B-O O
the B-O O
cell B-O O
cycle B-O O
the B-O O
three B-O O
genes B-O O
were B-O O
differently B-O O
regulated B-O O
. B-O O

In B-O O
human B-O B-RNA
histiocytic B-O I-RNA
U937 B-O I-RNA
cells B-O I-RNA
mRNA B-O I-RNA
of B-O O
clone B-O B-DNA
pAT B-O I-DNA
133 B-O I-DNA
was B-O O
constitutively B-O O
expressed B-O O
, B-O O
whereas B-O O
mRNA B-O B-RNA
of B-O O
pAT B-O B-protein
225/EGR1 B-O I-protein
was B-O O
induced B-O O
upon B-O O
induction B-O O
of B-O O
terminal B-O O
differentiation B-O O
. B-O O

In B-O O
contrast B-O O
mRNA B-O O
representing B-O O
pAT B-O O
591/EGR2 B-O B-protein
was B-O O
not B-O O
expressed B-O O
in B-O O
these B-O O
cells B-O O
. B-O O

This B-O O
difference B-O O
in B-O O
gene B-O O
regulation B-O O
suggests B-O O
distinct B-O O
biological B-O O
roles B-O O
in B-O O
the B-O O
control B-O O
of B-O O
cell B-O O
proliferation B-O O
for B-O O
the B-O O
respective B-O O
proteins B-O O
. B-O O

v-erbA B-O B-protein
overexpression B-O O
is B-O O
required B-O O
to B-O O
extinguish B-O O
c-erbA B-O B-protein
function B-O O
in B-O O
erythroid B-O B-cell_type
cell B-O I-cell_type
differentiation B-O O
and B-O O
regulation B-O O
of B-O O
the B-O O
erbA B-O B-DNA
target B-O I-DNA
gene B-O I-DNA
CAII B-O B-DNA
. B-O O

The B-O O
v-erbA B-O B-protein
oncoprotein B-O I-protein
represents B-O O
a B-O O
retrovirus-transduced B-O O
oncogenic B-O O
version B-O O
of B-O O
the B-O O
thyroid B-O B-protein
hormone B-O I-protein
( B-O I-protein
T3/T4 B-O I-protein
) B-O I-protein
receptor B-O I-protein
c-erbA B-O B-protein
( B-O I-protein
type B-O I-protein
alpha B-O I-protein
) B-O I-protein
. B-O O

It B-O O
contributes B-O O
to B-O O
virus-induced B-O O
erythroleukemia B-O O
by B-O O
efficiently B-O O
arresting B-O O
differentiation B-O O
of B-O O
red B-O B-cell_type
cell B-O I-cell_type
progenitors B-O I-cell_type
and B-O O
by B-O O
suppressing B-O O
transcription B-O O
of B-O O
erythrocyte-specific B-O B-DNA
genes B-O I-DNA
. B-O O

Here B-O O
, B-O O
we B-O O
show B-O O
that B-O O
v-erbA B-O B-protein
and B-O O
c-erbA B-O B-protein
bind B-O O
directly B-O O
to B-O O
sequences B-O O
within B-O O
the B-O O
promoter B-O B-DNA
of B-O O
the B-O O
erythrocyte-specific B-O B-protein
carbonic B-O I-protein
anhydrase B-O I-protein
II B-O I-protein
( B-O O
CAII B-O B-DNA
) B-O O
, B-O O
a B-O O
gene B-O O
whose B-O O
transcription B-O O
is B-O O
efficiently B-O O
suppressed B-O O
by B-O O
v-erbA B-O B-protein
. B-O O

This B-O O
erbA-binding B-O B-DNA
site B-O I-DNA
confers B-O O
thyroid B-O O
hormone B-O O
responsiveness B-O O
to B-O O
a B-O O
heterologous B-O B-DNA
promoter B-O I-DNA
in B-O O
transient B-O O
expression B-O O
experiments B-O O
and B-O O
is B-O O
a B-O O
target B-O O
for B-O O
efficient B-O O
down-regulation B-O O
of B-O O
CAII B-O B-DNA
transcription B-O O
by B-O O
the B-O O
v-erbA B-O B-protein
oncoprotein B-O I-protein
. B-O O

In B-O O
stably B-O B-cell_line
transformed B-O I-cell_line
erythroblasts B-O I-cell_line
coexpressing B-O O
the B-O O
v-erbA B-O B-protein
oncoprotein B-O I-protein
and B-O O
the B-O O
c-erbA/T3 B-O B-protein
receptor B-O I-protein
at B-O O
an B-O O
approximately B-O O
equimolar B-O O
ratio B-O O
, B-O O
c-erbA B-O B-protein
activity B-O O
is B-O O
dominant B-O O
over B-O O
v-erbA B-O B-protein
. B-O O

T3 B-O O
efficiently B-O O
induced B-O O
erythroid B-O O
differentiation B-O O
in B-O O
these B-O O
cells B-O O
, B-O O
thus B-O O
overcoming B-O O
the B-O O
v-erbA B-O B-protein
-mediated B-O O
differentiation B-O O
arrest B-O O
. B-O O

Likewise B-O O
, B-O O
T3 B-O O
activated B-O O
CAII B-O B-DNA
transcription B-O O
as B-O O
well B-O O
as B-O O
transient B-O O
expression B-O O
of B-O O
a B-O O
T3 B-O B-DNA
-responsive B-O I-DNA
reporter B-O I-DNA
gene B-O I-DNA
containing B-O O
the B-O O
CAII B-O B-DNA
-specific B-O I-DNA
erbA-binding B-O I-DNA
site B-O I-DNA
. B-O O

The B-O O
c-erbA B-O B-protein
-dependent B-O O
activation B-O O
of B-O O
this B-O O
CAII B-O B-DNA
reporter B-O I-DNA
construct B-O I-DNA
could B-O O
only B-O O
be B-O O
suppressed B-O O
by B-O O
very B-O O
high B-O O
amounts B-O O
of B-O O
v-erbA B-O B-protein
. B-O O

Our B-O O
results B-O O
suggest B-O O
that B-O O
overexpression B-O O
of B-O O
v-erbA B-O B-protein
is B-O O
required B-O O
for B-O O
its B-O O
function B-O O
as B-O O
an B-O O
oncoprotein B-O B-protein
. B-O O

Anti-CD2 B-O B-protein
receptor B-O I-protein
antibodies B-O I-protein
activate B-O O
the B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

The B-O O
CD2 B-O B-protein
T B-O I-protein
lymphocyte B-O I-protein
glycoprotein B-O I-protein
surface B-O I-protein
molecule B-O I-protein
mediates B-O O
both B-O O
cell B-O O
to B-O O
cell B-O O
adhesion B-O O
and B-O O
T B-O O
cell B-O O
activation B-O O
, B-O O
two B-O O
processes B-O O
that B-O O
are B-O O
involved B-O O
in B-O O
the B-O O
spread B-O O
of B-O O
HIV B-O O
infection B-O O
. B-O O

Treatment B-O O
of B-O O
chronically B-O O
HIV-infected B-O O
PBMC B-O B-cell_type
with B-O O
anti-CD2 B-O B-protein
mAb B-O I-protein
has B-O O
been B-O O
shown B-O O
to B-O O
induce B-O O
the B-O O
expression B-O O
of B-O O
infectious B-O O
virus B-O O
from B-O O
these B-O O
cultures B-O O
. B-O O

In B-O O
this B-O O
study B-O O
we B-O O
investigated B-O O
the B-O O
mechanisms B-O O
whereby B-O O
anti-CD2 B-O B-protein
antibodies B-O I-protein
stimulate B-O O
viral B-O O
production B-O O
. B-O O

We B-O O
demonstrate B-O O
that B-O O
treatment B-O O
of B-O O
transiently B-O O
transfected B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
with B-O O
anti-CD2 B-O B-protein
antibodies B-O I-protein
results B-O O
in B-O O
activation B-O O
of B-O O
the B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
. B-O O

Furthermore B-O O
, B-O O
CAT B-O B-protein
assays B-O O
using B-O O
mutated B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
-CAT B-O I-DNA
constructs B-O I-DNA
and B-O O
gel B-O O
shift B-O O
assays B-O O
demonstrate B-O O
that B-O O
this B-O O
activation B-O O
is B-O O
dependent B-O O
on B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
enhancer B-O I-DNA
. B-O O

These B-O O
studies B-O O
suggest B-O O
that B-O O
interaction B-O O
of B-O O
CD2 B-O B-protein
with B-O O
its B-O O
natural B-O O
ligand B-O O
, B-O O
LFA-3 B-O B-protein
, B-O O
may B-O O
play B-O O
a B-O O
role B-O O
in B-O O
regulation B-O O
of B-O O
HIV B-O O
expression B-O O
. B-O O

Reactive B-O O
oxygen B-O O
intermediates B-O O
as B-O O
apparently B-O O
widely B-O O
used B-O O
messengers B-O O
in B-O O
the B-O O
activation B-O O
of B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
transcription B-O B-protein
factor B-O I-protein
and B-O O
HIV-1 B-O O
. B-O O

Hydrogen B-O O
peroxide B-O O
and B-O O
oxygen B-O O
radicals B-O O
are B-O O
agents B-O O
commonly B-O O
produced B-O O
during B-O O
inflammatory B-O O
processes B-O O
. B-O O

In B-O O
this B-O O
study B-O O
, B-O O
we B-O O
show B-O O
that B-O O
micromolar B-O O
concentrations B-O O
of B-O O
H2O2 B-O O
can B-O O
induce B-O O
the B-O O
expression B-O O
and B-O O
replication B-O O
of B-O O
HIV-1 B-O O
in B-O O
a B-O O
human B-O B-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
. B-O O

The B-O O
effect B-O O
is B-O O
mediated B-O O
by B-O O
the B-O O
NF-kappa B-O B-protein
B B-O I-protein
transcription B-O I-protein
factor B-O I-protein
which B-O O
is B-O O
potently B-O O
and B-O O
rapidly B-O O
activated B-O O
by B-O O
an B-O O
H2O2 B-O O
treatment B-O O
of B-O O
cells B-O O
from B-O O
its B-O O
inactive B-O B-protein
cytoplasmic B-O I-protein
form B-O I-protein
. B-O O

N-acetyl-L-cysteine B-O O
( B-O O
NAC B-O O
) B-O O
, B-O O
a B-O O
well B-O O
characterized B-O O
antioxidant B-O O
which B-O O
counteracts B-O O
the B-O O
effects B-O O
of B-O O
reactive B-O O
oxygen B-O O
intermediates B-O O
( B-O O
ROI B-O O
) B-O O
in B-O O
living B-O O
cells B-O O
, B-O O
prevented B-O O
the B-O O
activation B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
by B-O O
H2O2 B-O O
. B-O O

NAC B-O O
and B-O O
other B-O O
thiol B-O O
compounds B-O O
also B-O O
blocked B-O O
the B-O O
activation B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
by B-O O
cycloheximide B-O O
, B-O O
double-stranded B-O B-RNA
RNA B-O I-RNA
, B-O O
calcium B-O O
ionophore B-O O
, B-O O
TNF-alpha B-O B-protein
, B-O O
active B-O O
phorbol B-O O
ester B-O O
, B-O O
interleukin-1 B-O B-protein
, B-O O
lipopolysaccharide B-O O
and B-O O
lectin B-O B-protein
. B-O O

This B-O O
suggests B-O O
that B-O O
diverse B-O O
agents B-O O
thought B-O O
to B-O O
activate B-O O
NF-kappa B-O B-protein
B B-O I-protein
by B-O O
distinct B-O O
intracellular B-O O
pathways B-O O
might B-O O
all B-O O
act B-O O
through B-O O
a B-O O
common B-O O
mechanism B-O O
involving B-O O
the B-O O
synthesis B-O O
of B-O O
ROI B-O O
. B-O O

ROI B-O O
appear B-O O
to B-O O
serve B-O O
as B-O O
messengers B-O O
mediating B-O O
directly B-O O
or B-O O
indirectly B-O O
the B-O O
release B-O O
of B-O O
the B-O O
inhibitory B-O B-protein
subunit B-O I-protein
I B-O B-protein
kappa B-O I-protein
B B-O I-protein
from B-O O
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

Inhibition B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
belonging B-O O
to B-O O
the B-O O
rel/ B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
family B-O I-protein
by B-O O
a B-O O
transdominant B-O B-protein
negative B-O I-protein
mutant B-O I-protein
. B-O O

The B-O O
KBF1 B-O B-protein
factor B-O I-protein
, B-O O
which B-O O
binds B-O O
to B-O O
the B-O O
enhancer B-O B-DNA
A B-O I-DNA
located B-O O
in B-O O
the B-O O
promoter B-O B-DNA
of B-O O
the B-O O
mouse B-O B-DNA
MHC B-O I-DNA
class B-O I-DNA
I B-O I-DNA
gene B-O I-DNA
H-2Kb B-O O
, B-O O
is B-O O
indistinguishable B-O O
from B-O O
the B-O O
p50 B-O B-protein
DNA B-O I-protein
binding B-O I-protein
subunit B-O I-protein
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
which B-O O
regulates B-O O
a B-O O
series B-O O
of B-O O
genes B-O B-DNA
involved B-O O
in B-O O
immune B-O O
and B-O O
inflammatory B-O O
responses B-O O
. B-O O

The B-O O
KBF1/p50 B-O B-protein
factor B-O I-protein
binds B-O O
as B-O O
a B-O O
homodimer B-O B-protein
but B-O O
can B-O O
also B-O O
form B-O O
heterodimers B-O B-protein
with B-O O
the B-O O
products B-O O
of B-O O
other B-O O
members B-O O
of B-O O
the B-O O
same B-O O
family B-O O
, B-O O
like B-O O
the B-O O
c-rel B-O B-DNA
and B-O I-DNA
v-rel B-O I-DNA
( B-O I-DNA
proto B-O I-DNA
) B-O I-DNA
oncogenes B-O I-DNA
. B-O O

The B-O O
dimerization B-O B-protein
domain B-O I-protein
of B-O O
KBF1/p50 B-O B-protein
is B-O O
contained B-O O
between B-O O
amino B-O B-protein
acids B-O I-protein
201 B-O I-protein
and B-O I-protein
367 B-O I-protein
. B-O O

A B-O O
mutant B-O O
of B-O O
KBF1/p50 B-O B-protein
( B-O O
delta B-O B-protein
SP B-O I-protein
) B-O O
, B-O O
unable B-O O
to B-O O
bind B-O O
to B-O O
DNA B-O O
but B-O O
able B-O O
to B-O O
form B-O O
homo- B-O O
or B-O O
heterodimers B-O B-protein
, B-O O
has B-O O
been B-O O
constructed B-O O
. B-O O

This B-O O
protein B-O O
reduces B-O O
or B-O O
abolishes B-O O
in B-O O
vitro B-O O
the B-O O
DNA B-O O
binding B-O O
activity B-O O
of B-O O
wild-type B-O B-protein
proteins B-O I-protein
of B-O O
the B-O O
same B-O O
family B-O O
( B-O O
KBF1/p50 B-O B-protein
, B-O O
c- B-O O
and B-O O
v- B-O B-protein
rel B-O I-protein
) B-O O
. B-O O

This B-O O
mutant B-O O
also B-O O
functions B-O O
in B-O O
vivo B-O O
as B-O O
a B-O O
trans-acting B-O B-protein
dominant B-O I-protein
negative B-O I-protein
regulator B-O I-protein
: B-O O
the B-O O
transcriptional B-O O
inducibility B-O O
of B-O O
the B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
which B-O O
contains B-O O
two B-O O
potential B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
binding B-O I-DNA
sites B-O I-DNA
) B-O O
by B-O O
phorbol B-O O
ester B-O O
( B-O O
PMA B-O O
) B-O O
is B-O O
inhibited B-O O
when B-O O
it B-O O
is B-O O
co-transfected B-O O
into B-O O
CD4+ B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
with B-O O
the B-O O
delta B-O B-protein
SP B-O I-protein
mutant B-O I-protein
. B-O O

Similarly B-O O
the B-O O
basal B-O O
as B-O O
well B-O O
as B-O O
TNF B-O B-protein
or B-O O
IL1-induced B-O O
activity B-O O
of B-O O
the B-O O
MHC B-O B-DNA
class B-O I-DNA
I B-O I-DNA
H-2Kb B-O I-DNA
promoter B-O I-DNA
can B-O O
be B-O O
inhibited B-O O
by B-O O
this B-O O
mutant B-O O
in B-O O
two B-O O
different B-O O
cell B-O B-cell_line
lines B-O I-cell_line
. B-O O

These B-O O
results B-O O
constitute B-O O
the B-O O
first B-O O
formal B-O O
demonstration B-O O
that B-O O
these B-O O
genes B-O O
are B-O O
regulated B-O O
by B-O O
members B-O O
of B-O O
the B-O O
rel/ B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
family B-O I-protein
. B-O O

Tissue-specific B-O O
expression B-O O
of B-O O
the B-O O
platelet B-O B-DNA
GPIIb B-O I-DNA
gene B-O I-DNA
. B-O O

One B-O O
of B-O O
the B-O O
major B-O O
objectives B-O O
in B-O O
the B-O O
study B-O O
of B-O O
thrombogenesis B-O O
is B-O O
to B-O O
determine B-O O
the B-O O
mechanisms B-O O
by B-O O
which B-O O
a B-O O
hematopoietic B-O B-cell_type
progenitor B-O I-cell_type
is B-O O
activated B-O O
and B-O O
committed B-O O
to B-O O
the B-O O
megakaryocytic B-O B-cell_type
lineage B-O I-cell_type
. B-O O

Recent B-O O
development B-O O
of B-O O
primary B-O B-cell_line
cultures B-O I-cell_line
of B-O O
human B-O B-cell_type
megakaryocytes B-O I-cell_type
and B-O O
the B-O O
molecular B-O O
cloning B-O O
of B-O O
genes B-O O
that B-O O
are B-O O
specific B-O O
to B-O O
this B-O O
lineage B-O O
offer B-O O
the B-O O
possibility B-O O
of B-O O
getting B-O O
some B-O O
insights B-O O
into B-O O
the B-O O
genetic B-O O
mechanisms B-O O
that B-O O
control B-O O
megakaryocytopoiesis B-O O
. B-O O

One B-O O
gene B-O O
of B-O O
interest B-O O
is B-O O
the B-O O
glycoprotein B-O B-DNA
IIb B-O I-DNA
( B-O I-DNA
GPIIb B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
; B-O O
GPIIb B-O B-protein
, B-O O
the B-O O
alpha B-O B-protein
subunit B-O I-protein
of B-O O
the B-O O
platelet B-O B-protein
cytoadhesin B-O I-protein
GPIIb-IIIa B-O I-protein
, B-O O
is B-O O
produced B-O O
in B-O O
megakaryocytes B-O B-cell_type
at B-O O
an B-O O
early B-O O
stage B-O O
of B-O O
the B-O O
differentiation B-O O
, B-O O
whereas B-O O
the B-O O
other B-O O
subunit B-O O
of B-O O
this B-O O
complex B-O O
, B-O O
GPIIIa B-O B-protein
, B-O O
is B-O O
expressed B-O O
in B-O O
other B-O O
cells B-O O
. B-O O

For B-O O
these B-O O
reasons B-O O
, B-O O
the B-O O
5'-flanking B-O B-DNA
region B-O I-DNA
of B-O O
the B-O O
GPIIb B-O B-DNA
gene B-O I-DNA
was B-O O
used B-O O
to B-O O
identify B-O O
the B-O O
regions B-O O
that B-O O
interact B-O O
with B-O O
DNA-binding B-O B-protein
nuclear B-O I-protein
factors B-O I-protein
. B-O O

A B-O O
fragment B-O O
extending B-O O
from B-O O
-643 B-O B-DNA
to B-O I-DNA
+33 B-O I-DNA
is B-O O
capable B-O O
of B-O O
controlling B-O O
the B-O O
tissue-specific B-O O
expression B-O O
of B-O O
the B-O O
CAT B-O B-DNA
gene B-O I-DNA
in B-O O
transfection B-O O
experiments B-O O
. B-O O

Within B-O O
this B-O O
region B-O O
, B-O O
we B-O O
have B-O O
identified B-O O
several B-O O
sequences B-O O
that B-O O
are B-O O
implicated B-O O
in B-O O
DNA B-O O
protein B-O O
interactions B-O O
as B-O O
shown B-O O
in B-O O
DNAse B-O B-protein
I B-O I-protein
footprints B-O O
and B-O O
gel B-O O
mobility B-O O
shift B-O O
assays B-O O
. B-O O

One B-O O
region B-O O
, B-O O
centered B-O O
at B-O O
-54 B-O O
, B-O O
is B-O O
similar B-O O
to B-O O
a B-O O
nuclear B-O B-DNA
factor B-O I-DNA
E1-binding B-O I-DNA
site B-O I-DNA
, B-O O
and B-O O
a B-O O
region B-O O
located B-O O
at B-O O
position B-O B-DNA
-233 B-O I-DNA
contains B-O O
a B-O O
CCAAT B-O B-DNA
motif B-O I-DNA
. B-O O

Two B-O O
domains B-O O
centered B-O O
at B-O O
positions B-O B-DNA
-345 B-O I-DNA
and B-O I-DNA
-540 B-O I-DNA
, B-O O
respectively B-O O
, B-O O
bind B-O O
proteins B-O O
that B-O O
are B-O O
present B-O O
in B-O O
megakaryocytic B-O B-cell_type
cells B-O I-cell_type
and B-O O
nonrelated B-O B-cell_type
cells B-O I-cell_type
as B-O O
well B-O O
. B-O O

Finally B-O O
, B-O O
two B-O O
other B-O O
domains B-O O
, B-O O
located B-O O
at B-O O
positions B-O B-DNA
-460 B-O I-DNA
and B-O I-DNA
-510 B-O I-DNA
, B-O O
interact B-O O
with B-O O
proteins B-O O
that B-O O
are B-O O
only B-O O
present B-O O
in B-O O
megakaryocytic B-O B-cell_type
cells B-O I-cell_type
. B-O O

In B-O O
addition B-O O
, B-O O
deletion B-O O
of B-O O
the B-O O
region B-O O
containing B-O O
these B-O O
two B-O O
domains B-O O
results B-O O
in B-O O
a B-O O
significant B-O O
decrease B-O O
of B-O O
the B-O O
promoter B-O O
activity B-O O
. B-O O

It B-O O
is B-O O
very B-O O
likely B-O O
that B-O O
these B-O O
domains B-O O
bind B-O O
megakaryocyte-specific B-O B-protein
nuclear B-O I-protein
proteins B-O I-protein
acting B-O O
as B-O O
positive B-O B-protein
transcription B-O I-protein
factors B-O I-protein
. B-O O

Lymphocyte B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
binding B-O O
during B-O O
depression B-O O
and B-O O
after B-O O
clinical B-O O
recovery B-O O
. B-O O

Lymphocyte B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
binding B-O O
parameters B-O O
were B-O O
studied B-O O
in B-O O
15 B-O O
severely B-O O
depressed B-O O
patients B-O O
during B-O O
depression B-O O
and B-O O
after B-O O
clinical B-O O
recovery B-O O
, B-O O
and B-O O
in B-O O
15 B-O O
healthy B-O O
controls B-O O
. B-O O

There B-O O
was B-O O
no B-O O
difference B-O O
in B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
number B-O O
or B-O O
affinity B-O O
between B-O O
depressed B-O O
patients B-O O
and B-O O
recovered B-O O
or B-O O
control B-O O
subjects B-O O
. B-O O

Afternoon B-O O
ACTH B-O O
and B-O O
cortisol B-O O
concentrations B-O O
did B-O O
not B-O O
differ B-O O
significantly B-O O
between B-O O
the B-O O
three B-O O
groups B-O O
. B-O O

No B-O O
relationship B-O O
could B-O O
be B-O O
established B-O O
between B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
binding B-O O
and B-O O
antidepressant B-O O
medication B-O O
. B-O O

These B-O O
data B-O O
support B-O O
the B-O O
view B-O O
of B-O O
an B-O O
impaired B-O O
ligand-induced B-O O
plasticity B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
regulation B-O O
rather B-O O
than B-O O
the B-O O
hypothesis B-O O
of B-O O
decreased B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
numbers B-O O
during B-O O
depression B-O O
. B-O O

Every B-O O
enhancer B-O B-DNA
works B-O O
with B-O O
every B-O O
promoter B-O B-DNA
for B-O O
all B-O O
the B-O O
combinations B-O O
tested B-O O
: B-O O
could B-O O
new B-O O
regulatory B-O O
pathways B-O O
evolve B-O O
by B-O O
enhancer B-O O
shuffling B-O O
? B-O O

The B-O O
promoters B-O B-DNA
and B-O O
enhancers B-O B-DNA
of B-O O
cell B-O B-DNA
type-specific B-O I-DNA
genes B-O I-DNA
are B-O O
often B-O O
conserved B-O O
in B-O O
evolution B-O O
, B-O O
and B-O O
hence B-O O
one B-O O
might B-O O
expect B-O O
that B-O O
a B-O O
given B-O O
enhancer B-O B-DNA
has B-O O
evolved B-O O
to B-O O
work B-O O
best B-O O
with B-O O
its B-O O
own B-O O
promoter B-O B-DNA
. B-O O

While B-O O
this B-O O
expectation B-O O
may B-O O
be B-O O
realized B-O O
in B-O O
some B-O O
cases B-O O
, B-O O
we B-O O
have B-O O
not B-O O
found B-O O
evidence B-O O
for B-O O
it B-O O
. B-O O

A B-O O
total B-O O
of B-O O
27 B-O O
combinations B-O O
of B-O O
different B-O O
promoters B-O B-DNA
and B-O O
enhancers B-O B-DNA
were B-O O
tested B-O O
by B-O O
transfection B-O O
into B-O O
cultured B-O B-cell_line
cells B-O I-cell_line
. B-O O

We B-O O
found B-O O
that B-O O
the B-O O
relative B-O O
efficiency B-O O
of B-O O
the B-O O
enhancers B-O B-DNA
is B-O O
approximately B-O O
the B-O O
same B-O O
, B-O O
irrespective B-O O
of B-O O
the B-O O
type B-O O
of B-O O
promoter B-O B-DNA
used B-O O
, B-O O
i.e. B-O O
, B-O O
there B-O O
was B-O O
no B-O O
strong B-O O
preference B-O O
for B-O O
any B-O O
given B-O O
enhancer/ B-O O
promoter B-O O
combination B-O O
. B-O O

Notably B-O O
, B-O O
we B-O O
do B-O O
not B-O O
see B-O O
particularly B-O O
strong B-O O
transcription B-O O
when B-O O
the B-O O
immunoglobulin B-O B-DNA
kappa B-O I-DNA
enhancer B-O I-DNA
( B-O O
or B-O O
the B-O O
immunoglobulin B-O B-DNA
heavy B-O I-DNA
chain B-O I-DNA
enhancer B-O I-DNA
) B-O O
is B-O O
used B-O O
to B-O O
activate B-O O
a B-O O
kappa B-O B-DNA
gene B-O I-DNA
promoter B-O I-DNA
. B-O O

We B-O O
propose B-O O
that B-O O
a B-O O
generally B-O O
permissive B-O O
enhancer/ B-O O
promoter B-O O
interaction B-O O
is B-O O
of B-O O
evolutionary B-O O
benefit B-O O
for B-O O
higher B-O O
eukaryotes B-O O
: B-O O
by B-O O
enhancer B-O O
shuffling B-O O
, B-O O
genes B-O O
could B-O O
be B-O O
easily B-O O
brought B-O O
under B-O O
a B-O O
new B-O O
type B-O O
of B-O O
inducibility/cell B-O O
type B-O O
specificity B-O O
. B-O O

Towards B-O O
a B-O O
molecular B-O O
understanding B-O O
of B-O O
T-cell B-O O
differentiation B-O O
. B-O O

Lymphoid B-O O
differentiation B-O O
is B-O O
one B-O O
of B-O O
the B-O O
best B-O O
studied B-O O
examples B-O O
of B-O O
mammalian B-O O
development B-O O
. B-O O

Here B-O O
Hans B-O O
Clevers B-O O
and B-O O
Michael B-O O
Owen B-O O
describe B-O O
how B-O O
the B-O O
cloning B-O O
of B-O O
the B-O O
genes B-O O
that B-O O
encode B-O O
T-cell-specific B-O B-protein
membrane B-O I-protein
proteins B-O I-protein
allows B-O O
the B-O O
identification B-O O
of B-O O
transcription B-O B-protein
factors B-O I-protein
that B-O O
control B-O O
the B-O O
expression B-O O
of B-O O
these B-O O
T-cell B-O B-DNA
genes B-O I-DNA
. B-O O

Such B-O O
transcription B-O B-protein
factors B-O I-protein
play B-O O
a B-O O
key B-O O
role B-O O
in B-O O
the B-O O
development B-O O
of B-O O
the B-O O
mature B-O B-cell_type
T-cell B-O I-cell_type
phenotype B-O I-cell_type
by B-O O
functioning B-O O
as B-O O
' B-O O
master B-O B-protein
regulators B-O I-protein
of B-O O
T-cell B-O O
differentiation B-O O
' B-O O
. B-O O

A B-O O
study B-O O
on B-O O
the B-O O
circadian B-O O
rhythm B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
. B-O O

Circadian B-O O
rhythm B-O O
in B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
( B-O O
GR B-O B-protein
) B-O O
was B-O O
studied B-O O
in B-O O
the B-O O
rat B-O O
liver B-O O
and B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
leukocytes B-O I-cell_type
. B-O O

For B-O O
rats B-O O
exposed B-O O
to B-O O
a B-O O
natural B-O O
environmental B-O O
photic B-O O
cycle B-O O
or B-O O
a B-O O
12L B-O O
: B-O O
12D B-O O
artificial B-O O
light B-O O
regime B-O O
, B-O O
peak B-O O
values B-O O
of B-O O
hepatic B-O B-protein
GR B-O I-protein
were B-O O
detected B-O O
between B-O O
23 B-O O
: B-O O
00 B-O O
and B-O O
02 B-O O
: B-O O
00 B-O O
h B-O O
. B-O O

Except B-O O
for B-O O
a B-O O
4-hour B-O O
advancement B-O O
of B-O O
the B-O O
peak B-O O
, B-O O
a B-O O
similar B-O O
circadian B-O O
rhythm B-O O
of B-O O
hepatic B-O B-protein
GR B-O I-protein
was B-O O
detected B-O O
in B-O O
rats B-O O
reared B-O O
under B-O O
a B-O O
reversed B-O O
lighting B-O O
regimen B-O O
( B-O O
12D B-O O
: B-O O
12L B-O O
; B-O O
lights B-O O
on B-O O
between B-O O
18 B-O O
: B-O O
30 B-O O
and B-O O
06 B-O O
: B-O O
30 B-O O
h B-O O
) B-O O
. B-O O

In B-O O
human B-O B-cell_type
leukocytes B-O I-cell_type
, B-O O
the B-O O
peak B-O O
value B-O O
of B-O O
GR B-O B-protein
was B-O O
found B-O O
to B-O O
parallel B-O O
that B-O O
of B-O O
plasma B-O O
cortisol B-O O
with B-O O
high B-O O
and B-O O
low B-O O
values B-O O
detected B-O O
at B-O O
04 B-O O
: B-O O
00-08 B-O O
: B-O O
00 B-O O
h B-O O
and B-O O
23 B-O O
: B-O O
00-24 B-O O
: B-O O
00 B-O O
h B-O O
, B-O O
respectively B-O O
. B-O O

In B-O O
patients B-O O
suffering B-O O
from B-O O
Cushing B-O O
's B-O O
syndrome B-O O
, B-O O
the B-O O
circadian B-O O
rhythm B-O O
of B-O O
plasma B-O O
cortisol B-O O
either B-O O
disappeared B-O O
or B-O O
was B-O O
inverted B-O O
while B-O O
that B-O O
of B-O O
GR B-O B-protein
did B-O O
not B-O O
significantly B-O O
deviate B-O O
from B-O O
the B-O O
normal B-O O
subjects B-O O
. B-O O

For B-O O
apoplexic B-O O
patients B-O O
with B-O O
lesions B-O O
localized B-O O
to B-O O
the B-O O
base B-O O
of B-O O
the B-O O
brain B-O O
as B-O O
indicated B-O O
by B-O O
computerized B-O O
tomography B-O O
, B-O O
the B-O O
diurnal B-O O
variation B-O O
of B-O O
GR B-O B-protein
was B-O O
abolished B-O O
. B-O O

Conversely B-O O
, B-O O
diurnal B-O O
rhythmicity B-O O
persisted B-O O
in B-O O
apoplexy B-O O
patients B-O O
whose B-O O
lesions B-O O
were B-O O
in B-O O
the B-O O
cerebral B-O O
cortex B-O O
. B-O O

Thus B-O O
, B-O O
we B-O O
postulated B-O O
that B-O O
the B-O O
circadian B-O O
modification B-O O
of B-O O
GR B-O B-protein
was B-O O
independent B-O O
of B-O O
the B-O O
diurnal B-O O
fluctuations B-O O
in B-O O
plasma B-O O
cortisol B-O O
level B-O O
or B-O O
the B-O O
circadian B-O O
variations B-O O
in B-O O
environmental B-O O
lighting B-O O
and B-O O
that B-O O
the B-O O
rhythmicity B-O O
might B-O O
be B-O O
regulated B-O O
by B-O O
the B-O O
' B-O O
circadian B-O O
pacemaker B-O O
' B-O O
located B-O O
in B-O O
the B-O O
human B-O O
basal B-O O
brain B-O O
. B-O O

These B-O O
diurnal B-O O
variations B-O O
in B-O O
GR B-O B-protein
might B-O O
serve B-O O
to B-O O
coordinate B-O O
the B-O O
reactivity B-O O
of B-O O
the B-O O
target B-O B-cell_type
cells B-O I-cell_type
to B-O O
cortisol B-O O
because B-O O
the B-O O
diurnal B-O O
rhythms B-O O
of B-O O
a B-O O
GR B-O B-protein
-mediated B-O O
response B-O O
, B-O O
the B-O O
fractional B-O O
inhibition B-O O
of B-O O
chemotactic B-O O
migration B-O O
rate B-O O
of B-O O
polymorphonuclear B-O B-cell_type
leukocytes B-O I-cell_type
by B-O O
cortisol B-O O
, B-O O
were B-O O
found B-O O
to B-O O
be B-O O
synchronous B-O O
with B-O O
those B-O O
of B-O O
GR B-O B-protein
. B-O O

Transcription B-O B-protein
factor B-O I-protein
requirements B-O O
for B-O O
U2 B-O B-RNA
snRNA B-O I-RNA
-encoding B-O O
gene B-O O
activation B-O O
in B-O O
B B-O B-cell_type
lymphoid B-O I-cell_type
cells B-O I-cell_type
. B-O O

Transcription B-O O
of B-O O
a B-O O
human B-O B-DNA
U2 B-O I-DNA
small B-O I-DNA
nuclear B-O I-DNA
RNA B-O I-DNA
( B-O I-DNA
snRNA B-O I-DNA
) B-O I-DNA
-encoding B-O I-DNA
gene B-O I-DNA
in B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
requires B-O O
a B-O O
distal B-O B-DNA
enhancer B-O I-DNA
element B-O I-DNA
, B-O O
which B-O O
is B-O O
composed B-O O
of B-O O
one B-O O
octamer B-O B-DNA
motif B-O I-DNA
( B-O O
Oct B-O B-DNA
) B-O O
and B-O O
three B-O O
Sp B-O B-DNA
1-binding B-O I-DNA
sites B-O I-DNA
. B-O O

To B-O O
study B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
requirement B-O O
in B-O O
B-cells B-O B-cell_type
, B-O O
different B-O O
U2 B-O B-DNA
enhancer B-O I-DNA
constructions B-O I-DNA
were B-O O
transfected B-O O
into B-O O
the B-O O
lymphoid B-O B-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
BJA-B B-O B-cell_line
. B-O O

The B-O O
results B-O O
showed B-O O
that B-O O
the B-O O
activation B-O O
of B-O O
U2 B-O B-RNA
snRNA B-O I-RNA
transcription B-O O
in B-O O
B-cells B-O B-cell_type
also B-O O
requires B-O O
an B-O O
enhancer B-O B-DNA
comprising B-O O
both B-O O
the B-O O
Oct B-O B-DNA
and B-O O
at B-O O
least B-O O
one B-O O
Sp B-O B-DNA
1-binding B-O I-DNA
site B-O I-DNA
. B-O O

Deletion B-O O
of B-O O
all B-O O
the B-O O
Sp B-O B-DNA
1-binding B-O I-DNA
sites B-O I-DNA
from B-O O
the B-O O
enhancer B-O B-DNA
reduces B-O O
transcription B-O O
by B-O O
80-90 B-O O
% B-O O
in B-O O
HeLa B-O B-cell_line
, B-O O
as B-O O
well B-O O
as B-O O
in B-O O
BJA-B B-O B-cell_line
cells B-O I-cell_line
, B-O O
whereas B-O O
the B-O O
removal B-O O
of B-O O
the B-O O
octamer-binding B-O B-DNA
site B-O I-DNA
reduces B-O O
transcription B-O O
to B-O O
levels B-O O
below B-O O
detection B-O O
in B-O O
both B-O O
cell B-O O
types B-O O
. B-O O

Enhancers B-O B-DNA
containing B-O O
a B-O O
single B-O O
Oct B-O B-DNA
have B-O O
, B-O O
nevertheless B-O O
, B-O O
the B-O O
capacity B-O O
to B-O O
partially B-O O
activate B-O O
U2 B-O B-RNA
snRNA B-O I-RNA
transcription B-O O
in B-O O
both B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
, B-O O
in B-O O
which B-O O
only B-O O
OTF-1 B-O B-protein
is B-O O
expressed B-O O
, B-O O
and B-O O
in B-O O
BJA-B B-O B-cell_line
cells B-O I-cell_line
in B-O O
which B-O O
OTF-2 B-O B-protein
is B-O O
the B-O O
predominantly B-O O
expressed B-O O
octamer-binding B-O B-protein
factor B-O I-protein
. B-O O

The B-O O
most B-O O
likely B-O O
interpretation B-O O
of B-O O
our B-O O
results B-O O
is B-O O
that B-O O
both B-O O
the B-O O
ubiquitous B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
OTF-1 B-O B-protein
, B-O O
and B-O O
the B-O O
B-cell-specific B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
OTF-2 B-O B-protein
, B-O O
can B-O O
activate B-O O
U2 B-O B-RNA
snRNA B-O I-RNA
transcription B-O O
. B-O O

The B-O O
results B-O O
also B-O O
revealed B-O O
a B-O O
similar B-O O
functional B-O O
cooperation B-O O
between B-O O
the B-O O
transcription B-O B-protein
factors B-O I-protein
which B-O O
bind B-O O
to B-O O
the B-O O
Oct B-O B-DNA
and B-O O
the B-O O
adjacent B-O O
Sp B-O B-DNA
1-binding B-O I-DNA
site B-O I-DNA
in B-O O
BJA-B B-O B-cell_line
cells B-O I-cell_line
, B-O O
as B-O O
has B-O O
been B-O O
observed B-O O
in B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
, B-O O
since B-O O
a B-O O
template B-O O
which B-O O
contains B-O O
a B-O O
weak B-O O
binding B-O O
site B-O O
for B-O O
OTFs B-O B-protein
expresses B-O O
wild-type B-O O
levels B-O O
of B-O O
U2 B-O B-RNA
snRNA B-O I-RNA
in B-O O
both B-O O
cell B-O O
types B-O O
when B-O O
the B-O O
weak B-O O
octamer-binding B-O B-DNA
site B-O I-DNA
is B-O O
combined B-O O
with B-O O
a B-O O
Sp B-O B-DNA
1-binding B-O I-DNA
site B-O I-DNA
. B-O O

One B-O O
base B-O O
pair B-O O
change B-O O
abolishes B-O O
the B-O O
T B-O O
cell-restricted B-O O
activity B-O O
of B-O O
a B-O O
kB-like B-O B-DNA
proto-enhancer B-O I-DNA
element B-O I-DNA
from B-O O
the B-O O
interleukin B-O B-DNA
2 B-O I-DNA
promoter B-O I-DNA
. B-O O

The B-O O
inducible B-O O
, B-O O
T B-O B-DNA
cell-specific B-O I-DNA
enhancers B-O I-DNA
of B-O O
murine B-O B-DNA
and B-O I-DNA
human B-O I-DNA
Interleukin B-O I-DNA
2 B-O I-DNA
( B-O I-DNA
Il-2 B-O I-DNA
) B-O I-DNA
genes B-O I-DNA
contain B-O O
the B-O O
kB-like B-O B-DNA
sequence B-O I-DNA
GGGATTTCACC B-O O
as B-O O
an B-O O
essential B-O B-DNA
cis-acting B-O I-DNA
enhancer B-O I-DNA
motif B-O I-DNA
. B-O O

When B-O O
cloned B-O O
in B-O O
multiple B-O O
copies B-O O
this B-O O
so-called B-O O
TCEd B-O B-DNA
( B-O O
distal B-O B-DNA
T B-O I-DNA
cell B-O I-DNA
element B-O I-DNA
) B-O O
acts B-O O
as B-O O
an B-O O
inducible B-O O
proto-enhancer B-O B-DNA
element B-O I-DNA
in B-O O
E14 B-O B-cell_line
T B-O I-cell_line
lymphoma B-O I-cell_line
cells B-O I-cell_line
, B-O O
but B-O O
not B-O O
in B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
. B-O O

In B-O O
extracts B-O O
of B-O O
induced B-O O
, B-O O
Il-2 B-O B-protein
secreting B-O O
El4 B-O O
cells B-O O
three B-O O
individual B-O O
protein B-O B-protein
factors B-O I-protein
bind B-O O
to B-O O
TCEd B-O B-DNA
DNA B-O I-DNA
. B-O O

The B-O O
binding B-O O
of B-O O
the B-O O
most B-O O
prominent B-O O
factor B-O O
, B-O O
named B-O O
TCF-1 B-O B-protein
( B-O O
T B-O B-protein
cell B-O I-protein
factor B-O I-protein
1 B-O I-protein
) B-O O
, B-O O
is B-O O
correlated B-O O
with B-O O
the B-O O
proto-enhancer B-O B-DNA
activity B-O O
of B-O O
TCEd B-O B-DNA
. B-O O

TCF-1 B-O B-protein
consists B-O O
of B-O O
two B-O O
polypeptides B-O O
of B-O O
about B-O O
50 B-O B-protein
kD B-O I-protein
and B-O O
105 B-O O
kD B-O O
; B-O O
the B-O O
former B-O O
seems B-O O
to B-O O
be B-O O
related B-O O
to B-O O
the B-O O
50 B-O B-protein
kD B-O I-protein
polypeptide B-O I-protein
of B-O O
NF-kB B-O B-protein
. B-O O

Purified B-O O
NF-kB B-O B-protein
is B-O O
also B-O O
able B-O O
to B-O O
bind B-O O
to B-O O
the B-O O
TCEd B-O B-DNA
, B-O O
but B-O O
TCF-1 B-O B-protein
binds B-O O
stronger B-O O
than B-O O
NF-kB B-O B-protein
to B-O O
TCEd B-O B-DNA
DNA B-O I-DNA
. B-O O

The B-O O
conversion B-O O
of B-O O
the B-O O
TCEd B-O B-DNA
to B-O O
a B-O O
' B-O B-DNA
perfect B-O I-DNA
' B-O I-DNA
NF-kB B-O I-DNA
binding B-O I-DNA
site B-O I-DNA
leads B-O O
to B-O O
a B-O O
tighter B-O O
binding B-O O
of B-O O
NF-kB B-O B-protein
to B-O O
TCEd B-O B-DNA
DNA B-O I-DNA
and B-O O
, B-O O
as B-O O
a B-O O
functional B-O O
consequence B-O O
, B-O O
to B-O O
the B-O O
activity B-O O
of B-O O
the B-O O
' B-O B-DNA
converted B-O I-DNA
' B-O I-DNA
TCEd B-O I-DNA
motifs B-O I-DNA
in B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
. B-O O

Thus B-O O
, B-O O
the B-O O
substitution B-O O
of B-O O
the B-O O
underlined B-O O
A B-O O
residue B-O O
to B-O O
a B-O O
C B-O O
within B-O O
the B-O O
GGGATTTCACC B-O B-DNA
motif B-O I-DNA
abolishes B-O O
its B-O O
T B-O O
cell-restricted B-O O
activity B-O O
and B-O O
leads B-O O
to B-O O
its B-O O
functioning B-O O
in B-O O
both B-O O
El4 B-O B-cell_line
cells B-O I-cell_line
and B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
lymphocyte-specific B-O B-protein
factors B-O I-protein
binding B-O O
to B-O O
the B-O O
TCEd B-O B-DNA
are B-O O
involved B-O O
in B-O O
the B-O O
control B-O O
of B-O O
T B-O O
cell B-O O
specific-transcription B-O O
of B-O O
the B-O O
Il-2 B-O B-DNA
gene B-O I-DNA
. B-O O

An B-O O
erythroid B-O B-DNA
specific B-O I-DNA
enhancer B-O I-DNA
upstream B-O O
to B-O O
the B-O O
gene B-O O
encoding B-O O
the B-O O
cell-type B-O B-protein
specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
GATA-1 B-O B-protein
. B-O O

The B-O O
transcription B-O B-protein
factor B-O I-protein
GATA-1 B-O B-protein
is B-O O
expressed B-O O
in B-O O
a B-O O
subset B-O O
of B-O O
hemopoietic B-O B-cell_type
cells B-O I-cell_type
, B-O O
where B-O O
it B-O O
mediates B-O O
the B-O O
cell-type B-O O
specific B-O O
expression B-O O
of B-O O
several B-O O
genes B-O O
. B-O O

We B-O O
have B-O O
cloned B-O O
the B-O O
mouse B-O B-DNA
and B-O I-DNA
human B-O I-DNA
GATA-1 B-O I-DNA
genes B-O I-DNA
. B-O O

A B-O O
region B-O O
upstream B-O O
to B-O O
the B-O O
first B-O B-DNA
exon B-O I-DNA
, B-O O
and B-O O
highly B-O O
conserved B-O O
between B-O O
mouse B-O O
and B-O O
man B-O O
, B-O O
acts B-O O
as B-O O
an B-O O
erythroid B-O B-DNA
specific B-O I-DNA
enhancer B-O I-DNA
in B-O O
transient B-O O
assays B-O O
, B-O O
if B-O O
linked B-O O
to B-O O
the B-O O
GATA-1 B-O B-protein
or B-O O
to B-O O
the B-O O
SV40 B-O B-DNA
promoter B-O I-DNA
. B-O O

The B-O O
activity B-O O
of B-O O
the B-O O
enhancer B-O B-DNA
is B-O O
almost B-O O
completely B-O O
dependent B-O O
on B-O O
the B-O O
integrity B-O O
of B-O O
a B-O O
dimeric B-O B-DNA
GATA-1 B-O I-DNA
binding B-O I-DNA
site B-O I-DNA
. B-O O

Demonstration B-O O
of B-O O
a B-O O
1 B-O B-protein
, B-O I-protein
25-dihydroxyvitamin B-O I-protein
D3 B-O I-protein
-responsive B-O I-protein
protein B-O I-protein
in B-O O
human B-O B-cell_type
lymphocytes B-O I-cell_type
: B-O O
immunologic B-O O
crossreactivity B-O O
and B-O O
inverse B-O O
regulation B-O O
with B-O O
the B-O O
vitamin B-O B-protein
D B-O I-protein
receptor B-O I-protein
. B-O O

Using B-O O
Western B-O O
blot B-O O
analysis B-O O
with B-O O
a B-O O
monoclonal B-O B-protein
antibody B-O I-protein
recognizing B-O O
a B-O O
17-amino B-O B-protein
acid B-O I-protein
epitope B-O I-protein
of B-O O
the B-O O
1 B-O B-protein
, B-O I-protein
25-dihydroxyvitamin B-O I-protein
D3 B-O I-protein
[ B-O I-protein
1 B-O I-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
] B-O I-protein
receptor B-O I-protein
, B-O O
we B-O O
have B-O O
detected B-O O
two B-O O
crossreacting B-O B-protein
proteins B-O I-protein
in B-O O
activated B-O B-cell_type
normal B-O I-cell_type
human B-O I-cell_type
lymphocytes B-O I-cell_type
. B-O O

The B-O O
smaller B-O O
of B-O O
the B-O O
two B-O O
proteins B-O O
( B-O O
50 B-O B-protein
kDa B-O I-protein
) B-O O
was B-O O
indistinguishable B-O O
from B-O O
the B-O O
classical B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptor B-O I-protein
and B-O O
, B-O O
similar B-O O
to B-O O
the B-O O
classical B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptor B-O I-protein
, B-O O
was B-O O
upregulated B-O O
in B-O O
a B-O O
dose-dependent B-O O
fashion B-O O
by B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
. B-O O

The B-O O
larger B-O O
crossreacting B-O B-protein
protein B-O I-protein
exhibited B-O O
an B-O O
electrophoretic B-O O
mobility B-O O
of B-O O
80 B-O B-protein
kDa B-O I-protein
, B-O O
was B-O O
localized B-O O
in B-O O
the B-O O
cell B-O O
cytosol B-O O
, B-O O
and B-O O
appeared B-O O
to B-O O
be B-O O
specific B-O O
for B-O O
activated B-O B-cell_type
lymphocytes B-O I-cell_type
since B-O O
it B-O O
was B-O O
not B-O O
detected B-O O
in B-O O
several B-O O
other B-O O
human B-O B-cell_type
cells B-O I-cell_type
including B-O O
monocytes B-O B-cell_type
. B-O O

More B-O O
strikingly B-O O
, B-O O
the B-O O
80-kDa B-O B-protein
protein B-O I-protein
was B-O O
downregulated B-O O
in B-O O
a B-O O
dose-dependent B-O O
fashion B-O O
by B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
; B-O O
this B-O O
effect B-O O
was B-O O
independent B-O O
of B-O O
the B-O O
mode B-O O
of B-O O
lymphocyte B-O O
activation B-O O
and B-O O
specific B-O O
for B-O O
the B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
metabolite B-O O
of B-O O
vitamin B-O O
D3 B-O O
. B-O O

However B-O O
, B-O O
two B-O O
potent B-O O
immunosuppressive B-O O
agents B-O O
, B-O O
glucocorticoids B-O O
and B-O O
cyclosporin B-O O
A B-O O
, B-O O
also B-O O
inhibited B-O O
the B-O O
80-kDa B-O B-protein
protein B-O I-protein
. B-O O

Regulation B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
human B-O B-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
: B-O O
effects B-O O
of B-O O
glucocorticoid B-O O
treatment B-O O
, B-O O
Cushing B-O O
's B-O O
disease B-O O
and B-O O
ketoconazole B-O O
. B-O O

Glucocorticoid B-O B-protein
receptors B-O I-protein
( B-O O
GcR B-O B-protein
) B-O O
were B-O O
determined B-O O
by B-O O
a B-O O
whole B-O O
cell B-O O
assay B-O O
in B-O O
human B-O B-cell_type
mononulear B-O I-cell_type
leukocytes B-O I-cell_type
( B-O O
hMNL B-O B-cell_type
) B-O O
from B-O O
control B-O O
subjects B-O O
, B-O O
patients B-O O
receiving B-O O
glucocorticoid B-O O
therapy B-O O
for B-O O
systemic B-O O
diseases B-O O
and B-O O
Cushing B-O O
's B-O O
disease B-O O
patients B-O O
with B-O O
or B-O O
without B-O O
ketoconazole B-O O
therapy B-O O
. B-O O

Prolonged B-O O
corticosteroid B-O O
treatment B-O O
resulted B-O O
in B-O O
down-regulation B-O O
of B-O O
GcR B-O B-protein
, B-O O
while B-O O
the B-O O
mean B-O O
level B-O O
of B-O O
GcR B-O B-protein
in B-O O
Cushing B-O O
's B-O O
disease B-O O
was B-O O
normal B-O O
. B-O O

In B-O O
this B-O O
group B-O O
, B-O O
however B-O O
, B-O O
receptor B-O O
levels B-O O
and B-O O
morning B-O O
plasma B-O O
cortisol B-O O
values B-O O
showed B-O O
a B-O O
negative B-O O
correlation B-O O
, B-O O
indicating B-O O
a B-O O
subtle B-O O
down-regulatory B-O O
effect B-O O
. B-O O

Furthermore B-O O
, B-O O
GcR B-O B-protein
were B-O O
unaltered B-O O
after B-O O
these B-O O
patients B-O O
received B-O O
ketoconazole B-O O
, B-O O
in B-O O
spite B-O O
of B-O O
a B-O O
marked B-O O
reduction B-O O
in B-O O
morning B-O O
plasma B-O O
cortisol B-O O
and B-O O
urinary B-O O
free B-O O
cortisol B-O O
. B-O O

We B-O O
also B-O O
observed B-O O
that B-O O
ketoconazole B-O O
was B-O O
a B-O O
weak B-O O
competitor B-O O
of B-O O
GcR B-O B-protein
in B-O O
intact B-O B-cell_type
cells B-O I-cell_type
, B-O O
although B-O O
it B-O O
significantly B-O O
inhibited B-O O
[ B-O O
3H B-O O
] B-O O
dexamethasone B-O O
binding B-O O
in B-O O
cytosolic B-O O
preparations B-O O
from B-O O
rat B-O O
tissues B-O O
. B-O O

The B-O O
results B-O O
suggested B-O O
that B-O O
GcR B-O B-protein
in B-O O
hMNL B-O B-cell_type
are B-O O
down-regulated B-O O
by B-O O
synthetic B-O O
steroids B-O O
given B-O O
in B-O O
vivo B-O O
, B-O O
but B-O O
they B-O O
showed B-O O
very B-O O
mild B-O O
down-regulation B-O O
in B-O O
hypercortisolemic B-O O
patients B-O O
suffering B-O O
from B-O O
Cushing B-O O
's B-O O
disease B-O O
. B-O O

Finally B-O O
, B-O O
we B-O O
did B-O O
not B-O O
observed B-O O
either B-O O
up-regulation B-O O
or B-O O
antagonism B-O O
of B-O O
GcR B-O B-protein
by B-O O
ketoconazole B-O O
treatment B-O O
, B-O O
at B-O O
the B-O O
time B-O O
that B-O O
cortisol B-O O
levels B-O O
of B-O O
patients B-O O
with B-O O
Cushing B-O O
's B-O O
disease B-O O
were B-O O
reduced B-O O
. B-O O

This B-O O
indicates B-O O
that B-O O
the B-O O
beneficial B-O O
effects B-O O
of B-O O
ketoconazole B-O O
in B-O O
Cushing B-O O
's B-O O
disease B-O O
are B-O O
due B-O O
to B-O O
adrenal B-O O
cortisol B-O O
suppression B-O O
and B-O O
not B-O O
to B-O O
interaction B-O O
with B-O O
GcR B-O B-protein
of B-O O
target B-O B-cell_type
cells B-O I-cell_type
, B-O O
and B-O O
that B-O O
the B-O O
process B-O O
of B-O O
GcR B-O B-protein
regulation B-O O
in B-O O
hMNL B-O B-cell_type
is B-O O
a B-O O
complex B-O O
phenomenon B-O O
awaiting B-O O
further B-O O
elucidation B-O O
. B-O O

HTLV-1 B-O O
Tax B-O B-protein
induces B-O O
expression B-O O
of B-O O
various B-O O
immediate B-O B-DNA
early B-O I-DNA
serum B-O I-DNA
responsive B-O I-DNA
genes B-O I-DNA
. B-O O

Human B-O O
T-cell B-O O
leukemia B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HTLV-1 B-O O
) B-O O
is B-O O
an B-O O
etiological B-O O
agent B-O O
of B-O O
adult B-O O
T-cell B-O O
leukemia B-O O
( B-O O
ATL B-O O
) B-O O
. B-O O

We B-O O
showed B-O O
here B-O O
by B-O O
mobility-shift B-O O
assay B-O O
that B-O O
T-cell B-O B-cell_line
lines B-O I-cell_line
transformed B-O O
with B-O O
the B-O O
virus B-O O
contained B-O O
high B-O O
levels B-O O
of B-O O
AP-1 B-O B-protein
activities B-O O
. B-O O

Consistent B-O O
with B-O O
this B-O O
result B-O O
, B-O O
these B-O O
cell B-O B-cell_line
lines B-O I-cell_line
expressed B-O O
increased B-O O
levels B-O O
of B-O O
mRNAs B-O B-RNA
encoding B-O O
the B-O O
AP-1 B-O B-protein
proteins B-O I-protein
, B-O O
c-Fos B-O B-protein
, B-O O
Fra-1 B-O B-protein
, B-O O
c-Jun B-O B-protein
, B-O O
JunB B-O B-protein
, B-O O
and B-O O
JunD B-O B-protein
. B-O O

Previously B-O O
, B-O O
transcription B-O O
of B-O O
the B-O O
c-fos B-O B-DNA
gene B-O I-DNA
has B-O O
been B-O O
reported B-O O
to B-O O
be B-O O
transactivated B-O O
by B-O O
the B-O O
viral B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
Tax1 B-O B-protein
. B-O O

By B-O O
using B-O O
the B-O O
human B-O B-cell_line
T-cell B-O I-cell_line
line B-O I-cell_line
( B-O O
JPX-9 B-O B-cell_line
) B-O O
, B-O O
in B-O O
which B-O O
expression B-O O
of B-O O
the B-O O
Tax1 B-O B-protein
is B-O O
inducible B-O O
, B-O O
we B-O O
showed B-O O
that B-O O
expression B-O O
of B-O O
mRNAs B-O B-RNA
for B-O O
Fra-1 B-O B-protein
, B-O O
c-Jun B-O B-protein
, B-O O
and B-O O
JunD B-O B-protein
was B-O O
also B-O O
transactivated B-O O
by B-O O
Tax1 B-O B-protein
. B-O O

Moreover B-O O
, B-O O
Tax1 B-O B-protein
activated B-O O
expression B-O O
of B-O O
two B-O O
other B-O O
transcription B-O B-protein
factors B-O I-protein
having B-O O
zinc B-O B-protein
finger B-O I-protein
motifs B-O I-protein
, B-O O
Egr-1 B-O B-protein
and B-O O
Egr-2 B-O B-protein
, B-O O
in B-O O
the B-O O
same B-O O
cells B-O O
. B-O O

The B-O O
Tax1 B-O B-protein
-inducible B-O I-protein
transcription B-O I-protein
factors B-O I-protein
identified B-O O
here B-O O
are B-O O
encoded B-O O
by B-O O
the B-O O
members B-O O
of B-O O
immediate B-O B-DNA
early B-O I-DNA
genes B-O I-DNA
under B-O O
the B-O O
control B-O O
of B-O O
growth B-O O
signals B-O O
. B-O O

Thus B-O O
, B-O O
Tax1 B-O B-protein
was B-O O
suggested B-O O
to B-O O
replace B-O O
growth B-O O
signals B-O O
, B-O O
at B-O O
least B-O O
in B-O O
part B-O O
, B-O O
by B-O O
this B-O O
mechanism B-O O
. B-O O

Glucocorticoid B-O B-protein
receptor B-O I-protein
characteristics B-O O
in B-O O
monocytes B-O B-cell_type
of B-O O
patients B-O O
with B-O O
corticosteroid B-O O
-resistant B-O O
bronchial B-O O
asthma B-O O
. B-O O

The B-O O
mechanism B-O O
of B-O O
corticosteroid B-O O
resistance B-O O
in B-O O
bronchial B-O O
asthma B-O O
has B-O O
been B-O O
studied B-O O
by B-O O
determining B-O O
the B-O O
rank B-O O
order B-O O
of B-O O
potency B-O O
for B-O O
different B-O O
corticosteroids B-O O
in B-O O
inhibiting B-O O
the B-O O
generation B-O O
of B-O O
a B-O O
3 B-O O
kD B-O O
molecule B-O O
from B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
isolated B-O O
from B-O O
corticosteroid-sensitive B-O O
( B-O O
CS B-O O
) B-O O
and B-O O
corticosteroid-resistant B-O O
( B-O O
CR B-O O
) B-O O
asthmatic B-O O
subjects B-O O
, B-O O
which B-O O
augments B-O O
leukotriene B-O O
B4 B-O O
( B-O O
LTB4 B-O O
) B-O O
generation B-O O
by B-O O
human B-O B-cell_type
neutrophils B-O I-cell_type
( B-O O
PMN B-O B-cell_type
) B-O O
stimulated B-O O
by B-O O
calcium B-O O
ionophore B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
binding B-O O
studies B-O O
with B-O O
( B-O O
3H B-O O
) B-O O
dexamethasone B-O O
have B-O O
been B-O O
performed B-O O
to B-O O
determine B-O O
the B-O O
dissociation B-O O
constant B-O O
( B-O O
Kd B-O O
) B-O O
and B-O O
receptor B-O O
numbers B-O O
( B-O O
Ro B-O O
) B-O O
in B-O O
the B-O O
monocytes B-O B-cell_type
of B-O O
these B-O O
two B-O O
groups B-O O
of B-O O
subjects B-O O
. B-O O

The B-O O
concentration B-O O
of B-O O
corticosteroid B-O O
producing B-O O
50 B-O O
% B-O O
inhibition B-O O
( B-O O
IC50 B-O O
) B-O O
was B-O O
600 B-O O
nM B-O O
, B-O O
70 B-O O
nM B-O O
, B-O O
and B-O O
0.5 B-O O
nM B-O O
for B-O O
hydrocortisone B-O O
, B-O O
methylprednisolone B-O O
, B-O O
and B-O O
dexamethasone B-O O
, B-O O
respectively B-O O
, B-O O
in B-O O
monocytes B-O B-cell_type
from B-O O
CS B-O O
individuals B-O O
. B-O O

There B-O O
was B-O O
only B-O O
weak B-O O
inhibition B-O O
of B-O O
the B-O O
generation B-O O
of B-O O
enhancing B-O O
activity B-O O
by B-O O
the B-O O
corticosteroids B-O O
in B-O O
the B-O O
CR B-O O
asthmatic B-O O
individuals B-O O
. B-O O

The B-O O
dexamethasone B-O O
Kd B-O O
was B-O O
2.45 B-O O
+/- B-O O
0.58 B-O O
nM B-O O
( B-O O
mean B-O O
+/- B-O O
SEM B-O O
, B-O O
n B-O O
= B-O O
6 B-O O
) B-O O
in B-O O
the B-O O
CS B-O O
group B-O O
and B-O O
1.6 B-O O
+/- B-O O
0.35 B-O O
nM B-O O
( B-O O
mean B-O O
+/- B-O O
SEM B-O O
, B-O O
n B-O O
= B-O O
6 B-O O
) B-O O
in B-O O
the B-O O
CR B-O O
group B-O O
of B-O O
patients B-O O
( B-O O
p B-O O
= B-O O
0.14 B-O O
) B-O O
. B-O O

The B-O O
Ro B-O O
in B-O O
the B-O O
CS B-O O
group B-O O
was B-O O
3 B-O O
, B-O O
605 B-O O
+/- B-O O
984 B-O O
binding B-O O
sites B-O O
per B-O O
nucleus B-O O
( B-O O
mean B-O O
+/- B-O O
SEM B-O O
, B-O O
n B-O O
= B-O O
6 B-O O
) B-O O
and B-O O
4 B-O O
, B-O O
757 B-O O
+/- B-O O
692 B-O O
binding B-O O
sites B-O O
per B-O O
nucleus B-O O
( B-O O
mean B-O O
+/- B-O O
SEM B-O O
, B-O O
n B-O O
= B-O O
6 B-O O
) B-O O
in B-O O
the B-O O
CR B-O O
group B-O O
( B-O O
p B-O O
= B-O O
0.23 B-O O
) B-O O
. B-O O

These B-O O
findings B-O O
indicate B-O O
that B-O O
corticosteroid B-O O
resistance B-O O
in B-O O
bronchial B-O O
asthma B-O O
can B-O O
not B-O O
be B-O O
explained B-O O
by B-O O
abnormalities B-O O
in B-O O
corticosteroid B-O O
receptor B-O O
characteristics B-O O
. B-O O

Vitamin B-O B-protein
D B-O I-protein
receptor B-O I-protein
expression B-O O
in B-O O
human B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

Signal B-O O
requirements B-O O
and B-O O
characterization B-O O
by B-O O
western B-O O
blots B-O O
and B-O O
DNA B-O O
sequencing B-O O
. B-O O

The B-O O
signals B-O O
controlling B-O O
the B-O O
expression B-O O
of B-O O
the B-O O
receptor B-O B-protein
protein B-O I-protein
for B-O O
1 B-O O
alpha B-O O
, B-O O
25-dihydroxyvitamin B-O O
D3 B-O O
in B-O O
normal B-O B-cell_type
human B-O I-cell_type
lymphocytes B-O I-cell_type
and B-O O
the B-O O
relationship B-O O
of B-O O
this B-O O
protein B-O O
to B-O O
the B-O O
classical B-O B-protein
vitamin B-O I-protein
D B-O I-protein
receptor B-O I-protein
were B-O O
examined B-O O
. B-O O

Lymphocytes B-O B-cell_type
activated B-O O
with B-O O
the B-O O
OKT3 B-O B-protein
antibody B-O I-protein
to B-O O
the B-O O
T-cell B-O B-protein
antigen B-O I-protein
receptor B-O I-protein
expressed B-O O
fewer B-O O
binding B-O O
sites B-O O
as B-O O
compared B-O O
to B-O O
lymphocytes B-O B-cell_type
that B-O O
were B-O O
activated B-O O
by B-O O
the B-O O
polyclonal B-O O
activator B-O O
phytohemagglutinin B-O B-protein
( B-O O
PHA B-O B-protein
) B-O O
. B-O O

However B-O O
, B-O O
combination B-O O
of B-O O
OKT3 B-O B-protein
and B-O O
phorbol B-O O
myristate B-O O
acetate B-O O
produced B-O O
a B-O O
concentration B-O O
of B-O O
binding B-O O
sites B-O O
similar B-O O
to B-O O
the B-O O
PHA B-O B-cell_line
-activated B-O I-cell_line
cells B-O I-cell_line
. B-O O

The B-O O
receptor B-O O
from B-O O
OKT3 B-O B-protein
and B-O O
OKT3 B-O B-protein
+ B-O O
phorbol B-O O
myristate B-O O
acetate B-O O
-activated B-O B-cell_type
lymphocytes B-O I-cell_type
exhibited B-O O
decreased B-O O
binding B-O O
to B-O O
DNA-cellulose B-O O
compared B-O O
to B-O O
PHA B-O B-protein
-activated B-O O
lymphocytes B-O O
. B-O O

In B-O O
lymphocytes B-O B-cell_type
activated B-O O
either B-O O
by B-O O
PHA B-O B-protein
or B-O O
OKT3 B-O B-protein
( B-O O
but B-O O
not B-O O
in B-O O
resting B-O B-cell_type
cells B-O I-cell_type
) B-O O
, B-O O
a B-O O
50-kDa B-O B-protein
species B-O I-protein
cross-reacting B-O O
with B-O O
a B-O O
monoclonal B-O B-protein
antibody B-O I-protein
against B-O O
the B-O O
intestinal B-O B-protein
vitamin B-O I-protein
D B-O I-protein
receptor B-O I-protein
was B-O O
detected B-O O
. B-O O

Finally B-O O
, B-O O
RNA B-O O
from B-O O
activated B-O B-cell_type
lymphocytes B-O I-cell_type
was B-O O
amplified B-O O
by B-O O
polymerase B-O O
chain B-O O
reaction B-O O
using B-O O
oligonucleotide B-O O
primers B-O O
flanking B-O O
the B-O O
196 B-O B-DNA
base B-O I-DNA
pair B-O I-DNA
long B-O I-DNA
region B-O I-DNA
encoding B-O O
the B-O O
DNA-binding B-O B-protein
domain B-O I-protein
of B-O O
the B-O O
human B-O B-protein
intestinal B-O I-protein
receptor B-O I-protein
. B-O O

The B-O O
amplified B-O O
product B-O O
showed B-O O
an B-O O
identical B-O B-DNA
nucleotide B-O I-DNA
sequence B-O I-DNA
to B-O O
the B-O O
DNA-binding B-O B-protein
domain B-O I-protein
of B-O O
the B-O O
human B-O B-protein
intestinal B-O I-protein
receptor B-O I-protein
. B-O O

These B-O O
findings B-O O
suggest B-O O
that B-O O
expression B-O O
of B-O O
the B-O O
1 B-O B-protein
, B-O I-protein
25- B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptor B-O I-protein
in B-O O
lymphocytes B-O B-cell_type
is B-O O
triggered B-O O
by B-O O
distinct B-O O
and B-O O
contingent B-O O
signals B-O O
, B-O O
and B-O O
that B-O O
the B-O O
protein B-O O
and B-O O
the B-O O
mRNA B-O B-RNA
encoding B-O O
it B-O O
are B-O O
identical B-O O
to B-O O
the B-O O
classical B-O B-protein
vitamin B-O I-protein
D B-O I-protein
receptor B-O I-protein
. B-O O

Comparison B-O O
of B-O O
constitutive B-O O
and B-O O
inducible B-O O
transcriptional B-O O
enhancement B-O O
mediated B-O O
by B-O O
kappa B-O B-DNA
B-related B-O I-DNA
sequences B-O I-DNA
: B-O O
modulation B-O O
of B-O O
activity B-O O
in B-O O
B B-O B-cell_type
cells B-O I-cell_type
by B-O O
human B-O B-DNA
T-cell B-O I-DNA
leukemia B-O I-DNA
virus B-O I-DNA
type B-O I-DNA
I B-O I-DNA
tax B-O I-DNA
gene B-O I-DNA
. B-O O

The B-O O
kappa B-O B-DNA
B B-O I-DNA
sequence B-O I-DNA
( B-O O
GGGACTTTCC B-O O
) B-O O
binds B-O O
a B-O O
factor B-O O
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
that B-O O
is B-O O
constitutively B-O O
found B-O O
in B-O O
its B-O O
functional B-O O
, B-O O
DNA B-O B-protein
binding B-O I-protein
form B-O I-protein
only B-O O
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

A B-O O
factor B-O O
with B-O O
apparently B-O O
indistinguishable B-O O
sequence B-O O
specificity B-O O
can B-O O
be B-O O
induced B-O O
in B-O O
many B-O O
other B-O O
cell B-O O
types B-O O
, B-O O
where B-O O
it B-O O
is B-O O
used B-O O
to B-O O
regulate B-O O
inducible B-O O
gene B-O O
expression B-O O
. B-O O

For B-O O
example B-O O
, B-O O
kappa B-O B-DNA
B-related B-O I-DNA
sequences B-O I-DNA
have B-O O
been B-O O
shown B-O O
to B-O O
be B-O O
important B-O O
for B-O O
the B-O O
transcription B-O O
of B-O O
a B-O O
few B-O O
inducible B-O O
genes B-O O
, B-O O
such B-O O
as B-O O
the B-O O
interleukin B-O B-DNA
2 B-O I-DNA
receptor B-O I-DNA
alpha-chain B-O I-DNA
gene B-O I-DNA
and B-O O
the B-O O
beta-interferon B-O B-DNA
gene B-O I-DNA
. B-O O

However B-O O
, B-O O
these B-O O
genes B-O O
are B-O O
not B-O O
constitutively B-O O
active B-O O
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
, B-O O
suggesting B-O O
that B-O O
other B-O O
regulatory B-O O
mechanisms B-O O
must B-O O
play B-O O
a B-O O
role B-O O
in B-O O
determining B-O O
the B-O O
patterns B-O O
of B-O O
expression B-O O
. B-O O

We B-O O
have B-O O
investigated B-O O
the B-O O
constitutive B-O O
and B-O O
inducible B-O O
transcriptional B-O O
activity B-O O
mediated B-O O
by B-O O
five B-O O
kappa B-O B-DNA
B-related B-O I-DNA
sequence B-O I-DNA
elements B-O I-DNA
in B-O O
two B-O O
different B-O O
cell B-O O
types B-O O
. B-O O

We B-O O
show B-O O
that B-O O
in B-O O
S194 B-O B-cell_line
plasma B-O I-cell_line
cells B-O I-cell_line
the B-O O
activity B-O O
of B-O O
each B-O O
element B-O O
correlates B-O O
well B-O O
with B-O O
the B-O O
relative B-O O
affinity B-O O
of B-O O
B-cell-derived B-O O
NF-kappa B-O B-protein
B B-O I-protein
for B-O O
that B-O O
element B-O O
. B-O O

This B-O O
leads B-O O
to B-O O
significantly B-O O
lower B-O O
transcription B-O O
enhancement B-O O
by B-O O
sites B-O O
derived B-O O
from B-O O
the B-O O
interleukin B-O B-protein
2 B-O I-protein
receptor B-O I-protein
or B-O O
T-cell B-O B-DNA
receptor B-O I-DNA
genes B-O I-DNA
in B-O O
S194 B-O B-cell_line
cells B-O I-cell_line
. B-O O

However B-O O
, B-O O
in B-O O
either B-O O
EL-4 B-O B-cell_line
( B-O I-cell_line
T B-O I-cell_line
) B-O I-cell_line
cells B-O I-cell_line
or B-O O
S194 B-O B-cell_line
cells B-O I-cell_line
, B-O O
both B-O O
lower-affinity B-O B-DNA
sites B-O I-DNA
can B-O O
be B-O O
significantly B-O O
induced B-O O
by B-O O
the B-O O
tax B-O B-protein
gene B-O I-protein
product B-O I-protein
of B-O O
human B-O O
T-cell B-O O
leukemia B-O O
virus B-O O
type B-O O
I B-O O
, B-O O
showing B-O O
that B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
can B-O O
be B-O O
modulated B-O O
even B-O O
in B-O O
a B-O O
B-cell B-O B-cell_line
line B-O I-cell_line
that B-O O
constitutively B-O O
expresses B-O O
this B-O O
factor B-O O
. B-O O

Specific B-O O
depletion B-O O
of B-O O
the B-O O
B-cell B-O B-cell_line
population B-O I-cell_line
induced B-O O
by B-O O
aberrant B-O O
expression B-O O
of B-O O
human B-O B-DNA
interferon B-O I-DNA
regulatory B-O I-DNA
factor B-O I-DNA
1 B-O I-DNA
gene B-O I-DNA
in B-O O
transgenic B-O O
mice B-O O
. B-O O

Interferons B-O B-protein
( B-O O
IFNs B-O B-protein
) B-O O
are B-O O
well B-O O
known B-O O
both B-O O
as B-O O
antiviral B-O B-protein
proteins B-O I-protein
and B-O O
as B-O O
potent B-O O
regulators B-O O
of B-O O
cell B-O O
growth B-O O
and B-O O
differentiation B-O O
. B-O O

In B-O O
fact B-O O
, B-O O
IFNs B-O B-protein
inhibit B-O O
growth B-O O
of B-O O
various B-O O
normal B-O O
and B-O O
transformed B-O B-cell_type
cell B-O I-cell_type
types B-O I-cell_type
. B-O O

Previously B-O O
, B-O O
a B-O O
nuclear B-O B-protein
factor B-O I-protein
, B-O O
IRF-1 B-O B-protein
( B-O O
interferon B-O B-protein
regulatory B-O I-protein
factor B-O I-protein
1 B-O I-protein
) B-O O
, B-O O
which B-O O
binds B-O O
to B-O O
type B-O B-protein
I B-O I-protein
IFN B-O I-protein
and B-O O
some B-O O
IFN B-O B-DNA
-inducible B-O I-DNA
gene B-O I-DNA
promoters B-O I-DNA
, B-O O
was B-O O
identified B-O O
and B-O O
cloned B-O O
. B-O O

Since B-O O
the B-O O
IRF-1 B-O B-DNA
gene B-O I-DNA
is B-O O
both B-O O
virus B-O O
and B-O O
IFN B-O B-protein
inducible B-O O
, B-O O
an B-O O
intriguing B-O O
issue B-O O
is B-O O
raised B-O O
as B-O O
to B-O O
whether B-O O
the B-O O
IRF-1 B-O B-DNA
gene B-O I-DNA
is B-O O
functioning B-O O
in B-O O
IFN B-O B-protein
-mediated B-O O
regulation B-O O
of B-O O
cell B-O O
growth B-O O
and B-O O
differentiation B-O O
. B-O O

In B-O O
this B-O O
study B-O O
, B-O O
we B-O O
generated B-O O
transgenic B-O O
mice B-O O
carrying B-O O
the B-O O
human B-O B-DNA
IRF-1 B-O I-DNA
gene B-O I-DNA
linked B-O O
to B-O O
the B-O O
human B-O B-DNA
immunoglobulin B-O I-DNA
heavy-chain B-O I-DNA
enhancer B-O I-DNA
. B-O O

In B-O O
the B-O O
transgenic B-O O
mice B-O O
, B-O O
all B-O O
the B-O O
lymphoid B-O O
tissues B-O O
examined B-O O
showed B-O O
a B-O O
dramatic B-O O
reduction B-O O
in B-O O
the B-O O
number B-O O
of B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
( B-O O
B B-O B-cell_type
cells B-O I-cell_type
) B-O O
. B-O O

Preparation B-O O
and B-O O
analysis B-O O
of B-O O
bone B-O B-cell_type
marrow B-O I-cell_type
cells B-O I-cell_type
from B-O O
the B-O O
chimeric B-O O
mice B-O O
indicated B-O O
that B-O O
the B-O O
bone B-O O
marrow B-O O
is B-O O
the B-O O
effective B-O O
site B-O O
for B-O O
specific B-O O
depletion B-O O
of B-O O
the B-O O
B-cell B-O B-cell_type
population B-O I-cell_type
. B-O O

In B-O O
fact B-O O
, B-O O
transgenic B-O B-cell_type
bone B-O I-cell_type
marrow B-O I-cell_type
cells B-O I-cell_type
cocultured B-O O
with B-O O
a B-O O
bone B-O B-cell_line
marrow-derived B-O I-cell_line
stromal B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
revealed B-O O
an B-O O
altered B-O O
B-cell B-O O
maturation B-O O
pattern B-O O
. B-O O

Characterization B-O O
of B-O O
a B-O O
cofactor B-O B-protein
that B-O O
regulates B-O O
dimerization B-O O
of B-O O
a B-O O
mammalian B-O B-protein
homeodomain B-O I-protein
protein B-O I-protein
. B-O O

Dimerization B-O O
among B-O O
transcription B-O B-protein
factors B-O I-protein
has B-O O
become B-O O
a B-O O
recurrent B-O O
theme B-O O
in B-O O
the B-O O
regulation B-O O
of B-O O
eukaryotic B-O B-DNA
gene B-O I-DNA
expression B-O O
. B-O O

Hepatocyte B-O B-protein
nuclear B-O I-protein
factor-1 B-O I-protein
alpha B-O I-protein
( B-O O
HNF-1 B-O B-protein
alpha B-O I-protein
) B-O O
is B-O O
a B-O O
homeodomain-containing B-O B-protein
protein B-O I-protein
that B-O O
functions B-O O
as B-O O
a B-O O
dimer B-O B-protein
. B-O O

A B-O O
dimerization B-O B-protein
cofactor B-O I-protein
of B-O O
HNF-1 B-O B-protein
alpha B-O I-protein
( B-O O
DCoH B-O B-protein
) B-O O
was B-O O
identified B-O O
that B-O O
displayed B-O O
a B-O O
restricted B-O O
tissue B-O O
distribution B-O O
and B-O O
did B-O O
not B-O O
bind B-O O
to B-O O
DNA B-O O
, B-O O
but B-O O
, B-O O
rather B-O O
, B-O O
selectively B-O O
stabilized B-O O
HNF-1 B-O B-protein
alpha B-O I-protein
dimers B-O I-protein
. B-O O

The B-O O
formation B-O O
of B-O O
a B-O O
stable B-O O
tetrameric B-O B-protein
DCoH-HNF-1 B-O I-protein
alpha B-O I-protein
complex B-O I-protein
, B-O O
which B-O O
required B-O O
the B-O O
dimerization B-O B-protein
domain B-O I-protein
of B-O O
HNF-1 B-O B-protein
alpha B-O I-protein
, B-O O
did B-O O
not B-O O
change B-O O
the B-O O
DNA B-O O
binding B-O O
characteristics B-O O
of B-O O
HNF-1 B-O B-protein
alpha B-O I-protein
, B-O O
but B-O O
enhanced B-O O
its B-O O
transcriptional B-O O
activity B-O O
. B-O O

However B-O O
, B-O O
DCoH B-O B-protein
did B-O O
not B-O O
confer B-O O
transcriptional B-O O
activation B-O O
to B-O O
the B-O O
GAL4 B-O B-protein
DNA B-O I-protein
binding B-O I-protein
domain B-O I-protein
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
DCoH B-O B-protein
regulates B-O O
formation B-O O
of B-O O
transcriptionally B-O O
active B-O O
tetrameric B-O B-protein
complexes B-O I-protein
and B-O O
may B-O O
contribute B-O O
to B-O O
the B-O O
developmental B-O O
specificity B-O O
of B-O O
the B-O O
complex B-O O
. B-O O

Glucocorticoid B-O O
resistance B-O O
in B-O O
chronic B-O O
asthma B-O O
. B-O O

Glucocorticoid B-O O
pharmacokinetics B-O O
, B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
characteristics B-O O
, B-O O
and B-O O
inhibition B-O O
of B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
T B-O I-cell_type
cell B-O I-cell_type
proliferation B-O O
by B-O O
glucocorticoids B-O O
in B-O O
vitro B-O O
. B-O O

A B-O O
total B-O O
of B-O O
37 B-O O
chronic B-O O
, B-O O
severe B-O O
, B-O O
nonsmoking B-O O
asthmatic B-O O
patients B-O O
with B-O O
documented B-O O
reversible B-O O
airways B-O O
obstruction B-O O
were B-O O
classified B-O O
as B-O O
glucocorticoid-sensitive B-O O
or B-O O
-resistant B-O O
on B-O O
the B-O O
basis B-O O
of B-O O
changes B-O O
in B-O O
FEV1 B-O O
, B-O O
FVC B-O O
, B-O O
and B-O O
peak B-O O
expiratory B-O O
flow B-O O
( B-O O
PEF B-O B-protein
) B-O O
after B-O O
oral B-O O
prednisolone B-O O
. B-O O

The B-O O
resistant B-O O
patients B-O O
showed B-O O
no B-O O
significant B-O O
improvements B-O O
in B-O O
airflow B-O O
limitation B-O O
. B-O O

Phytohemagglutinin B-O B-protein
( B-O O
PHA B-O B-protein
) B-O O
-induced B-O O
proliferation B-O O
of B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
from B-O O
the B-O O
sensitive B-O O
but B-O O
not B-O O
the B-O O
resistant B-O O
asthmatic B-O O
patients B-O O
was B-O O
significantly B-O O
( B-O O
p B-O O
less B-O O
than B-O O
0.01 B-O O
) B-O O
inhibited B-O O
by B-O O
dexamethasone B-O O
( B-O O
10 B-O O
( B-O O
-7 B-O O
) B-O O
mol/L B-O O
) B-O O
, B-O O
reflecting B-O O
a B-O O
shift B-O O
of B-O O
the B-O O
dose-response B-O O
curve B-O O
. B-O O

When B-O O
all B-O O
the B-O O
asthmatic B-O O
patients B-O O
were B-O O
analyzed B-O O
together B-O O
, B-O O
there B-O O
was B-O O
a B-O O
significant B-O O
correlation B-O O
between B-O O
the B-O O
degree B-O O
of B-O O
sensitivity B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
to B-O O
dexamethasone B-O O
and B-O O
the B-O O
clinical B-O O
responsiveness B-O O
to B-O O
prednisolone B-O O
( B-O O
p B-O O
less B-O O
than B-O O
0.01 B-O O
) B-O O
. B-O O

No B-O O
differences B-O O
were B-O O
observed B-O O
between B-O O
six B-O O
of B-O O
the B-O O
sensitive B-O O
and B-O O
resistant B-O O
patients B-O O
in B-O O
the B-O O
clearance B-O O
of B-O O
plasma B-O O
prednisolone B-O O
derived B-O O
from B-O O
orally B-O O
administered B-O O
prednisone B-O O
. B-O O

Peripheral B-O B-protein
blood B-O I-protein
mononuclear B-O I-protein
cell B-O I-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
were B-O O
also B-O O
characterized B-O O
in B-O O
five B-O O
sensitive B-O O
and B-O O
seven B-O O
resistant B-O O
patients B-O O
. B-O O

The B-O O
numbers B-O O
and B-O O
binding B-O O
affinities B-O O
of B-O O
these B-O O
receptors B-O O
could B-O O
not B-O O
account B-O O
for B-O O
the B-O O
observed B-O O
difference B-O O
in B-O O
the B-O O
susceptibility B-O O
of B-O O
these B-O O
cells B-O O
to B-O O
functional B-O O
inhibition B-O O
by B-O O
dexamethasone B-O O
in B-O O
vitro B-O O
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
clinical B-O O
glucocorticoid B-O O
resistance B-O O
in B-O O
chronic B-O O
asthma B-O O
does B-O O
not B-O O
reflect B-O O
abnormal B-O O
glucocorticoid B-O O
clearance B-O O
but B-O O
may B-O O
be B-O O
due B-O O
at B-O O
least B-O O
partly B-O O
to B-O O
a B-O O
relative B-O O
insensitivity B-O O
of B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
to B-O O
glucocorticoids B-O O
. B-O O

This B-O O
lack B-O O
of B-O O
sensitivity B-O O
is B-O O
unexplained B-O O
but B-O O
is B-O O
not B-O O
attributable B-O O
to B-O O
abnormalities B-O O
of B-O O
cellular B-O B-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
. B-O O

Inhibition B-O O
of B-O O
phorbol B-O O
ester-induced B-O O
monocytic B-O O
differentiation B-O O
by B-O O
dexamethasone B-O O
is B-O O
associated B-O O
with B-O O
down-regulation B-O O
of B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
( B-O O
AP-1 B-O B-protein
) B-O O
. B-O O

Previous B-O O
studies B-O O
have B-O O
shown B-O O
that B-O O
treatment B-O O
of B-O O
human B-O B-cell_type
myeloid B-O I-cell_type
leukemia B-O I-cell_type
cells B-O I-cell_type
with B-O O
12-O-tetradecanoylphorbol-13-acetate B-O O
( B-O O
TPA B-O O
) B-O O
is B-O O
associated B-O O
with B-O O
induction B-O O
of B-O O
monocytic B-O O
differentiation B-O O
and B-O O
expression B-O O
of B-O O
the B-O O
c-jun B-O B-DNA
and B-O I-DNA
c-fos B-O I-DNA
early B-O I-DNA
response B-O I-DNA
genes B-O I-DNA
. B-O O

The B-O O
present B-O O
work B-O O
demonstrates B-O O
that B-O O
the B-O O
glucocorticoid B-O O
dexamethasone B-O O
inhibits B-O O
TPA B-O O
-induced B-O O
increases B-O O
in B-O O
c-jun B-O B-DNA
and B-O O
c-fos B-O B-RNA
mRNA B-O I-RNA
levels B-O O
in B-O O
U-937 B-O B-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
. B-O O

These B-O O
findings B-O O
were B-O O
associated B-O O
with B-O O
a B-O O
block B-O O
in B-O O
appearance B-O O
of B-O O
the B-O O
monocytic B-O B-cell_type
phenotype B-O I-cell_type
, B-O O
including B-O O
inhibition B-O O
of B-O O
TPA B-O O
-induced B-O O
increases B-O O
in B-O O
lamin B-O O
A B-O O
, B-O O
lamin B-O O
C B-O O
, B-O O
and B-O O
vimentin B-O B-protein
transcripts B-O I-protein
. B-O O

Other B-O O
studies B-O O
have B-O O
demonstrated B-O O
that B-O O
TPA B-O O
-induced B-O O
monocytic B-O O
differentiation B-O O
and B-O O
expression B-O O
of B-O O
the B-O O
c-jun B-O B-DNA
and B-O O
c-fos B-O B-DNA
genes B-O I-DNA
in B-O O
myeloid B-O B-cell_type
leukemia B-O I-cell_type
cells B-O I-cell_type
are B-O O
regulated B-O O
by B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
. B-O O

The B-O O
finding B-O O
that B-O O
dexamethasone B-O O
has B-O O
no B-O O
effect B-O O
on B-O O
TPA B-O O
-induced B-O O
activation B-O O
of B-O O
PKC B-O B-protein
suggests B-O O
that B-O O
this B-O O
glucocorticoid B-O O
inhibits B-O O
signals B-O O
downstream B-O O
or B-O O
parallel B-O O
to B-O O
this B-O O
enzyme B-O B-protein
. B-O O

Nuclear B-O O
run-on B-O O
assays B-O O
demonstrate B-O O
that B-O O
: B-O O
( B-O O
1 B-O O
) B-O O
induction B-O O
of B-O O
c-jun B-O B-DNA
and B-O O
c-fos B-O B-DNA
expression B-O O
by B-O O
TPA B-O O
is B-O O
regulated B-O O
by B-O O
transcriptional B-O O
mechanisms B-O O
, B-O O
( B-O O
2 B-O O
) B-O O
TPA B-O O
-induced B-O O
expression B-O O
of B-O O
c-jun B-O B-DNA
and B-O O
c-fos B-O B-DNA
does B-O O
not B-O O
require B-O O
protein B-O O
synthesis B-O O
, B-O O
and B-O O
( B-O O
3 B-O O
) B-O O
TPA B-O O
-induced B-O O
expression B-O O
of B-O O
both B-O O
genes B-O O
is B-O O
inhibited B-O O
at B-O O
the B-O O
transcriptional B-O O
level B-O O
by B-O O
dexamethasone B-O O
. B-O O

To B-O O
further B-O O
define B-O O
the B-O O
effects B-O O
of B-O O
dexamethasone B-O O
at B-O O
the B-O O
molecular B-O O
level B-O O
, B-O O
we B-O O
prepared B-O O
a B-O O
series B-O O
of B-O O
deleted B-O O
c-jun B-O B-DNA
promoter B-O I-DNA
fragments B-O I-DNA
linked B-O O
to B-O O
the B-O O
chloramphenicol B-O B-DNA
acetyltransferase B-O I-DNA
( B-O I-DNA
CAT B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
. B-O O

Increases B-O O
in B-O O
CAT B-O B-protein
activity B-O O
during B-O O
transient B-O O
expression B-O O
of B-O O
these B-O O
constructs B-O O
in B-O O
TPA B-O B-cell_line
-treated B-O I-cell_line
U-937 B-O I-cell_line
cells B-O I-cell_line
could B-O O
be B-O O
assigned B-O O
to B-O O
the B-O O
region B-O O
( B-O O
-97 B-O B-DNA
to B-O I-DNA
-20 B-O I-DNA
) B-O O
of B-O O
the B-O O
promoter B-O B-DNA
that B-O O
contains B-O O
the B-O O
AP-1 B-O B-DNA
binding B-O I-DNA
site B-O I-DNA
. B-O O

This B-O O
induction B-O O
of B-O O
CAT B-O B-protein
activity B-O O
was B-O O
sensitive B-O O
to B-O O
dexamethasone B-O O
. B-O O

These B-O O
findings B-O O
suggest B-O O
that B-O O
dexamethasone B-O O
down-regulates B-O O
TPA B-O O
-induced B-O O
transcription B-O O
of B-O O
the B-O O
c-jun B-O B-DNA
gene B-O I-DNA
during B-O O
monocytic B-O O
differentiation B-O O
by B-O O
inhibiting B-O O
activation B-O O
of B-O O
the B-O O
AP-1 B-O B-DNA
site B-O I-DNA
. B-O O

Tumor B-O B-RNA
necrosis B-O I-RNA
factor-alpha B-O I-RNA
mRNA B-O I-RNA
accumulation B-O O
in B-O O
human B-O B-cell_line
myelomonocytic B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

Role B-O O
of B-O O
transcriptional B-O O
regulation B-O O
by B-O O
DNA B-O B-DNA
sequence B-O I-DNA
motifs B-O I-DNA
and B-O O
mRNA B-O O
stabilization B-O O
. B-O O

The B-O O
cytokine B-O B-protein
TNF B-O B-protein
mediates B-O O
many B-O O
of B-O O
the B-O O
pathologic B-O O
signs B-O O
of B-O O
cachexia B-O O
, B-O O
inflammation B-O O
, B-O O
and B-O O
sepsis B-O O
. B-O O

The B-O O
current B-O O
work B-O O
describes B-O O
the B-O O
regulation B-O O
of B-O O
TNF B-O B-protein
in B-O O
human B-O B-cell_line
myelomonocytic B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
after B-O O
PMA B-O O
stimulation B-O O
. B-O O

The B-O O
cell B-O B-cell_line
lines B-O I-cell_line
exhibit B-O O
a B-O O
low B-O O
level B-O O
of B-O O
constitutive B-O O
TNF B-O B-RNA
mRNA B-O I-RNA
expression B-O O
. B-O O

Within B-O O
2 B-O O
to B-O O
4 B-O O
h B-O O
of B-O O
PMA B-O O
exposure B-O O
, B-O O
steady B-O O
state B-O O
levels B-O O
of B-O O
TNF B-O B-RNA
mRNA B-O I-RNA
are B-O O
markedly B-O O
elevated B-O O
in B-O O
all B-O O
myelomonocytic B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
studied B-O O
. B-O O

This B-O O
rise B-O O
is B-O O
due B-O O
to B-O O
increased B-O O
mRNA B-O B-RNA
stability B-O O
, B-O O
which B-O O
increased B-O O
by B-O O
almost B-O O
twofold B-O O
, B-O O
and B-O O
to B-O O
an B-O O
overall B-O O
increase B-O O
in B-O O
transcription B-O O
, B-O O
which B-O O
rises B-O O
by B-O O
more B-O O
than B-O O
sixfold B-O O
. B-O O

At B-O O
the B-O O
level B-O O
of B-O O
the B-O O
genomic B-O B-DNA
TNF B-O I-DNA
gene B-O I-DNA
, B-O O
a B-O O
DNase B-O B-DNA
I B-O I-DNA
hypersensitive B-O I-DNA
site B-O I-DNA
is B-O O
detected B-O O
within B-O O
the B-O O
TNF B-O B-DNA
promoter B-O I-DNA
between B-O O
-200 B-O B-DNA
to B-O I-DNA
-100 B-O I-DNA
bp B-O I-DNA
relative B-O O
to B-O O
the B-O O
transcription B-O B-DNA
initiation B-O I-DNA
site B-O I-DNA
. B-O O

Although B-O O
absent B-O O
in B-O O
nonexpressing B-O B-cell_line
erythroleukemia B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
the B-O O
DNase B-O B-DNA
I B-O I-DNA
site B-O I-DNA
is B-O O
present B-O O
in B-O O
uninduced B-O B-cell_line
myelomonocytic B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
and B-O O
is B-O O
not B-O O
changed B-O O
after B-O O
PMA B-O O
induction B-O O
. B-O O

The B-O O
PMA B-O O
induction B-O O
of B-O O
c-fos B-O B-RNA
mRNA B-O I-RNA
correlated B-O O
well B-O O
with B-O O
TNF B-O B-protein
gene B-O O
induction B-O O
; B-O O
expression B-O O
of B-O O
genes B-O B-DNA
encoding B-O O
other B-O O
proteins B-O O
in B-O O
the B-O O
AP-1 B-O B-protein
complex B-O I-protein
( B-O O
junB B-O B-DNA
and B-O O
junD B-O B-protein
) B-O O
were B-O O
also B-O O
induced B-O O
by B-O O
PMA B-O O
. B-O O

The B-O O
nuclear B-O O
extracts B-O O
from B-O O
resting B-O O
and B-O O
induced B-O O
ML-1 B-O B-cell_line
cells B-O I-cell_line
contain B-O O
proteins B-O O
binding B-O O
specifically B-O O
to B-O O
the B-O O
AP-1 B-O B-protein
, B-O O
AP-2 B-O B-protein
, B-O O
and B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
sequence B-O O
located B-O O
within B-O O
the B-O O
TNF B-O B-DNA
promoter B-O I-DNA
. B-O O

PMA B-O O
induction B-O O
increases B-O O
the B-O O
level B-O O
of B-O O
a B-O O
number B-O O
of B-O O
specific B-O B-protein
binding B-O I-protein
complexes B-O I-protein
relative B-O O
to B-O O
the B-O O
resting B-O B-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
regulatory B-O O
mechanisms B-O O
of B-O O
the B-O O
human B-O B-DNA
and B-O I-DNA
murine B-O I-DNA
TNF B-O I-DNA
genes B-O I-DNA
are B-O O
discussed B-O O
. B-O O

Enhancement B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
1 B-O O
replication B-O O
in B-O O
monocytes B-O B-cell_type
by B-O O
1 B-O O
, B-O O
25-dihydroxycholecalciferol B-O O
. B-O O

Human B-O O
immunodeficiency B-O O
virus B-O O
( B-O O
HIV B-O O
) B-O O
expression B-O O
and B-O O
replication B-O O
are B-O O
under B-O O
tight B-O O
regulatory B-O O
control B-O O
. B-O O

We B-O O
demonstrate B-O O
that B-O O
1 B-O O
, B-O O
25-dihydroxycholecalciferol B-O O
[ B-O O
1 B-O O
, B-O O
25- B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
] B-O O
enhances B-O O
the B-O O
replication B-O O
of B-O O
monocyte- B-O O
and B-O O
lymphocyte-tropic B-O O
strains B-O O
of B-O O
HIV-1 B-O O
up B-O O
to B-O O
10 B-O O
, B-O O
000-fold B-O O
in B-O O
monocyte B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
, B-O O
and B-O O
unfractionated B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
. B-O O

1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
is B-O O
therefore B-O O
one B-O O
of B-O O
the B-O O
most B-O O
potent B-O O
regulators B-O O
of B-O O
HIV-1 B-O O
replication B-O O
described B-O O
to B-O O
date B-O O
. B-O O

Precursors B-O O
of B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
enhance B-O O
HIV-1 B-O O
replication B-O O
in B-O O
proportion B-O O
to B-O O
their B-O O
affinity B-O O
for B-O O
the B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
intracellular B-O I-protein
receptor B-O I-protein
, B-O O
suggesting B-O O
that B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
influences B-O O
HIV-1 B-O O
replication B-O O
by B-O O
mechanisms B-O O
involving B-O O
this B-O O
receptor B-O O
. B-O O

These B-O O
studies B-O O
may B-O O
have B-O O
important B-O O
implications B-O O
for B-O O
the B-O O
design B-O O
of B-O O
effective B-O O
therapy B-O O
of B-O O
HIV-1 B-O O
infection B-O O
. B-O O

Transforming B-O B-protein
growth B-O I-protein
factor-beta B-O I-protein
suppresses B-O O
human B-O B-protein
B B-O I-protein
lymphocyte B-O I-protein
Ig B-O I-protein
production B-O O
by B-O O
inhibiting B-O O
synthesis B-O O
and B-O O
the B-O O
switch B-O O
from B-O O
the B-O O
membrane B-O B-RNA
form B-O I-RNA
to B-O O
the B-O O
secreted B-O B-RNA
form B-O I-RNA
of B-O O
Ig B-O B-RNA
mRNA B-O I-RNA
. B-O O

Transforming B-O B-protein
growth B-O I-protein
factor-beta B-O I-protein
( B-O O
TGF-beta B-O B-protein
) B-O O
inhibits B-O O
B B-O B-cell_type
cell B-O I-cell_type
Ig B-O B-protein
secretion B-O O
and B-O O
reduces B-O O
B B-O B-cell_type
cell B-O I-cell_type
membrane B-O O
Ig B-O O
expression B-O O
. B-O O

The B-O O
addition B-O O
of B-O O
TGF-beta B-O B-protein
to B-O O
human B-O B-cell_line
B B-O I-cell_line
lymphocyte B-O I-cell_line
cultures B-O I-cell_line
stimulated B-O O
with B-O O
Staphylococcus B-O O
aureus B-O O
Cowan B-O O
strain B-O O
I B-O O
and B-O O
IL-2 B-O B-protein
completely B-O O
inhibited B-O O
B B-O B-cell_type
cell B-O I-cell_type
Ig B-O B-protein
secretion B-O O
( B-O O
greater B-O O
than B-O O
90 B-O O
% B-O O
) B-O O
and B-O O
decreased B-O O
B B-O O
cell B-O O
surface B-O O
IgM B-O B-protein
, B-O O
IgD B-O B-protein
, B-O O
kappa B-O B-protein
L B-O I-protein
chain B-O I-protein
, B-O O
and B-O O
lambda B-O B-protein
L B-O I-protein
chain B-O I-protein
expression B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
TGF-beta B-O B-protein
had B-O O
only B-O O
minimal B-O O
effects B-O O
on B-O O
two B-O O
other B-O O
B B-O B-protein
cell B-O I-protein
membrane B-O I-protein
proteins B-O I-protein
, B-O O
HLA-DR B-O B-protein
and B-O O
CD20 B-O B-protein
. B-O O

Internal B-O O
labeling B-O O
with B-O O
[ B-O O
35S B-O O
] B-O O
methionine B-O O
and B-O O
immunoprecipitation B-O O
with B-O O
anti-IgM B-O B-protein
, B-O O
anti-kappa B-O B-protein
, B-O O
and B-O O
anti-lambda B-O B-protein
antibodies B-O I-protein
revealed B-O O
a B-O O
striking B-O O
reduction B-O O
in B-O O
kappa B-O B-protein
L B-O I-protein
chain B-O I-protein
in B-O O
the B-O O
presence B-O O
of B-O O
TGF-beta B-O B-protein
. B-O O

A B-O O
less B-O O
pronounced B-O O
reduction B-O O
in B-O O
lambda B-O B-protein
L B-O I-protein
chain B-O I-protein
and B-O O
microH B-O B-protein
chain B-O I-protein
was B-O O
also B-O O
noted B-O O
. B-O O

Northern B-O O
blot B-O O
analysis B-O O
of B-O O
RNA B-O B-RNA
purified B-O O
from B-O O
B B-O B-cell_type
cells B-O I-cell_type
treated B-O O
with B-O O
TGF-beta B-O B-protein
for B-O O
varying B-O O
time B-O O
intervals B-O O
revealed B-O O
a B-O O
significant B-O O
decrease B-O O
in B-O O
steady B-O O
state B-O O
kappa B-O O
and B-O O
lambda B-O O
L B-O O
chain B-O O
mRNA B-O O
levels B-O O
. B-O O

Furthermore B-O O
, B-O O
a B-O O
significant B-O O
decrease B-O O
in B-O O
the B-O O
switch B-O O
from B-O O
the B-O O
membrane B-O B-RNA
forms B-O I-RNA
of B-O O
mu B-O O
and B-O O
gamma B-O O
to B-O O
their B-O O
respective B-O O
secreted B-O B-RNA
forms B-O I-RNA
was B-O O
noted B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
TGF-beta B-O B-protein
. B-O O

Nuclear B-O O
run-on B-O O
experiments B-O O
demonstrated B-O O
decreased B-O O
transcription B-O O
of B-O O
kappa B-O B-protein
L B-O I-protein
chain B-O I-protein
. B-O O

The B-O O
effects B-O O
of B-O O
TGF-beta B-O B-protein
on B-O O
two B-O O
transcriptional B-O B-protein
regulatory B-O I-protein
factors B-O I-protein
, B-O O
Oct-2 B-O B-protein
and B-O O
nuclear B-O B-protein
factor B-O I-protein
( B-O I-protein
NF B-O I-protein
) B-O I-protein
kappa B-O I-protein
B B-O I-protein
, B-O O
known B-O O
to B-O O
be B-O O
important B-O O
in B-O O
Ig B-O B-DNA
gene B-O I-DNA
transcription B-O O
were B-O O
examined B-O O
. B-O O

Oct-2 B-O B-RNA
mRNA B-O I-RNA
levels B-O O
and B-O O
both B-O O
Oct-2 B-O B-protein
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
proteins B-O I-protein
in B-O O
nuclear B-O O
extracts B-O O
were B-O O
not B-O O
altered B-O O
by B-O O
treatment B-O O
with B-O O
TGF-beta B-O B-protein
. B-O O

In B-O O
contrast B-O O
, B-O O
levels B-O O
of B-O O
the B-O O
transcriptional B-O B-protein
factor B-O I-protein
AP-1 B-O B-protein
, B-O O
which B-O O
is B-O O
not B-O O
known B-O O
to B-O O
be B-O O
important B-O O
in B-O O
B B-O B-cell_type
cell B-O I-cell_type
Ig B-O B-protein
production B-O O
, B-O O
were B-O O
reduced B-O O
by B-O O
TGF-beta B-O B-protein
. B-O O

These B-O O
findings B-O O
demonstrate B-O O
that B-O O
TGF-beta B-O B-protein
decreases B-O O
B B-O B-cell_type
lymphocyte B-O I-cell_type
Ig B-O B-protein
secretion B-O O
by B-O O
inhibiting B-O O
the B-O O
synthesis B-O O
of B-O O
Ig B-O B-RNA
mRNA B-O I-RNA
and B-O O
inhibiting B-O O
the B-O O
switch B-O O
from B-O O
the B-O O
membrane B-O B-RNA
form B-O I-RNA
to B-O O
the B-O O
secreted B-O B-RNA
forms B-O I-RNA
of B-O O
mu B-O B-RNA
and B-O I-RNA
gamma B-O I-RNA
mRNA B-O I-RNA
. B-O O

The B-O O
mechanism B-O O
by B-O O
which B-O O
TGF-beta B-O B-protein
inhibits B-O O
Ig B-O B-protein
chain B-O I-protein
synthesis B-O O
is B-O O
unclear B-O O
although B-O O
it B-O O
does B-O O
not B-O O
involve B-O O
inhibition B-O O
of B-O O
the B-O O
binding B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
or B-O O
Oct-2 B-O B-protein
to B-O O
their B-O O
respective B-O O
target B-O B-DNA
sequences B-O I-DNA
. B-O O

Murine B-O B-protein
and B-O I-protein
human B-O I-protein
T-lymphocyte B-O I-protein
GATA-3 B-O I-protein
factors B-O I-protein
mediate B-O O
transcription B-O O
through B-O O
a B-O O
cis-regulatory B-O B-DNA
element B-O I-DNA
within B-O O
the B-O O
human B-O B-DNA
T-cell B-O I-DNA
receptor B-O I-DNA
delta B-O I-DNA
gene B-O I-DNA
enhancer B-O I-DNA
. B-O O

A B-O O
family B-O O
of B-O O
transcriptional B-O B-protein
activators B-O I-protein
has B-O O
recently B-O O
been B-O O
identified B-O O
in B-O O
chickens B-O O
; B-O O
these B-O O
transcriptional B-O B-protein
activators B-O I-protein
recognize B-O O
a B-O O
common B-O O
consensus B-O B-DNA
motif B-O I-DNA
( B-O O
WGATAR B-O B-DNA
) B-O O
through B-O O
a B-O O
conserved B-O O
C4 B-O B-protein
zinc B-O I-protein
finger B-O I-protein
DNA-binding B-O I-protein
domain B-O I-protein
. B-O O

One B-O O
of B-O O
the B-O O
members B-O O
of B-O O
this B-O O
multigene B-O O
family B-O O
, B-O O
cGATA-3 B-O B-protein
, B-O O
is B-O O
most B-O O
abundantly B-O O
expressed B-O O
in B-O O
the B-O O
T-lymphocyte B-O B-cell_type
cell B-O I-cell_type
lineage B-O I-cell_type
. B-O O

Analysis B-O O
of B-O O
human B-O B-protein
and B-O I-protein
murine B-O I-protein
GATA-3 B-O I-protein
factors B-O I-protein
shows B-O O
a B-O O
striking B-O O
degree B-O O
of B-O O
amino B-O O
acid B-O O
sequence B-O O
identity B-O O
and B-O O
similar B-O O
patterns B-O O
of B-O O
tissue B-O O
specificity B-O O
of B-O O
expression B-O O
in B-O O
these B-O O
three B-O O
organisms B-O O
. B-O O

The B-O O
murine B-O B-protein
and B-O I-protein
human B-O I-protein
factors B-O I-protein
are B-O O
abundantly B-O O
expressed B-O O
in B-O O
a B-O O
variety B-O O
of B-O O
human B-O B-cell_line
and B-O I-cell_line
murine B-O I-cell_line
T-cell B-O I-cell_line
lines B-O I-cell_line
and B-O O
can B-O O
activate B-O O
transcription B-O O
through B-O O
a B-O O
tissue-specific B-O B-DNA
GATA-binding B-O I-DNA
site B-O I-DNA
identified B-O O
within B-O O
the B-O O
human B-O B-DNA
T-cell B-O I-DNA
receptor B-O I-DNA
delta B-O I-DNA
gene B-O I-DNA
enhancer B-O I-DNA
. B-O O

We B-O O
infer B-O O
that B-O O
the B-O O
murine B-O B-protein
and B-O I-protein
human B-O I-protein
GATA-3 B-O I-protein
proteins B-O I-protein
play B-O O
a B-O O
central B-O O
and B-O O
highly B-O O
conserved B-O O
role B-O O
in B-O O
vertebrate B-O O
T-cell-specific B-O O
transcriptional B-O O
regulation B-O O
. B-O O

Processing B-O O
of B-O O
the B-O O
precursor B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
by B-O O
the B-O O
HIV-1 B-O B-protein
protease B-O I-protein
during B-O O
acute B-O O
infection B-O O
. B-O O

Transcription B-O O
of B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
type-1 B-O I-DNA
( B-O I-DNA
HIV-1 B-O I-DNA
) B-O I-DNA
genome B-O I-DNA
is B-O O
regulated B-O O
in B-O O
part B-O O
by B-O O
cellular B-O B-protein
factors B-O I-protein
and B-O O
is B-O O
stimulated B-O O
by B-O O
activation B-O O
of B-O O
latently B-O B-cell_type
infected B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

T-cell B-O O
activation B-O O
also B-O O
correlates B-O O
with B-O O
the B-O O
induction B-O O
of B-O O
the B-O O
factor B-O O
NF-kappa B-O B-protein
B B-O I-protein
which B-O O
binds B-O O
to B-O O
two B-O O
adjacent B-O O
sites B-O O
in B-O O
the B-O O
HIV-1 B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
. B-O O

This B-O O
factor B-O O
consists B-O O
of B-O O
two B-O O
DNA-binding B-O B-protein
subunits B-O I-protein
of B-O O
relative B-O O
molecular B-O O
mass B-O O
50 B-O O
, B-O O
000 B-O O
( B-O O
50K B-O O
) B-O O
associated B-O O
with B-O O
two B-O O
65K B-O B-protein
subunits B-O I-protein
. B-O O

It B-O O
is B-O O
located B-O O
in B-O O
the B-O O
nucleus B-O O
in B-O O
mature B-O B-cell_type
B B-O I-cell_type
cells B-O I-cell_type
, B-O O
but B-O O
is B-O O
present B-O O
in B-O O
other B-O O
cell B-O O
types B-O O
as B-O O
an B-O O
inactive B-O B-protein
cytoplasmic B-O I-protein
complex B-O I-protein
. B-O O

External B-O O
stimuli B-O O
, B-O O
including B-O O
those B-O O
that B-O O
activate B-O O
T B-O B-cell_type
cells B-O I-cell_type
, B-O O
result B-O O
in B-O O
nuclear B-O O
translocation B-O O
of B-O O
active B-O O
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

The B-O O
cloning B-O O
of B-O O
the B-O O
complementary B-O B-DNA
DNA B-O I-DNA
for B-O O
the B-O O
50K B-O B-protein
subunit B-O I-protein
helped B-O O
to B-O O
identify B-O O
an B-O O
exclusively B-O O
cytoplasmic B-O B-protein
105K B-O I-protein
precursor B-O I-protein
( B-O O
p105 B-O B-protein
) B-O O
( B-O O
V.B. B-O O
, B-O O
P.K. B-O O
and B-O O
A.I. B-O O
, B-O O
manuscript B-O O
submitted B-O O
) B-O O
. B-O O

The B-O O
expression B-O O
of B-O O
active B-O O
NF-kappa B-O B-protein
B B-O I-protein
might B-O O
therefore B-O O
also B-O O
be B-O O
regulated B-O O
by B-O O
the B-O O
extent B-O O
of B-O O
processing B-O O
of B-O O
p105 B-O B-protein
. B-O O

Because B-O O
HIV-1 B-O O
requires B-O O
active B-O O
NF-kappa B-O B-protein
B B-O I-protein
for B-O O
efficient B-O O
transcription B-O O
, B-O O
we B-O O
tested B-O O
the B-O O
effect B-O O
of B-O O
HIV-1 B-O O
infection B-O O
on B-O O
the B-O O
processing B-O O
of B-O O
the B-O O
human B-O B-protein
105K B-O I-protein
precursor B-O I-protein
. B-O O

We B-O O
show B-O O
here B-O O
that B-O O
the B-O O
HIV-1 B-O B-protein
protease B-O I-protein
can B-O O
process B-O O
p105 B-O B-protein
and B-O O
increases B-O O
levels B-O O
of B-O O
active B-O O
nuclear B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
complex B-O I-protein
. B-O O

1 B-O B-RNA
, B-O I-RNA
25-Dihydroxyvitamin B-O I-RNA
D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
: B-O O
expression B-O O
in B-O O
hematopoietic B-O B-cell_type
cells B-O I-cell_type
. B-O O

1 B-O O
, B-O O
25-Dihydroxyvitamin B-O O
D3 B-O O
[ B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
] B-O O
induces B-O O
differentiation B-O O
and B-O O
inhibits B-O O
proliferation B-O O
of B-O O
myeloid B-O B-cell_type
leukemic B-O I-cell_type
cells B-O I-cell_type
from B-O O
various B-O O
lines B-O O
and B-O O
patients B-O O
; B-O O
these B-O O
effects B-O O
are B-O O
probably B-O O
mediated B-O O
through B-O O
the B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptor B-O I-protein
. B-O O

Little B-O O
is B-O O
known B-O O
of B-O O
expression B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
in B-O O
hematopoietic B-O B-cell_type
cells B-O I-cell_type
. B-O O

We B-O O
examined B-O O
the B-O O
expression B-O O
and B-O O
modulation B-O O
of B-O O
expression B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
in B-O O
various B-O O
proliferating B-O O
and B-O O
nonproliferating B-O B-cell_type
hematopoietic B-O I-cell_type
cells B-O I-cell_type
. B-O O

Constitutive B-O O
expression B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
was B-O O
detected B-O O
in B-O O
various B-O O
kinds B-O O
of B-O O
hematopoietic B-O B-cell_type
cells B-O I-cell_type
, B-O O
including B-O O
macrophages B-O B-cell_type
and B-O O
activated B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
, B-O O
as B-O O
well B-O O
as B-O O
in B-O O
cell B-O O
lines B-O O
KG-1 B-O B-cell_line
( B-O O
myeloblasts B-O B-cell_type
) B-O O
, B-O O
HL-60 B-O B-cell_line
( B-O O
promyelocytes B-O B-cell_line
) B-O O
, B-O O
ML-3 B-O B-cell_line
( B-O O
myelomonoblasts B-O B-cell_line
) B-O O
, B-O O
U937 B-O B-cell_line
, B-O O
THP-1 B-O B-cell_line
( B-O O
monoblasts B-O B-cell_line
) B-O O
, B-O O
K562 B-O B-cell_line
( B-O O
erythroblasts B-O B-cell_type
) B-O O
, B-O O
and B-O O
S-LB1 B-O B-cell_line
( B-O O
HTLV-1-transfected B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
) B-O O
. B-O O

Receptor B-O B-RNA
transcripts B-O I-RNA
were B-O O
4.6 B-O O
kilobases B-O O
( B-O O
kb B-O O
) B-O O
, B-O O
and B-O O
no B-O O
variant B-O O
sizes B-O O
were B-O O
observed B-O O
. B-O O

All B-O O
cell B-O B-cell_line
lines B-O I-cell_line
examined B-O O
in B-O O
this B-O O
group B-O O
also B-O O
expressed B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
. B-O O

Most B-O O
B B-O B-cell_line
lymphocyte B-O I-cell_line
lines B-O I-cell_line
expressed B-O O
negligible B-O O
levels B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
and B-O O
protein B-O O
; B-O O
however B-O O
; B-O O
analysis B-O O
of B-O O
a B-O O
lymphoid/myeloid B-O B-cell_line
somatic B-O I-cell_line
hybrid B-O I-cell_line
suggested B-O O
that B-O O
suppression B-O O
of B-O O
expression B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
may B-O O
be B-O O
a B-O O
dominant B-O O
characteristic B-O O
. B-O O

HL-60 B-O B-cell_line
cells B-O I-cell_line
were B-O O
cultured B-O O
with B-O O
10 B-O O
( B-O O
-7 B-O O
) B-O O
mol/L B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
for B-O O
24 B-O O
to B-O O
72 B-O O
hours B-O O
, B-O O
and B-O O
levels B-O O
of B-O O
expression B-O O
of B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptor B-O I-protein
and B-O O
its B-O O
RNA B-O O
were B-O O
examined B-O O
. B-O O

Levels B-O O
of B-O O
RNA B-O O
coding B-O O
for B-O O
the B-O O
receptor B-O O
were B-O O
not B-O O
modulated B-O O
by B-O O
exposure B-O O
to B-O O
high B-O O
levels B-O O
of B-O O
ligand B-O O
. B-O O

Levels B-O O
of B-O O
occupied B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptor B-O I-protein
protein B-O I-protein
increased B-O O
in B-O O
these B-O O
HL-60 B-O B-cell_line
cells B-O I-cell_line
; B-O O
but B-O O
the B-O O
total B-O O
number B-O O
of B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
decreased B-O O
about B-O O
50 B-O O
% B-O O
at B-O O
24 B-O O
hours B-O O
and B-O O
returned B-O O
toward B-O O
normal B-O O
at B-O O
72 B-O O
hours B-O O
. B-O O

Steady-state B-O O
levels B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
were B-O O
not B-O O
affected B-O O
by B-O O
terminal B-O O
differentiation B-O O
of B-O O
HL-60 B-O B-cell_line
toward B-O O
either B-O O
granulocytes B-O B-cell_type
or B-O O
macrophages B-O B-cell_type
. B-O O

Nondividing B-O O
macrophages B-O B-cell_type
from B-O O
normal B-O O
individuals B-O O
also B-O O
expressed B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
. B-O O

In B-O O
contrast B-O O
, B-O O
nondividing B-O B-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
lymphocytes B-O I-cell_type
from B-O O
normal B-O O
individuals B-O O
did B-O O
not B-O O
express B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
; B-O O
with B-O O
stimulation B-O O
of B-O O
proliferation B-O O
of B-O O
these B-O O
cells B-O O
, B-O O
accumulation B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
increased B-O O
markedly B-O O
. B-O O

Half-life B-O O
( B-O O
t1/2 B-O O
) B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
was B-O O
short B-O O
( B-O O
1 B-O O
hour B-O O
) B-O O
as B-O O
determined B-O O
by B-O O
measuring B-O O
decay B-O O
of B-O O
the B-O O
message B-O O
after B-O O
addition B-O O
of B-O O
actinomycin B-O O
D B-O O
. B-O O

Consistent B-O O
with B-O O
this B-O O
short B-O O
t1/2 B-O O
, B-O O
accumulation B-O O
of B-O O
1 B-O B-RNA
, B-O I-RNA
25 B-O I-RNA
( B-O I-RNA
OH B-O I-RNA
) B-O I-RNA
2D3 B-O I-RNA
receptor B-O I-RNA
RNA B-O I-RNA
increased B-O O
in B-O O
cells B-O O
as B-O O
their B-O O
protein B-O O
synthesis B-O O
was B-O O
inhibited B-O O
. B-O O

Further B-O O
studies B-O O
are B-O O
required B-O O
to B-O O
understand B-O O
the B-O O
physiologic B-O O
role B-O O
of B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
in B-O O
myeloid B-O B-cell_type
cells B-O I-cell_type
and B-O O
proliferating B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
. B-O O

Expression B-O O
of B-O O
c-jun B-O B-DNA
, B-O O
jun B-O B-DNA
B B-O I-DNA
and B-O O
jun B-O B-DNA
D B-O I-DNA
proto-oncogenes B-O I-DNA
in B-O O
human B-O B-cell_type
peripheral-blood B-O I-cell_type
granulocytes B-O I-cell_type
. B-O O

We B-O O
have B-O O
found B-O O
that B-O O
purified B-O B-cell_type
human B-O I-cell_type
peripheral-blood B-O I-cell_type
granulocytes B-O I-cell_type
express B-O O
constitutively B-O O
significant B-O O
levels B-O O
of B-O O
proto-oncogenes B-O B-DNA
c-jun B-O B-RNA
, B-O I-RNA
jun B-O I-RNA
B B-O I-RNA
and B-O I-RNA
jun B-O I-RNA
D B-O I-RNA
mRNA B-O I-RNA
. B-O O

Upon B-O O
functional B-O O
activation B-O O
of B-O O
granulocytes B-O B-cell_type
by B-O O
4 B-O O
beta-phorbol B-O O
12-myristate B-O O
13-acetate B-O O
( B-O O
PMA B-O O
) B-O O
, B-O O
the B-O O
levels B-O O
of B-O O
c-jun B-O B-RNA
, B-O I-RNA
jun B-O I-RNA
B B-O I-RNA
and B-O I-RNA
jun B-O I-RNA
D B-O I-RNA
transcripts B-O I-RNA
were B-O O
increased B-O O
. B-O O

The B-O O
three B-O O
jun B-O B-DNA
genes B-O I-DNA
showed B-O O
a B-O O
similar B-O O
time B-O O
course B-O O
in B-O O
their B-O O
induction B-O O
by B-O O
PMA B-O O
, B-O O
maximal B-O O
mRNA B-O O
levels B-O O
being B-O O
reached B-O O
after B-O O
60 B-O O
min B-O O
of B-O O
induction B-O O
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
expression B-O O
of B-O O
c-jun B-O B-DNA
, B-O O
jun B-O B-DNA
B B-O I-DNA
and B-O O
jun B-O B-DNA
D B-O I-DNA
genes B-O I-DNA
might B-O O
be B-O O
involved B-O O
in B-O O
terminal B-O B-cell_type
granulocyte B-O I-cell_type
differentiation B-O O
or B-O O
in B-O O
regulating B-O O
granulocyte B-O B-cell_type
functionality B-O O
. B-O O

The B-O O
29-kDa B-O B-protein
proteins B-O I-protein
phosphorylated B-O O
in B-O O
thrombin-activated B-O B-cell_type
human B-O I-cell_type
platelets B-O I-cell_type
are B-O O
forms B-O O
of B-O O
the B-O O
estrogen B-O B-protein
receptor B-O I-protein
-related B-O I-protein
27-kDa B-O I-protein
heat B-O I-protein
shock B-O I-protein
protein B-O I-protein
. B-O O

Thrombin B-O B-protein
plays B-O O
a B-O O
critical B-O O
role B-O O
in B-O O
platelet B-O O
activation B-O O
, B-O O
hemostasis B-O O
, B-O O
and B-O O
thrombosis B-O O
. B-O O

Cellular B-O O
activation B-O O
by B-O O
thrombin B-O B-protein
leads B-O O
to B-O O
the B-O O
phosphorylation B-O O
of B-O O
multiple B-O B-protein
proteins B-O I-protein
, B-O O
most B-O O
of B-O O
which B-O O
are B-O O
unidentified B-O O
. B-O O

We B-O O
have B-O O
characterized B-O O
several B-O O
29-kDa B-O B-protein
proteins B-O I-protein
that B-O O
are B-O O
rapidly B-O O
phosphorylated B-O O
following B-O O
exposure B-O O
of B-O O
intact B-O B-cell_type
human B-O I-cell_type
platelets B-O I-cell_type
to B-O O
thrombin B-O B-protein
. B-O O

A B-O O
murine B-O B-protein
monoclonal B-O I-protein
antibody B-O I-protein
raised B-O O
to B-O O
an B-O O
unidentified B-O B-protein
estrogen B-O I-protein
receptor-related B-O I-protein
29-kDa B-O I-protein
protein B-O I-protein
selectively B-O O
recognized B-O O
these B-O O
proteins B-O O
as B-O O
well B-O O
as B-O O
a B-O O
more B-O O
basic B-O O
, B-O O
unphosphorylated B-O B-protein
27-kDa B-O I-protein
protein B-O I-protein
. B-O O

Cellular B-O O
activation B-O O
by B-O O
thrombin B-O B-protein
led B-O O
to B-O O
a B-O O
marked B-O O
shift B-O O
in B-O O
the B-O O
proportion B-O O
of B-O O
protein B-O O
from B-O O
the B-O O
27-kDa B-O B-protein
unphosphorylated B-O I-protein
form B-O I-protein
to B-O O
the B-O O
29-kDa B-O B-protein
phosphoprotein B-O I-protein
species B-O I-protein
. B-O O

Using B-O O
this B-O O
antibody B-O O
, B-O O
we B-O O
isolated B-O O
and B-O O
sequenced B-O O
a B-O O
human B-O B-DNA
cDNA B-O I-DNA
clone B-O I-DNA
encoding B-O O
a B-O O
protein B-O O
that B-O O
was B-O O
identical B-O O
to B-O O
the B-O O
mammalian B-O B-protein
27-kDa B-O I-protein
heat B-O I-protein
shock B-O I-protein
protein B-O I-protein
( B-O O
HSP27 B-O B-protein
) B-O O
, B-O O
a B-O O
protein B-O O
of B-O O
uncertain B-O O
function B-O O
that B-O O
is B-O O
known B-O O
to B-O O
be B-O O
phosphorylated B-O O
to B-O O
several B-O O
forms B-O O
and B-O O
to B-O O
be B-O O
transcriptionally B-O O
induced B-O O
by B-O O
estrogen B-O O
. B-O O

The B-O O
29-kDa B-O B-protein
proteins B-O I-protein
were B-O O
confirmed B-O O
to B-O O
be B-O O
phosphorylated B-O O
forms B-O O
of B-O O
HSP27 B-O B-protein
by B-O O
immunoprecipitation B-O O
studies B-O O
. B-O O

Thus B-O O
, B-O O
the B-O O
`` B-O O
estrogen B-O B-protein
receptor-related B-O I-protein
protein B-O I-protein
`` B-O O
is B-O O
HSP27 B-O B-protein
, B-O O
and B-O O
the B-O O
three B-O O
major B-O O
29-kDa B-O B-protein
proteins B-O I-protein
phosphorylated B-O O
in B-O O
thrombin B-O B-protein
-activated B-O B-cell_type
platelets B-O I-cell_type
are B-O O
forms B-O O
of B-O O
HSP27 B-O B-protein
. B-O O

These B-O O
data B-O O
suggest B-O O
a B-O O
role B-O O
for B-O O
HSP27 B-O B-protein
in B-O O
the B-O O
signal B-O O
transduction B-O O
events B-O O
of B-O O
platelet B-O B-cell_type
activation B-O O
. B-O O

Isolation B-O O
of B-O O
a B-O O
candidate B-O B-protein
repressor/activator B-O I-protein
, B-O O
NF-E1 B-O B-protein
( B-O O
YY-1 B-O B-protein
, B-O O
delta B-O B-protein
) B-O O
, B-O O
that B-O O
binds B-O O
to B-O O
the B-O O
immunoglobulin B-O B-DNA
kappa B-O I-DNA
3 B-O I-DNA
' B-O I-DNA
enhancer B-O I-DNA
and B-O O
the B-O O
immunoglobulin B-O B-DNA
heavy-chain B-O I-DNA
mu B-O I-DNA
E1 B-O I-DNA
site B-O I-DNA
. B-O O

We B-O O
have B-O O
determined B-O O
that B-O O
the B-O O
developmental B-O O
control B-O O
of B-O O
immunoglobulin B-O B-DNA
kappa B-O I-DNA
3 B-O I-DNA
' B-O I-DNA
enhancer B-O I-DNA
( B-O O
kappa B-O B-DNA
E3 B-O I-DNA
' B-O I-DNA
) B-O O
activity B-O O
is B-O O
the B-O O
result B-O O
of B-O O
the B-O O
combined B-O O
influence B-O O
of B-O O
positive- B-O B-DNA
and B-O I-DNA
negative-acting B-O I-DNA
elements B-O I-DNA
. B-O O

We B-O O
show B-O O
that B-O O
a B-O O
central B-O O
core B-O O
in B-O O
the B-O O
kappa B-O B-DNA
E3 B-O I-DNA
' B-O I-DNA
enhancer B-O I-DNA
is B-O O
active B-O O
at B-O O
the B-O O
pre-B-cell B-O O
stage B-O O
but B-O O
is B-O O
repressed B-O O
by B-O O
flanking B-O B-DNA
negative-acting B-O I-DNA
elements B-O I-DNA
. B-O O

The B-O O
negative-acting B-O B-DNA
sequences B-O I-DNA
repress B-O O
enhancer B-O O
activity B-O O
in B-O O
a B-O O
position- B-O O
and B-O O
orientation-independent B-O O
manner B-O O
at B-O O
the B-O O
pre-B-cell B-O O
stage B-O O
. B-O O

We B-O O
have B-O O
isolated B-O O
a B-O O
human B-O B-DNA
cDNA B-O I-DNA
clone B-O I-DNA
encoding B-O O
a B-O O
zinc B-O B-protein
finger B-O I-protein
protein B-O I-protein
( B-O O
NF-E1 B-O B-protein
) B-O O
that B-O O
binds B-O O
to B-O O
the B-O O
negative-acting B-O B-DNA
segment B-O I-DNA
of B-O O
the B-O O
kappa B-O B-DNA
E3 B-O I-DNA
' B-O I-DNA
enhancer B-O I-DNA
. B-O O

This B-O O
protein B-O O
also B-O O
binds B-O O
to B-O O
the B-O O
immunoglobulin B-O B-DNA
heavy-chain B-O I-DNA
enhancer B-O I-DNA
mu B-O I-DNA
E1 B-O I-DNA
site B-O I-DNA
. B-O O

NF-E1 B-O B-protein
is B-O O
encoded B-O O
by B-O O
the B-O O
same B-O O
gene B-O O
as B-O O
the B-O O
YY-1 B-O B-protein
protein B-O I-protein
, B-O O
which B-O O
binds B-O O
to B-O O
the B-O O
adeno-associated B-O B-DNA
virus B-O I-DNA
P5 B-O I-DNA
promoter B-O I-DNA
. B-O O

NF-E1 B-O B-protein
is B-O O
also B-O O
the B-O O
human B-O B-protein
homologue B-O I-protein
of B-O O
the B-O O
mouse B-O B-protein
delta B-O I-protein
protein B-O I-protein
, B-O O
which B-O O
binds B-O O
to B-O O
ribosomal B-O B-DNA
protein B-O I-DNA
gene B-O I-DNA
promoters B-O I-DNA
. B-O O

The B-O O
predicted B-O O
amino B-O O
acid B-O O
sequence B-O O
of B-O O
this B-O O
protein B-O O
contains B-O O
features B-O O
characteristic B-O O
of B-O O
transcriptional B-O B-protein
activators B-O I-protein
as B-O O
well B-O O
as B-O O
transcriptional B-O B-protein
repressors B-O I-protein
. B-O O

Cotransfection B-O O
studies B-O O
with B-O O
this B-O O
cDNA B-O B-DNA
indicate B-O O
that B-O O
it B-O O
can B-O O
repress B-O O
basal B-O B-DNA
promoter B-O I-DNA
activity B-O O
. B-O O

The B-O O
apparent B-O O
dual B-O O
function B-O O
of B-O O
this B-O O
protein B-O O
is B-O O
discussed B-O O
. B-O O

A B-O O
human B-O B-DNA
putative B-O I-DNA
lymphocyte B-O I-DNA
G0/G1 B-O I-DNA
switch B-O I-DNA
gene B-O I-DNA
containing B-O O
a B-O O
CpG-rich B-O B-DNA
island B-O I-DNA
encodes B-O O
a B-O O
small B-O B-protein
basic B-O I-protein
protein B-O I-protein
with B-O O
the B-O O
potential B-O O
to B-O O
be B-O O
phosphorylated B-O O
. B-O O

Genes B-O O
actively B-O O
involved B-O O
in B-O O
the B-O O
G0/G1 B-O B-DNA
switch B-O I-DNA
( B-O O
G0S B-O B-DNA
genes B-O I-DNA
) B-O O
may B-O O
be B-O O
differentially B-O O
expressed B-O O
during B-O O
the B-O O
lectin B-O B-protein
-induced B-O O
switch B-O O
of B-O O
lymphocytes B-O B-cell_type
from B-O O
the B-O O
G0 B-O O
to B-O O
the B-O O
G1 B-O O
phases B-O O
of B-O O
the B-O O
cell B-O O
cycle B-O O
. B-O O

This B-O O
paper B-O O
presents B-O O
studies B-O O
of B-O O
G0S2 B-O B-DNA
, B-O O
a B-O O
member B-O O
of B-O O
a B-O O
set B-O O
of B-O O
putative B-O B-DNA
G0S B-O I-DNA
genes B-O I-DNA
, B-O O
for B-O O
which B-O O
cDNAs B-O B-DNA
were B-O O
cloned B-O O
and B-O O
selected B-O O
on B-O O
the B-O O
basis B-O O
of B-O O
differential B-O O
cDNA B-O O
hybridization B-O O
. B-O O

G0S2 B-O B-RNA
mRNA B-O I-RNA
increases B-O O
transiently B-O O
within B-O O
1-2 B-O O
hr B-O O
of B-O O
the B-O O
addition B-O O
of B-O O
lectin B-O B-protein
or B-O O
cycloheximide B-O O
to B-O O
cultured B-O B-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
. B-O O

Comparison B-O O
of B-O O
a B-O O
nearly B-O B-DNA
full-length B-O I-DNA
cDNA B-O I-DNA
sequence B-O I-DNA
with B-O O
the B-O O
corresponding B-O O
genomic B-O B-DNA
sequence B-O I-DNA
reveals B-O O
one B-O O
small B-O O
intron B-O O
and B-O O
an B-O O
open B-O B-DNA
reading B-O I-DNA
frame B-O I-DNA
in B-O O
the B-O O
second B-O O
exon B-O B-DNA
. B-O O

The B-O O
derived B-O O
103-amino-acid B-O B-protein
basic B-O I-protein
protein B-O I-protein
has B-O O
two B-O O
potential B-O O
alpha-helical B-O B-protein
domains B-O I-protein
separated B-O O
by B-O O
a B-O O
hydrophobic B-O B-protein
region B-O I-protein
with B-O O
the B-O O
potential B-O O
to B-O O
generate B-O O
turns B-O O
and B-O O
assume B-O O
a B-O O
beta-sheet B-O O
conformation B-O O
. B-O O

Consistent B-O O
with B-O O
involvement B-O O
in B-O O
the B-O O
G0/G1 B-O B-DNA
switch B-O I-DNA
, B-O O
the B-O O
protein B-O O
contains B-O O
potential B-O O
sites B-O O
for B-O O
phosphorylation B-O O
by B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
and B-O O
casein B-O B-protein
kinase B-O I-protein
II B-O I-protein
. B-O O

The B-O O
gene B-O O
contains B-O O
a B-O O
CpG-rich B-O B-protein
island B-O I-protein
suggesting B-O O
expression B-O O
in B-O O
the B-O O
germ B-O B-DNA
line B-O I-DNA
. B-O O

An B-O O
upstream B-O B-DNA
segment B-O I-DNA
contains B-O O
tandem B-O B-DNA
dinucleotide B-O I-DNA
repeats B-O I-DNA
( B-O O
CT B-O O
) B-O O
19/ B-O O
( B-O O
CA B-O O
) B-O O
16 B-O O
. B-O O

There B-O O
is B-O O
a B-O O
suitably B-O O
located B-O O
TATA B-O B-DNA
box B-O I-DNA
, B-O O
but B-O O
potential B-O O
sites B-O O
for B-O O
CCAAT-box B-O B-protein
binding B-O I-protein
factors B-O I-protein
are B-O O
far B-O O
upstream B-O O
, B-O O
embedded B-O O
in B-O O
a B-O O
42-nucleotide B-O B-DNA
repeat B-O I-DNA
element B-O I-DNA
. B-O O

Potential B-O O
sites B-O O
for B-O O
transcription B-O B-protein
factors B-O I-protein
AP1 B-O B-protein
, B-O O
AP2 B-O B-protein
, B-O O
and B-O O
AP3 B-O B-protein
are B-O O
consistent B-O O
with B-O O
rapid B-O O
transcriptional B-O O
activation B-O O
in B-O O
response B-O O
to B-O O
inducing B-O O
agents B-O O
. B-O O

USF-related B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
HIV-TF1 B-O B-protein
, B-O O
stimulates B-O O
transcription B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus-1 B-O O
. B-O O

The B-O O
transcription B-O B-protein
factor B-O I-protein
HIV-TF1 B-O B-protein
, B-O O
which B-O O
binds B-O O
to B-O O
a B-O O
region B-O O
about B-O O
60 B-O B-DNA
bp B-O I-DNA
upstream B-O I-DNA
from B-O O
the B-O O
enhancer B-O B-DNA
of B-O O
the B-O O
human B-O O
immunodeficiency B-O O
virus-1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
, B-O O
was B-O O
purified B-O O
from B-O O
human B-O B-cell_type
B B-O I-cell_type
cells B-O I-cell_type
. B-O O

HIV-TF1 B-O B-protein
had B-O O
a B-O O
molecular B-O O
weight B-O O
of B-O O
39 B-O O
, B-O O
000 B-O O
. B-O O

Binding B-O O
of B-O O
HIV-TF1 B-O B-protein
to B-O O
the B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
LTR B-O B-DNA
) B-O O
activated B-O O
transcription B-O O
from B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
in B-O O
vitro B-O O
. B-O O

The B-O O
HIV-TF1 B-O B-DNA
-binding B-O I-DNA
site B-O I-DNA
in B-O O
HIV B-O B-DNA
LTR B-O I-DNA
was B-O O
similar B-O O
to B-O O
the B-O O
site B-O O
recognized B-O O
by B-O O
upstream B-O B-protein
stimulatory B-O I-protein
factor B-O I-protein
( B-O O
USF B-O B-protein
) B-O O
in B-O O
the B-O O
adenovirus B-O B-DNA
major B-O I-DNA
late B-O I-DNA
promoter B-O I-DNA
. B-O O

DNA-binding B-O O
properties B-O O
of B-O O
HIV-TF1 B-O B-protein
suggested B-O O
that B-O O
HIV-TF1 B-O B-protein
might B-O O
be B-O O
identical B-O O
or B-O O
related B-O O
to B-O O
USF B-O B-protein
. B-O O

Interestingly B-O O
, B-O O
treatment B-O O
of B-O O
purified B-O O
HIV-TF1 B-O B-protein
by B-O O
phosphatase B-O B-protein
greatly B-O O
reduced B-O O
its B-O O
DNA-binding B-O O
activity B-O O
, B-O O
suggesting B-O O
that B-O O
phosphorylation B-O O
of B-O O
HIV-TF1 B-O B-protein
was B-O O
essential B-O O
for B-O O
DNA B-O O
binding B-O O
. B-O O

The B-O O
disruption B-O O
of B-O O
HIV-TF1 B-O B-DNA
-binding B-O I-DNA
site B-O I-DNA
induced B-O O
a B-O O
60 B-O O
% B-O O
decrease B-O O
in B-O O
the B-O O
level B-O O
of B-O O
transcription B-O O
from B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
in B-O O
vivo B-O O
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
HIV-TF1 B-O B-protein
is B-O O
involved B-O O
in B-O O
transcriptional B-O O
regulation B-O O
of B-O O
HIV-1 B-O O
. B-O O

Severe B-O O
5-fluorouracil B-O O
toxicity B-O O
secondary B-O O
to B-O O
dihydropyrimidine B-O B-protein
dehydrogenase B-O I-protein
deficiency B-O O
. B-O O

A B-O O
potentially B-O O
more B-O O
common B-O O
pharmacogenetic B-O O
syndrome B-O O
. B-O O

This B-O O
study B-O O
describes B-O O
the B-O O
inheritance B-O O
of B-O O
a B-O O
defect B-O O
in B-O O
pyrimidine B-O O
catabolism B-O O
and B-O O
its B-O O
association B-O O
with B-O O
drug-induced B-O O
toxicity B-O O
in B-O O
a B-O O
patient B-O O
receiving B-O O
5-fluorouracil B-O O
( B-O O
FUra B-O O
) B-O O
as B-O O
adjuvant B-O O
chemotherapy B-O O
for B-O O
breast B-O O
carcinoma B-O O
. B-O O

The B-O O
study B-O O
population B-O O
included B-O O
the B-O O
affected B-O O
patient B-O O
( B-O O
proband B-O O
) B-O O
, B-O O
nine B-O O
of B-O O
her B-O O
blood B-O O
relatives B-O O
, B-O O
and B-O O
seven B-O O
healthy B-O O
volunteers B-O O
. B-O O

The B-O O
activity B-O O
of B-O O
dihydropyrimidine B-O B-protein
dehydrogenase B-O I-protein
( B-O O
DPD B-O B-protein
) B-O O
, B-O O
the B-O O
initial B-O O
enzyme B-O O
of B-O O
pyrimidine B-O O
( B-O O
and B-O O
FUra B-O O
) B-O O
catabolism B-O O
, B-O O
in B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
was B-O O
measured B-O O
in B-O O
each B-O O
subject B-O O
by B-O O
a B-O O
specific B-O O
radiometric B-O O
assay B-O O
using B-O O
FUra B-O O
as B-O O
the B-O O
substrate B-O O
. B-O O

The B-O O
proband B-O O
had B-O O
no B-O O
detectable B-O O
DPD B-O B-protein
activity B-O O
. B-O O

When B-O O
enzyme B-O O
levels B-O O
in B-O O
the B-O O
proband B-O O
and B-O O
relatives B-O O
were B-O O
compared B-O O
with B-O O
that B-O O
in B-O O
controls B-O O
, B-O O
an B-O O
autosomal B-O O
recessive B-O O
pattern B-O O
of B-O O
inheritance B-O O
was B-O O
demonstrated B-O O
. B-O O

This B-O O
is B-O O
the B-O O
third B-O O
patient B-O O
with B-O O
severe B-O O
FUra B-O O
toxicity B-O O
secondary B-O O
to B-O O
an B-O O
alteration B-O O
in B-O O
pyrimidine B-O O
catabolism B-O O
and B-O O
the B-O O
second B-O O
from B-O O
our B-O O
clinic B-O O
population B-O O
suggesting B-O O
that B-O O
the B-O O
frequency B-O O
of B-O O
this B-O O
genetic B-O O
defect B-O O
may B-O O
be B-O O
greater B-O O
than B-O O
previously B-O O
thought B-O O
. B-O O

Monitoring B-O O
DPD B-O B-protein
activity B-O O
may B-O O
be B-O O
important B-O O
in B-O O
the B-O O
management B-O O
of B-O O
patients B-O O
experiencing B-O O
severe B-O O
toxicity B-O O
secondary B-O O
to B-O O
FUra B-O O
chemotherapy B-O O
. B-O O

Transactivation B-O O
of B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
promoter B-O I-DNA
by B-O O
human B-O O
herpesvirus B-O O
6 B-O O
( B-O O
HHV-6 B-O O
) B-O O
strains B-O O
GS B-O O
and B-O O
Z-29 B-O B-protein
in B-O O
primary B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
and B-O O
identification B-O O
of B-O O
transactivating B-O B-DNA
HHV-6 B-O I-DNA
( B-O I-DNA
GS B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
fragments B-O I-DNA
. B-O O

Human B-O O
herpesvirus B-O O
6 B-O O
( B-O O
HHV-6 B-O O
) B-O O
can B-O O
activate B-O O
the B-O O
human B-O B-DNA
immunodeficiency B-O I-DNA
virus B-O I-DNA
( B-O I-DNA
HIV B-O I-DNA
) B-O I-DNA
promoter B-O I-DNA
and B-O O
accelerate B-O O
cytopathic B-O O
effects B-O O
in B-O O
HIV-infected B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

This B-O O
study B-O O
examines B-O O
the B-O O
regions B-O O
of B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
required B-O O
for B-O O
HHV-6 B-O O
transactivation B-O O
in B-O O
a B-O O
heterogeneous B-O O
population B-O O
of B-O O
primary B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
with B-O O
or B-O O
without B-O O
antigenic B-O O
stimulation B-O O
. B-O O

Two B-O O
different B-O O
strains B-O O
of B-O O
HHV-6 B-O O
, B-O O
GS B-O O
and B-O O
Z29 B-O B-protein
, B-O O
transactivated B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
. B-O O

The B-O O
GS B-O O
strain B-O O
transactivated B-O O
the B-O O
promoter B-O B-DNA
in B-O O
both B-O O
stimulated B-O O
and B-O O
resting B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
, B-O O
while B-O O
the B-O O
Z29 B-O O
strain B-O O
increased B-O O
HIV B-O B-DNA
promoter B-O I-DNA
activity B-O O
only B-O O
in B-O O
stimulated B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Three B-O O
DNA B-O B-DNA
clones B-O I-DNA
containing B-O O
HHV-6 B-O B-DNA
( B-O I-DNA
GS B-O I-DNA
) B-O I-DNA
genomic B-O I-DNA
fragments B-O I-DNA
transactivated B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
in B-O O
cotransfected B-O B-cell_line
T B-O I-cell_line
cells B-O I-cell_line
. B-O O

A B-O O
21.4-kb B-O B-DNA
DNA B-O I-DNA
clone B-O I-DNA
, B-O O
pZVB70 B-O B-DNA
, B-O O
showed B-O O
the B-O O
highest B-O O
transactivating B-O O
ability B-O O
, B-O O
while B-O O
two B-O O
other B-O O
DNA B-O B-DNA
fragments B-O I-DNA
, B-O O
pZVB10 B-O B-DNA
( B-O O
6.2 B-O O
kb B-O O
) B-O O
and B-O O
pZVH14 B-O B-DNA
( B-O O
8.7 B-O O
kb B-O O
) B-O O
, B-O O
showed B-O O
lower B-O O
activity B-O O
. B-O O

One B-O O
of B-O O
these B-O O
clones B-O O
, B-O O
pZVH14 B-O B-DNA
, B-O O
activated B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
construct B-O I-DNA
containing B-O O
a B-O O
mutation B-O O
in B-O O
the B-O O
NF B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
site B-O I-DNA
. B-O O

However B-O O
, B-O O
this B-O O
mutated B-O B-DNA
NF B-O I-DNA
kappa B-O I-DNA
B B-O I-DNA
promoter B-O I-DNA
was B-O O
not B-O O
transactivated B-O O
during B-O O
HHV-6 B-O O
( B-O O
GS B-O O
) B-O O
infection B-O O
or B-O O
after B-O O
cotransfection B-O O
with B-O O
pZVB70 B-O B-DNA
or B-O O
pZVB10 B-O B-DNA
. B-O O

These B-O O
data B-O O
indicate B-O O
that B-O O
the B-O O
NF B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
sites B-O I-DNA
of B-O O
the B-O O
HIV B-O B-DNA
promoter B-O I-DNA
are B-O O
essential B-O O
for B-O O
its B-O O
transactivation B-O O
during B-O O
HHV-6 B-O O
( B-O O
GS B-O O
) B-O O
infection B-O O
. B-O O

By B-O O
increasing B-O O
HIV B-O B-DNA
promoter B-O I-DNA
activity B-O O
in B-O O
primary B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
, B-O O
HHV-6 B-O O
may B-O O
consequently B-O O
increase B-O O
HIV B-O O
replication B-O O
, B-O O
leading B-O O
to B-O O
an B-O O
increase B-O O
in B-O O
the B-O O
cytopathic B-O O
effect B-O O
on B-O O
coinfected B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Inhibition B-O O
of B-O O
HIV-1 B-O O
replication B-O O
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
by B-O O
cysteine B-O O
and B-O O
cysteine B-O O
derivatives B-O O
. B-O O

HIV-1 B-O B-DNA
proviral B-O I-DNA
DNA B-O I-DNA
contains B-O O
two B-O O
binding B-O B-DNA
sites B-O I-DNA
for B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

HIV-1 B-O O
-infected B-O O
individuals B-O O
have B-O O
, B-O O
on B-O O
average B-O O
, B-O O
abnormally B-O O
high B-O O
levels B-O O
of B-O O
tumour B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
alpha B-O I-protein
( B-O O
TNF B-O B-protein
alpha B-O I-protein
) B-O O
and B-O O
abnormally B-O O
low B-O O
plasma B-O O
cysteine B-O O
levels B-O O
. B-O O

We B-O O
therefore B-O O
investigated B-O O
the B-O O
effects B-O O
of B-O O
cysteine B-O O
and B-O O
related B-O O
thiols B-O O
on B-O O
HIV-1 B-O O
replication B-O O
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
expression B-O O
. B-O O

The B-O O
experiments B-O O
in B-O O
this B-O O
report B-O O
show B-O O
that B-O O
cysteine B-O O
or B-O O
N-acetylcysteine B-O O
( B-O O
NAC B-O O
) B-O O
raise B-O O
the B-O O
intracellular B-O O
glutathione B-O O
( B-O O
GSH B-O O
) B-O O
level B-O O
and B-O O
inhibit B-O O
HIV-1 B-O O
replication B-O O
in B-O O
persistently B-O O
infected B-O O
Molt-4 B-O B-cell_line
and B-O O
U937 B-O B-cell_line
cells B-O I-cell_line
. B-O O

However B-O O
, B-O O
inhibition B-O O
of B-O O
HIV-1 B-O O
replication B-O O
appears B-O O
not B-O O
to B-O O
be B-O O
directly B-O O
correlated B-O O
with B-O O
GSH B-O O
levels B-O O
. B-O O

Cysteine B-O O
and B-O O
NAC B-O O
also B-O O
inhibit B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
as B-O O
determined B-O O
by B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
and B-O O
chloramphenicol B-O B-protein
acetyl-transferase B-O I-protein
( B-O O
CAT B-O O
) B-O O
gene B-O O
expression B-O O
under B-O O
control B-O O
of B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
binding B-O I-DNA
sites B-O I-DNA
in B-O O
uninfected B-O B-cell_type
cells B-O I-cell_type
. B-O O

This B-O O
suggests B-O O
that B-O O
the B-O O
cysteine B-O O
deficiency B-O O
in B-O O
HIV-1 B-O O
-infected B-O O
individuals B-O O
may B-O O
cause B-O O
an B-O O
over-expression B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
-dependent B-O O
genes B-O O
and B-O O
enhance B-O O
HIV-1 B-O O
replication B-O O
. B-O O

NAC B-O O
may B-O O
be B-O O
considered B-O O
for B-O O
the B-O O
treatment B-O O
of B-O O
HIV-1 B-O O
-infected B-O O
individuals B-O O
. B-O O

A B-O O
thymus-specific B-O B-protein
member B-O I-protein
of B-O O
the B-O O
HMG B-O B-protein
protein B-O I-protein
family B-O I-protein
regulates B-O O
the B-O O
human B-O B-DNA
T B-O I-DNA
cell B-O I-DNA
receptor B-O I-DNA
C B-O I-DNA
alpha B-O I-DNA
enhancer B-O I-DNA
. B-O O

The B-O O
human B-O B-protein
T B-O I-protein
cell-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
TCF-1 B-O B-protein
alpha B-O I-protein
plays B-O O
a B-O O
key B-O O
role B-O O
in B-O O
the B-O O
tissue-specific B-O O
activation B-O O
of B-O O
the B-O O
T B-O B-protein
cell B-O I-protein
receptor B-O I-protein
( B-O O
TCR B-O B-protein
) B-O O
C B-O O
alpha B-O O
enhancer B-O O
and B-O O
binds B-O O
to B-O O
pyrimidine B-O O
-rich B-O B-DNA
elements B-O I-DNA
( B-O O
5'-PyCTTTG-3 B-O O
' B-O O
) B-O O
present B-O O
in B-O O
a B-O O
variety B-O O
of B-O O
other B-O O
T B-O B-DNA
cell-specific B-O I-DNA
control B-O I-DNA
regions B-O I-DNA
. B-O O

Using B-O O
amino B-O O
acid B-O O
sequence B-O O
information B-O O
derived B-O O
from B-O O
the B-O O
DNA B-O B-protein
affinity-purified B-O I-protein
protein B-O I-protein
, B-O O
we B-O O
have B-O O
now B-O O
isolated B-O O
cDNA B-O B-DNA
clones B-O I-DNA
encoding B-O O
TCF-1 B-O B-protein
alpha B-O I-protein
. B-O O

The B-O O
TCF-1 B-O B-DNA
alpha B-O I-DNA
cDNA B-O I-DNA
contains B-O O
a B-O O
single B-O O
68-amino-acid B-O B-protein
domain B-O I-protein
that B-O O
is B-O O
homologous B-O O
to B-O O
a B-O O
region B-O O
conserved B-O O
among B-O O
high-mobility B-O B-protein
group B-O I-protein
( B-O O
HMG B-O B-protein
) B-O O
and B-O O
nonhistone B-O B-protein
chromosomal B-O I-protein
proteins B-O I-protein
. B-O O

Expression B-O O
of B-O O
full-length B-O O
and B-O O
mutant B-O B-DNA
cDNA B-O I-DNA
clones B-O I-DNA
in B-O O
bacteria B-O O
reveal B-O O
that B-O O
the B-O O
single B-O B-protein
HMG B-O I-protein
motif B-O I-protein
, B-O O
which B-O O
is B-O O
predicted B-O O
to B-O O
contain B-O O
two B-O O
extended B-O O
alpha-helical B-O B-protein
segments B-O I-protein
, B-O O
is B-O O
sufficient B-O O
to B-O O
direct B-O O
the B-O O
sequence-specific B-O O
binding B-O O
of B-O O
TCF-1 B-O B-protein
alpha B-O I-protein
to B-O O
DNA B-O O
. B-O O

Northern B-O O
blot B-O O
experiments B-O O
demonstrate B-O O
further B-O O
that B-O O
TCF-1 B-O B-RNA
alpha B-O I-RNA
mRNA B-O I-RNA
is B-O O
highly B-O O
tissue B-O O
specific B-O O
, B-O O
found B-O O
primarily B-O O
in B-O O
the B-O O
thymus B-O B-cell_line
or B-O I-cell_line
T B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

The B-O O
immature B-O B-cell_line
CEM B-O I-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
expresses B-O O
relatively B-O O
low B-O O
levels B-O O
of B-O O
TCF-1 B-O B-RNA
alpha B-O I-RNA
mRNA B-O I-RNA
, B-O O
which B-O O
are B-O O
increased B-O O
upon B-O O
activation B-O O
of B-O O
these B-O O
cells B-O O
by B-O O
phorbol B-O O
esters B-O O
. B-O O

Interestingly B-O O
, B-O O
the B-O O
cloned B-O O
TCF-1 B-O B-protein
alpha B-O I-protein
protein B-O I-protein
is B-O O
a B-O O
potent B-O O
transcriptional B-O B-protein
activator B-O I-protein
of B-O O
the B-O O
human B-O B-DNA
TCR B-O I-DNA
alpha B-O I-DNA
enhancer B-O I-DNA
in B-O O
nonlymphoid B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
whereas B-O O
the B-O O
activity B-O O
of B-O O
the B-O O
endogenous B-O B-protein
protein B-O I-protein
in B-O O
T B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
is B-O O
strongly B-O O
dependent B-O O
on B-O O
an B-O O
additional B-O O
T B-O B-protein
cell-specific B-O I-protein
protein B-O I-protein
that B-O O
interacts B-O O
with B-O O
the B-O O
core B-O B-DNA
enhancer B-O I-DNA
. B-O O

TCF-1 B-O B-protein
alpha B-O I-protein
is B-O O
currently B-O O
unique B-O O
among B-O O
the B-O O
newly B-O O
emerging B-O O
family B-O O
of B-O O
DNA-binding B-O B-protein
regulatory B-O I-protein
proteins B-O I-protein
that B-O O
share B-O O
the B-O O
HMG B-O B-protein
motif B-O I-protein
in B-O O
that B-O O
it B-O O
is B-O O
a B-O O
highly B-O B-protein
tissue-specific B-O I-protein
RNA B-O I-protein
polymerase B-O I-protein
II B-O I-protein
transcription B-O I-protein
factor B-O I-protein
. B-O O

A B-O O
novel B-O O
HIV-1 B-O O
isolate B-O O
containing B-O O
alterations B-O O
affecting B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
element B-O I-DNA
. B-O O

Three B-O O
molecular B-O O
clones B-O O
of B-O O
HIV-1 B-O O
, B-O O
derived B-O O
from B-O O
a B-O O
single B-O O
isolate B-O O
( B-O O
AL1 B-O B-protein
) B-O O
, B-O O
exhibited B-O O
distinct B-O O
replicative B-O O
and B-O O
cytopathic B-O O
properties B-O O
during B-O O
propagation B-O O
in B-O O
a B-O O
human B-O B-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
. B-O O

The B-O O
phenotypic B-O O
differences B-O O
observed B-O O
were B-O O
attributable B-O O
, B-O O
in B-O O
large B-O O
part B-O O
, B-O O
to B-O O
changes B-O O
affecting B-O O
the B-O O
viral B-O B-DNA
LTR B-O I-DNA
. B-O O

Nucleotide B-O B-DNA
sequence B-O I-DNA
and B-O O
PCR B-O O
analyses B-O O
demonstrated B-O O
the B-O O
presence B-O O
of B-O O
novel B-O O
duplications B-O O
or B-O O
deletions B-O O
involving B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
motif B-O I-DNA
. B-O O

These B-O O
changes B-O O
in B-O O
the B-O O
enhancer B-O B-DNA
element B-O I-DNA
were B-O O
identified B-O O
in B-O O
the B-O O
original B-O O
AL1 B-O O
virus B-O O
stock B-O O
. B-O O

Subcloning B-O O
of B-O O
the B-O O
variant B-O B-DNA
NF-kappa B-O I-DNA
B B-O I-DNA
segments B-O I-DNA
into B-O O
LTR-driven B-O B-DNA
CAT B-O I-DNA
expression B-O I-DNA
vectors B-O I-DNA
confirmed B-O O
a B-O O
correlation B-O O
between B-O O
promoter B-O O
activity B-O O
and B-O O
replicative/cytopathic B-O O
capacity B-O O
. B-O O

Multiple B-O O
Oct2 B-O B-protein
isoforms B-O I-protein
are B-O O
generated B-O O
by B-O O
alternative B-O O
splicing B-O O
. B-O O

The B-O O
interaction B-O O
of B-O O
the B-O O
Oct2 B-O B-protein
transcription B-O I-protein
factor B-O I-protein
with B-O O
the B-O O
cognate B-O B-DNA
octamer B-O I-DNA
motif B-O I-DNA
ATGCAAAT B-O O
is B-O O
a B-O O
critical B-O O
determinant B-O O
of B-O O
the B-O O
lymphoid-specific B-O O
expression B-O O
of B-O O
immunoglobulin B-O B-DNA
genes B-O I-DNA
. B-O O

Ectopic B-O O
expression B-O O
of B-O O
cloned B-O B-DNA
Oct2 B-O I-DNA
cDNA B-O I-DNA
was B-O O
shown B-O O
to B-O O
be B-O O
sufficient B-O O
to B-O O
reconstitute B-O O
at B-O O
least B-O O
some B-O O
aspects B-O O
of B-O O
this B-O O
regulation B-O O
in B-O O
non-lymphoid B-O B-cell_type
cells B-O I-cell_type
. B-O O

We B-O O
describe B-O O
the B-O O
isolation B-O O
and B-O O
characterization B-O O
of B-O O
multiple B-O B-DNA
cDNAs B-O I-DNA
encoding B-O O
mouse B-O B-protein
Oct2 B-O I-protein
from B-O O
a B-O O
mature B-O B-cell_line
B-cell B-O I-cell_line
line B-O I-cell_line
and B-O O
we B-O O
show B-O O
that B-O O
a B-O O
variety B-O O
of B-O O
isoforms B-O O
of B-O O
this B-O O
transcription B-O B-protein
factor B-O I-protein
is B-O O
generated B-O O
from B-O O
a B-O O
single B-O O
gene B-O O
by B-O O
an B-O O
alternative B-O O
splicing B-O O
mechanism B-O O
. B-O O

All B-O O
the B-O O
isoforms B-O B-protein
retain B-O O
the B-O O
previously B-O O
characterized B-O O
POU-domain B-O B-protein
and B-O O
are B-O O
therefore B-O O
able B-O O
to B-O O
bind B-O O
to B-O O
the B-O O
octamer B-O B-DNA
motif B-O I-DNA
. B-O O

Different B-O O
amounts B-O O
of B-O O
the B-O O
various B-O O
isoforms B-O B-protein
are B-O O
present B-O O
within B-O O
the B-O O
same B-O O
B-cell B-O B-cell_type
regardless B-O O
of B-O O
the B-O O
developmental B-O O
stage B-O O
of B-O O
B-cell B-O B-cell_type
differentiation B-O O
and B-O O
at B-O O
least B-O O
some B-O O
of B-O O
the B-O O
isoforms B-O B-protein
are B-O O
conserved B-O O
between B-O O
mouse B-O O
and B-O O
humans B-O O
. B-O O

In B-O O
cotransfection B-O O
experiments B-O O
we B-O O
show B-O O
that B-O O
all B-O O
the B-O O
isoforms B-O B-protein
are B-O O
able B-O O
to B-O O
activate B-O O
an B-O O
octamer B-O B-DNA
containing B-O O
promoter B-O B-DNA
element B-O I-DNA
in B-O O
fibroblasts B-O B-cell_type
revealing B-O O
an B-O O
unexpected B-O O
functional B-O O
redundancy B-O O
. B-O O

Finally B-O O
, B-O O
we B-O O
show B-O O
that B-O O
one B-O O
of B-O O
the B-O O
isoforms B-O B-protein
encodes B-O O
the B-O O
previously B-O O
described B-O O
lymphoid-specific B-O B-protein
Oct2B B-O I-protein
protein B-O I-protein
which B-O O
has B-O O
been B-O O
suggested B-O O
to B-O O
be B-O O
involved B-O O
in B-O O
the B-O O
function B-O O
of B-O O
the B-O O
octamer B-O B-DNA
motif B-O I-DNA
in B-O O
the B-O O
context B-O O
of B-O O
the B-O O
immunoglobulin B-O B-DNA
heavy-chain B-O I-DNA
( B-O I-DNA
IgH B-O I-DNA
) B-O I-DNA
enhancer B-O I-DNA
. B-O O

[ B-O O
Regulation B-O O
of B-O O
intracellular B-O O
cholesterol B-O O
synthesis B-O O
in B-O O
hypercholesterolemia B-O O
by B-O O
glucocorticoids B-O O
] B-O O

The B-O O
rate B-O O
of B-O O
endogenous B-O O
cholesterol B-O O
synthesis B-O O
in B-O O
blood B-O B-cell_type
lymphocytes B-O I-cell_type
and B-O O
skin B-O B-cell_type
fibroblasts B-O I-cell_type
from B-O O
patients B-O O
with B-O O
type B-O O
IIa B-O O
hyperlipidemia B-O O
was B-O O
found B-O O
to B-O O
be B-O O
increased B-O O
in B-O O
comparison B-O O
with B-O O
healthy B-O O
donors B-O O
. B-O O

The B-O O
cells B-O O
of B-O O
hyperlipidemic B-O O
patients B-O O
had B-O O
lowered B-O O
levels B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
concomitantly B-O O
with B-O O
a B-O O
partial B-O O
loss B-O O
of B-O O
their B-O O
sensitivity B-O O
to B-O O
glucocorticoids B-O O
. B-O O

In B-O O
fibroblasts B-O B-cell_type
from B-O O
patients B-O O
with B-O O
hereditary B-O O
hypercholesteremia B-O O
of B-O O
homozygous B-O O
type B-O O
the B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
did B-O O
not B-O O
exceed B-O O
10 B-O O
% B-O O
of B-O O
their B-O O
content B-O O
in B-O O
normal B-O B-cell_type
cells B-O I-cell_type
. B-O O

The B-O O
decrease B-O O
of B-O O
the B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
patients B-O O
with B-O O
type B-O O
IIa B-O O
hyperlipidemia B-O O
seems B-O O
to B-O O
be B-O O
a B-O O
compensatory B-O O
response B-O O
of B-O O
cells B-O O
culminating B-O O
in B-O O
activation B-O O
of B-O O
endogenous B-O O
cholesterol B-O O
synthesis B-O O
. B-O O

Negative B-O O
regulation B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
expression B-O O
in B-O O
monocytes B-O B-cell_type
: B-O O
role B-O O
of B-O O
the B-O O
65-kDa B-O B-protein
plus B-O O
50-kDa B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
dimer B-O I-protein
. B-O O

Although B-O O
monocytic B-O B-cell_type
cells B-O I-cell_type
can B-O O
provide B-O O
a B-O O
reservoir B-O O
for B-O O
viral B-O O
production B-O O
in B-O O
vivo B-O O
, B-O O
their B-O O
regulation B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
transcription B-O O
can B-O O
be B-O O
either B-O O
latent B-O O
, B-O O
restricted B-O O
, B-O O
or B-O O
productive B-O O
. B-O O

These B-O O
differences B-O O
in B-O O
gene B-O O
expression B-O O
have B-O O
not B-O O
been B-O O
molecularly B-O O
defined B-O O
. B-O O

In B-O O
THP-1 B-O B-cell_line
cells B-O I-cell_line
with B-O O
restricted B-O O
HIV B-O O
expression B-O O
, B-O O
there B-O O
is B-O O
an B-O O
absence B-O O
of B-O O
DNA-protein B-O B-protein
binding B-O I-protein
complex B-O I-protein
formation B-O O
with B-O O
the B-O O
HIV-1 B-O B-DNA
promoter-enhancer B-O I-DNA
associated B-O O
with B-O O
markedly B-O O
less B-O O
viral B-O B-RNA
RNA B-O I-RNA
production B-O O
. B-O O

This B-O O
absence B-O O
of B-O O
binding B-O O
was B-O O
localized B-O O
to B-O O
the B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
region B-O I-DNA
of B-O O
the B-O O
HIV-1 B-O B-DNA
enhancer B-O I-DNA
; B-O O
the B-O O
65-kDa B-O B-protein
plus B-O O
50-kDa B-O B-protein
NF-kappa B-O I-protein
B B-O I-protein
heterodimer B-O I-protein
was B-O O
preferentially B-O O
lost B-O O
. B-O O

Adding B-O O
purified B-O O
NF-kappa B-O B-protein
B B-O I-protein
protein B-O I-protein
to B-O O
nuclear B-O O
extracts B-O O
from B-O O
cells B-O O
with B-O O
restricted B-O O
expression B-O O
overcomes B-O O
this B-O O
lack B-O O
of B-O O
binding B-O O
. B-O O

In B-O O
addition B-O O
, B-O O
treatment B-O O
of B-O O
these B-O O
nuclear B-O O
extracts B-O O
with B-O O
sodium B-O O
deoxycholate B-O O
restored B-O O
their B-O O
ability B-O O
to B-O O
form B-O O
the B-O O
heterodimer B-O B-protein
, B-O O
suggesting B-O O
the B-O O
presence B-O O
of B-O O
an B-O O
inhibitor B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
. B-O O

Furthermore B-O O
, B-O O
treatment B-O O
of B-O O
nuclear B-O O
extracts B-O O
from B-O O
these B-O O
cells B-O O
that B-O O
had B-O O
restricted B-O O
expression B-O O
with B-O O
lipopolysaccharide B-O O
increased B-O O
viral B-O O
production B-O O
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
activity B-O O
. B-O O

Antiserum B-O O
specific B-O O
for B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O I-protein
proteins B-O I-protein
, B-O O
but B-O O
not B-O O
c-rel-specific B-O O
antiserum B-O O
, B-O O
disrupted B-O O
heterodimer B-O B-protein
complex B-O I-protein
formation B-O O
. B-O O

Thus B-O O
, B-O O
both B-O O
NF-kappa B-O B-protein
B B-O I-protein
-binding B-O O
complexes B-O O
are B-O O
needed B-O O
for B-O O
optimal B-O O
viral B-O O
transcription B-O O
. B-O O

Binding B-O O
of B-O O
the B-O O
65-kDa B-O B-protein
plus B-O O
50-kDa B-O B-protein
heterodimer B-O I-protein
to B-O O
the B-O O
HIV-1 B-O B-DNA
enhancer B-O I-DNA
can B-O O
be B-O O
negatively B-O O
regulated B-O O
in B-O O
monocytes B-O B-cell_type
, B-O O
providing B-O O
one B-O O
mechanism B-O O
restricting B-O O
HIV-1 B-O B-DNA
gene B-O I-DNA
expression B-O O
. B-O O

Glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
normal B-O B-cell_type
leukocytes B-O I-cell_type
: B-O O
effects B-O O
of B-O O
age B-O O
, B-O O
gender B-O O
, B-O O
season B-O O
, B-O O
and B-O O
plasma B-O O
cortisol B-O O
concentrations B-O O
. B-O O

We B-O O
measured B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
( B-O O
GR B-O B-protein
) B-O O
in B-O O
mononuclear B-O B-cell_type
leukocytes B-O I-cell_type
( B-O O
MNL B-O B-cell_type
) B-O O
isolated B-O O
from B-O O
peripheral B-O O
blood B-O O
of B-O O
145 B-O O
apparently B-O O
healthy B-O O
volunteers B-O O
( B-O O
86 B-O O
men B-O O
and B-O O
59 B-O O
women B-O O
) B-O O
. B-O O

An B-O O
age-related B-O O
decrease B-O O
in B-O O
the B-O O
number B-O O
of B-O O
GR B-O B-protein
was B-O O
suggested B-O O
between B-O O
subjects B-O O
younger B-O O
than B-O O
20 B-O O
years B-O O
and B-O O
elderly B-O O
subjects B-O O
; B-O O
there B-O O
was B-O O
no B-O O
apparent B-O O
seasonal B-O O
variation B-O O
in B-O O
GR B-O B-protein
. B-O O

Gender B-O O
difference B-O O
in B-O O
the B-O O
number B-O O
of B-O O
GR B-O B-protein
was B-O O
not B-O O
significant B-O O
, B-O O
although B-O O
women B-O O
showed B-O O
slightly B-O O
fewer B-O O
GR B-O B-protein
. B-O O

Eight B-O O
patients B-O O
with B-O O
dermatomyositis/polymyositis B-O O
were B-O O
examined B-O O
to B-O O
determine B-O O
whether B-O O
the B-O O
number B-O O
of B-O O
GR B-O B-protein
in B-O O
MNL B-O B-cell_type
could B-O O
be B-O O
down-regulated B-O O
by B-O O
their B-O O
cognate B-O O
ligands B-O O
. B-O O

The B-O O
number B-O O
of B-O O
GR B-O B-protein
in B-O O
MNL B-O B-cell_type
from B-O O
these B-O O
patients B-O O
was B-O O
significantly B-O O
decreased B-O O
one B-O O
month B-O O
after B-O O
the B-O O
initiation B-O O
of B-O O
prednisolone B-O O
therapy B-O O
. B-O O

However B-O O
, B-O O
in B-O O
normal B-O O
subjects B-O O
, B-O O
the B-O O
GR B-O B-protein
in B-O O
MNL B-O B-cell_type
did B-O O
not B-O O
demonstrate B-O O
circadian B-O O
variation B-O O
, B-O O
in B-O O
contrast B-O O
to B-O O
concentrations B-O O
of B-O O
plasma B-O O
cortisol B-O O
. B-O O

Synergism B-O O
between B-O O
two B-O O
distinct B-O O
elements B-O O
of B-O O
the B-O O
HTLV-I B-O B-DNA
enhancer B-O I-DNA
during B-O O
activation B-O O
by B-O O
the B-O O
trans-activator B-O B-protein
of B-O O
HTLV-I B-O O
. B-O O

We B-O O
have B-O O
conducted B-O O
functional B-O O
studies B-O O
of B-O O
the B-O O
enhancer B-O B-DNA
elements B-O I-DNA
of B-O O
human B-O O
T-cell B-O O
leukemia B-O O
virus B-O O
type B-O O
I B-O O
( B-O O
HTLV-I B-O O
) B-O O
using B-O O
the B-O O
human B-O B-cell_line
T-cell B-O I-cell_line
lines B-O I-cell_line
Jurkat B-O B-cell_line
and B-O O
MOLT B-O B-cell_line
4 B-O I-cell_line
, B-O O
which B-O O
are B-O O
negative B-O O
for B-O O
HTLV-I B-O O
, B-O O
and B-O O
MT-2 B-O B-cell_line
and B-O O
TL-Mor B-O O
, B-O O
which B-O O
carry B-O O
the B-O O
proviral B-O B-DNA
genome B-O I-DNA
of B-O O
HTLV-I B-O O
. B-O O

Two B-O O
distinct B-O O
elements B-O O
have B-O O
been B-O O
implicated B-O O
in B-O O
function B-O O
of B-O O
the B-O O
HTLV-I B-O B-DNA
enhancer B-O I-DNA
. B-O O

One B-O O
is B-O O
the B-O O
21-base-pair B-O B-DNA
( B-O I-DNA
bp B-O I-DNA
) B-O I-DNA
core B-O I-DNA
element B-O I-DNA
that B-O O
is B-O O
responsible B-O O
for B-O O
trans-activation B-O O
by B-O O
the B-O O
HTLV-I B-O B-protein
trans-activator B-O I-protein
p40tax B-O B-protein
and B-O O
that B-O O
has B-O O
the B-O O
ability B-O O
to B-O O
bind B-O O
to B-O O
cyclic-AMP B-O B-protein
responsive B-O I-protein
element B-O I-protein
binding B-O I-protein
factor B-O I-protein
( B-O O
CREB B-O B-protein
) B-O O
-like B-O O
factor B-O O
( B-O O
s B-O O
) B-O O
. B-O O

The B-O O
other B-O O
is B-O O
a B-O O
region B-O O
interposed B-O O
between B-O O
the B-O O
21-bp B-O B-DNA
elements B-O I-DNA
. B-O O

In B-O O
this B-O O
study B-O O
we B-O O
demonstrate B-O O
that B-O O
a B-O O
subfragment B-O O
( B-O O
C26 B-O B-protein
) B-O O
in B-O O
the B-O O
region B-O O
between B-O O
the B-O O
21-bp B-O B-DNA
elements B-O I-DNA
is B-O O
involved B-O O
in B-O O
trans-activation B-O O
by B-O O
p40tax B-O B-protein
, B-O O
possibly B-O O
through B-O O
binding B-O O
to B-O O
an B-O O
NF-kappa B-O B-protein
B B-O I-protein
-like B-O O
nuclear B-O O
factor B-O O
or B-O O
factors B-O O
. B-O O

Formation B-O O
of B-O O
the B-O O
protein-DNA B-O B-protein
complex B-O I-protein
with B-O O
the B-O O
C26 B-O B-protein
subfragment B-O I-protein
was B-O O
positively B-O O
affected B-O O
by B-O O
p40tax B-O B-protein
. B-O O

The B-O O
C26 B-O B-DNA
element B-O I-DNA
conferred B-O O
partial B-O O
responsiveness B-O O
to B-O O
p40tax B-O B-protein
when B-O O
linked B-O O
to B-O O
one B-O O
copy B-O O
of B-O O
the B-O O
21-bp B-O B-DNA
element B-O I-DNA
that B-O O
, B-O O
by B-O O
itself B-O O
, B-O O
showed B-O O
little B-O O
activation B-O O
in B-O O
response B-O O
to B-O O
p40tax B-O B-protein
. B-O O

However B-O O
, B-O O
the B-O O
C26 B-O B-DNA
element B-O I-DNA
alone B-O O
, B-O O
even B-O O
when B-O O
repeated B-O O
, B-O O
could B-O O
not B-O O
be B-O O
activated B-O O
by B-O O
p40tax B-O B-protein
, B-O O
unlike B-O O
other B-O O
NF-kappa B-O B-protein
B B-O I-protein
-binding B-O O
elements B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
the B-O O
C26 B-O B-DNA
element B-O I-DNA
itself B-O O
was B-O O
profoundly B-O O
activated B-O O
upon B-O O
stimulation B-O O
with B-O O
12-O-tetradecanoylphorbol-13-acetate B-O O
. B-O O

These B-O O
findings B-O O
therefore B-O O
suggest B-O O
that B-O O
the B-O O
HTLV-I B-O B-DNA
enhancer B-O I-DNA
contains B-O O
multiple B-O B-DNA
functional B-O I-DNA
elements B-O I-DNA
, B-O O
including B-O O
binding B-O B-DNA
sites B-O I-DNA
for B-O O
at B-O O
least B-O O
CREB- B-O O
and B-O O
NF-kappa B-O B-protein
B- B-O I-protein
like B-O O
factors B-O O
, B-O O
which B-O O
synergistically B-O O
cooperate B-O O
in B-O O
activation B-O O
of B-O O
the B-O O
HTLV-I B-O B-DNA
enhancer B-O I-DNA
in B-O O
response B-O O
to B-O O
p40tax B-O B-protein
. B-O O

Our B-O O
results B-O O
also B-O O
demonstrate B-O O
that B-O O
TPA-dependent B-O O
activation B-O O
of B-O O
the B-O O
HTLV-I B-O B-DNA
enhancer B-O I-DNA
may B-O O
be B-O O
mediated B-O O
through B-O O
the B-O O
C26 B-O B-DNA
element B-O I-DNA
. B-O O

Human B-O B-DNA
tumor B-O I-DNA
necrosis B-O I-DNA
factor B-O I-DNA
alpha B-O I-DNA
gene B-O I-DNA
regulation B-O O
in B-O O
phorbol B-O O
ester B-O O
stimulated B-O O
T B-O B-cell_line
and B-O I-cell_line
B B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

The B-O O
minimal B-O O
region B-O O
of B-O O
the B-O O
human B-O B-DNA
tumor B-O I-DNA
necrosis B-O I-DNA
factor B-O I-DNA
alpha B-O I-DNA
( B-O I-DNA
TNF-alpha B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
promoter B-O I-DNA
necessary B-O O
for B-O O
its B-O O
transcriptional B-O O
induction B-O O
by B-O O
phorbol B-O O
esters B-O O
( B-O O
PMA B-O O
) B-O O
in B-O O
human B-O B-cell_line
T B-O I-cell_line
and B-O I-cell_line
B B-O I-cell_line
lymphocyte B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
has B-O O
been B-O O
localized B-O O
between B-O O
-52 B-O B-DNA
and B-O I-DNA
+89 B-O I-DNA
nucleotides B-O I-DNA
( B-O O
nt B-O O
) B-O O
relative B-O O
to B-O O
the B-O O
gene B-O B-DNA
's B-O I-DNA
transcriptional B-O I-DNA
start B-O I-DNA
site B-O I-DNA
. B-O O

Comparison B-O O
of B-O O
these B-O O
sequences B-O O
to B-O O
those B-O O
required B-O O
to B-O O
mediate B-O O
virus B-O O
or B-O O
lipopolysaccharide B-O O
( B-O O
LPS B-O O
) B-O O
induction B-O O
of B-O O
the B-O O
gene B-O O
reveal B-O O
significant B-O O
differences B-O O
, B-O O
and B-O O
thus B-O O
, B-O O
the B-O O
sequence B-O O
requirements B-O O
for B-O O
PMA B-O O
induction B-O O
are B-O O
distinct B-O O
from B-O O
those B-O O
that B-O O
mediate B-O O
induction B-O O
by B-O O
virus B-O O
or B-O O
LPS B-O O
. B-O O

Although B-O O
three B-O O
sites B-O O
in B-O O
the B-O O
TNF-alpha B-O B-DNA
promoter B-O I-DNA
( B-O O
kappa B-O O
1 B-O O
, B-O O
kappa B-O O
2 B-O O
, B-O O
and B-O O
kappa B-O B-DNA
3 B-O I-DNA
) B-O O
specifically B-O O
bind B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
NF-kappa B-O B-protein
B B-O I-protein
in B-O O
lymphoid B-O O
nuclear B-O O
extracts B-O O
, B-O O
TNF-alpha B-O B-RNA
mRNA B-O I-RNA
induction B-O O
by B-O O
PMA B-O O
does B-O O
not B-O O
correlate B-O O
with B-O O
NF-kappa B-O B-protein
B B-O I-protein
binding B-O O
activities B-O O
displayed B-O O
by B-O O
different B-O O
T B-O B-cell_line
and B-O I-cell_line
B B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
. B-O O

Moreover B-O O
, B-O O
kappa B-O B-DNA
1 B-O I-DNA
- B-O I-DNA
kappa B-O I-DNA
3 B-O I-DNA
can B-O O
each B-O O
be B-O O
deleted B-O O
from B-O O
the B-O O
TNF-alpha B-O B-DNA
promoter B-O I-DNA
with B-O O
little B-O O
effect B-O O
on B-O O
the B-O O
gene B-O O
's B-O O
inducibility B-O O
by B-O O
PMA B-O O
. B-O O

Therefore B-O O
, B-O O
TNF-alpha B-O B-RNA
mRNA B-O I-RNA
induction B-O O
by B-O O
PMA B-O O
, B-O O
like B-O O
its B-O O
induction B-O O
by B-O O
virus B-O O
and B-O O
LPS B-O O
, B-O O
is B-O O
not B-O O
primarily B-O O
mediated B-O O
by B-O O
NF-kappa B-O B-protein
B B-O I-protein
, B-O O
but B-O O
rather B-O O
is B-O O
mediated B-O O
through B-O O
other B-O O
sequences B-O O
and B-O O
protein B-O B-protein
factors B-O I-protein
. B-O O

Surprisingly B-O O
, B-O O
multimers B-O O
of B-O O
kappa B-O B-DNA
1 B-O I-DNA
- B-O O
kappa B-O B-DNA
3 B-O I-DNA
can B-O O
confer B-O O
PMA B-O O
inducibility B-O O
on B-O O
a B-O O
heterologous B-O B-DNA
promoter B-O I-DNA
in B-O O
a B-O O
B B-O O
( B-O O
Raji B-O B-cell_line
) B-O O
, B-O O
but B-O O
not B-O O
a B-O O
T B-O B-cell_line
( B-O I-cell_line
HUT78 B-O I-cell_line
) B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
. B-O O

However B-O O
they B-O O
are B-O O
not B-O O
functional B-O O
on B-O O
a B-O O
truncated B-O O
TNF-alpha B-O B-DNA
promoter B-O I-DNA
, B-O O
indicating B-O O
that B-O O
promoter B-O O
context B-O O
and B-O O
cell B-O O
type B-O O
specificity B-O O
influence B-O O
the B-O O
PMA B-O O
inducible B-O O
function B-O O
of B-O O
these B-O O
NF-kappa B-O B-DNA
B B-O I-DNA
binding B-O I-DNA
sites B-O I-DNA
. B-O O

Differentiation-associated B-O O
expression B-O O
of B-O O
the B-O O
Epstein-Barr B-O B-protein
virus B-O I-protein
BZLF1 B-O I-protein
transactivator B-O I-protein
protein B-O I-protein
in B-O O
oral B-O O
hairy B-O O
leukoplakia B-O O
. B-O O

The B-O O
BZLF1 B-O B-protein
protein B-O I-protein
of B-O O
Epstein-Barr B-O O
virus B-O O
( B-O O
EBV B-O O
) B-O O
is B-O O
a B-O O
key B-O O
immediate-early B-O B-protein
protein B-O I-protein
which B-O O
has B-O O
been B-O O
shown B-O O
to B-O O
disrupt B-O O
virus B-O O
latency B-O O
in B-O O
EBV B-O B-cell_type
-infected B-O I-cell_type
B B-O I-cell_type
cells B-O I-cell_type
. B-O O

We B-O O
have B-O O
generated B-O O
a B-O O
monoclonal B-O B-protein
antibody B-O I-protein
, B-O O
BZ1 B-O B-protein
, B-O O
to B-O O
BZLF1 B-O B-protein
which B-O O
reacts B-O O
in B-O O
immunohistology B-O O
, B-O O
immunoblotting B-O O
, B-O O
and B-O O
immunoprecipitation B-O O
and B-O O
which B-O O
recognizes B-O O
both B-O O
the B-O O
active B-O O
, B-O O
dimeric B-O B-protein
form B-O I-protein
and B-O O
the B-O O
inactive B-O B-protein
, B-O I-protein
monomeric B-O I-protein
form B-O I-protein
of B-O O
the B-O O
protein B-O O
. B-O O

Biopsies B-O O
of B-O O
oral B-O O
hairy B-O O
leukoplakia B-O O
, B-O O
an B-O O
AIDS-associated B-O O
lesion B-O O
characterized B-O O
by B-O O
high-level B-O O
EBV B-O O
replication B-O O
, B-O O
were B-O O
examined B-O O
by B-O O
immunohistochemistry B-O O
using B-O O
the B-O O
BZ1 B-O B-protein
monoclonal B-O I-protein
antibody B-O I-protein
. B-O O

A B-O O
differentiation-associated B-O O
pattern B-O O
of B-O O
BZLF1 B-O B-protein
expression B-O O
was B-O O
observed B-O O
, B-O O
BZ1 B-O B-protein
reacting B-O O
with B-O O
nuclei B-O O
of B-O O
the B-O O
upper B-O O
spinous B-O O
layer B-O O
of B-O O
the B-O O
lesion B-O O
. B-O O

This B-O O
finding B-O O
suggests B-O O
that B-O O
the B-O O
BZLF1 B-O B-DNA
promoter B-O I-DNA
may B-O O
be B-O O
regulated B-O O
by B-O O
the B-O O
degree B-O O
of B-O O
squamous B-O O
differentiation B-O O
. B-O O

A B-O O
comparison B-O O
of B-O O
in B-O O
situ B-O O
hybridization B-O O
to B-O O
EBV B-O B-DNA
DNA B-O I-DNA
and B-O O
viral B-O B-protein
capsid B-O I-protein
antigen B-O I-protein
staining B-O O
with B-O O
BZ1 B-O B-protein
reactivity B-O O
suggested B-O O
that B-O O
BZLF1 B-O B-protein
expression B-O O
precedes B-O O
rampant B-O O
virus B-O O
replication B-O O
. B-O O

The B-O O
inability B-O O
to B-O O
detect B-O O
EBV B-O O
in B-O O
the B-O O
lower B-O O
epithelial B-O O
layers B-O O
of B-O O
oral B-O O
hairy B-O O
leukoplakia B-O O
raises B-O O
questions B-O O
concerning B-O O
the B-O O
nature B-O O
of B-O O
EBV B-O O
latency B-O O
and B-O O
persistence B-O O
in B-O O
stratified B-O O
squamous B-O O
epithelium B-O O
. B-O O

[ B-O O
Changes B-O O
in B-O O
levels B-O O
of B-O O
leucocytic B-O B-protein
estrogen B-O I-protein
receptor B-O I-protein
in B-O O
patients B-O O
with B-O O
menopausal B-O O
type B-O O
II B-O O
diabetes B-O O
and B-O O
its B-O O
significance B-O O
] B-O O

The B-O O
number B-O O
of B-O O
estrogen B-O B-protein
receptors B-O I-protein
( B-O O
ER B-O B-protein
) B-O O
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
leucocytes B-O I-cell_type
in B-O O
12 B-O O
women B-O O
with B-O O
menopausal B-O O
type B-O O
II B-O O
diabetes B-O O
was B-O O
measured B-O O
with B-O O
radio-ligand B-O O
binding B-O O
method B-O O
. B-O O

The B-O O
results B-O O
were B-O O
compared B-O O
with B-O O
those B-O O
of B-O O
12 B-O O
menopausal B-O O
women B-O O
without B-O O
diabetes B-O O
and B-O O
12 B-O O
normal B-O O
women B-O O
of B-O O
childbearing B-O O
age B-O O
. B-O O

It B-O O
was B-O O
found B-O O
that B-O O
the B-O O
number B-O O
of B-O O
ER B-O B-protein
in B-O O
the B-O O
patients B-O O
was B-O O
significantly B-O O
decreased B-O O
. B-O O

Our B-O O
data B-O O
indicate B-O O
that B-O O
decrease B-O O
of B-O O
ER B-O B-protein
level B-O O
in B-O O
leukocytes B-O B-cell_type
may B-O O
be B-O O
related B-O O
to B-O O
the B-O O
pathogenesis B-O O
of B-O O
type B-O O
II B-O O
diabetes B-O O
in B-O O
menopausal B-O O
period B-O O
. B-O O

Lymphocyte B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
number B-O O
in B-O O
posttraumatic B-O O
stress B-O O
disorder B-O O
. B-O O

OBJECTIVE B-O O
: B-O O
The B-O O
authors B-O O
' B-O O
objective B-O O
was B-O O
to B-O O
investigate B-O O
the B-O O
possibility B-O O
that B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
changes B-O O
may B-O O
be B-O O
involved B-O O
in B-O O
the B-O O
dysregulation B-O O
of B-O O
the B-O O
hypothalamic-pituitary-adrenal B-O O
( B-O O
HPA B-O O
) B-O O
axis B-O O
in B-O O
posttraumatic B-O O
stress B-O O
disorder B-O O
( B-O O
PTSD B-O O
) B-O O
. B-O O

METHOD B-O O
: B-O O
They B-O O
measured B-O O
the B-O O
number B-O O
of B-O O
lymphocyte B-O B-protein
cytosolic B-O I-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
and B-O O
plasma B-O O
cortisol B-O O
concentrations B-O O
in B-O O
15 B-O O
consecutively B-O O
admitted B-O O
male B-O O
combat B-O O
Vietnam B-O O
veterans B-O O
with B-O O
PTSD B-O O
and B-O O
in B-O O
a B-O O
normal B-O O
comparison B-O O
group B-O O
of B-O O
11 B-O O
subjects B-O O
. B-O O

RESULTS B-O O
: B-O O
Both B-O O
the B-O O
patients B-O O
and B-O O
the B-O O
normal B-O O
comparison B-O O
subjects B-O O
showed B-O O
a B-O O
morning-to-afternoon B-O O
decline B-O O
in B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
concentrations B-O O
, B-O O
paralleling B-O O
the B-O O
normal B-O O
diurnal B-O O
decline B-O O
in B-O O
cortisol B-O O
levels B-O O
. B-O O

The B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
was B-O O
63 B-O O
% B-O O
greater B-O O
in B-O O
the B-O O
morning B-O O
and B-O O
26 B-O O
% B-O O
greater B-O O
in B-O O
the B-O O
afternoon B-O O
in B-O O
the B-O O
patients B-O O
with B-O O
PTSD B-O O
than B-O O
in B-O O
the B-O O
normal B-O O
subjects B-O O
. B-O O

No B-O O
group B-O O
differences B-O O
in B-O O
cortisol B-O O
levels B-O O
were B-O O
observed B-O O
, B-O O
nor B-O O
were B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
number B-O O
and B-O O
cortisol B-O O
levels B-O O
correlated B-O O
. B-O O

The B-O O
number B-O O
of B-O O
morning B-O B-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
was B-O O
positively B-O O
correlated B-O O
with B-O O
symptoms B-O O
of B-O O
PTSD B-O O
and B-O O
anxiety B-O O
. B-O O

CONCLUSIONS B-O O
: B-O O
These B-O O
results B-O O
provide B-O O
further B-O O
evidence B-O O
for B-O O
a B-O O
dysregulation B-O O
of B-O O
the B-O O
HPA B-O O
axis B-O O
in B-O O
PTSD B-O O
. B-O O

The B-O O
finding B-O O
that B-O O
patients B-O O
with B-O O
PTSD B-O O
had B-O O
a B-O O
substantially B-O O
greater B-O O
number B-O O
of B-O O
lymphocyte B-O B-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
than B-O O
normal B-O O
comparison B-O O
subjects B-O O
is B-O O
consistent B-O O
with B-O O
the B-O O
authors B-O O
' B-O O
previous B-O O
observations B-O O
of B-O O
low B-O O
24-hour B-O O
urinary B-O O
cortisol B-O O
excretion B-O O
in B-O O
subjects B-O O
with B-O O
PTSD B-O O
. B-O O

Furthermore B-O O
, B-O O
the B-O O
receptor B-O O
changes B-O O
observed B-O O
are B-O O
opposite B-O O
of B-O O
those B-O O
reported B-O O
in B-O O
major B-O O
depressive B-O O
disorder B-O O
. B-O O

The B-O O
present B-O O
data B-O O
, B-O O
along B-O O
with B-O O
other B-O O
findings B-O O
of B-O O
HPA B-O O
abnormalities B-O O
in B-O O
PTSD B-O O
, B-O O
support B-O O
the B-O O
possibility B-O O
of B-O O
a B-O O
greater B-O O
negative B-O O
feedback B-O O
sensitivity B-O O
at B-O O
one B-O O
or B-O O
more B-O O
levels B-O O
of B-O O
the B-O O
HPA B-O O
axis B-O O
. B-O O

Induction B-O O
of B-O O
NF-kappa B-O B-protein
B B-O I-protein
during B-O O
monocyte B-O O
differentiation B-O O
is B-O O
associated B-O O
with B-O O
activation B-O O
of B-O O
HIV B-O O
-gene B-O O
expression B-O O
. B-O O

Cells B-O O
of B-O O
the B-O O
monocyte-macrophage B-O B-cell_type
lineage B-O I-cell_type
are B-O O
important B-O O
targets B-O O
of B-O O
HIV B-O O
infection B-O O
. B-O O

We B-O O
report B-O O
here B-O O
that B-O O
the B-O O
phenotypic B-O O
differentiation B-O O
of B-O O
monocyte B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
induced B-O O
by B-O O
phorbol B-O O
esters B-O O
or B-O O
tumour B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
alpha B-O I-protein
( B-O O
TNF B-O B-protein
alpha B-O I-protein
) B-O O
is B-O O
associated B-O O
with B-O O
expression B-O O
of B-O O
nuclear B-O B-protein
factor B-O I-protein
kappa B-O I-protein
B B-O I-protein
( B-O O
NF-kappa B-O B-protein
B B-O I-protein
) B-O O
. B-O O

In B-O O
parallel B-O O
with B-O O
such B-O O
differentiation B-O O
, B-O O
HIV B-O O
transcription B-O O
, B-O O
monitored B-O O
using B-O O
an B-O O
HIV B-O B-DNA
long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
reporter B-O I-DNA
gene B-O I-DNA
construct B-O I-DNA
, B-O O
is B-O O
activated B-O O
in B-O O
such B-O O
cells B-O O
under B-O O
the B-O O
influence B-O O
of B-O O
enhanced B-O O
NF-kappa B-O B-protein
B B-O I-protein
expression B-O O
. B-O O

Also B-O O
, B-O O
in B-O O
a B-O O
promonocyte B-O B-cell_line
cell B-O I-cell_line
line B-O I-cell_line
chronically B-O O
infected B-O O
with B-O O
HIV B-O O
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
expression B-O O
and B-O O
HIV B-O O
transcription B-O O
were B-O O
enhanced B-O O
on B-O O
stimulation B-O O
with B-O O
phorbol B-O O
ester B-O O
or B-O O
TNF B-O B-protein
alpha B-O I-protein
. B-O O

Thus B-O O
, B-O O
stimulation B-O O
of B-O O
monocyte B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
by B-O O
phorbol B-O O
esters B-O O
or B-O O
TNF B-O B-protein
alpha B-O I-protein
induces B-O O
cell B-O O
differentiation B-O O
and B-O O
activates B-O O
HIV B-O O
transcription B-O O
. B-O O

Such B-O O
a B-O O
process B-O O
may B-O O
have B-O O
fundamental B-O O
implications B-O O
in B-O O
AIDS B-O O
pathogenesis B-O O
in B-O O
vivo B-O O
and B-O O
may B-O O
be B-O O
important B-O O
in B-O O
disease B-O O
progression B-O O
induced B-O O
by B-O O
opportunistic B-O O
infections B-O O
directly B-O O
or B-O O
indirectly B-O O
involving B-O O
macrophages B-O B-cell_type
. B-O O

Demonstration B-O O
of B-O O
estrogen B-O B-protein
and B-O O
progesterone B-O B-protein
receptors B-O I-protein
as B-O O
well B-O O
as B-O O
Ki-67 B-O B-protein
and B-O I-protein
p-145 B-O I-protein
antigens B-O I-protein
in B-O O
single B-O B-cell_type
tumor B-O I-cell_type
cells B-O I-cell_type
from B-O O
blood B-O O
and B-O O
pleural B-O O
effusions B-O O
using B-O O
a B-O O
slide B-O O
assay B-O O
. B-O O

We B-O O
describe B-O O
a B-O O
slide B-O O
assay B-O O
that B-O O
allows B-O O
the B-O O
demonstration B-O O
of B-O O
antigens B-O B-protein
localized B-O O
in B-O O
the B-O O
nucleus B-O O
from B-O O
isolated B-O B-cell_type
white B-O I-cell_type
blood B-O I-cell_type
cells B-O I-cell_type
as B-O O
well B-O O
as B-O O
from B-O O
single B-O B-cell_type
tumor B-O I-cell_type
cells B-O I-cell_type
derived B-O O
from B-O O
malignant B-O O
effusions B-O O
. B-O O

With B-O O
the B-O O
antibodies B-O O
Ki-67 B-O B-protein
and B-O O
anti-p-145 B-O B-protein
an B-O O
increased B-O O
rate B-O O
of B-O O
nuclear B-O O
and B-O O
nucleolar B-O O
staining B-O O
resulted B-O O
in B-O O
cells B-O O
from B-O O
highly B-O O
malignant B-O O
lymphomas B-O O
. B-O O

An B-O O
almost B-O O
identical B-O O
reaction B-O O
was B-O O
obtained B-O O
when B-O O
tumor B-O B-cell_type
cells B-O I-cell_type
from B-O O
malignant B-O O
effusions B-O O
were B-O O
tested B-O O
. B-O O

Cells B-O O
isolated B-O O
from B-O O
the B-O O
blood B-O O
of B-O O
patients B-O O
with B-O O
leukemic B-O O
spread B-O O
of B-O O
lymphomas B-O O
of B-O O
low B-O O
malignancy B-O O
yielded B-O O
a B-O O
weak B-O O
staining B-O O
comparable B-O O
to B-O O
that B-O O
of B-O O
normal B-O B-cell_type
mesothelial B-O I-cell_type
cells B-O I-cell_type
from B-O O
non-tumorous B-O O
cavity B-O O
fluids B-O O
. B-O O

The B-O O
detection B-O O
of B-O O
estrogen B-O B-protein
and B-O O
progesterone B-O B-protein
receptors B-O I-protein
( B-O O
ER B-O B-protein
and B-O O
PR B-O B-protein
) B-O O
localized B-O O
in B-O O
the B-O O
cell B-O O
nucleus B-O O
can B-O O
be B-O O
achieved B-O O
by B-O O
the B-O O
same B-O O
assay B-O O
. B-O O

The B-O O
reaction B-O O
is B-O O
enhanced B-O O
by B-O O
incubation B-O O
of B-O O
the B-O O
tumor B-O B-cell_type
cells B-O I-cell_type
for B-O O
30 B-O O
min B-O O
at B-O O
37 B-O O
degrees B-O O
C B-O O
prior B-O O
to B-O O
fixation B-O O
. B-O O

Pleural B-O O
effusions B-O O
from B-O O
20 B-O O
patients B-O O
with B-O O
breast B-O O
cancer B-O O
were B-O O
tested B-O O
. B-O O

ER B-O B-protein
was B-O O
positive B-O O
in B-O O
13 B-O O
and B-O O
PR B-O B-protein
was B-O O
positive B-O O
in B-O O
12 B-O O
of B-O O
the B-O O
20 B-O O
samples B-O O
. B-O O

In B-O O
5 B-O O
cases B-O O
there B-O O
was B-O O
a B-O O
divergent B-O O
reaction B-O O
with B-O O
ER B-O B-protein
and B-O O
PR B-O B-protein
antibody B-O O
. B-O O

The B-O O
hormone B-O B-protein
receptors B-O I-protein
of B-O O
the B-O O
primary B-O O
tumor B-O O
were B-O O
known B-O O
in B-O O
15 B-O O
( B-O O
ER B-O B-protein
) B-O O
and B-O O
14 B-O O
( B-O O
PR B-O B-protein
) B-O O
patients B-O O
, B-O O
respectively B-O O
. B-O O

In B-O O
each B-O O
cohort B-O O
there B-O O
was B-O O
only B-O O
one B-O O
case B-O O
with B-O O
a B-O O
negative B-O O
reaction B-O O
of B-O O
the B-O O
primary B-O O
tumor B-O O
and B-O O
a B-O O
positive B-O O
reaction B-O O
with B-O O
the B-O O
isolated B-O O
tumor B-O B-cell_type
cells B-O I-cell_type
from B-O O
the B-O O
pleural B-O O
effusions B-O O
. B-O O

These B-O O
results B-O O
indicate B-O O
that B-O O
the B-O O
demonstration B-O O
of B-O O
hormone B-O B-protein
receptor B-O I-protein
proteins B-O I-protein
in B-O O
cells B-O O
from B-O O
malignant B-O O
effusions B-O O
is B-O O
possible B-O O
and B-O O
that B-O O
there B-O O
is B-O O
a B-O O
correlation B-O O
with B-O O
the B-O O
status B-O O
of B-O O
the B-O O
primary B-O O
site B-O O
of B-O O
cancer B-O O
. B-O O

Constitutive B-O O
activation B-O O
of B-O O
NF-kB B-O B-protein
in B-O O
human B-O B-cell_type
thymocytes B-O I-cell_type
. B-O O

NF-kB B-O B-protein
is B-O O
a B-O O
eukaryotic B-O B-protein
transcription B-O I-protein
regulatory B-O I-protein
factor B-O I-protein
. B-O O

In B-O O
T B-O B-cell_type
cells B-O I-cell_type
and B-O O
T B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
NF-kB B-O B-protein
is B-O O
bound B-O O
to B-O O
a B-O O
cytoplasmic B-O B-protein
proteic B-O I-protein
inhibitor B-O I-protein
, B-O O
the B-O O
IkB B-O B-protein
. B-O O

Treatment B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
with B-O O
mitogens B-O O
( B-O O
phorbol B-O O
esters B-O O
) B-O O
or B-O O
cytokines B-O B-protein
( B-O O
TNF B-O B-protein
alpha B-O I-protein
) B-O O
induces B-O O
NF-kB B-O B-protein
nuclear B-O O
translocation B-O O
and B-O O
the B-O O
subsequent B-O O
expression B-O O
of B-O O
NF-kB B-O B-DNA
dependent B-O I-DNA
T B-O I-DNA
cell B-O I-DNA
genes B-O I-DNA
. B-O O

Here B-O O
we B-O O
examined B-O O
the B-O O
activation B-O O
of B-O O
NF-kB B-O B-protein
in B-O O
human B-O B-cell_type
T B-O I-cell_type
cell B-O I-cell_type
thymic B-O I-cell_type
progenitors B-O I-cell_type
. B-O O

We B-O O
report B-O O
differences B-O O
in B-O O
( B-O O
Ca2+ B-O O
) B-O O
i B-O O
requirement B-O O
for B-O O
NF-kB B-O B-protein
activation B-O O
in B-O O
thymocytes B-O B-cell_type
as B-O O
compared B-O O
to B-O O
mature B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

Furthermore B-O O
, B-O O
our B-O O
results B-O O
indicated B-O O
that B-O O
thymocytes B-O B-cell_type
have B-O O
a B-O O
constitutively B-O O
active B-O O
form B-O O
of B-O O
NF-kB B-O B-protein
, B-O O
suggesting B-O O
that B-O O
they B-O O
are B-O O
activated B-O O
in B-O O
vivo B-O O
. B-O O

TCF-1 B-O B-protein
, B-O O
a B-O O
T B-O B-protein
cell-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
of B-O O
the B-O O
HMG B-O B-protein
box B-O I-protein
family B-O I-protein
, B-O O
interacts B-O O
with B-O O
sequence B-O B-DNA
motifs B-O I-DNA
in B-O O
the B-O O
TCR B-O B-DNA
beta B-O I-DNA
and B-O I-DNA
TCR B-O I-DNA
delta B-O I-DNA
enhancers B-O I-DNA
. B-O O

We B-O O
have B-O O
recently B-O O
identified B-O O
and B-O O
cloned B-O O
TCF-1 B-O B-protein
, B-O O
a B-O O
T B-O B-protein
cell-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
with B-O O
specificity B-O O
for B-O O
the B-O O
AACAAAG B-O B-DNA
motif B-O I-DNA
in B-O O
the B-O O
CD3 B-O B-DNA
epsilon B-O I-DNA
enhancer B-O I-DNA
and B-O O
for B-O O
the B-O O
TTCAAAG B-O B-DNA
motif B-O I-DNA
in B-O O
the B-O O
TCR B-O B-DNA
alpha B-O I-DNA
enhancer B-O I-DNA
. B-O O

TCF-1 B-O B-protein
belongs B-O O
to B-O O
the B-O O
family B-O O
of B-O O
transcription-regulating B-O B-protein
proteins B-O I-protein
which B-O O
share B-O O
a B-O O
region B-O O
of B-O O
homology B-O O
termed B-O O
the B-O O
HMG-box B-O B-protein
. B-O O

Here B-O O
, B-O O
we B-O O
show B-O O
by B-O O
gel B-O O
retardation B-O O
analysis B-O O
that B-O O
TCF-1 B-O B-protein
specifically B-O O
recognizes B-O O
the B-O O
T B-O B-DNA
beta B-O I-DNA
5 B-O I-DNA
element B-O I-DNA
of B-O O
the B-O O
TCR B-O B-DNA
beta B-O I-DNA
enhancer B-O I-DNA
and B-O O
the B-O O
T B-O B-DNA
delta B-O I-DNA
7 B-O I-DNA
element B-O I-DNA
of B-O O
the B-O O
TCR B-O B-DNA
delta B-O I-DNA
enhancer B-O I-DNA
. B-O O

Comparison B-O O
of B-O O
the B-O O
sequences B-O O
of B-O O
all B-O O
elements B-O B-DNA
recognized B-O O
by B-O O
TCF-1 B-O B-protein
defines B-O O
a B-O O
consensus B-O B-DNA
motif B-O I-DNA
A/T B-O O
A/T B-O O
C B-O O
A B-O O
A/G B-O O
A B-O O
G B-O O
. B-O O

These B-O O
observations B-O O
imply B-O O
that B-O O
TCF-1 B-O B-protein
is B-O O
involved B-O O
in B-O O
the B-O O
control B-O O
of B-O O
several B-O O
T B-O B-DNA
cell-specific B-O I-DNA
genes B-O I-DNA
and B-O O
might B-O O
thus B-O O
play B-O O
an B-O O
important B-O O
role B-O O
in B-O O
the B-O O
establishment B-O O
and B-O O
maintenance B-O O
of B-O O
the B-O O
mature B-O B-cell_type
T B-O I-cell_type
cell B-O I-cell_type
phenotype B-O I-cell_type
. B-O O

[ B-O O
Regulatory B-O O
effect B-O O
of B-O O
insulin B-O B-protein
on B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
leukocytes B-O I-cell_type
] B-O O

The B-O O
regulatory B-O O
effect B-O O
of B-O O
insulin B-O B-protein
on B-O O
the B-O O
specific B-O O
binding B-O O
power B-O O
of B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
( B-O O
GR B-O B-protein
) B-O O
of B-O O
human B-O B-cell_type
leukocytes B-O I-cell_type
was B-O O
assessed B-O O
by B-O O
the B-O O
unoccupied B-O B-protein
receptor B-O I-protein
sites B-O I-protein
capable B-O O
of B-O O
combining B-O O
with B-O O
[ B-O O
3H B-O O
] B-O O
labelled B-O O
dexamethasone B-O O
measured B-O O
at B-O O
3 B-O O
and B-O O
24 B-O O
h B-O O
after B-O O
incubation B-O O
with B-O O
various B-O O
concentrations B-O O
of B-O O
insulin B-O B-protein
added B-O O
to B-O O
the B-O O
medium B-O O
. B-O O

After B-O O
3 B-O O
h B-O O
incubation B-O O
the B-O O
specific B-O O
binding B-O O
power B-O O
with B-O O
[ B-O O
3H B-O O
] B-O O
Dex B-O O
was B-O O
decreased B-O O
by B-O O
23.3 B-O O
+/- B-O O
10.0 B-O O
, B-O O
32.2 B-O O
+/- B-O O
13.2 B-O O
and B-O O
54.3 B-O O
+/- B-O O
9.2 B-O O
% B-O O
( B-O O
P B-O O
greater B-O O
than B-O O
0.05 B-O O
, B-O O
P B-O O
greater B-O O
than B-O O
0.05 B-O O
and B-O O
P B-O O
less B-O O
than B-O O
0.01 B-O O
as B-O O
compared B-O O
with B-O O
the B-O O
control B-O O
value B-O O
of B-O O
100 B-O O
in B-O O
the B-O O
absence B-O O
of B-O O
insulin B-O B-protein
) B-O O
respectively B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
20 B-O O
mU/L B-O O
( B-O O
physiological B-O O
testing B-O O
concentration B-O O
) B-O O
, B-O O
200 B-O O
mU/L B-O O
( B-O O
physiological B-O O
upper B-O O
limit B-O O
) B-O O
and B-O O
2 B-O O
, B-O O
000 B-O O
mU/L B-O O
( B-O O
pharmacological B-O O
concentration B-O O
) B-O O
insulin B-O O
in B-O O
the B-O O
incubation B-O O
medium B-O O
. B-O O

After B-O O
24 B-O O
h B-O O
incubation B-O O
the B-O O
decrease B-O O
of B-O O
these B-O O
values B-O O
increased B-O O
respectively B-O O
to B-O O
43.5 B-O O
+/- B-O O
19.0 B-O O
, B-O O
56.1 B-O O
+/- B-O O
20.7 B-O O
and B-O O
80.2 B-O O
+/- B-O O
15.5 B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.05 B-O O
, B-O O
P B-O O
less B-O O
than B-O O
0.01 B-O O
and B-O O
P B-O O
less B-O O
than B-O O
0.01 B-O O
compared B-O O
with B-O O
control B-O O
) B-O O
. B-O O

Thus B-O O
the B-O O
inhibitory B-O O
effect B-O O
of B-O O
insulin B-O B-protein
on B-O O
the B-O O
GR B-O B-protein
binding B-O O
power B-O O
is B-O O
both B-O O
dose- B-O O
and B-O O
time-dependent B-O O
, B-O O
which B-O O
strongly B-O O
suggests B-O O
that B-O O
GR B-O B-protein
is B-O O
tonically B-O O
controlled B-O O
by B-O O
insulin B-O B-protein
concentration B-O O
change B-O O
under B-O O
physiological B-O O
conditions B-O O
. B-O O

The B-O O
effect B-O O
of B-O O
toremifene B-O O
therapy B-O O
on B-O O
serum B-O B-protein
immunoglobulin B-O I-protein
levels B-O O
in B-O O
breast B-O O
cancer B-O O
. B-O O

Estrogens B-O O
and B-O O
anti-estrogens B-O O
enhance B-O O
the B-O O
number B-O O
of B-O O
immunoglobulin B-O B-cell_type
( B-O I-cell_type
Ig B-O I-cell_type
) B-O I-cell_type
-secreting B-O I-cell_type
cells B-O I-cell_type
in B-O O
pokeweed B-O B-cell_line
mitogen B-O I-cell_line
( B-O I-cell_line
PWM B-O I-cell_line
) B-O I-cell_line
-stimulated B-O I-cell_line
lymphocyte B-O I-cell_line
cultures B-O I-cell_line
. B-O O

Lymphocytes B-O B-cell_type
from B-O O
patients B-O O
who B-O O
have B-O O
received B-O O
anti-estrogen B-O O
therapy B-O O
show B-O O
similar B-O O
enhancement B-O O
of B-O O
Ig-secreting B-O B-cell_type
cells B-O I-cell_type
after B-O O
PWM B-O B-protein
stimulation B-O O
. B-O O

In B-O O
this B-O O
study B-O O
the B-O O
effect B-O O
of B-O O
anti-estrogen B-O O
( B-O O
toremifene B-O O
) B-O O
therapy B-O O
on B-O O
serum B-O B-protein
immunoglobulin B-O I-protein
( B-O O
IgA B-O B-protein
, B-O O
IgM B-O B-protein
, B-O O
IgG B-O B-protein
) B-O O
levels B-O O
in B-O O
breast B-O O
cancer B-O O
patients B-O O
was B-O O
investigated B-O O
. B-O O

Serum B-O O
Ig B-O O
levels B-O O
were B-O O
followed B-O O
up B-O O
to B-O O
two B-O O
years B-O O
after B-O O
or B-O O
during B-O O
the B-O O
therapy B-O O
. B-O O

An B-O O
unexpected B-O O
finding B-O O
was B-O O
that B-O O
the B-O O
Ig B-O O
levels B-O O
decreased B-O O
during B-O O
the B-O O
follow-up B-O O
period B-O O
. B-O O

This B-O O
decrease B-O O
was B-O O
seen B-O O
in B-O O
patients B-O O
who B-O O
responded B-O O
to B-O O
the B-O O
therapy B-O O
as B-O O
well B-O O
as B-O O
in B-O O
those B-O O
who B-O O
did B-O O
not B-O O
. B-O O

Human B-O B-protein
erythroid B-O I-protein
5-aminolevulinate B-O I-protein
synthase B-O I-protein
: B-O O
promoter B-O O
analysis B-O O
and B-O O
identification B-O O
of B-O O
an B-O O
iron-responsive B-O B-DNA
element B-O I-DNA
in B-O O
the B-O O
mRNA B-O B-RNA
. B-O O

5-Aminolevulinate B-O B-protein
synthase B-O I-protein
( B-O O
ALAS B-O B-protein
) B-O O
catalyzes B-O O
the B-O O
first B-O O
step B-O O
of B-O O
the B-O O
heme B-O B-protein
biosynthetic B-O O
pathway B-O O
. B-O O

cDNA B-O B-DNA
clones B-O I-DNA
for B-O O
the B-O O
human B-O B-protein
erythroid B-O I-protein
ALAS B-O I-protein
isozyme B-O I-protein
were B-O O
isolated B-O O
from B-O O
a B-O O
fetal B-O B-DNA
liver B-O I-DNA
library B-O I-DNA
. B-O O

It B-O O
can B-O O
be B-O O
deduced B-O O
that B-O O
the B-O O
erythroid B-O B-protein
ALAS B-O I-protein
precursor B-O I-protein
protein B-O I-protein
has B-O O
a B-O O
molecular B-O O
weight B-O O
of B-O O
64.6 B-O O
kd B-O O
, B-O O
and B-O O
is B-O O
similar B-O O
in B-O O
size B-O O
to B-O O
the B-O O
previously B-O O
isolated B-O O
human B-O B-protein
housekeeping B-O I-protein
ALAS B-O I-protein
precursor B-O I-protein
of B-O O
molecular B-O O
weight B-O O
70.6 B-O O
kd B-O O
. B-O O

The B-O O
mature B-O O
mitochondrial B-O O
forms B-O O
of B-O O
the B-O O
erythroid B-O O
and B-O O
housekeeping B-O B-protein
ALAS B-O I-protein
isozymes B-O I-protein
are B-O O
predicted B-O O
to B-O O
have B-O O
molecular B-O O
weights B-O O
of B-O O
59.5 B-O O
kd B-O O
and B-O O
64.6 B-O O
kd B-O O
, B-O O
respectively B-O O
. B-O O

The B-O O
two B-O O
isozymes B-O B-protein
show B-O O
little B-O O
amino B-O O
acid B-O O
identity B-O O
in B-O O
their B-O O
N-terminal B-O B-protein
signal B-O I-protein
sequences B-O I-protein
but B-O O
have B-O O
considerable B-O O
sequence B-O O
identity B-O O
in B-O O
the B-O O
C-terminal B-O B-protein
two-thirds B-O I-protein
of B-O O
their B-O O
proteins B-O O
. B-O O

An B-O O
analysis B-O O
of B-O O
the B-O O
immediate B-O B-DNA
promoter B-O I-DNA
of B-O O
the B-O O
human B-O B-DNA
erythroid B-O I-DNA
ALAS B-O I-DNA
gene B-O I-DNA
revealed B-O O
several B-O O
putative B-O O
erythroid-specific B-O B-DNA
cis-acting B-O I-DNA
elements B-O I-DNA
including B-O O
both B-O O
a B-O O
GATA-1 B-O B-protein
and B-O O
an B-O O
NF-E2 B-O B-DNA
binding B-O I-DNA
site B-O I-DNA
. B-O O

An B-O O
iron-responsive B-O B-DNA
element B-O I-DNA
( B-O O
IRE B-O B-DNA
) B-O O
motif B-O O
has B-O O
been B-O O
identified B-O O
in B-O O
the B-O O
5'-untranslated B-O B-DNA
region B-O I-DNA
of B-O O
the B-O O
human B-O B-RNA
erythroid B-O I-RNA
ALAS B-O I-RNA
mRNA B-O I-RNA
, B-O O
but B-O O
is B-O O
not B-O O
present B-O O
in B-O O
the B-O O
housekeeping B-O B-RNA
ALAS B-O I-RNA
mRNA B-O I-RNA
. B-O O

Gel B-O O
retardation B-O O
experiments B-O O
established B-O O
that B-O O
this B-O O
IRE B-O B-DNA
motif B-O I-DNA
formed B-O O
a B-O O
complex B-O I-protein
with B-O O
cytosolic B-O O
extracts B-O O
from B-O O
human B-O B-cell_line
K562 B-O I-cell_line
cells B-O I-cell_line
and B-O O
this B-O O
binding B-O O
was B-O O
strongly B-O O
competed B-O O
with B-O O
IRE B-O B-RNA
transcripts B-O I-RNA
from B-O O
ferritin B-O B-RNA
or B-O I-RNA
transferrin B-O I-RNA
receptor B-O I-RNA
mRNAs B-O I-RNA
. B-O O

A B-O O
transcript B-O O
of B-O O
the B-O O
ALAS B-O B-DNA
IRE B-O I-DNA
, B-O O
mutated B-O O
in B-O O
the B-O O
conserved B-O O
loop B-O O
of B-O O
the B-O O
IRE B-O B-DNA
, B-O O
did B-O O
not B-O O
readily B-O O
form B-O O
this B-O O
complex B-O I-protein
. B-O O

These B-O O
results B-O O
suggest B-O O
that B-O O
the B-O O
IRE B-O B-DNA
motif B-O I-DNA
in B-O O
the B-O O
ALAS B-O B-RNA
mRNA B-O I-RNA
is B-O O
functional B-O O
and B-O O
imply B-O O
that B-O O
translation B-O O
of B-O O
the B-O O
mRNA B-O B-RNA
is B-O O
controlled B-O O
by B-O O
cellular B-O O
iron B-O O
availability B-O O
during B-O O
erythropoiesis B-O O
. B-O O

Regulation B-O O
of B-O O
jun B-O B-DNA
and B-O I-DNA
fos B-O I-DNA
gene B-O I-DNA
expression B-O O
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
by B-O O
the B-O O
macrophage B-O B-protein
colony-stimulating B-O I-protein
factor B-O I-protein
. B-O O

The B-O O
macrophage B-O B-protein
colony-stimulating B-O I-protein
factor B-O I-protein
( B-O O
M-CSF B-O B-protein
) B-O O
is B-O O
required B-O O
for B-O O
the B-O O
growth B-O O
and B-O O
differentiation B-O O
of B-O O
mononuclear B-O B-cell_type
phagocytes B-O I-cell_type
. B-O O

However B-O O
, B-O O
the B-O O
signaling B-O O
events B-O O
responsible B-O O
for B-O O
these B-O O
effects B-O O
remain B-O O
unclear B-O O
. B-O O

The B-O O
present B-O O
studies B-O O
have B-O O
examined B-O O
the B-O O
effects B-O O
of B-O O
M-CSF B-O B-protein
on B-O O
potential B-O O
signaling B-O O
pathways B-O O
involving B-O O
expression B-O O
of B-O O
the B-O O
jun B-O B-DNA
and B-O I-DNA
fos B-O I-DNA
early B-O I-DNA
response B-O I-DNA
genes B-O I-DNA
. B-O O

Low B-O O
levels B-O O
of B-O O
c-jun B-O B-RNA
transcripts B-O I-RNA
were B-O O
detectable B-O O
in B-O O
resting B-O B-cell_type
human B-O I-cell_type
peripheral B-O I-cell_type
blood B-O I-cell_type
monocytes B-O I-cell_type
. B-O O

Treatment B-O O
of B-O O
these B-O O
cells B-O O
with B-O O
10 B-O O
( B-O O
3 B-O O
) B-O O
units/ml B-O O
human B-O B-protein
recombinant B-O I-protein
M-CSF B-O I-protein
was B-O O
associated B-O O
with B-O O
rapid B-O O
and B-O O
transient B-O O
increases B-O O
in B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
levels B-O O
. B-O O

Nuclear B-O O
run-on B-O O
assays B-O O
and B-O O
mRNA B-O O
stability B-O O
studies B-O O
demonstrated B-O O
that B-O O
M-CSF B-O B-protein
regulates B-O O
c-jun B-O B-DNA
expression B-O O
by B-O O
both B-O O
an B-O O
increase B-O O
in B-O O
transcription B-O O
rate B-O O
and B-O O
a B-O O
prolongation B-O O
in B-O O
the B-O O
half-life B-O O
of B-O O
c-jun B-O B-RNA
transcripts B-O I-RNA
. B-O O

M-CSF B-O B-protein
treatment B-O O
was B-O O
also B-O O
associated B-O O
with B-O O
a B-O O
rapid B-O O
induction B-O O
of B-O O
the B-O O
jun-B B-O B-DNA
gene B-O I-DNA
, B-O O
although B-O O
expression B-O O
of B-O O
this B-O O
gene B-O O
was B-O O
prolonged B-O O
compared B-O O
to B-O O
that B-O O
of B-O O
c-jun B-O B-DNA
. B-O O

We B-O O
further B-O O
demonstrate B-O O
that B-O O
M-CSF B-O B-protein
increases B-O O
c-fos B-O B-RNA
mRNA B-O I-RNA
levels B-O O
in B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
through B-O O
control B-O O
at B-O O
both B-O O
the B-O O
transcriptional B-O O
and B-O O
posttranscriptional B-O O
levels B-O O
. B-O O

Maximal B-O O
induction B-O O
of B-O O
the B-O O
c-fos B-O B-DNA
gene B-O I-DNA
was B-O O
followed B-O O
by B-O O
that B-O O
for B-O O
the B-O O
fos-B B-O B-DNA
gene B-O I-DNA
. B-O O

Moreover B-O O
, B-O O
M-CSF B-O B-protein
-induced B-O O
expression B-O O
of B-O O
the B-O O
fos-related B-O B-DNA
gene B-O I-DNA
, B-O O
fra-1 B-O B-DNA
, B-O O
was B-O O
delayed B-O O
compared B-O O
to B-O O
that B-O O
for B-O O
both B-O O
c-fos B-O B-DNA
and B-O O
fos-B B-O B-DNA
. B-O O

Taken B-O O
together B-O O
, B-O O
the B-O O
results B-O O
indicate B-O O
that B-O O
M-CSF B-O B-protein
treatment B-O O
is B-O O
associated B-O O
with B-O O
differential B-O O
activation B-O O
of B-O O
multiple B-O O
members B-O O
of B-O O
the B-O O
jun/fos B-O B-protein
family B-O I-protein
and B-O O
that B-O O
expression B-O O
of B-O O
these B-O O
genes B-O O
could B-O O
contribute B-O O
to B-O O
nuclear B-O O
signaling B-O O
mechanisms B-O O
that B-O O
regulate B-O O
a B-O O
specific B-O O
program B-O O
of B-O O
monocyte B-O O
differentiation B-O O
. B-O O

Glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
systemic B-O O
lupus B-O O
erythematosus B-O O
. B-O O

Glucocorticosteroids B-O O
remain B-O O
the B-O O
major B-O O
treatment B-O O
modality B-O O
for B-O O
systemic B-O O
lupus B-O O
erythematosus B-O O
( B-O O
SLE B-O O
) B-O O
, B-O O
but B-O O
their B-O O
mechanism B-O O
of B-O O
action B-O O
is B-O O
unclear B-O O
. B-O O

Over B-O O
the B-O O
past B-O O
decade B-O O
it B-O O
has B-O O
become B-O O
clear B-O O
that B-O O
glucocorticosteroid B-O B-protein
receptors B-O I-protein
play B-O O
a B-O O
significant B-O O
role B-O O
in B-O O
the B-O O
mechanism B-O O
of B-O O
glucocorticosteroid B-O O
action B-O O
. B-O O

We B-O O
studied B-O O
glucocorticosteroid B-O B-protein
receptor B-O I-protein
density B-O O
and B-O O
affinity B-O O
on B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
by B-O O
the B-O O
glucocorticosteroid B-O O
binding B-O O
assay B-O O
in B-O O
33 B-O O
patients B-O O
with B-O O
SLE B-O O
who B-O O
had B-O O
taken B-O O
no B-O O
glucocorticosteroid B-O O
for B-O O
the B-O O
previous B-O O
6 B-O O
months B-O O
and B-O O
in B-O O
32 B-O O
healthy B-O O
controls B-O O
. B-O O

Patients B-O O
' B-O O
disease B-O O
activity B-O O
was B-O O
measured B-O O
by B-O O
the B-O O
SLE B-O O
Disease B-O O
Activity B-O O
Index B-O O
( B-O O
SLEDAI B-O O
) B-O O
. B-O O

Glucocorticosteroid B-O B-protein
receptors B-O I-protein
on B-O O
leukocytes B-O B-cell_type
of B-O O
patients B-O O
with B-O O
SLE B-O O
were B-O O
significantly B-O O
higher B-O O
than B-O O
in B-O O
healthy B-O O
controls B-O O
( B-O O
4419 B-O O
+/- B-O O
306 B-O O
vs B-O O
3369 B-O O
+/- B-O O
196 B-O O
, B-O O
p B-O O
less B-O O
than B-O O
0.005 B-O O
) B-O O
. B-O O

The B-O O
binding B-O O
affinity B-O O
was B-O O
not B-O O
different B-O O
between B-O O
patients B-O O
and B-O O
controls B-O O
. B-O O

There B-O O
was B-O O
no B-O O
correlation B-O O
between B-O O
glucocorticosteroid B-O B-protein
receptor B-O I-protein
number B-O O
and B-O O
SLE B-O O
disease B-O O
activity B-O O
. B-O O

Kappa B-O B-protein
B B-O I-protein
binding B-O I-protein
proteins B-O I-protein
are B-O O
constitutively B-O O
expressed B-O O
in B-O O
an B-O O
IL-2 B-O B-cell_line
autocrine B-O I-cell_line
human B-O I-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
. B-O O

The B-O O
IL-2 B-O B-protein
and B-O O
the B-O O
IL-2-R B-O B-DNA
alpha B-O I-DNA
genes B-O I-DNA
are B-O O
both B-O O
expressed B-O O
transiently B-O O
in B-O O
normal B-O B-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
after B-O O
Ag B-O B-protein
or B-O O
mitogen B-O B-protein
activation B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
the B-O O
human B-O B-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
, B-O O
IARC B-O B-cell_line
301 B-O I-cell_line
, B-O O
expresses B-O O
these B-O O
two B-O O
genes B-O O
constitutively B-O O
and B-O O
we B-O O
have B-O O
previously B-O O
demonstrated B-O O
that B-O O
its B-O O
growth B-O O
depends B-O O
on B-O O
the B-O O
autocrine B-O O
production B-O O
of B-O O
this B-O O
T B-O B-protein
cell B-O I-protein
growth B-O I-protein
factor B-O I-protein
and B-O O
high B-O B-protein
affinity B-O I-protein
IL-2R B-O I-protein
. B-O O

To B-O O
dissect B-O O
the B-O O
molecular B-O O
basis B-O O
for B-O O
the B-O O
unusual B-O O
persistent B-O O
expression B-O O
of B-O O
the B-O O
IL-2 B-O B-DNA
and B-O I-DNA
IL-2-R B-O I-DNA
alpha B-O I-DNA
genes B-O I-DNA
in B-O O
these B-O O
IARC B-O B-cell_line
301 B-O I-cell_line
T B-O I-cell_line
cells B-O I-cell_line
, B-O O
we B-O O
have B-O O
analyzed B-O O
the B-O O
interactions B-O O
of B-O O
constitutively B-O O
expressed B-O O
nuclear B-O B-protein
proteins B-O I-protein
with B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
flanking B-O I-DNA
regions B-O I-DNA
of B-O O
the B-O O
IL-2 B-O B-DNA
and B-O I-DNA
IL-2-R B-O I-DNA
alpha B-O I-DNA
genes B-O I-DNA
using B-O O
both B-O O
DNase B-O B-protein
I B-O I-protein
footprinting B-O O
and B-O O
gel B-O O
retardation B-O O
techniques B-O O
. B-O O

We B-O O
have B-O O
found B-O O
that B-O O
a B-O O
region B-O O
in B-O O
both B-O O
genes B-O O
( B-O O
-276 B-O B-DNA
to B-O I-DNA
-250 B-O I-DNA
for B-O O
IL-2-R B-O B-protein
alpha B-O I-protein
and B-O O
-203 B-O B-DNA
to B-O I-DNA
-183 B-O I-DNA
for B-O O
IL-2 B-O B-protein
) B-O O
, B-O O
which B-O O
corresponds B-O O
to B-O O
a B-O O
kappa B-O B-DNA
B B-O I-DNA
enhancer B-O I-DNA
element B-O I-DNA
, B-O O
is B-O O
specifically B-O O
protected B-O O
by B-O O
nuclear B-O B-protein
proteins B-O I-protein
from B-O O
IARC B-O B-cell_line
301 B-O I-cell_line
. B-O O

In B-O O
agreement B-O O
with B-O O
this B-O O
finding B-O O
, B-O O
both B-O O
the B-O O
IL-2 B-O B-DNA
and B-O I-DNA
IL-2-R B-O I-DNA
alpha B-O I-DNA
promoters B-O I-DNA
are B-O O
active B-O O
in B-O O
transient B-O O
transfection B-O O
assays B-O O
in B-O O
IARC B-O B-cell_line
301 B-O I-cell_line
cells B-O I-cell_line
. B-O O

In B-O O
contrast B-O O
, B-O O
mutation B-O O
of B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
enhancer B-O I-DNA
results B-O O
in B-O O
markedly B-O O
attenuated B-O O
activities B-O O
of B-O O
both B-O O
promoters B-O B-DNA
. B-O O

Two B-O O
proteins B-O O
binding B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
sequence B-O I-DNA
, B-O O
NF-kappa B-O B-protein
B B-O I-protein
and B-O O
KBF1 B-O B-protein
, B-O O
are B-O O
constitutively B-O O
expressed B-O O
in B-O O
IARC B-O B-cell_line
301 B-O I-cell_line
nuclei B-O O
and B-O O
induced B-O O
by B-O O
PMA B-O O
and B-O O
PHA B-O B-protein
in B-O O
Jurkat B-O B-cell_line
. B-O O

They B-O O
bind B-O O
to B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
motifs B-O I-DNA
with B-O O
different B-O O
relative B-O O
affinities B-O O
that B-O O
may B-O O
reflect B-O O
their B-O O
different B-O O
contribution B-O O
in B-O O
the B-O O
expression B-O O
of B-O O
various B-O O
promoters B-O B-DNA
. B-O O

HIV1 B-O O
infection B-O O
of B-O O
human B-O B-cell_type
monocytes B-O I-cell_type
and B-O O
macrophages B-O B-cell_type
promotes B-O O
induction B-O O
or B-O O
translocation B-O O
of B-O O
NF-KB-related B-O B-protein
factors B-O I-protein
. B-O O

In B-O O
1991 B-O O
, B-O O
we B-O O
demonstrated B-O O
, B-O O
using B-O O
electrophoretic B-O O
mobility B-O O
shift B-O O
assays B-O O
, B-O O
that B-O O
3 B-O O
different B-O O
factors B-O O
( B-O O
termed B-O O
B1 B-O B-protein
, B-O O
B2 B-O B-protein
and B-O O
B3 B-O B-protein
) B-O O
with B-O O
affinity B-O O
for B-O O
the B-O O
KB-enhancer B-O B-DNA
target B-O I-DNA
sequence B-O I-DNA
were B-O O
specifically B-O O
detected B-O O
in B-O O
nuclear B-O O
extracts B-O O
from B-O O
HIV1 B-O B-cell_type
-infected B-O I-cell_type
monocytes B-O I-cell_type
and B-O O
macrophages B-O B-cell_type
. B-O O

The B-O O
B2 B-O B-protein
factor B-O I-protein
was B-O O
induced B-O O
in B-O O
the B-O O
nuclei B-O O
of B-O O
these B-O O
cells B-O O
only B-O O
upon B-O O
HIV1 B-O O
infection B-O O
. B-O O

The B-O O
B3 B-O B-protein
factor B-O I-protein
was B-O O
only B-O O
slightly B-O O
evident B-O O
in B-O O
nuclei B-O O
of B-O O
uninfected B-O B-cell_type
cells B-O I-cell_type
but B-O O
was B-O O
readily B-O O
detectable B-O O
in B-O O
nuclei B-O O
of B-O O
infected B-O B-cell_type
monocytes B-O I-cell_type
. B-O O

Its B-O O
expression B-O O
remained B-O O
very B-O O
low B-O O
in B-O O
nuclei B-O O
of B-O O
HIV1 B-O B-cell_type
-infected B-O I-cell_type
macrophages B-O I-cell_type
. B-O O

In B-O O
this B-O O
paper B-O O
, B-O O
we B-O O
demonstrate B-O O
that B-O O
the B-O O
B2 B-O B-protein
factor B-O I-protein
is B-O O
expressed B-O O
in B-O O
the B-O O
cytosol B-O O
of B-O O
monocytes B-O B-cell_type
and B-O O
macrophages B-O B-cell_type
as B-O O
a B-O O
DNA-binding B-O B-protein
protein B-O I-protein
, B-O O
indicating B-O O
that B-O O
it B-O O
is B-O O
not B-O O
associated B-O O
with B-O O
an B-O O
inhibitor B-O O
( B-O O
IKB B-O B-protein
) B-O O
. B-O O

This B-O O
factor B-O O
remained B-O O
clustered B-O O
in B-O O
the B-O O
cytosol B-O O
and B-O O
was B-O O
translocated B-O O
to B-O O
the B-O O
nuclei B-O O
only B-O O
after B-O O
HIV1 B-O O
infection B-O O
. B-O O

The B-O O
B3 B-O B-protein
factor B-O I-protein
is B-O O
detected B-O O
in B-O O
the B-O O
cytosol B-O O
only B-O O
when B-O O
cells B-O O
are B-O O
HIV1 B-O O
-infected B-O O
. B-O O

The B-O O
role B-O O
of B-O O
HIV1 B-O O
infection B-O O
in B-O O
the B-O O
expression B-O O
and B-O O
the B-O O
translocation B-O O
of B-O O
these B-O O
factors B-O O
is B-O O
discussed B-O O
. B-O O

Identification B-O O
and B-O O
cloning B-O O
of B-O O
TCF-1 B-O B-protein
, B-O O
a B-O O
T B-O B-protein
lymphocyte-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
containing B-O O
a B-O O
sequence-specific B-O B-protein
HMG B-O I-protein
box B-O I-protein
. B-O O

CD3 B-O B-protein
-epsilon B-O O
expression B-O O
is B-O O
controlled B-O O
by B-O O
a B-O O
downstream B-O B-DNA
T B-O I-DNA
lymphocyte-specific B-O I-DNA
enhancer B-O I-DNA
element B-O I-DNA
. B-O O

We B-O O
report B-O O
the B-O O
identification B-O O
of B-O O
a B-O O
T B-O B-protein
cell-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
TCF-1 B-O B-protein
, B-O O
binding B-O O
to B-O O
this B-O O
element B-O O
. B-O O

The B-O O
multimerized B-O B-protein
recognition B-O I-protein
motif B-O I-protein
of B-O O
TCF-1 B-O B-protein
constituted B-O O
a B-O O
T B-O B-DNA
cell-specific B-O I-DNA
enhancer B-O I-DNA
. B-O O

Subsequent B-O O
cloning B-O O
of B-O O
TCF-1 B-O B-protein
identified B-O O
three B-O O
splice B-O B-protein
alternatives B-O I-protein
. B-O O

TCF-1 B-O B-protein
contained B-O O
a B-O O
single B-O O
DNA-binding B-O B-protein
HMG B-O I-protein
box B-O I-protein
most B-O O
closely B-O O
related B-O O
to B-O O
similar B-O O
boxes B-O O
in B-O O
the B-O O
putative B-O B-DNA
mammalian B-O I-DNA
sex-determining B-O I-DNA
gene B-O I-DNA
SRY B-O B-DNA
and B-O O
in B-O O
the B-O O
Schizosaccharomyces B-O B-DNA
pombe B-O I-DNA
Mc B-O I-DNA
mating B-O I-DNA
type B-O I-DNA
gene B-O I-DNA
. B-O O

TCF-1 B-O B-RNA
mRNA B-O I-RNA
was B-O O
expressed B-O O
uniquely B-O O
in B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

Upon B-O O
cotransfection B-O O
into B-O O
non-T B-O B-cell_type
cells B-O I-cell_type
, B-O O
TCF-1 B-O B-protein
could B-O O
transactivate B-O O
through B-O O
its B-O O
cognate B-O O
motif B-O O
. B-O O

These B-O O
results B-O O
identify B-O O
TCF-1 B-O B-protein
as B-O O
a B-O O
T B-O B-protein
cell-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
which B-O O
might B-O O
play B-O O
a B-O O
role B-O O
in B-O O
the B-O O
establishment B-O O
of B-O O
the B-O O
mature B-O B-cell_type
T B-O I-cell_type
cell B-O I-cell_type
phenotype B-O I-cell_type
. B-O O

Identification B-O O
of B-O O
transcriptional B-O B-protein
suppressor B-O I-protein
proteins B-O I-protein
that B-O O
bind B-O O
to B-O O
the B-O O
negative B-O B-DNA
regulatory B-O I-DNA
element B-O I-DNA
of B-O O
the B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
. B-O O

Two B-O O
different B-O O
proteins B-O O
which B-O O
independently B-O O
bound B-O O
to B-O O
neighboring B-O O
sequences B-O O
within B-O O
the B-O O
negative B-O B-DNA
regulatory B-O I-DNA
element B-O I-DNA
( B-O O
NRE B-O B-DNA
) B-O O
of B-O O
human B-O O
immunodeficiency B-O O
virus B-O O
type B-O O
1 B-O O
( B-O O
HIV-1 B-O O
) B-O O
were B-O O
detected B-O O
in B-O O
the B-O O
nuclear B-O O
extract B-O O
of B-O O
a B-O O
virus-infected B-O B-cell_line
human B-O I-cell_line
T B-O I-cell_line
cell B-O I-cell_line
line B-O I-cell_line
. B-O O

One B-O O
of B-O O
the B-O O
factors B-O O
bound B-O O
to B-O O
a B-O O
novel B-O B-DNA
dyad B-O I-DNA
symmetrical B-O I-DNA
sequence B-O I-DNA
. B-O O

This B-O O
sequence B-O O
is B-O O
well B-O O
conserved B-O O
in B-O O
various B-O O
HIV-1 B-O O
isolates B-O O
and B-O O
partial B-O O
homology B-O O
was B-O O
found B-O O
with B-O O
the B-O O
promoter B-O B-DNA
region B-O I-DNA
of B-O O
the B-O O
human B-O B-DNA
retinoblastoma B-O I-DNA
gene B-O I-DNA
. B-O O

Similar B-O O
DNA B-O O
binding B-O O
activity B-O O
was B-O O
detected B-O O
in B-O O
a B-O O
variety B-O O
of B-O O
virus-uninfected B-O B-cell_line
human B-O I-cell_line
T B-O I-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
and B-O O
HeLa B-O B-cell_line
cells B-O I-cell_line
by B-O O
means B-O O
of B-O O
a B-O O
gel B-O O
mobility B-O O
shift B-O O
assay B-O O
. B-O O

The B-O O
other B-O O
factor B-O O
bound B-O O
to B-O O
a B-O O
putative B-O B-DNA
AP-1 B-O I-DNA
recognition B-O I-DNA
sequence B-O I-DNA
predicted B-O O
for B-O O
the B-O O
HIV-1 B-O B-DNA
NRE B-O I-DNA
. B-O O

However B-O O
, B-O O
this B-O O
factor B-O O
did B-O O
not B-O O
bind B-O O
to B-O O
a B-O O
typical B-O O
AP-1 B-O B-DNA
site B-O I-DNA
. B-O O

The B-O O
insertion B-O O
of B-O O
multiple B-O O
copies B-O O
of B-O O
the B-O O
binding B-O B-DNA
site B-O I-DNA
for B-O O
the B-O O
former B-O O
or B-O O
latter B-O O
factor B-O O
into B-O O
a B-O O
heterologous B-O B-DNA
promoter B-O I-DNA
reduced B-O O
the B-O O
promoter B-O O
activity B-O O
to B-O O
one-tenth B-O O
or B-O O
one-third B-O O
, B-O O
respectively B-O O
. B-O O

Thus B-O O
, B-O O
each B-O O
factor B-O O
may B-O O
function B-O O
as B-O O
a B-O O
novel B-O O
negative B-O O
regulator B-O O
of B-O O
transcription B-O O
. B-O O

Protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
activation B-O O
and B-O O
protooncogene B-O B-DNA
expression B-O O
in B-O O
differentiation/retrodifferentiation B-O O
of B-O O
human B-O B-cell_line
U-937 B-O I-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
. B-O O

Human B-O B-cell_line
U-937 B-O I-cell_line
leukemia B-O I-cell_line
cells B-O I-cell_line
differentiate B-O O
along B-O O
the B-O O
monocytic B-O B-cell_type
lineage B-O I-cell_type
following B-O O
3-day B-O O
exposures B-O O
to B-O O
12-O-tetradecanoylphorbol-13-acetate B-O O
( B-O O
TPA B-O O
) B-O O
. B-O O

This B-O O
induction B-O O
of B-O O
differentiation B-O O
is B-O O
accompanied B-O O
by B-O O
adherence B-O O
and B-O O
loss B-O O
of B-O O
proliferation B-O O
, B-O O
as B-O O
well B-O O
as B-O O
expression/repression B-O O
of B-O O
differentiation-associated B-O B-DNA
genes B-O I-DNA
. B-O O

Long B-O O
term B-O O
culture B-O O
of B-O O
TPA B-O B-cell_line
-differentiated B-O I-cell_line
U-937 B-O I-cell_line
cells B-O I-cell_line
in B-O O
the B-O O
absence B-O O
of B-O O
phorbol B-O O
ester B-O O
for B-O O
32-36 B-O O
days B-O O
resulted B-O O
in B-O O
a B-O O
process B-O O
of B-O O
retrodifferentiation B-O O
. B-O O

The B-O O
retrodifferentiated B-O O
cells B-O O
detached B-O O
from B-O O
the B-O O
substrate B-O O
and B-O O
reinitiated B-O O
proliferation B-O O
. B-O O

Other B-O O
cellular B-O O
parameters B-O O
, B-O O
such B-O O
as B-O O
glycosidase B-O O
activities B-O O
, B-O O
cytokine B-O B-protein
release B-O O
, B-O O
and B-O O
filament B-O O
expression B-O O
, B-O O
returned B-O O
to B-O O
levels B-O O
similar B-O O
to B-O O
that B-O O
observed B-O O
in B-O O
uninduced B-O B-cell_type
cells B-O I-cell_type
. B-O O

Treatment B-O O
of B-O O
U-937 B-O B-cell_line
cells B-O I-cell_line
with B-O O
TPA B-O O
resulted B-O O
in B-O O
a B-O O
rapid B-O O
translocation B-O O
of B-O O
protein B-O B-protein
kinase B-O I-protein
C B-O I-protein
( B-O O
PKC B-O B-protein
) B-O O
from B-O O
the B-O O
cytosol B-O O
to B-O O
cell B-O O
membrane B-O O
fractions B-O O
within B-O O
2-8 B-O O
min B-O O
. B-O O

Increased B-O O
levels B-O O
of B-O O
membrane-associated B-O O
PKC B-O B-protein
activity B-O O
persisted B-O O
until B-O O
17-29 B-O O
days B-O O
. B-O O

However B-O O
, B-O O
longer B-O O
periods B-O O
of B-O O
incubation B-O O
were B-O O
associated B-O O
with B-O O
a B-O O
return B-O O
to B-O O
the B-O O
distribution B-O O
of B-O O
PKC B-O B-protein
in B-O O
control B-O B-cell_type
cells B-O I-cell_type
. B-O O

Activation B-O O
of B-O O
PKC B-O B-protein
has B-O O
been B-O O
implicated B-O O
in B-O O
the B-O O
regulation B-O O
of B-O O
certain B-O O
immediate B-O B-DNA
early B-O I-DNA
response B-O I-DNA
genes B-O I-DNA
, B-O O
and B-O O
in B-O O
the B-O O
present B-O O
studies B-O O
, B-O O
TPA B-O O
rapidly B-O O
induced B-O O
c-fos B-O B-DNA
and B-O O
c-jun B-O B-DNA
gene B-O O
expression B-O O
. B-O O

Levels B-O O
of B-O O
c-fos B-O B-RNA
and B-O I-RNA
c-jun B-O I-RNA
transcripts B-O I-RNA
remained B-O O
elevated B-O O
during B-O O
periods B-O O
of B-O O
PKC B-O B-protein
activation B-O O
and B-O O
also B-O O
returned B-O O
to B-O O
levels B-O O
observed B-O O
in B-O O
control B-O B-cell_type
cells B-O I-cell_type
by B-O O
30-36 B-O O
days B-O O
, B-O O
when B-O O
the B-O O
cells B-O O
entered B-O O
retrodifferentiation B-O O
. B-O O

Staurosporine B-O O
, B-O O
a B-O O
nonspecific B-O O
inhibitor B-O O
of B-O O
PKC B-O B-protein
, B-O O
partially B-O O
blocked B-O O
TPA B-O O
-induced B-O O
adherence B-O O
and B-O O
growth B-O O
inhibition B-O O
and B-O O
concomitantly B-O O
prevented B-O O
TPA-induced B-O O
c-fos B-O O
and B-O O
c-jun B-O B-DNA
gene B-O O
expression B-O O
. B-O O

( B-O O
ABSTRACT B-O O
TRUNCATED B-O O
AT B-O O
250 B-O O
WORDS B-O O
) B-O O

Kappa B-O B-protein
B-specific B-O I-protein
DNA B-O I-protein
binding B-O I-protein
proteins B-O I-protein
are B-O O
differentially B-O O
inhibited B-O O
by B-O O
enhancer B-O O
mutations B-O O
and B-O O
biological B-O O
oxidation B-O O
. B-O O

Kappa B-O B-protein
B B-O I-protein
( B-O I-protein
kappa B-O I-protein
B B-O I-protein
) B-O I-protein
enhancer B-O I-protein
binding B-O I-protein
proteins B-O I-protein
isolated B-O O
from B-O O
the B-O O
nuclei B-O O
of B-O O
activated B-O B-cell_type
human B-O I-cell_type
T B-O I-cell_type
cells B-O I-cell_type
produce B-O O
two B-O O
distinct B-O O
nucleoprotein B-O B-protein
complexes B-O I-protein
when B-O O
incubated B-O O
with B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
element B-O I-DNA
from B-O O
the B-O O
interleukin-2 B-O B-DNA
receptor-alpha B-O I-DNA
( B-O I-DNA
IL-2R B-O I-DNA
alpha B-O I-DNA
) B-O I-DNA
gene B-O I-DNA
. B-O O

These B-O O
two B-O O
DNA-protein B-O B-protein
complexes B-O I-protein
are B-O O
composed B-O O
of B-O O
at B-O O
least B-O O
four B-O O
host B-O O
proteins B-O O
( B-O O
p50 B-O B-protein
, B-O O
p55 B-O B-protein
, B-O O
p75 B-O B-protein
, B-O O
p85 B-O B-protein
) B-O O
, B-O O
each B-O O
of B-O O
which B-O O
shares B-O O
structural B-O O
similarity B-O O
with B-O O
the B-O O
v-rel B-O B-protein
oncogene B-O I-protein
product B-O I-protein
. B-O O

Nuclear B-O O
expression B-O O
of B-O O
these B-O O
proteins B-O O
is B-O O
induced B-O O
with B-O O
distinctly B-O O
biphasic B-O O
kinetics B-O O
following B-O O
phorbol B-O O
ester B-O O
activation B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
( B-O O
p55/p75 B-O B-protein
early B-O I-protein
and B-O O
p50/p85 B-O B-protein
late B-O O
) B-O O
. B-O O

DNA-protein B-O O
crosslinking B-O O
studies B-O O
have B-O O
revealed B-O O
that B-O O
the B-O O
more B-O O
rapidly B-O O
migrating B-O O
B2 B-O B-protein
complex B-O I-protein
contains B-O O
both B-O O
p50 B-O B-protein
and B-O O
p55 B-O B-protein
while B-O O
the B-O O
more B-O O
slowly B-O O
migrating B-O O
B1 B-O B-protein
complex B-O I-protein
is B-O O
composed B-O O
of B-O O
p50 B-O B-protein
, B-O O
p55 B-O B-protein
, B-O O
p75 B-O B-protein
, B-O O
and B-O O
p85 B-O B-protein
. B-O O

Site-directed B-O O
mutagenesis B-O O
of B-O O
the B-O O
wild-type B-O B-DNA
IL-2R B-O I-DNA
alpha B-O I-DNA
kappa B-O I-DNA
B B-O I-DNA
enhancer B-O I-DNA
( B-O O
GGGGAATCTCCC B-O O
) B-O O
has B-O O
revealed B-O O
that B-O O
the B-O O
binding B-O O
of B-O O
p50 B-O B-protein
and B-O O
p55 B-O B-protein
( B-O O
B2 B-O B-protein
complex B-O I-protein
) B-O O
is B-O O
particularly B-O O
sensitive B-O O
to B-O O
alteration B-O O
of B-O O
the B-O O
5 B-O B-DNA
' B-O I-DNA
triplet B-O I-DNA
of B-O O
deoxyguanosine B-O O
residues B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
formation B-O O
of B-O O
the B-O O
B1 B-O B-protein
complex B-O I-protein
, B-O O
reflecting B-O O
the B-O O
binding B-O O
of B-O O
p75 B-O B-protein
and B-O O
p85 B-O B-protein
, B-O O
critically B-O O
depends B-O O
upon B-O O
the B-O O
more B-O O
3 B-O B-DNA
' B-O I-DNA
sequences B-O I-DNA
of B-O O
this B-O O
enhancer B-O B-DNA
element B-O I-DNA
. B-O O

DNA B-O O
binding B-O O
by B-O O
all B-O O
four B-O O
of B-O O
these B-O O
Rel-related B-O B-protein
factors B-O I-protein
is B-O O
blocked B-O O
by B-O O
selective B-O O
chemical B-O O
modification B-O O
of B-O O
lysine B-O O
and B-O O
arginine B-O O
residues B-O O
, B-O O
suggesting B-O O
that B-O O
both B-O O
of B-O O
these B-O O
basic B-O O
amino B-O O
acids B-O O
are B-O O
required B-O O
for B-O O
binding B-O O
to B-O O
the B-O O
kappa B-O B-DNA
B B-O I-DNA
element B-O I-DNA
. B-O O

Similarly B-O O
, B-O O
covalent B-O O
modification B-O O
of B-O O
free B-O O
sulfhydryl B-O O
groups B-O O
with B-O O
diamide B-O O
( B-O O
reversible B-O O
) B-O O
or B-O O
N-ethylmaleimide B-O O
( B-O O
irreversible B-O O
) B-O O
results B-O O
in B-O O
a B-O O
complete B-O O
loss B-O O
of B-O O
DNA B-O O
binding B-O O
activity B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
mild B-O O
oxidation B-O O
with B-O O
glucose B-O B-protein
oxidase B-O I-protein
selectively B-O O
inhibits B-O O
p75 B-O B-protein
and B-O O
p85 B-O B-protein
binding B-O O
while B-O O
not B-O O
blocking B-O O
p50 B-O B-protein
and B-O O
p55 B-O B-protein
interactions B-O O
. B-O O

These B-O O
findings B-O O
suggest B-O O
that B-O O
reduced B-O O
cysteine B-O O
thiols B-O O
play B-O O
an B-O O
important B-O O
role B-O O
in B-O O
the B-O O
DNA B-O O
binding B-O O
activity B-O O
of B-O O
this B-O O
family B-O O
of B-O O
Rel-related B-O B-protein
transcription B-O I-protein
factors B-O I-protein
. B-O O

[ B-O O
Changes B-O O
in B-O O
leucocytic B-O B-protein
estrogen B-O I-protein
receptor B-O I-protein
levels B-O O
in B-O O
patients B-O O
with B-O O
climacteric B-O O
syndrome B-O O
and B-O O
therapeutic B-O O
effect B-O O
of B-O O
liuwei B-O O
dihuang B-O O
pills B-O O
] B-O O

The B-O O
numbers B-O O
of B-O O
estrogen B-O B-protein
receptor B-O I-protein
( B-O O
ER B-O B-protein
) B-O O
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
leucocytes B-O I-cell_type
in B-O O
22 B-O O
women B-O O
with B-O O
climacteric B-O O
syndrome B-O O
were B-O O
measured B-O O
by B-O O
radioligand B-O O
method B-O O
. B-O O

The B-O O
results B-O O
were B-O O
compared B-O O
with B-O O
those B-O O
of B-O O
12 B-O O
normal B-O O
child-bearing-age B-O O
women B-O O
. B-O O

It B-O O
wat B-O O
found B-O O
that B-O O
the B-O O
contents B-O O
of B-O O
leucocytic B-O B-protein
ER B-O I-protein
in B-O O
climacteric B-O O
syndrome B-O O
patients B-O O
were B-O O
significantly B-O O
lower B-O O
than B-O O
normal B-O O
child-bearing-age B-O O
women B-O O
. B-O O

The B-O O
authors B-O O
used B-O O
a B-O O
Chinese B-O O
prescription B-O O
-- B-O O
Liuwei B-O O
Dihuang B-O O
Pills B-O O
( B-O O
LDP B-O O
) B-O O
to B-O O
treat B-O O
the B-O O
patients B-O O
for B-O O
2 B-O O
months B-O O
. B-O O

The B-O O
numbers B-O O
of B-O O
leucocytic B-O B-protein
ER B-O I-protein
were B-O O
significantly B-O O
increased B-O O
after B-O O
treatment B-O O
. B-O O

The B-O O
data B-O O
indicate B-O O
that B-O O
decrease B-O O
of B-O O
ER B-O B-protein
levels B-O O
in B-O O
cell B-O O
may B-O O
involve B-O O
in B-O O
the B-O O
pathogenesis B-O O
of B-O O
climacteric B-O O
syndrome B-O O
. B-O O

LDP B-O O
not B-O O
only B-O O
increases B-O O
plasma B-O O
estradiol B-O O
levels B-O O
, B-O O
but B-O O
also B-O O
increases B-O O
the B-O O
leucocytic B-O O
ER B-O B-protein
levels B-O O
. B-O O

This B-O O
may B-O O
be B-O O
the B-O O
basis B-O O
of B-O O
the B-O O
therapeutic B-O O
effect B-O O
on B-O O
the B-O O
disease B-O O
. B-O O

Evaluation B-O O
of B-O O
the B-O O
role B-O O
of B-O O
ligand B-O O
and B-O O
thermal B-O O
activation B-O O
of B-O O
specific B-O O
DNA B-O O
binding B-O O
by B-O O
in B-O O
vitro B-O O
synthesized B-O O
human B-O B-protein
glucocorticoid B-O I-protein
receptor B-O I-protein
. B-O O

We B-O O
have B-O O
used B-O O
a B-O O
DNA-binding/immunoprecipitation B-O O
assay B-O O
to B-O O
analyze B-O O
the B-O O
capacity B-O O
of B-O O
human B-O B-protein
glucocorticoid B-O I-protein
receptor B-O I-protein
( B-O O
hGR B-O B-protein
) B-O O
, B-O O
generated B-O O
in B-O O
rabbit B-O O
reticulocyte B-O O
lysates B-O O
, B-O O
to B-O O
bind B-O O
DNA B-O O
. B-O O

In B-O O
vitro B-O O
translated B-O O
hGR B-O B-protein
was B-O O
indistinguishable B-O O
from B-O O
native B-O B-protein
hGR B-O I-protein
, B-O O
as B-O O
determined B-O O
by B-O O
migration B-O O
on B-O O
sodium B-O O
dodecyl B-O O
sulfate-polyacrylamide B-O O
gels B-O O
, B-O O
sedimentation B-O O
on B-O O
sucrose B-O O
density B-O O
gradients B-O O
, B-O O
and B-O O
reactivity B-O O
with B-O O
antipeptide B-O B-protein
antibodies B-O I-protein
generated B-O O
against B-O O
hGR B-O B-protein
. B-O O

In B-O O
addition B-O O
, B-O O
cell-free B-O B-protein
synthesized B-O I-protein
hGR B-O I-protein
was B-O O
capable B-O O
of B-O O
specific B-O O
binding B-O O
to B-O O
glucocorticoid B-O B-DNA
response B-O I-DNA
element B-O I-DNA
( B-O O
GRE B-O B-DNA
) B-O O
-containing B-O O
DNA B-O O
fragments B-O O
. B-O O

Using B-O O
this B-O O
assay B-O O
system B-O O
, B-O O
we B-O O
have B-O O
evaluated B-O O
the B-O O
contributions B-O O
of B-O O
ligand B-O O
binding B-O O
and B-O O
heat B-O O
activation B-O O
to B-O O
DNA B-O O
binding B-O O
by B-O O
these B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
. B-O O

In B-O O
vitro B-O O
translated B-O O
hGR B-O B-protein
was B-O O
capable B-O O
of B-O O
selective B-O O
DNA B-O O
binding B-O O
even B-O O
in B-O O
the B-O O
absence B-O O
of B-O O
glucocorticoid B-O O
. B-O O

Treatment B-O O
with B-O O
dexamethasone B-O O
or B-O O
the B-O O
antiglucocorticoid B-O O
RU486 B-O O
had B-O O
no B-O O
additional B-O O
effect B-O O
on B-O O
the B-O O
DNA-binding B-O O
capacity B-O O
when B-O O
receptor B-O O
preparations B-O O
were B-O O
maintained B-O O
at B-O O
0 B-O O
C B-O O
( B-O O
no B-O O
activation B-O O
) B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
addition B-O O
of B-O O
either B-O O
ligand B-O O
or B-O O
antagonist B-O O
in B-O O
combination B-O O
with B-O O
a B-O O
heat B-O O
activation B-O O
step B-O O
promoted B-O O
DNA B-O O
binding B-O O
by B-O O
approximately B-O O
3-fold B-O O
over B-O O
that B-O O
of B-O O
heat-activated B-O B-protein
unliganded B-O I-protein
receptors B-O I-protein
. B-O O

Agonist B-O O
( B-O O
dexamethasone B-O O
) B-O O
was B-O O
slightly B-O O
more B-O O
effective B-O O
in B-O O
supporting B-O O
specific B-O O
DNA B-O O
binding B-O O
than B-O O
antagonist B-O O
( B-O O
RU486 B-O O
) B-O O
. B-O O

DNA B-O O
binding B-O O
by B-O O
in B-O O
vitro B-O O
synthesized B-O O
GR B-O B-protein
was B-O O
blocked B-O O
by B-O O
the B-O O
addition B-O O
of B-O O
sodium B-O O
molybdate B-O O
to B-O O
the B-O O
receptor B-O O
preparations B-O O
before B-O O
steroid B-O O
addition B-O O
and B-O O
thermal B-O O
activation B-O O
. B-O O

Addition B-O O
of B-O O
KCl B-O O
resulted B-O O
in B-O O
less B-O O
DNA B-O O
binding B-O O
either B-O O
due B-O O
to B-O O
blockage B-O O
of B-O O
DNA- B-O O
receptor B-O O
complex B-O O
formation B-O O
or B-O O
disruption B-O O
of B-O O
the B-O O
complexes B-O O
. B-O O

The B-O O
specificity B-O O
of B-O O
DNA B-O O
binding B-O O
by B-O O
cell-free B-O B-protein
synthesized B-O I-protein
hGR B-O I-protein
was B-O O
analyzed B-O O
further B-O O
by B-O O
examining B-O O
the B-O O
abilities B-O O
of B-O O
various B-O B-DNA
DNAs B-O I-DNA
to B-O O
compete B-O O
for B-O O
binding B-O O
to B-O O
a B-O O
naturally B-O O
occurring B-O O
GRE B-O B-DNA
found B-O O
in B-O O
the B-O O
mouse B-O B-DNA
mammary B-O I-DNA
tumor B-O I-DNA
virus-long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
. B-O O

Oligonucleotides B-O O
containing B-O O
the B-O O
consensus B-O B-DNA
GRE B-O I-DNA
were B-O O
the B-O O
most B-O O
efficient B-O O
competitors B-O O
, B-O O
and B-O O
fragments B-O O
containing B-O O
regulatory B-O B-DNA
sequences B-O I-DNA
from B-O O
glucocorticoid B-O B-DNA
-repressible B-O I-DNA
genes B-O I-DNA
were B-O O
somewhat B-O O
competitive B-O O
, B-O O
whereas B-O O
single B-O O
stranded B-O O
oligonucleotides B-O O
were B-O O
unable B-O O
to B-O O
compete B-O O
for B-O O
mouse B-O B-DNA
mammary B-O I-DNA
tumor B-O I-DNA
virus-long B-O I-DNA
terminal B-O I-DNA
repeat B-O I-DNA
DNA B-O O
binding B-O O
, B-O O
except B-O O
when B-O O
competitor B-O O
was B-O O
present B-O O
at B-O O
extremely B-O O
high B-O O
concentrations B-O O
. B-O O

Together B-O O
these B-O O
studies B-O O
indicate B-O O
that B-O O
hGR B-O B-protein
synthesized B-O O
in B-O O
rabbit B-O O
reticulocyte B-O O
lysates B-O O
displays B-O O
many B-O O
of B-O O
the B-O O
same B-O O
properties B-O O
, B-O O
including B-O O
GRE B-O B-DNA
-specific B-O O
DNA B-O O
binding B-O O
, B-O O
observed B-O O
for B-O O
glucocorticoid B-O B-protein
receptor B-O I-protein
present B-O O
in B-O O
cytosolic B-O O
extracts B-O O
of B-O O
mammalian B-O B-cell_type
cells B-O I-cell_type
and B-O O
tissues B-O O
. B-O O

Similarities B-O O
between B-O O
the B-O O
effects B-O O
of B-O O
dexamethasone B-O O
and B-O O
RU486 B-O O
suggest B-O O
that B-O O
the B-O O
antiglucocorticoid B-O O
properties B-O O
of B-O O
RU486 B-O O
do B-O O
not B-O O
occur B-O O
at B-O O
the B-O O
level B-O O
of B-O O
specific B-O O
DNA B-O O
binding B-O O
. B-O O

Expression B-O O
of B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
on B-O O
alveolar B-O B-cell_type
lymphocytes B-O I-cell_type
from B-O O
patients B-O O
with B-O O
pulmonary B-O O
granulomatous B-O O
diseases B-O O
. B-O O

1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
is B-O O
known B-O O
to B-O O
be B-O O
produced B-O O
at B-O O
sites B-O O
of B-O O
granulomatous B-O O
reactions B-O O
. B-O O

In B-O O
order B-O O
to B-O O
characterize B-O O
the B-O O
cell B-O O
types B-O O
that B-O O
are B-O O
targets B-O O
for B-O O
this B-O O
immunoregulatory B-O O
hormone B-O O
, B-O O
we B-O O
have B-O O
evaluated B-O O
the B-O O
expression B-O O
of B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
on B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
T-lymphocytes B-O I-cell_type
and B-O O
those B-O O
recovered B-O O
from B-O O
the B-O O
lung B-O O
by B-O O
bronchoalveolar B-O O
lavage B-O O
from B-O O
patients B-O O
with B-O O
pulmonary B-O O
granulomatous B-O O
diseases B-O O
( B-O O
tuberculosis B-O O
and B-O O
sarcoidosis B-O O
) B-O O
and B-O O
from B-O O
normal B-O O
control B-O O
subjects B-O O
using B-O O
combined B-O O
autoradiographic B-O O
and B-O O
immunohistochemical B-O O
techniques B-O O
. B-O O

Lavage B-O B-cell_type
T-lymphocytes B-O I-cell_type
from B-O O
patients B-O O
with B-O O
tuberculosis B-O O
or B-O O
with B-O O
sarcoidosis B-O O
, B-O O
but B-O O
not B-O O
those B-O O
from B-O O
normal B-O O
control B-O O
subjects B-O O
, B-O O
expressed B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
as B-O O
demonstrated B-O O
by B-O O
binding B-O O
of B-O O
[ B-O O
3H B-O O
] B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
, B-O O
which B-O O
was B-O O
inhibited B-O O
by B-O O
the B-O O
presence B-O O
of B-O O
excess B-O O
unlabeled B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
, B-O O
but B-O O
not B-O O
by B-O O
the B-O O
presence B-O O
of B-O O
unlabeled B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
D3 B-O O
( B-O O
receptor-positive B-O B-cell_type
lymphocytes B-O I-cell_type
: B-O O
sarcoidosis B-O O
, B-O O
20 B-O O
+/- B-O O
12 B-O O
% B-O O
; B-O O
tuberculosis B-O O
, B-O O
31 B-O O
+/- B-O O
17 B-O O
% B-O O
) B-O O
. B-O O

In B-O O
contrast B-O O
, B-O O
blood B-O B-cell_type
lymphocytes B-O I-cell_type
from B-O O
patients B-O O
with B-O O
granulomatous B-O O
diseases B-O O
did B-O O
not B-O O
express B-O O
detectable B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
. B-O O

The B-O O
percentage B-O O
of B-O O
lavage B-O B-cell_type
T-lymphocytes B-O I-cell_type
expressing B-O O
1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
was B-O O
significantly B-O O
greater B-O O
for B-O O
patients B-O O
with B-O O
tuberculosis B-O O
presenting B-O O
with B-O O
isolated B-O O
hilar B-O O
adenopathy B-O O
than B-O O
for B-O O
patients B-O O
with B-O O
pulmonary B-O O
infiltrates B-O O
and/or B-O O
cavities B-O O
. B-O O

1 B-O B-protein
, B-O I-protein
25 B-O I-protein
( B-O I-protein
OH B-O I-protein
) B-O I-protein
2D3 B-O I-protein
receptors B-O I-protein
were B-O O
expressed B-O O
to B-O O
a B-O O
greater B-O O
extent B-O O
on B-O O
CD8+ B-O B-cell_type
T-lymphocytes B-O I-cell_type
than B-O O
on B-O O
CD4+ B-O B-cell_type
T-lymphocytes B-O I-cell_type
in B-O O
sarcoidosis B-O O
, B-O O
whereas B-O O
a B-O O
greater B-O O
proportion B-O O
of B-O O
CD4+ B-O B-cell_type
than B-O O
of B-O O
CD8+ B-O B-cell_type
T-lymphocytes B-O I-cell_type
from B-O O
patients B-O O
with B-O O
tuberculosis B-O O
were B-O O
receptor-positive B-O O
. B-O O

These B-O O
findings B-O O
support B-O O
the B-O O
conclusion B-O O
that B-O O
the B-O O
interaction B-O O
of B-O O
1 B-O O
, B-O O
25 B-O O
( B-O O
OH B-O O
) B-O O
2D3 B-O O
with B-O O
its B-O O
receptor B-O O
on B-O O
T-lymphocytes B-O B-cell_type
may B-O O
play B-O O
an B-O O
important B-O O
role B-O O
in B-O O
the B-O O
regulation B-O O
of B-O O
granulomatous B-O O
reactions B-O O
, B-O O
but B-O O
because B-O O
these B-O O
receptors B-O O
are B-O O
expressed B-O O
on B-O O
different B-O O
lymphocyte B-O B-cell_type
populations B-O I-cell_type
, B-O O
the B-O O
net B-O O
effect B-O O
of B-O O
this B-O O
potent B-O O
immunoregulatory B-O B-protein
molecule B-O I-protein
is B-O O
likely B-O O
different B-O O
in B-O O
sarcoidosis B-O O
and B-O O
tuberculosis B-O O
. B-O O

Role B-O O
for B-O O
the B-O O
Epstein-Barr B-O B-protein
virus B-O I-protein
nuclear B-O I-protein
antigen B-O I-protein
2 B-O I-protein
in B-O O
viral B-O B-DNA
promoter B-O I-DNA
switching B-O O
during B-O O
initial B-O O
stages B-O O
of B-O O
infection B-O O
. B-O O

During B-O O
latent B-O O
Epstein-Barr B-O O
virus B-O O
( B-O O
EBV B-O O
) B-O O
infection B-O O
of B-O O
human B-O B-cell_type
B B-O I-cell_type
lymphocytes B-O I-cell_type
, B-O O
six B-O O
viral B-O B-protein
nuclear B-O I-protein
antigen B-O I-protein
( B-O O
EBNAs B-O B-protein
) B-O O
are B-O O
expressed B-O O
from B-O O
long B-O B-RNA
primary B-O I-RNA
transcripts B-O I-RNA
by B-O O
means B-O O
of B-O O
alternative B-O O
splicing B-O O
and B-O O
alternative B-O B-DNA
polyadenylylation B-O I-DNA
sites B-O I-DNA
. B-O O

These B-O O
transcripts B-O O
initiate B-O O
from B-O O
one B-O O
of B-O O
two B-O O
promoters B-O B-DNA
, B-O O
Cp B-O B-DNA
or B-O O
Wp B-O B-DNA
, B-O O
that B-O O
function B-O O
in B-O O
a B-O O
mutually B-O O
exclusive B-O O
fashion B-O O
. B-O O

Wp B-O B-DNA
is B-O O
exclusively B-O O
utilized B-O O
during B-O O
the B-O O
initial B-O O
stages B-O O
of B-O O
infection B-O O
of B-O O
primary B-O B-cell_type
B B-O I-cell_type
lymphocytes B-O I-cell_type
, B-O O
followed B-O O
by B-O O
a B-O O
switch B-O O
to B-O O
Cp B-O B-DNA
usage B-O O
. B-O O

These B-O O
studies B-O O
have B-O O
been B-O O
extended B-O O
to B-O O
show B-O O
that B-O O
( B-O O
i B-O O
) B-O O
a B-O O
mutant B-O O
EBV B-O O
strain B-O O
lacking B-O O
the B-O O
gene B-O O
encoding B-O O
EBNA B-O B-protein
2 B-O I-protein
fails B-O O
to B-O O
switch B-O O
from B-O O
Wp B-O B-DNA
to B-O O
Cp B-O B-DNA
usage B-O O
in B-O O
primary B-O B-cell_type
B B-O I-cell_type
lymphocytes B-O I-cell_type
, B-O O
although B-O O
the B-O O
virus B-O O
contains B-O O
a B-O O
functional B-O O
Cp B-O B-DNA
; B-O O
( B-O O
ii B-O O
) B-O O
a B-O O
region B-O O
from B-O O
-429 B-O B-DNA
to B-O I-DNA
-245 B-O I-DNA
base B-O I-DNA
pairs B-O I-DNA
upstream B-O O
of B-O O
Cp B-O B-DNA
is B-O O
essential B-O O
for B-O O
Cp B-O B-DNA
activity B-O O
in B-O O
B B-O B-cell_type
lymphocytes B-O I-cell_type
, B-O O
but B-O O
only B-O O
in B-O O
the B-O O
context B-O O
of B-O O
upstream B-O B-DNA
and B-O I-DNA
downstream B-O I-DNA
sequences B-O I-DNA
; B-O O
( B-O O
iii B-O O
) B-O O
this B-O O
region B-O O
contains B-O O
an B-O O
EBNA B-O B-DNA
2 B-O I-DNA
-dependent B-O I-DNA
enhancer B-O I-DNA
; B-O O
and B-O O
( B-O O
iv B-O O
) B-O O
DNase B-O B-protein
I B-O I-protein
protection B-O O
employing B-O O
nuclear B-O O
extracts B-O O
from B-O O
B B-O B-cell_type
and B-O I-cell_type
T B-O I-cell_type
lymphocytes B-O I-cell_type
revealed B-O O
a B-O O
B-cell-specific B-O B-DNA
footprint B-O I-DNA
in B-O O
the B-O O
region B-O O
of B-O O
the B-O O
EBNA B-O B-DNA
2 B-O I-DNA
-dependent B-O I-DNA
enhancer B-O I-DNA
. B-O O

These B-O O
results B-O O
support B-O O
a B-O O
model B-O O
for B-O O
viral B-O B-DNA
promoter B-O I-DNA
switching B-O O
during B-O O
the B-O O
initial B-O O
stages B-O O
of B-O O
infection B-O O
in B-O O
which B-O O
Wp B-O B-DNA
activity B-O O
leads B-O O
to B-O O
the B-O O
expression B-O O
of B-O O
EBNA B-O B-protein
2 B-O I-protein
, B-O O
followed B-O O
by B-O O
activation B-O O
of B-O O
Cp B-O B-DNA
through B-O O
the B-O O
EBNA B-O B-DNA
2 B-O I-DNA
-dependent B-O I-DNA
enhancer B-O I-DNA
. B-O O

Immune B-O O
response B-O O
of B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
to B-O O
HBx-antigen B-O B-protein
of B-O O
hepatitis B-O O
B B-O O
virus B-O O
. B-O O

The B-O O
hepatitis B-O B-DNA
B B-O I-DNA
virus B-O I-DNA
genome B-O I-DNA
encodes B-O O
a B-O O
transcriptional B-O B-protein
transactivator B-O I-protein
protein B-O I-protein
designated B-O O
HBxAg B-O B-protein
. B-O O

We B-O O
have B-O O
investigated B-O O
whether B-O O
this B-O O
antigen B-O O
is B-O O
a B-O O
target B-O O
structure B-O O
for B-O O
human B-O B-cell_type
T-lymphocytes B-O I-cell_type
. B-O O

Using B-O O
recombinant B-O B-protein
HBxAg B-O I-protein
protein B-O I-protein
, B-O O
we B-O O
found B-O O
HBxAg B-O B-protein
-specific B-O O
stimulation B-O O
of B-O O
peripheral B-O B-cell_type
blood B-O I-cell_type
mononuclear B-O I-cell_type
cells B-O I-cell_type
in B-O O
patients B-O O
with B-O O
acute B-O O
hepatitis B-O O
B B-O O
virus B-O O
infection B-O O
( B-O O
6 B-O O
of B-O O
6 B-O O
) B-O O
and B-O O
chronic B-O O
hepatitis B-O O
B B-O O
virus B-O O
infection B-O O
( B-O O
6 B-O O
of B-O O
17 B-O O
) B-O O
but B-O O
not B-O O
in B-O O
healthy B-O O
individuals B-O O
. B-O O

With B-O O
HBxAg B-O B-protein
-specific B-O O
synthetic B-O O
polypeptides B-O O
, B-O O
several B-O O
T-cell B-O B-protein
epitopes B-O I-protein
were B-O O
identified B-O O
. B-O O

Most B-O O
were B-O O
located B-O O
in B-O O
the B-O O
carboxyterminal B-O B-protein
half B-O I-protein
of B-O O
the B-O O
HBxAg B-O B-protein
protein B-O I-protein
. B-O O

Five B-O O
T-cell B-O B-cell_line
clones B-O I-cell_line
specific B-O O
for B-O O
a B-O O
T-cell B-O B-protein
epitope B-O I-protein
located B-O O
at B-O O
the B-O O
carboxyterminal B-O B-protein
region B-O I-protein
of B-O O
HBxAg B-O B-protein
were B-O O
established B-O O
and B-O O
found B-O O
to B-O O
belong B-O O
to B-O O
the B-O O
CD2/CD4-positive B-O B-cell_line
, B-O I-cell_line
CD8-negative B-O I-cell_line
subtype B-O I-cell_line
. B-O O

These B-O O
data B-O O
establish B-O O
for B-O O
the B-O O
first B-O O
time B-O O
HBxAg B-O B-protein
as B-O O
an B-O O
antigen B-O O
in B-O O
the B-O O
cellular B-O O
immune B-O O
response B-O O
. B-O O

[ B-O O
Changes B-O O
in B-O O
leucocytic B-O B-protein
estrogen B-O I-protein
receptor B-O I-protein
levels B-O O
in B-O O
patients B-O O
with B-O O
gynecomastia B-O O
] B-O O

The B-O O
number B-O O
of B-O O
estrogen B-O B-protein
receptor B-O I-protein
( B-O O
ER B-O B-protein
) B-O O
in B-O O
human B-O B-cell_type
peripheral B-O I-cell_type
leucocytes B-O I-cell_type
in B-O O
13 B-O O
men B-O O
with B-O O
gynecomastia B-O O
were B-O O
measured B-O O
by B-O O
radioligand B-O O
binding B-O O
method B-O O
. B-O O
The B-O O
results B-O O
were B-O O
compared B-O O
with B-O O
those B-O O
of B-O O
13 B-O O
sex- B-O O
and B-O O
age-matched B-O O
healthy B-O O
subjects B-O O
. B-O O

It B-O O
was B-O O
found B-O O
that B-O O
the B-O O
number B-O O
of B-O O
ER B-O B-protein
in B-O O
leucocytes B-O B-cell_type
was B-O O
significantly B-O O
increased B-O O
in B-O O
gynecomastia B-O O
( B-O O
Rs B-O O
of B-O O
leucocytes B-O B-cell_type
were B-O O
1054 B-O O
+/- B-O O
254 B-O O
sites/cell B-O O
) B-O O
. B-O O

It B-O O
suggested B-O O
that B-O O
increase B-O O
of B-O O
ER B-O B-protein
levels B-O O
play B-O O
an B-O O
important B-O O
role B-O O
in B-O O
the B-O O
pathogenesis B-O O
of B-O O
gynecomastia B-O O
. B-O O

The B-O O
NF B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
independent B-O I-DNA
cis-acting B-O I-DNA
sequences B-O I-DNA
in B-O O
HIV-1 B-O B-DNA
LTR B-O I-DNA
responsive B-O O
to B-O O
T-cell B-O O
activation B-O O
. B-O O

The B-O O
rate B-O O
of B-O O
transcription B-O O
initiation B-O O
directed B-O O
by B-O O
the B-O O
long B-O B-DNA
terminal B-O I-DNA
repeat B-O I-DNA
( B-O O
LTR B-O B-DNA
) B-O O
of B-O O
HIV-1 B-O O
increases B-O O
in B-O O
response B-O O
to B-O O
mitogenic B-O O
stimuli B-O O
of B-O O
T B-O B-cell_type
cells B-O I-cell_type
. B-O O

Here B-O O
we B-O O
show B-O O
that B-O O
the B-O O
response B-O O
of B-O O
the B-O O
HIV-1 B-O B-DNA
LTR B-O I-DNA
may B-O O
be B-O O
governed B-O O
by B-O O
two B-O O
independent B-O O
sequences B-O O
located B-O O
5 B-O O
' B-O O
to B-O O
the B-O O
site B-O O
of B-O O
transcription B-O B-DNA
initiation B-O I-DNA
sequences B-O I-DNA
that B-O O
bind B-O O
either B-O O
NFAT-1 B-O B-protein
or B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
. B-O O

The B-O O
rate B-O O
of B-O O
LTR B-O B-DNA
-directed B-O O
gene B-O O
expression B-O O
increased B-O O
in B-O O
response B-O O
to B-O O
treatment B-O O
with B-O O
either B-O O
a B-O O
phorbol B-O O
ester B-O O
or B-O O
tumor B-O B-protein
necrosis B-O I-protein
factor B-O I-protein
alpha B-O I-protein
if B-O O
either B-O O
the B-O O
NFAT-1 B-O B-protein
or B-O O
NF B-O B-DNA
kappa B-O I-DNA
B B-O I-DNA
binding B-O I-DNA
sites B-O I-DNA
were B-O O
deleted B-O O
, B-O O
but B-O O
failed B-O O
to B-O O
respond B-O O
to B-O O
these B-O O
mitogenic B-O O
stimuli B-O O
if B-O O
both B-O O
sequences B-O O
were B-O O
absent B-O O
. B-O O

The B-O O
HIV-1 B-O O
mutant B-O O
virus B-O O
containing B-O O
both B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
and B-O O
NFAT-1 B-O B-protein
deletion B-O O
was B-O O
able B-O O
to B-O O
replicate B-O O
although B-O O
at B-O O
a B-O O
much B-O O
decreased B-O O
growth B-O O
rate B-O O
, B-O O
while B-O O
the B-O O
deletion B-O O
of B-O O
NFAT-1 B-O B-protein
alone B-O O
increased B-O O
the B-O O
viral B-O O
growth B-O O
rate B-O O
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
. B-O O

Neither B-O O
deletion B-O O
of B-O O
NF B-O B-protein
kappa B-O I-protein
B B-O I-protein
nor B-O O
deletion B-O O
of B-O O
NFAT-1 B-O B-protein
decreased B-O O
activation B-O O
of B-O O
viral B-O O
replication B-O O
by B-O O
phorbol B-O O
ester B-O O
. B-O O

cAMP B-O O
-dependent B-O O
regulation B-O O
of B-O O
proenkephalin B-O O
by B-O O
JunD B-O B-protein
and B-O O
JunB B-O B-protein
: B-O O
positive B-O O
and B-O O
negative B-O O
effects B-O O
of B-O O
AP-1 B-O B-protein
proteins B-O I-protein
. B-O O

We B-O O
demonstrate B-O O
that B-O O
JunD B-O B-protein
, B-O O
a B-O O
component B-O O
of B-O O
the B-O O
AP-1 B-O B-protein
transcription B-O I-protein
factor B-O I-protein
complex B-O I-protein
, B-O O
activates B-O O
transcription B-O O
of B-O O
the B-O O
human B-O B-DNA
proenkephalin B-O I-DNA
gene B-O I-DNA
in B-O O
a B-O O
fashion B-O O
that B-O O
is B-O O
completely B-O O
dependent B-O O
upon B-O O
the B-O O
cAMP-dependent B-O B-protein
protein B-O I-protein
kinase B-O I-protein
, B-O O
protein B-O B-protein
kinase B-O I-protein
A B-O I-protein
. B-O O

Activation B-O O
of B-O O
proenkephalin B-O O
transcription B-O O
by B-O O
JunD B-O B-protein
is B-O O
dependent B-O O
upon B-O O
a B-O O
previously B-O O
characterized B-O O
cAMP B-O O
- B-O O
, B-O O
phorbol B-O O
ester B-O O
- B-O O
, B-O O
and B-O O
Ca B-O B-DNA
( B-O I-DNA
2+ B-O I-DNA
) B-O I-DNA
-inducible B-O I-DNA
enhancer B-O I-DNA
, B-O O
and B-O O
JunD B-O B-protein
is B-O O
shown B-O O
to B-O O
bind B-O O
the B-O O
enhancer B-O B-DNA
as B-O O
a B-O O
homodimer B-O B-protein
. B-O O

Another B-O O
component B-O O
of B-O O
the B-O O
AP-1 B-O B-protein
transcription B-O I-protein
complex B-O I-protein
, B-O O
JunB B-O B-protein
, B-O O
is B-O O
shown B-O O
to B-O O
inhibit B-O O
activation B-O O
mediated B-O O
by B-O O
JunD B-O B-protein
. B-O O

As B-O O
a B-O O
homodimer B-O O
JunB B-O B-protein
is B-O O
unable B-O O
to B-O O
bind B-O O
the B-O O
enhancer B-O B-DNA
; B-O O
however B-O O
in B-O O
the B-O O
presence B-O O
of B-O O
c-Fos B-O B-protein
, B-O O
high-affinity B-O O
binding B-O O
is B-O O
observed B-O O
. B-O O

Furthermore B-O O
, B-O O
JunD B-O B-protein
is B-O O
shown B-O O
to B-O O
activate B-O O
transcription B-O O
of B-O O
genes B-O B-DNA
linked B-O O
to B-O O
both B-O O
cAMP B-O O
and B-O O
phorbol B-O O
ester B-O O
response B-O O
elements B-O O
in B-O O
a B-O O
protein B-O B-protein
kinase B-O I-protein
A B-O I-protein
-dependent B-O O
fashion B-O O
, B-O O
further B-O O
blurring B-O O
the B-O O
distinction B-O O
between B-O O
these B-O O
response B-O O
elements B-O O
. B-O O

These B-O O
results B-O O
demonstrate B-O O
that B-O O
the B-O O
transcriptional B-O O
activity B-O O
of B-O O
an B-O O
AP-1-related B-O B-protein
protein B-O I-protein
is B-O O
regulated B-O O
by B-O O
the B-O O
cAMP B-O O
-dependent B-O O
second-messenger B-O O
pathway B-O O
and B-O O
suggest B-O O
that B-O O
JunD B-O B-protein
and B-O O
other B-O O
AP-1-related B-O B-protein
proteins B-O I-protein
may B-O O
play B-O O
an B-O O
important B-O O
role B-O O
in B-O O
the B-O O
regulation B-O O
of B-O O
gene B-O O
expression B-O O
by B-O O
cAMP B-O O
-dependent B-O O
intracellular B-O O
signaling B-O O
pathways B-O O
. B-O O

[ B-O O
Plasma B-O O
cortisol B-O O
concentration B-O O
and B-O O
blood B-O O
leukocyte B-O O
content B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
patients B-O O
with B-O O
deficiency-cold B-O O
vs B-O O
deficiency-heat B-O O
syndromes B-O O
] B-O O

Plasma B-O O
cortisol B-O O
concentration B-O O
and B-O O
blood B-O O
leukocyte B-O O
content B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
( B-O O
GCR B-O B-protein
) B-O O
were B-O O
assayed B-O O
in B-O O
20 B-O O
patients B-O O
with B-O O
deficiency B-O O
syndromes B-O O
, B-O O
10 B-O O
cold B-O O
in B-O O
property B-O O
( B-O O
deficiency-cold B-O O
) B-O O
, B-O O
the B-O O
other B-O O
10 B-O O
hot B-O O
in B-O O
property B-O O
( B-O O
deficiency-heat B-O O
) B-O O
, B-O O
and B-O O
also B-O O
in B-O O
10 B-O O
healthy B-O O
individuals B-O O
as B-O O
normal B-O O
control B-O O
for B-O O
the B-O O
purpose B-O O
of B-O O
investigating B-O O
the B-O O
nature B-O O
of B-O O
cold B-O O
and B-O O
heat B-O O
syndromes B-O O
. B-O O

As B-O O
a B-O O
result B-O O
, B-O O
the B-O O
cases B-O O
of B-O O
deficiency-cold B-O O
syndrome B-O O
( B-O O
DCS B-O B-cell_type
) B-O O
had B-O O
a B-O O
normal B-O O
concentration B-O O
of B-O O
plasma B-O O
cortisol B-O O
but B-O O
a B-O O
lowered B-O O
content B-O O
of B-O O
GCR B-O B-protein
in B-O O
leukocytes B-O B-cell_type
when B-O O
compared B-O O
with B-O O
the B-O O
normal B-O O
control B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.05 B-O O
) B-O O
; B-O O
the B-O O
cases B-O O
of B-O O
deficiency-heat B-O O
syndrome B-O O
( B-O O
DHS B-O O
) B-O O
had B-O O
a B-O O
higher B-O O
concentration B-O O
of B-O O
plasma B-O O
cortisol B-O O
than B-O O
the B-O O
normal B-O O
control B-O O
( B-O O
P B-O O
less B-O O
than B-O O
0.05 B-O O
) B-O O
and B-O O
a B-O O
slightly B-O O
higher B-O O
content B-O O
of B-O O
GCR B-O B-protein
in B-O O
leukocytes B-O B-cell_type
. B-O O

It B-O O
was B-O O
concluded B-O O
that B-O O
the B-O O
DCS B-O B-cell_type
is B-O O
characterized B-O O
by B-O O
diminished B-O O
biological B-O O
effects B-O O
of B-O O
adrenocortical B-O O
activity B-O O
, B-O O
while B-O O
the B-O O
DHS B-O B-DNA
, B-O O
by B-O O
augmented B-O O
biological B-O O
effects B-O O
of B-O O
adrenocortical B-O O
activity B-O O
. B-O O

The B-O O
role B-O O
of B-O O
jun B-O B-DNA
and B-O I-DNA
fos B-O I-DNA
gene B-O I-DNA
family B-O I-DNA
members B-O I-DNA
in B-O O
12-O-tetradecanoylphorbol-13-acetate B-O O
induced B-O O
hemopoietic B-O O
differentiation B-O O
. B-O O

Terminal B-O O
differentiation B-O O
of B-O O
the B-O O
leukemic B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
U-937 B-O B-cell_line
and B-O O
HL-60 B-O B-cell_line
by B-O O
12-O-tetradecanoylphorbol-13-acetate B-O O
is B-O O
accompanied B-O O
by B-O O
marked B-O O
changes B-O O
in B-O O
gene B-O O
expression B-O O
. B-O O

In B-O O
this B-O O
study B-O O
, B-O O
we B-O O
demonstrate B-O O
that B-O O
the B-O O
expression B-O O
of B-O O
jun B-O B-DNA
and B-O I-DNA
fos B-O I-DNA
gene B-O I-DNA
family B-O I-DNA
members B-O I-DNA
is B-O O
induced B-O O
with B-O O
variable B-O O
kinetics B-O O
during B-O O
12-O-tetradecanoylphorbol-13-acetate B-O O
induced B-O O
differentiation B-O O
, B-O O
with B-O O
c-jun B-O B-DNA
expression B-O O
best B-O O
paralleling B-O O
differentiation B-O O
. B-O O

The B-O O
generation B-O O
of B-O O
AP-1 B-O B-protein
complexes B-O I-protein
, B-O O
as B-O O
measured B-O O
by B-O O
DNA B-O O
binding B-O O
activity B-O O
, B-O O
closely B-O O
parallels B-O O
morphological B-O O
differentiation B-O O
. B-O O

Furthermore B-O O
, B-O O
the B-O O
ability B-O O
of B-O O
these B-O O
complexes B-O O
to B-O O
regulate B-O O
gene B-O O
expression B-O O
is B-O O
demonstrated B-O O
by B-O O
increased B-O O
transcription B-O O
from B-O O
an B-O O
AP-1 B-O B-DNA
driven B-O I-DNA
reporter B-O I-DNA
construct B-O I-DNA
and B-O O
marked B-O O
increases B-O O
in B-O O
the B-O O
expression B-O O
of B-O O
endogenous B-O B-DNA
AP-1 B-O I-DNA
regulated B-O I-DNA
genes B-O I-DNA
. B-O O

Differentiation B-O O
assays B-O O
using B-O O
water B-O O
soluble B-O O
phorbol B-O O
esters B-O O
reveal B-O O
that B-O O
differentiation B-O O
becomes B-O O
irreversible B-O O
soon B-O O
after B-O O
AP-1 B-O B-protein
appears B-O O
. B-O O

This B-O O
tight B-O O
correlation B-O O
between B-O O
c-jun B-O B-DNA
expression B-O O
, B-O O
the B-O O
generation B-O O
of B-O O
AP-1 B-O B-protein
activity B-O O
, B-O O
and B-O O
differentiation B-O O
suggests B-O O
a B-O O
critical B-O O
role B-O O
for B-O O
this B-O O
gene B-O O
and B-O O
transcriptional B-O B-protein
complex B-O I-protein
during B-O O
this B-O O
process B-O O
. B-O O

Nuclear B-O O
association B-O O
of B-O O
a B-O O
T-cell B-O B-protein
transcription B-O I-protein
factor B-O I-protein
blocked B-O O
by B-O O
FK-506 B-O O
and B-O O
cyclosporin B-O O
A B-O O
[ B-O O
see B-O O
comments B-O O
] B-O O

Cyclosporin B-O O
A B-O O
and B-O O
FK506 B-O O
inhibit B-O O
T- B-O O
and B-O O
B-cell B-O O
activation B-O O
and B-O O
other B-O O
processes B-O O
essential B-O O
to B-O O
an B-O O
effective B-O O
immune B-O O
response B-O O
. B-O O

In B-O O
T B-O B-cell_type
lymphocytes B-O I-cell_type
these B-O O
drugs B-O O
disrupt B-O O
an B-O O
unknown B-O O
step B-O O
in B-O O
the B-O O
transmission B-O O
of B-O O
signals B-O O
from B-O O
the B-O O
T-cell B-O B-protein
antigen B-O I-protein
receptor B-O I-protein
to B-O O
cytokine B-O B-DNA
genes B-O I-DNA
that B-O O
coordinate B-O O
the B-O O
immune B-O O
response B-O O
. B-O O

The B-O O
putative B-O B-protein
intracellular B-O I-protein
receptors B-O I-protein
for B-O O
FK506 B-O O
and B-O O
cyclosporin B-O O
are B-O O
cis-trans B-O B-protein
prolyl B-O I-protein
isomerases B-O I-protein
. B-O O

Binding B-O O
of B-O O
the B-O O
drug B-O O
inhibits B-O O
isomerase B-O B-protein
activity B-O O
, B-O O
but B-O O
studies B-O O
with B-O O
other B-O O
prolyl B-O O
isomerase B-O B-protein
inhibitors B-O O
and B-O O
analysis B-O O
of B-O O
cyclosporin B-O B-protein
-resistant B-O I-protein
mutants B-O I-protein
in B-O O
yeast B-O O
suggest B-O O
that B-O O
the B-O O
effects B-O O
of B-O O
the B-O O
drug B-O O
result B-O O
from B-O O
the B-O O
formation B-O O
of B-O O
an B-O O
inhibitory B-O B-protein
complex B-O I-protein
between B-O O
the B-O O
drug B-O O
and B-O O
isomerase B-O B-protein
, B-O O
and B-O O
not B-O O
from B-O O
inhibition B-O O
of B-O O
isomerase B-O B-protein
activity B-O O
. B-O O

A B-O O
transcription B-O B-protein
factor B-O I-protein
, B-O O
NF-AT B-O B-protein
, B-O O
which B-O O
is B-O O
essential B-O O
for B-O O
early B-O B-DNA
T-cell B-O I-DNA
gene B-O I-DNA
activation B-O O
, B-O O
seems B-O O
to B-O O
be B-O O
a B-O O
specific B-O O
target B-O O
of B-O O
cyclosporin B-O O
A B-O O
and B-O O
FK506 B-O O
action B-O O
because B-O O
transcription B-O O
directed B-O O
by B-O O
this B-O O
protein B-O O
is B-O O
blocked B-O O
in B-O O
T B-O B-cell_type
cells B-O I-cell_type
treated B-O O
with B-O O
these B-O O
drugs B-O O
, B-O O
with B-O O
little B-O O
or B-O O
no B-O O
effect B-O O
on B-O O
other B-O O
transcription B-O B-protein
factors B-O I-protein
such B-O O
as B-O O
AP-1 B-O B-protein
and B-O O
NF-kappa B-O B-protein
B B-O I-protein
. B-O O

Here B-O O
we B-O O
demonstrate B-O O
that B-O O
NF-AT B-O B-protein
is B-O O
formed B-O O
when B-O O
a B-O O
signal B-O O
from B-O O
the B-O O
antigen B-O B-protein
receptor B-O I-protein
induces B-O O
a B-O O
pre-existing B-O O
cytoplasmic B-O O
subunit B-O O
to B-O O
translocate B-O O
to B-O O
the B-O O
nucleus B-O O
and B-O O
combine B-O O
with B-O O
a B-O O
newly B-O O
synthesized B-O O
nuclear B-O O
subunit B-O O
of B-O O
NF-AT B-O B-protein
. B-O O

FK506 B-O O
and B-O O
cyclosporin B-O O
A B-O O
block B-O O
translocation B-O O
of B-O O
the B-O O
cytoplasmic B-O B-protein
component B-O I-protein
without B-O O
affecting B-O O
synthesis B-O O
of B-O O
the B-O O
nuclear B-O B-protein
subunit B-O I-protein
. B-O O

Glucocorticoid B-O B-protein
receptors B-O I-protein
in B-O O
lymphocytes B-O B-cell_type
in B-O O
anorexia B-O O
nervosa B-O O
. B-O O

OBJECTIVE B-O O
: B-O O
The B-O O
aim B-O O
was B-O O
to B-O O
explore B-O O
the B-O O
down-regulation B-O O
of B-O O
the B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
during B-O O
hypercortisolaemia B-O O
in B-O O
anorexia B-O O
nervosa B-O O
. B-O O

DESIGN B-O O
: B-O O
Urine B-O O
and B-O O
plasma B-O O
samples B-O O
were B-O O
obtained B-O O
for B-O O
cortisol B-O O
determination B-O O
and B-O O
blood B-O B-cell_type
lymphocytes B-O I-cell_type
were B-O O
isolated B-O O
for B-O O
receptor B-O O
binding B-O O
studies B-O O
. B-O O

PATIENTS B-O O
: B-O O
Sixteen B-O O
anorexic B-O O
patients B-O O
, B-O O
aged B-O O
16-27 B-O O
years B-O O
, B-O O
with B-O O
a B-O O
mean B-O O
+/- B-O O
SEM B-O O
body B-O O
mass B-O O
index B-O O
of B-O O
14.2 B-O O
+/- B-O O
2.0 B-O O
( B-O O
ranging B-O O
from B-O O
11.1 B-O O
to B-O O
17.4 B-O O
) B-O O
, B-O O
and B-O O
15 B-O O
normal B-O O
women B-O O
were B-O O
studied B-O O
. B-O O

Six B-O O
patients B-O O
were B-O O
reinvestigated B-O O
after B-O O
a B-O O
significant B-O O
weight B-O O
gain B-O O
. B-O O

MEASUREMENTS B-O O
: B-O O
The B-O O
binding B-O O
capacity B-O O
and B-O O
affinity B-O O
of B-O O
the B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
were B-O O
measured B-O O
with B-O O
dexamethasone B-O O
as B-O O
ligand B-O O
on B-O O
lymphocytes B-O B-cell_type
. B-O O

RESULTS B-O O
: B-O O
In B-O O
patients B-O O
, B-O O
both B-O O
total B-O O
and B-O O
free B-O O
plasma B-O O
cortisol B-O O
concentrations B-O O
were B-O O
higher B-O O
than B-O O
in B-O O
the B-O O
normal B-O O
women B-O O
, B-O O
as B-O O
was B-O O
their B-O O
urinary B-O O
free B-O O
cortisol B-O O
; B-O O
the B-O O
number B-O O
of B-O O
glucocorticoid B-O B-protein
receptors B-O I-protein
per B-O O
cell B-O O
( B-O O
Ro B-O O
) B-O O
and B-O O
the B-O O
binding B-O O
affinity B-O O
( B-O O
Kd B-O O
) B-O O
for B-O O
dexamethasone B-O O
were B-O O
, B-O O
however B-O O
, B-O O
not B-O O
significantly B-O O
different B-O O
( B-O O
Ro B-O O
: B-O O
7687 B-O O
+/- B-O O
1750 B-O O
vs B-O O
7347 B-O O
+/- B-O O
1285 B-O O
sites/cell B-O O
; B-O O
Kd B-O O
: B-O O
7.7 B-O O
+/- B-O O
2.4 B-O O
vs B-O O
7.4 B-O O
+/- B-O O
1.7 B-O O
nM B-O O
at B-O O
24 B-O O
degrees B-O O
C B-O O
) B-O O
. B-O O

After B-O O
weight B-O O
gain B-O O
( B-O O
14 B-O O
+/- B-O O
2 B-O O
to B-O O
16 B-O O
+/- B-O O
2 B-O O
kg/m2 B-O O
) B-O O
, B-O O
receptor B-O O
numbers B-O O
were B-O O
8421 B-O O
+/- B-O O
2126 B-O O
( B-O O
pre B-O O
) B-O O
and B-O O
9011 B-O O
+/- B-O O
500 B-O O
( B-O O
post B-O O
) B-O O
sites/cell B-O O
, B-O O
which B-O O
are B-O O
not B-O O
significantly B-O O
different B-O O
( B-O O
P B-O O
greater B-O O
than B-O O
0.2 B-O O
) B-O O
; B-O O
the B-O O
Kd B-O O
was B-O O
unchanged B-O O
( B-O O
9.3 B-O O
+/- B-O O
2.6 B-O O
vs B-O O
9.2 B-O O
+/- B-O O
2.4 B-O O
nM B-O O
) B-O O
. B-O O

CONCLUSIONS B-O O
Hypercortisolaemia B-O O
does B-O O
not B-O O
down-regulate B-O O
the B-O O
lymphocyte B-O B-protein
glucocorticoid B-O I-protein
receptors B-O I-protein
in B-O O
anorexia B-O O
nervosa B-O O
and B-O O
a B-O O
post-receptor B-O O
defect B-O O
might B-O O
be B-O O
involved B-O O
in B-O O
peripheral B-O O
tissue B-O O
resistance B-O O
to B-O O
the B-O O
effects B-O O
of B-O O
glucocorticoid B-O O
hormones B-O O
in B-O O
undernutrition B-O O
. B-O O

Inhibition B-O O
of B-O O
protein B-O B-protein
phosphatases B-O I-protein
by B-O O
okadaic B-O O
acid B-O O
induces B-O O
AP1 B-O B-protein
in B-O O
human B-O B-cell_type
T B-O I-cell_type
cells B-O I-cell_type
. B-O O

To B-O O
examine B-O O
the B-O O
role B-O O
of B-O O
protein B-O B-protein
phosphatases B-O I-protein
in B-O O
T B-O O
cell B-O O
activation B-O O
, B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
were B-O O
treated B-O O
with B-O O
okadaic B-O O
acid B-O O
, B-O O
an B-O O
inhibitor B-O O
of B-O O
type B-O B-protein
1 B-O I-protein
and B-O I-protein
2A B-O I-protein
phosphatases B-O I-protein
, B-O O
and B-O O
nuclear B-O O
extracts B-O O
were B-O O
examined B-O O
for B-O O
the B-O O
presence B-O O
of B-O O
AP1 B-O B-protein
as B-O O
a B-O O
measure B-O O
of B-O O
early B-O O
T B-O O
cell B-O O
activation B-O O
. B-O O

Okadaic B-O O
acid B-O O
was B-O O
found B-O O
to B-O O
be B-O O
a B-O O
potent B-O O
inducer B-O O
of B-O O
AP1 B-O B-protein
. B-O O

In B-O O
contrast B-O O
to B-O O
phorbol B-O O
esters B-O O
such B-O O
as B-O O
phorbol B-O O
myristate B-O O
acetate B-O O
( B-O O
PMA B-O O
) B-O O
, B-O O
the B-O O
induction B-O O
of B-O O
AP1 B-O B-protein
by B-O O
okadaic B-O O
acid B-O O
occurs B-O O
predominantly B-O O
by B-O O
transcriptional B-O O
activation B-O O
of B-O O
the B-O O
jun B-O B-DNA
and B-O I-DNA
fos B-O I-DNA
family B-O I-DNA
of B-O O
proto-oncogenes B-O B-DNA
. B-O O

Surprisingly B-O O
, B-O O
while B-O O
the B-O O
addition B-O O
of B-O O
phytohemagglutinin B-O B-protein
further B-O O
enhanced B-O O
the B-O O
induction B-O O
of B-O O
AP1 B-O B-protein
, B-O O
the B-O O
addition B-O O
of B-O O
PMA B-O O
inhibited B-O O
it B-O O
. B-O O

Okadaic B-O O
acid B-O O
treatment B-O O
was B-O O
found B-O O
to B-O O
dramatically B-O O
increase B-O O
mRNA B-O B-RNA
transcripts B-O I-RNA
of B-O O
the B-O O
jun B-O B-protein
family B-O I-protein
of B-O O
proto-oncogenes B-O B-DNA
including B-O O
c-jun B-O B-DNA
, B-O O
junD B-O B-DNA
, B-O O
and B-O O
junB B-O B-DNA
and B-O O
to B-O O
a B-O O
lesser B-O O
extent B-O O
the B-O O
fos B-O B-DNA
family B-O I-DNA
including B-O O
c-fos B-O B-DNA
and B-O O
fra-1 B-O B-DNA
. B-O O

By B-O O
comparison B-O O
, B-O O
PMA B-O O
is B-O O
a B-O O
very B-O O
inefficient B-O O
inducer B-O O
of B-O O
the B-O O
jun B-O B-DNA
gene B-O I-DNA
family B-O I-DNA
in B-O O
Jurkat B-O B-cell_line
cells B-O I-cell_line
. B-O O

Similar B-O O
to B-O O
its B-O O
effect B-O O
on B-O O
the B-O O
induction B-O O
of B-O O
AP1 B-O B-protein
by B-O O
okadaic B-O O
acid B-O O
, B-O O
PMA B-O O
inhibits B-O O
the B-O O
induction B-O O
of B-O O
c-jun B-O B-RNA
mRNA B-O I-RNA
by B-O O
okadaic B-O O
acid B-O O
. B-O O

Transfection B-O O
of B-O O
c-jun B-O B-DNA
promoter B-O I-DNA
constructs B-O I-DNA
confirmed B-O O
the B-O O
marked B-O O
difference B-O O
between B-O O
PMA B-O O
and B-O O
okadaic B-O O
acid B-O O
in B-O O
inducing B-O O
c-jun B-O B-DNA
transcription B-O O
. B-O O

The B-O O
induction B-O O
of B-O O
AP1 B-O B-protein
by B-O O
okadaic B-O O
acid B-O O
suggests B-O O
that B-O O
protein B-O B-protein
phosphatases B-O I-protein
1 B-O I-protein
and B-O I-protein
2A B-O I-protein
( B-O O
PP1 B-O B-protein
and B-O O
PP2A B-O B-protein
) B-O O
may B-O O
be B-O O
involved B-O O
in B-O O
T B-O O
cell B-O O
activation B-O O
as B-O O
important B-O O
negative B-O O
regulators B-O O
of B-O O
the B-O O
transcription B-O B-protein
factor B-O I-protein
AP1 B-O B-protein
. B-O O

Cloning B-O O
of B-O O
murine B-O B-protein
TCF-1 B-O I-protein
, B-O O
a B-O O
T B-O B-protein
cell-specific B-O I-protein
transcription B-O I-protein
factor B-O I-protein
interacting B-O O
with B-O O
functional B-O B-DNA
motifs B-O I-DNA
in B-O O
the B-O O
CD3-epsilon B-O B-DNA
and B-O I-DNA
T B-O I-DNA
cell B-O I-DNA
receptor B-O I-DNA
alpha B-O I-DNA
enhancers B-O I-DNA
. B-O O

CD3 B-O B-protein
-epsilon B-O O
gene B-O O
expression B-O O
is B-O O
confined B-O O
to B-O O
the B-O O
T B-O B-cell_type
cell B-O I-cell_type
lineage B-O I-cell_type
. B-O O

We B-O O
have B-O O
recently B-O O
identified B-O O
and B-O O
cloned B-O O
a B-O O
human B-O B-protein
transcription B-O I-protein
factor B-O I-protein
, B-O O
TCF-1 B-O B-protein
, B-O O
that B-O O
binds B-O O
to B-O O
a B-O O
functional B-O O
element B-O O
in B-O O
the B-O O
T B-O B-DNA
lymphocyte-specific B-O I-DNA
enhancer B-O I-DNA
of B-O O
CD3-epsilon B-O B-protein
. B-O O

In B-O O
a B-O O
panel B-O O
of B-O O
human B-O B-cell_line
cell B-O I-cell_line
lines B-O I-cell_line
, B-O O
TCF-1 B-O B-protein
expression B-O O
was B-O O
restricted B-O O
to B-O O
T B-O B-cell_type
lineage B-O I-cell_type
cells B-O I-cell_type
. B-O O

TCF-1 B-O B-protein
belonged B-O O
to B-O O
a B-O O
novel B-O O
family B-O O
of B-O O
genes B-O O
that B-O O
contain B-O O
the B-O O
so-called B-O O
high B-O O
mobility B-O O
group B-O O
1 B-O O
( B-O O
HMG B-O B-protein
) B-O O
box B-O O
. B-O O

Here B-O O
we B-O O
report B-O O
the B-O O
cloning B-O O
of B-O O
murine B-O B-protein
TCF-1 B-O I-protein
. B-O O

Two B-O O
splice B-O O
alternatives B-O O
were B-O O
identified B-O O
that B-O O
were B-O O
not B-O O
previously B-O O
observed B-O O
in B-O O
human B-O B-protein
TCF-1 B-O I-protein
. B-O O

Murine B-O B-protein
and B-O I-protein
human B-O I-protein
TCF-1 B-O I-protein
displayed B-O O
a B-O O
95.5 B-O O
% B-O O
overall B-O O
amino B-O O
acid B-O O
homology B-O O
. B-O O

Recombinant B-O B-protein
murine B-O I-protein
and B-O I-protein
human B-O I-protein
TCF-1 B-O I-protein
recognized B-O O
the B-O O
same B-O O
sequence B-O O
motif B-O O
in B-O O
the B-O O
CD3-epsilon B-O B-DNA
enhancer B-O I-DNA
as B-O O
judged B-O O
by B-O O
gel B-O O
retardation B-O O
and B-O O
methylation B-O O
interference B-O O
assays B-O O
. B-O O

With B-O O
the B-O O
murine B-O B-DNA
cDNA B-O I-DNA
clones B-O I-DNA
several B-O O
aspects B-O O
of B-O O
TCF-1 B-O B-protein
were B-O O
analyzed B-O O
. B-O O

First B-O O
, B-O O
deletion B-O O
analysis B-O O
revealed B-O O
that B-O O
a B-O O
region B-O O
of B-O O
TCF-1 B-O B-protein
containing B-O O
the B-O O
HMG B-O B-DNA
box B-O I-DNA
was B-O O
sufficient B-O O
for B-O O
sequence-specific B-O O
binding B-O O
. B-O O

Second B-O O
, B-O O
by B-O O
high B-O O
stringency B-O O
Northern B-O O
blotting B-O O
and B-O O
in B-O O
situ B-O O
hybridization B-O O
, B-O O
TCF-1 B-O B-protein
expression B-O O
was B-O O
shown B-O O
to B-O O
be B-O O
confined B-O O
to B-O O
the B-O O
thymus B-O O
and B-O O
to B-O O
the B-O O
T B-O O
cell B-O O
areas B-O O
of B-O O
the B-O O
spleen B-O O
. B-O O

Third B-O O
, B-O O
TCF-1 B-O B-protein
bound B-O O
specifically B-O O
to B-O O
a B-O O
functional B-O O
T B-O B-DNA
cell-specific B-O I-DNA
element B-O I-DNA
in B-O O
the B-O O
T B-O B-DNA
cell B-O I-DNA
receptor B-O I-DNA
alpha B-O I-DNA
( B-O I-DNA
TCR-alpha B-O I-DNA
) B-O I-DNA
enhancer B-O I-DNA
. B-O O

The B-O O
T B-O O
lineage-specific B-O O
expression B-O O
and B-O O
the B-O O
affinity B-O O
for B-O O
functional B-O O
motifs B-O O
in B-O O
the B-O O
TCR-alpha B-O B-DNA
and B-O I-DNA
CD3-epsilon B-O I-DNA
enhancers B-O I-DNA
imply B-O O
an B-O O
important B-O O
role B-O O
for B-O O
TCF-1 B-O B-protein
in B-O O
the B-O O
establishment B-O O
of B-O O
the B-O O
mature B-O B-cell_type
T B-O I-cell_type
cell B-O I-cell_type
phenotype B-O I-cell_type
. B-O O

Cloning B-O O
of B-O O
a B-O O
human B-O B-DNA
homeobox B-O I-DNA
gene B-O I-DNA
that B-O O
resembles B-O O
a B-O O
diverged B-O B-DNA
Drosophila B-O I-DNA
homeobox B-O I-DNA
gene B-O I-DNA
and B-O O
is B-O O
expressed B-O O
in B-O O
activated B-O B-cell_type
lymphocytes B-O I-cell_type
. B-O O

A B-O O
new B-O O
homeobox B-O B-DNA
gene B-O I-DNA
, B-O O
HB24 B-O B-DNA
, B-O O
has B-O O
been B-O O
isolated B-O O
from B-O O
a B-O O
human B-O B-DNA
B-lymphocyte B-O I-DNA
cDNA B-O I-DNA
library B-O I-DNA
. B-O O

Northern B-O O
blot B-O O
analysis B-O O
of B-O O
polyadenylated B-O B-RNA
RNA B-O I-RNA
purified B-O O
from B-O O
activated B-O B-cell_type
human B-O I-cell_type
B B-O I-cell_type
cells B-O I-cell_type
revealed B-O O
a B-O O
single B-O B-RNA
mRNA B-O I-RNA
transcript B-O I-RNA
of B-O O
approximately B-O O
2.3 B-O O
kb B-O O
. B-O O

